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ABSTRACT
The aim of this research was to provide empirical evidence on psychological issues 
relevant to the potential clinical utility of genetic tests for susceptibility to complex 
diseases. The results of such tests could increase motivation to change health behaviours 
but could also be misinterpreted, causing psychological distress on the one hand, and 
complacency on the other. The research comprised three studies which addressed: 
public interest in genetic testing; the psychological impact of genetic testing; and the 
impact of genetic testing on health behaviours. Study 1 (n= 1,960) utilised questions 
included in the Office for National Statistics omnibus survey to examine the level of 
public interest in taking genetic tests. Two thirds of respondents expressed interest in 
taking genetic tests for two complex diseases, cancer and heart disease, and there was 
greatest interest among people with intermediate levels of educational attainment. Study 
2a-c (n= 1,024) was a postal questionnaire survey conducted in Oxfordshire, using a 2x2 
(cancer vs heart disease x leaflet vs no leaflet) experimental design. Study 2a examined 
the effects of the leaflet on attitudes, and found that interest in genetic testing was higher 
amongst respondents who received the leaflet, as was subjective understanding of 
genetic testing. Study 2b provided support for the hypothesis that vulnerable people 
may self-select themselves out of genetic testing, by showing that anticipated reactions 
were associated with interest in genetic testing. Study 2c looked at responses amongst 
the smokers in the sample, and found that smokers who were more motivated to quit 
were more likely to be interested in genetic testing, and that smokers with lower 
understanding and educational attainment were more likely to believe that receiving a 
lower-risk genetic test result would make them feel that it would be safe for them to 
carry on smoking. The findings from these studies were used to feed into the design and 
interpretation of Study 3 (n=61), an exploratory study in which smokers were randomly 
allocated to receive genetic test results for a gene associated with lung cancer 
susceptibility (GSTM1) or a control group, and followed up for two months. The results 
from Study 3 suggested that the process of genetic testing could increase motivation to 
quit smoking, but that the genetic test result itself may have relatively little impact. It is 
hoped that this research contributes to the current debate about how the clinical utility of 
emergent genetic tests for susceptibility to complex diseases might be evaluated in future 
research.
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CHAPTER 1
Human genetic variation and disease: from single-genes to complexity
1. The Human Genome Project and ELSI
Contemporary discussions about human genetics and disease are influenced to an 
unprecedented degree by considerations of the social, psychological, and ethical contexts 
and implications of developments in human genetics research. This is illustrated by the 
contrast between the original goals of the Human Genome Project (HGP)1 at its 
inception fifteen years ago and the current goals for human genomics research in 2005. 
When the HGP was established in 1990, the document outlining its goals (US 
Department of Health and Human Services, 1990) was dominated by technical elements 
of the project, such as to complete a map of human genetic markers, improve and 
develop new methods for DNA sequencing, map the genomes of other organisms, and 
develop effective software, databases, algorithms and analytic tools to interpret genomic 
information. The ethical, legal and social implications of human genome research 
program (ELSI) was allocated five percent of the total US scientific budget which, 
despite being a considerable proportion of the budget (Austin, 2004), took up just one 
page of the twenty-eight page document. The new five-year goals in 1993 (Collins & 
Galas, 1993) were similarly dominated by genetic maps, physical maps, DNA 
sequencing, model organism sequencing, gene identification, technology development, 
informatics, and technology transfer, and the same was again true in the final five year 
goals laid out in Science in 1998 (Collins, Patrinos, Jordan, Chakrivati, Gesteland, 
Walters et al, 1998; for reviews of HGP goals and achievements see also: Collins, 1999; 
Collins & McKusick, 2001; and Collins, Morgan & Patrinos, 2003).
In 2003, new priorities for human genomics research were proposed in a Nature article 
entitled “A vision for the future of genomics research” (Collins, Green, Guttmacher & 
Guyer, 2003). The difference between the tone of the documents published during the
1 The Human Genome Project (HGP) was an international collaboration which sequenced the human 
genome and several model organisms; it began in 1990 and was officially completed April 14, 2003, fifty 
years to the month after the discovery of the double helical structure of DNA by Watson and Crick (1953). 
Source: Austin, 2004.
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existence of the HGP and the picture painted by Francis Collins and colleagues at the 
point of the project’s completion was striking. The paper was the end product of a series 
of meetings of over 600 scientists convened by the US National Human Genome 
Research Institute (NHGRI) during 2001 and 2002, and far from being dominated by the 
biological aspects of genomics research, this time the plan was split equally into three 
themes: ‘Genomics to biology: elucidating the structure and function of genomes’, 
‘Genomics to health: translating genome-based knowledge into health benefits’, and 
‘Genomics to society: promoting the use of genomics to maximize benefits and 
minimize harms’.
Why was there such a dramatic increase in the proportion of attention given to the social 
aspects of genetics research? A consideration of the way in which genetics research has 
developed over the past couple of decades helps illuminate the answer to this question.
'j
The grand challenges presented in 2003 reflected the fact that this was a ‘different 
world’ (Collins, Green, Guttmacher, Guyer et al, 2003: p835) from that of only a few 
decades earlier when the HGP was conceived; most of the gene-disease associations for 
the rare single-gene disorders had now been identified and the focus was shifting ever 
more towards complex traits and conditions. This meant that more and more people 
would be affected by the outcomes of genetics research, and that the implications for 
society would become more far reaching. The following sections give a brief overview 
of single-gene and complex disorders and the types of genetic variations which are 
associated with each group of diseases.
2. Single-gene disorders and rare genetic mutations
Early genetics research methods, such as linkage analysis and positional cloning, were 
highly successful in identifying the rare genetic mutations and genes that caused single­
gene disorders (Risch, 2000; Hirschhom et al, 2002; Austin, 2004). Single-gene 
disorders (also known as monogenic disorders, Mendelian diseases, or sometimes 
genetic disorders), are caused by change in one gene or chromosome, and show clear 
patterns of inheritance in families, often referred to as ‘Mendelian patterns of
2 For each of the three themes, a series of ‘grand challenges’ were presented, “in the spirit of the proposals 
put forward for mathematics by David Hilbert at the turn of the twentieth century”. Source: Collins et al, 
2003.
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inheritance’ (Expert Working Group for NHS & HGC, 2000). One of the earliest 
examples of a single-gene disorder gene being identified was the successful mapping of 
the Huntington’s disease gene to chromosome 4 in 1983, using linkage analysis (Gusella 
et al, 1993 c.f. Collins & McKusick, 2001), and it is now known that Huntington’s 
disease is caused by a particular expanded DNA repeat sequence in that gene. Over 
1,500 single-gene disorders, like Huntington’s disease, have been identified 
(http://nebi.n 1 m.nih. gov/OMIM), and new gene-disease associations are being made at a 
rate of approximately five per week (Austin, 2004).
Mutations like the one that causes Huntington’s disease are referred to as having 
complete penetrance. This means that an individual who has the genetic mutation will 
inevitably have or develop the disease associated with the mutation. There are three 
main types of single-gene disorders which are caused by mutations of complete 
penetrance: X-linked disorders, inherited recessive disorders, and inherited dominant 
disorders.
X-linked disorders are caused by a mutation on the X-chromosome and therefore only 
affect males, although the disorders can be transmitted through healthy females. The 
female carrier is usually unaffected (or just mildly so) because, unlike the affected male, 
she has a second X chromosome which carries a working copy of the gene that can 
compensate for the malfunction of the faulty gene (Pembry, 1996). Examples of X- 
linked disorders include haemophilia, X-SCID, and muscular dystrophy.
Inherited recessive disorders are single-gene disorders in which the mutated copy of the 
gene must be inherited from both parents if the disease is to develop. This means that 
people can be carriers of a mutated copy of the gene, and be unaffected themselves, but 
pass the disorder on to their child if the other parent also has a faulty copy of the same 
gene. Because a recessive disease only occurs if both copies of a gene that an individual 
receives have the disease-associated mutation, each child bom to two carriers of a 
mutation in the same gene has a 25% risk of being affected with the disorder. Recessive 
disorders commonly have onset in childhood, and include cystic fibrosis, sickle cell 
disease, and thalassemia. Haemochromotosis is an example of a late-onset, or adult- 
onset, recessive disorder.
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Inherited dominant disorders are also single-gene disorders but, unlike recessive 
disorders, a mutated gene need only be inherited from one parent for the disease to 
develop. Again, having a mutated gene inevitably leads to having a disease. Examples 
of dominantly inherited diseases are Huntington’s disease, adult polycystic kidney 
disease, and some cancers, such as familial adenomatous polyposis (FAP). FAP is 
caused by mutations in the APC gene; without colectomy, colon cancer is inevitable for 
individuals with mutations in the APC gene, 95% of which will occur before the age of 
35 (GeneReviews, www.genetests.org, accessed 2004). Familial hypercholesterolemia 
(FH) is another inherited dominant disorder, and is a hereditary form of heart disease 
which is caused by a rare mutation in the low density lipoprotein (Goldstein & Brown, 
1995; Ellsworth et al, 1999; Yoon et al, 2001). Table 1.1. summarises the characteristics 
of the different types of single-gene disorders, and gives examples of each.
Table 1.1. Characteristics and examples of single-gene disorders
Disease characteristics Examples of disease type
Single-gene disorders
X-linked disorders Only affect males. Can be 
transmitted through healthy females.
Haemophilia
X-SCID
M uscular dystrophy
Inherited recessive disorders Mutated copy o f gene must be 
inherited from both parents if  the 
disease is to develop. Two copies o f 
mutated gene will inevitably lead to 
disease.
Cystic fibrosis 
Sickle cell disease 
Thalassemia 
Haemochromatosis
Inherited dominant disorders Mutated gene only has to be inherited 
from one parent in order for the 
disease to develop. One copy o f 
mutated gene will inevitably lead to 
disease.
Huntington’s disease 
Adult polycystic kidney disease 
Familial ademomatous polyposis (FAP) 
Familial hypercholesterolemia (FH)
In addition to familial hypercholesterolemia, additional rare forms of heart disease 
caused by monogenic mutations are long QT syndrome (Roberts & Brugada, 2000; Liew 
& Dzau, 2004), and familial hypertrophic cardiomyopathy (Ellsworth et al, 1999; Public 
Health Genetics Unit, Cambridge, 2001). These plus other rare diseases and syndromes 
with cardiovascular effects are summarized in Table 1.2 (adapted from Ellsworth et al, 
1999).
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Table 1.2. Selected single-gene mutations responsible for rare diseases and syndromes
with cardiovascular effects
Syndrome/disease Gene/locus
Dilated cardiomyopathy 
Ehlers-Danlos syndrome (type IV) 
Familial hypercholesterolemia 
Familial hypertrophic cardiomyopathy 
Gitelman syndrome
Glucocorticoid-remediable aldesteronism
Hereditary hemorrhagic telangiecstasia
Homocystinuria
Hypobetalipoproteinemia
Liddle syndrome (Pseudoaldosteronism)
Long QT syndrome 
Marfan syndrome
CMD1A
Type III collagen (COL3A1)
Low density lipoprotein receptor (LDLR) 
CMH1/2/3/4
Tiazide-sensitive Na+Cl- cotransporter (SLC12A3) 
Aldosterone synthase (CYP11B2)
11 B-hydroxylase (C Y P11B 1)
Endoglin (ENG)
Cystathionine-beta-synthase (CBS)
Apolipoprotein B (APOB)
Epithelial sodium channel-B subunit (BENaC) 
Epithelial sodium channel-Y subunit (yENaC) 
Voltage-gated potassium channel gene (KVLQT1) 
Human ether-a-go-go-related gene (HERG) 
Voltage-gated sodium channel gene (SCN5A) 
Fibrillin-1 (FBN1)
Source: Ellsworth et al (1999)
3. Complex diseases and rare genetic mutations
Although the developments in molecular and computational technology over the past 
two decades have enabled the identification of genes for many disorders, these successes 
have been restricted primarily to the types of simple, single-gene disorders described 
above, which are by their nature rare and affect only a few percent of the population 
(Pembry, 1996; Risch, 2000). This means that although important to the individuals and 
families who carry these genes, the successes have been of limited significance in terms 
of public health (Risch, 2000; Mathew, 2001). In contrast, western populations are 
estimated to have a 60% lifetime risk of developing a complex disease (Wright et al, 
1999), and so there is considerable public health benefit to be derived from the 
elucidation of the genetic components of this class of disease. Complex diseases 
(sometimes called multifactorial or polygenic diseases) can be defined as “disorders 
whose genetic components are not the sole cause, but which work with other, often 
environmental factors, in determining a disease outcome” (UK Advisory Committee on 
Genetic Testing, 1998), and examples include common forms of heart disease and 
cancers.
In single-gene disorders, genetic alterations tend to be sequence changes, insertions, or 
deletions that cause major disruption of a gene and its protein product, changes which 
generally cause the diseases with which they are associated (Austin, 2004). For complex
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diseases, on the other hand, risk alleles (versions of genetic variants) are less 
deterministic -  the presence of the high-risk allele may only mildly increase the chance 
of disease (Hirschhom et al, 2002). This is because the genetic alterations that are 
associated with complex diseases tend to be much more subtle, for example, changing 
the expression or activity of the gene product, sometimes only in certain environmental 
conditions. Thus the genetic alterations that are associated with common, complex 
diseases only increase or decrease susceptibility to these diseases, rather than cause them 
(Austin, 2004). Genetic alterations associated with complex diseases may be rare 
genetic mutations o f  high penetrance (i.e. relatively rare but strongly associated with 
disease), or common genetic variants o f low penetrance (i.e. found in high frequencies 
[more than 1%] in the population, and weakly associated with disease).
One area in which the elucidation of highly penetrant genetic mutations for complex 
disorders has already had a clinical impact is the field of cancer genetics (Weitzel, 1999; 
Coughlin & Burke, 2001; Emery, Lucassen & Murphy, 2001; Yoon et al, 2001; 
Balmain, Gray & Ponder, 2003). In Chapter 9 of the book, “Genetics and Public Health 
in the 21st Century”, Coughlin and Burke (2001) discuss how the focus has shifted from 
rare cancer syndromes, such as Li-Fraumeni syndrome and Von Hippel Lindau 
syndrome, to common, adult-onset cancers, primarily breast-ovarian cancer, colon 
cancer, and prostate cancer.
About 5% of breast cancer cases are attributed to rare genetic mutations of high 
penetrance (Ponder, 2001), primarily the BRCA1 gene, on chromosome 17 and the 
BRCA2 gene on chromosome 13, which were initially identified through linkage studies 
in families with early-onset familial breast and ovarian cancer (Miki et al, 1994; Wooster 
et al, 1994). Women from cancer-prone families who test positive for a BRCA1 or 
BRCA2 gene mutation may have very high lifetime risks of cancer. Estimates of the 
penetrance in these high risk families indicate that the lifetime risk of breast cancer in 
mutation carriers is similar for both genes (84% cumulative risk by age 70 for BRCA2 
compared to 85% for BRCA1), but that the risk of early onset breast cancer is somewhat 
lower for BRCA2 (28% cumulative risk by age 50 compared to 51% for BRCA1). The 
estimated risk of ovarian cancer is also lower for BRCA2 (27% cumulative risk by age 
70 compared to 66% for BRCA1) (Coughlin & Burke, 2001). BRCA1 and BRCA2
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mutations occur in higher frequencies in some populations; rates are particularly high 
among people of Ashkenazi Jewish descent (Kauff et al, 2002).
In the case of colon cancer, while the adenomatous polyposis syndromes account for 
only about 0.5% of colonic cancer cases, nonpolyposis syndromes may account for 5% 
or more. However, whereas familial adenomatous polyposis (FAP) inevitably leads to 
colon cancer without colectomy, individuals with hereditary non-polyposis colon cancer 
(HNPCC) have an approximately 80% lifetime risk for colon cancer. HNPCC is known 
to be associated with mutations in four genes involved in the mismatch repair pathway 
(MLH1, MSH2, MSH6, and PMS2) (GeneReviews, accessed 2004).
As with breast and colon cancer, familial clustering of prostate cancer has also been 
observed. Families demonstrating autosomal dominant transmission of isolated 
susceptibility to prostate cancer have been observed, and have been estimated to account 
for 9% of prostate cancer cases. Studies of such families have led to the identification of 
a possible genetic susceptibility locus on chromosome 1, termed HPC1 (hereditary 
prostate cancer 1). Table 1.3 summarizes the known highly penetrant mutations 
associated with breast, ovarian, colon and prostate cancers (adapted from Yoon et al, 
2001).
Table 1.3. Highly penetrant genetic mutations associated with cancer susceptibility
Cancer Gene(s) Mode of 
inheritance
Population prevalence
BRCA1 hereditary breast cancer 
BRCA2 hereditary breast cancer 
Prostate cancer
Hereditary nonpolyposis colon cancer (HNPCC)
BRCA1
BRCA2
PRC1, HPCX, 
PCAP (HPC2) 
MLH1, MSH2, 
MSH6, PMS1, 
PMS2,
TGFBR2
AD 
AD 
AL or XL
AL
10-20/10,000 
5-10/10,000 
Not known
2/1,000
AD, autosomal dominant; AL, autosomal loci not specified; XL, X linked
Source: Yoon et al (2001)
4. Complex diseases and common genetic variation
The previous section illustrated how the identification of highly penetrant genetic 
variants has already had an impact on clinical medicine, but there is some reason to 
believe that predisposition conferred by combinations of weak common genetic variants
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of low penetrance will be of even greater significance to public health, given the greater 
numbers of people that this will impact upon (Bell, 1998; Pharoah et al, 2002). In the 
case of breast cancer for example, population-based epidemiological studies have shown 
that only 15-20% of the observed familial clustering of breast cancer occurs in families 
that carry a strongly predisposing BRCA1 or BRCA2 mutation. Even in these high risk 
families, this therefore leaves 80-85% of the familial risk unexplained (Balmain, Gray & 
Ponder, 2003). In addition, only about 5-10% of all cancer cases are attributable to high 
penetrance genes (Balmain, Gray & Ponder, 2003). Thus, the vast majority of cancers 
that occur in western populations cannot be attributed to the highly penetrant genetic 
variants identified so far, and it is likely that multiple common genetic variants and 
environmental factors are accountable instead.
Hundreds of associations have already been identified between common genetic variants 
and susceptibility to common, complex disease using association studies (Hirschhom et 
al, 2002), but examination of common genetic variations of low penetrance using these 
methods has been difficult (Houlston & Tomlinson, 2000; Caporaso, 2002), and there 
has been a need for increasingly sophisticated molecular, technological and statistical 
methods (Ghosh & Collins, 1996; Whittemore & Nelson, 1999; Glazier, Nadeau & 
Aitman, 2002; Goldstein et al, 2003; Lin, Chakravati & Cutler, 2004; Churchill et al, 
2004). This is a rapidly developing field, and as little as five years ago, assumptions 
were made about the strength of gene-disease associations which have since turned out 
to be unfoundedly optimistic, which urges caution in interpreting reports of these 
findings.
Bearing this in mind, Hirschhom and colleagues (2002) conducted a comprehensive 
review of published significant associations between common, complex diseases or 
dichotomous traits and common polymorphisms in or near genes. 268 genes were 
identified that contained polymorphisms reported to be associated with 1 of 133 
common diseases or dichotomous traits. In total, these 268 genes accounted for 603 
different gene-disease associations. The common diseases listed in the review included: 
cancer (bladder, breast, cervical, colorectal, head/neck, lung, and prostate); 
cardiovascular disease (coronary artery disease/myocardial infarction, deep vein 
thrombosis, and hypertension), dermatology (juvenile onset psoriasis); endocrinology 
(Graves’ disease, male infertility, obesity, osteoporosis/fracture), Type 1 diabetes, Type
8
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2 diabetes); infectious diseases (HIV infection/AIDS); neonatal disease (cleft lip, neural 
tube defect); neurology (Alzheimer’s disease, Cruetzfeldt-Jakob disease, ischemic 
stroke, multiple sclerosis, Parkinson’s disease); obstetric disease (preeclampsia); 
pharmacogenetics (clozapine, drug-induced tardive dyskinesia, and tacrine response); 
psychiatry (anorexia, attention deficit hyperactivity disorder, bipolar disorder, 
depression, obsessive compulsive disorder, and schizophrenia); pulmonary disease 
(asthma/atopy, chronic obstructive pulmonary disease/emphysema), and rheumatology 
(systemic lupus erthematosius). This illustrates the range of complex conditions and 
traits that have been investigated.
Table 1.4. Common gene variants associated with heart disease and cancer
Disease Gene Polymorphism Risk allele/genotype Frequency
Cancer
Bladder cancer GSTM1 null (gene deletion) null/null 0.48-0.60
Bladder cancer GSTT1 null (gene deletion) null/null 0.15
Breast cancer CTP1A1 3 ’ C/T (MspI) site present/site present = C/C 0.04
Cervical cancer TP53 Pro72Arg Arg 0.66
Head/neck cancer CYP1A1 Ile462Val Ile/Val and Val/Val 0.08
Head/neck cancer CYP2E 5 ’ Rsal site site present/site present 0.56
Head/neck cancer GSTM1 null (gene deletion) null/null 0.48
Head/neck cancer GSTM3 A/B (M nll) B/B 0.06
Lung cancer CYP1A1 Ile462Val Val/Val 0.05
Lung cancer CYP1A1 3 ’ CT (MspI) site present/site present = C/C 0.11
Lung cancer CYP2E intron 6 Dral site present carrier 0.89
Lung cancer GSTM1 null (gene deletion) null/null 0.47
Prostate cancer AR exon 1 CAG repeat <20 repeats 0.27
Cardiovascular disease
CAD/Ml APOA1 3 ’ Pstl 3.3 kb allele 0.02
CAD/MI APOB Gln4154Lys = EcoRI Lys = 13.1 kb allele 0.11
CAD/Ml APOB Xbal 8.6 kb allele 0.50
CAD/MI APOE epsilon 2/3/4 Epsilon 4 0.13
CAD/MI ACE intron 16 Ins/Del Del/Del 0.24-0.29
CAD/MI ITGB3 Leu33Pro = PI A1/A2 Pro = A2 0.10
CAD/Ml LPL H indlll 8.7 kb homozygotes 0.34
CAD/Ml MTHFR 677C/T T/T (thermolabile) 0.05-0.07
CAD/Ml NOS3 Glu298Asp Asp 0.07
CAD/MI PON1 A rgl92G ln Arg 0.31
CAD/MI SERPINE1 4G/5G in promoter 4G 0.53
CAD/MI SERPINA8 Met235Thr Thr/Thr 0.38-0.65
DVT F2 20210G/A A 0.02
DVT F5 Arg506Gln Gin (leiden) 0.03
DVT MTFHR 677C/T T/T (thermolabile) 0.28
HTN ADD1 Gyl460Trp Trp 0.23-0.26
HTN AGTR1 1166 A/C C 0.38
HTN CYP11B2 344C/T T 0.49
HTN ACE intron 16 Ins/Del Del/Del 0.42
HTN GNB3 825C/T T 0.35
HTN SERPINA8 Met235Thr Thr 0.35-0.38
HTN SERPINA8 T hrl74M et Met 0.08
CAD/MI, coronary artery disease/myocardial infarction; DVT, deep vein thrombosis; HTN, hypertension.
Source: Hirschhom et al (2002)
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Cancer and heart disease have received particular attention due to their significant public 
health impact (Caporaso, 2002; Liew & Dzau, 2004). Table 1.4 summarises the 
common gene variants reported to be associated with cancer or heart disease in at least 
three studies (adapted from Hirschhom et al, 2002). The list only includes polymorphic 
gene variants, and so obviously excludes the rarer genetic mutations that are associated 
with the rarer forms of cancer, such as the BRCA1/2 mutations associated with 
breast/ovarian cancer discussed in the previous section.
4.1. Common genetic variation in the metabolism of carcinogens
The majority of the cancer-associated common genetic variations listed in Table 1.4 
come from one of the three ‘ superfamilies ’ of genes that are primarily involved in the 
metabolism of carcinogens; cytochromes P450 (CYPs), glutathione S-transferases 
(GSTs), and N-acetyltransferases (NATs). Reports during the past decade have 
suggested that certain alleles of these xenobiotic metabolizing genes may be associated 
with many of the common cancers such as lung, bladder, colon, breast and skin (Garte,
2001). Table 1.5 shows some of the polymorphisms in carcinogen metabolism genes 
(adapted from Wu et al, 2004). The association between common genetic variants and 
diseases such as lung cancer, raises new possibilities and issues around the implications 
of genetics research in to diseases which are linked to health behaviours such as 
smoking. In the following section I shall look at the gene-disease associations between 
the three gene ‘superfamilies’ and lung cancer susceptibility in more detail.
4.2. Common genetic variation and lung cancer susceptibility
There are at least 55 known carcinogens in tobacco smoke (Hecht, 1999), and the links 
between cigarette smoking and lung cancer have been well documented and are widely 
known. Peto et al (2000) estimated that the cumulative risk of death from lung cancer 
by age 75 years (in the absence of other causes of death) was 16% in 1990 in male 
cigarette smokers and 10% in female cigarette smokers, but the fact that not all smokers 
develop lung cancer has led to interest in the hypothesis that genetic factors may render 
some smokers particularly susceptible to lung cancer (Caporaso, Rothman & Wacholder, 
1999; Wu et al, 2004). The overall contribution of heritable genetic factors to lung 
cancer is difficult to discern because of the strong associations with cigarette smoking 
and other environmental exposures (Coughlin & Burke, 2000), but it has been argued
10
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that the familial aggregation of lung cancer is not fully explained by the familial 
aggregation of smoking. Several reviews have been written on the topic of susceptibility 
metabolizing genes and lung cancer (Bartsch et al, 1999; Coughlin & Burke, 2000; 
Haugen et al, 2000: Au et al, 2001).
Table 1.5. Genetic polymorphisms in carcinogen metabolism genes
Gene (enzyme) Nucleotide change Frequency Enzymatic activity
CYP1A1 T/C (MspI) 0.32 Increased
A/G 0.12 Increased
CYP2E1 G/C (Rsal) 0.45 Increased
C/T (PstI) 0.45 Increased
T/A (Dral) 0.13 Increased
CYP2A13 C/T 0.03 Reduced
EPHX C/T (337) 0.36 Decreased
GSTM1 Deletion 0.40 Null
GSTP1 A/G (313) 0.33 Reduced
T/C (341) 0.04 Reduced
GSTT1 Deletion 0.25 Null
N QO l C/T (609) 0.26 Reduced
NAT2 T /C (341) 0.32 Slow
C/T (481) 0.32 Slow
A /G (803) 0.37 Slow
G/A (590) 0.28 Slow
C/T (282) 0.38 Slow
G/A (857) 0.06 Slow
MPO G/A 0.18 Decreased
Su ltlA l G/A 0.18 Low
MnSOD T/C 0.39 Increased
Source: Wu et al, 2004
4.2.1. Cytochromes
Cytochrome P450 enzymes are primarily expressed in the liver, and carry out ‘phase 1 ’ 
of metabolism via a process called activation. Activation involves oxidizing the 
polycyclic aromatic hydrocarbons (PAHs) into DNA-binding intermediate metabolites. 
These metabolites can be highly toxic and damaging to DNA, and through this increase 
susceptibility to carcinogenesis (the development of cancer). However, in the normal 
process of converting carcinogens to excretable forms the metabolites are then detoxified 
by the Phase II enzymes. Several cytochrome P450 enzymes that activate chemical 
carcinogens have been associated with lung cancer susceptibility (Bennett et al, 1999). 
Cytochrome P450 enzymes activate benzo(a)pyrene and may activate or metabolize 
other carcinogens found in cigarette smoke.
CYP2A6 gene is one of three members in the human CYP2A gene subfamily, the other 
members being CYP2A7 and CYP2A13 (Pelkonin et al, 2000). Most studies have
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investigated CYP2A6 in relation to its role in the metabolism of nicotine (Messina, 
Tyndale & Sellers, 1997; Kitagawa et al, 1999; Oscarson et al, 1999; Sellers et al, 2000) 
but it has also been investigated in case-control studies on lung cancer due to its 
involvement in metabolic activation of carcinogenic nitrosamines in tobacco smoke 
including NNK, NNAL, NDEA, and NDMA (London et al, 1999). Although the 
frequency of the CYP2A6 whole gene deletion has been observed to be significantly 
lower in Japanese lung patients than that of healthy volunteers (Kamataki et al, 1999), 
other studies have failed to find an association between CYP2A6 mutations and lung 
cancer susceptibility (London et al, 1999; Loriot et al, 2001).
The CYP1A1 enzyme is known to activate carcinogenic PAHs including the 
benzo[a]pyrene component of tobacco smoke (Bennett et al, 1999). There is some 
evidence to suggest that CYP1A1 might be associated with increased risk o f lung cancer: 
for example, in one case control study the CYP1A1 MspI variant allele (CYP1A1*2A 
and *2B) genotype was associated with an increased risk of lung cancer (OR=1.2; 95% 
Cl: 1.0-1.6, Taioli et al, 2003). However, the results of studies that have looked for 
associations of lung cancer risk with CYP1A1 genotypes have been inconsistent 
(Watanabe, 1998; Bartsch et al, 1999; Dresler et al, 2000; Bouchardy et al, 2001). 
CYP1A1 has also been associated with susceptibility to oral cancer (Sato et al, 1999) 
and implicated in breast cancer but with inconsistent results (Basham et al, 2001).
The CYP2D6 (debrisoquine-4-hydroxylase) enzyme metabolizes debrisoquine and at 
least 30 other drugs, and lung cancer patients were reported in early studies to be over­
represented by individuals with the extensive metabolizer genotypes (El-Zein et al,
1997). Early papers additionally predicted that the gene could be involved in a number 
of diseases including lung cancer, liver cancer, and Parkinsons disease (Watanabe,
1998). However, the strength of the association with this phenotype has varied across 
studies, some studies have failed to find an association, and a consistent pattern has not 
emerged from more recent lung cancer studies that have looked for associations with 
CYP2D6 (Coughlin & Burke, 2000).
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4.2.2. Glutathione S-transferases
Glutathione S-transferase (GST) enzymes are the main phase II enzymes which detoxify 
PAHs. The GST multiple gene ‘superfamily’ is divided into four distinct classes named 
Alpha, Mu, Pi and Theta, largely on the basis of chromosomal location. The Mu and Pi 
classes of GST can detoxify carcinogenic PAHs such as BaP. They do this by catalyzing 
the incorporation of glutathione, which increases the molecule’s water solubility and 
excretability. GSTs have been studied as modulators of risk for lung cancer because 
they are involved in the metabolism of known carcinogens in tobacco smoke and are 
functionally polymorphic (Nazar-Stewart et al, 2003). Genetic polymorphisms have 
been identified for GSTM1, GSTM3, GSTP1 and GSTT1 (Bouchardy et al, 2001). A 
number of case-control studies have been conducted examining the association between 
GSTM1, GSTP1, and GSTT1 and lung cancer (Tang et al, 1998; Kihara et al, 1999; 
Hong et al, 1999; Ford et al, 2000; Belogubova et al, 2000; Yang et al, 2002; Miller et al, 
2002; Perera et al, 2002; Sweeney et al, 2003; Piipari et al, 2003). Very few studies 
have examined GSTM3 in relation to lung cancer, and there is not strong evidence to 
support an independent role for GSTT1 (Stucker et al, 2002; Wu et al, 2004) or GSTP1 
(Nazar-Stewart et al, 2003; Wu et al, 2004) in lung cancer risk. GSTM1 however shows 
a relatively robust, if  small, association with susceptibility to lung cancer.
GSTM1 is located on chromosome 1 and codes for M or Mu class GSTs that are 
involved in the detoxification of various carcinogens, including PAH intermediate 
metabolites. Some individuals are homozygous carriers of deletions in the GSTM1 gene 
(GSTM1 0/0 genotype). The frequency of the GSTM1 0/0 genotype is high in 
Caucasian populations at approximately 50%, with a reported range of 30-70% for 
different ethnic groups. GSTM1 is only weakly expressed in lung tissue, but the 
possession of the GSTM1 gene appears to determine the enzyme activity of both 
GSTM1 and GSTM3 in the lung. This may be related to the fact that the GSTM3 gene 
is also polymorphic and the GSTM3*B allele is linked to the GSTM1*A allele 
(McWilliams et al, 1995). Having the GSTM1 null genotype has been associated with 
increased susceptibility to a number of complex diseases, including bladder cancer 
(Engel et al, 2002) and heart disease (Li et al, 2000). A meta-analysis conducted on the 
available data in 1995 of 12 case-control studies comprising 1,593 cases and 2,135 
controls (McWilliams et al, 1995), showed a moderate increase of lung cancer across all
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histologies (squamous cell carcinoma, adenocarcinoma, and small cell lung cancer) with 
the GSTM1 null genotype, with an odds ratio of 1.41 (95% Cl: 1.23-1.61). In 1999, two 
meta-analyses were carried out: Houlston (1999) conducted a meta-analysis on 23 case- 
control studies and obtained an overall odds ratio of lung cancer risk associated with 
GSTM1 deficiency of 1.13 (95% Cl: 1.04-1.25), and Vineis et al (1999; c.f. Benhamou 
et al, 2002) obtained a summary odds ratio of 1.20. In the most recent meta-analysis 
(Benhamou et al, 2002) of 43 studies and 18,000 individuals an odds ratio of 1.17 was 
obtained (95% Cl: 1.07-1.27). An odds ratio above 1 was found in 31 of the 43 studies, 
but the increase in risk was statistically significant in only five of them. The association 
was significant for Caucasians and Asians, but not African-Americans or Mexican- 
Americans (see Table 1.6).
Table 1.6. Associations between the GSTM1 null genotype and lung cancer risk in 
different populations
No. o f studies Lung cancer patients Control individuals OR (95% Cl)
Total GSTM1 deficient 
(%)
Total GSTM1 deficient 
(%)
Total 43 7,463 52.4 10,789 50.0 1.17(1.07-1.27)
Caucasians 20 4,039 51.8 6,000 50.2 1.10(1.01-1.19)
Asians 12 1,841 58.9 2,787 53.0 1.33 (1.06-1.67)
African-Americans 3 383 27.4 503 24.3 1.19(0.88-1.62)
Mexican-Americans 1 60 55.0 146 40.4 1.80 (0.99-3.29)
Mixed 4 785 58.1 894 56.2 1.10(0.90-1.33)
Not stated 3 355 49.6 459 49.5 1.06 (0.79-1.40)
Results o f meta-analyses conducted by Benhamou et al (2002)
In addition to the association studies, a few studies have also been conducted that link 
the functional activities of these polymorphic genes with the development of cancer. 
Examples from the literature are summarized in Table 1.7 (adapted from Au et al, 2001), 
which lists reports according to the gene. According to Albertini et al (1996) and Au et 
al (2001), there are basically two types of biomarkers: biomarkers of exposure (e.g. 
adducts and sister-chromatid exchanges) and biomarkers of effects (e.g. micronuclei and 
chromosome aberrations). As shown in the table, inheritance of the GSTM1 null allele 
is significantly associated with the formation of DNA and protein adducts in circulating 
lymphocytes and in bronchial cells in the target tissues and, using another biomarker of 
exposure, sister chromatid exchanges, the GSTM1 null allele is shown to be associated 
with the expression of micronuclei and chromosome aberrations. These findings provide 
further support for a role of GSTM1 in the development of lung cancer.
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Table 1.7. Genetic polymorphisms and biological effects from cigarette smoking
Gene Biomarker Sample size 
(smokers)
Significance Reference
GSTM1 DNA adducts in bronchial tissue N.A. S., (P=N.A.) Bartsch et al, 1998
Sister-chromatid exchange 156 P=0.09 Van Poppel et al, 1993
Sister-chromatid exchange 56 P<0.01 Cheng et al, 1995
Chromosome aberration 44 PcO.001 El-Zein et al, 1997c
Chromosome aberration 62 P=0.026 Scarpato et al, 1997
DNA adducts in lymphocytes 170 P=0.045 Butkiewicz et al, 1998
DNA adducts in lymphocytes 154 N.S. Schocket et al, 1998
DNA adducts in lymphocytes 159 N.S. Mooney et al, 1997
DNA adducts in lymphocytes 63 N.S. Grinberg-Funes et al, 1994
Micronuclei 156 N.S. Van Poppel et al, 1993
GSTT1 Sister-chromatid exchange 13 P<0.005 Schroder et al, 1995
NAT1 *10 Chromosome aberration 17 P<0.02 Abdel-Rahman et al, 1998
CYP1A1 DNA adducts in lymphocytes 159 P=0.03 Mooney et al, 1997
CYP1A1/GSTM1 DNA adducts in lymphocytes 158 P=0.027 Wang et al, 1998
CYP2E1 Sister-chromatid exchange 44 N.S. W ong et al, 1998
Source: Au et al (2001)
4.2.3. N-acetyltransferases
There are two NAT genes, N-acetyltransferase-1 (NAT1) and N-acetyltransferase-2 
(NAT2), the latter of which functions as a phase II gene. Both are located on 
chromosome 8q. N-acetlytransferase 2 (NAT2) primarily catalyses the N-acetylation of 
aromatic amine procarcinogens contained in tobacco smoke. A genetic polymorphism in 
(NAT2) activity is one of the most common in the human population with wide 
phenotypic and allelic variation within human populations (Fretland et al, 2001). At 
least 19 variant NAT2 alleles have been detected in the human population, but the 
NAT2*5, *6 and *7 alleles account for virtually all of the slow acetylator alleles in 
Caucasian populations, providing evidence for a high concordance between genotype 
and phenotype (Hou et al, 2000). The slow acetylator phenotype and NAT2 genotype 
have been associated with lower risk for colorectal cancer (Le Marchand et al, 2001) but 
higher risk for occupational and smoking related bladder cancer (Inatomi et al, 1999; 
Vineis, Marinelli, Autrup et al, 2001). It has received less attention in relation to lung 
cancer susceptibility, but Hou et al (2000) suggest that NAT2-slow genotypes may 
constitute susceptible groups with increased risk to contract non-operable lung cancer at 
younger age and lower smoking dose.
N-acetyltransferase 1 (NAT1) exhibits polymorphisms with a number of alleles. Of 
these alleles NAT1*10 is responsible for increased NAT1 enzyme levels and is reported
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to be associated with increased risk for a number of cancers, including colorectal, 
bladder, and gastric cancers (Abdel-Rahman et al, 1998; Gonzalez et al, 2002). It has 
been suggested that NAT1*10 is associated with increased chromosome aberrations and 
higher lung cancer risk in cigarette smokers (Abdel-Rahman et al, 1998).
5. Summary
In summary, genetics research has been successful in identifying genes for single-gene 
disorders caused by rare genetic mutations. There has also been some success at 
identifying genes which confer an increased risk of some rare subtypes of common 
diseases, such as breast cancer. However, these rare diseases do not have a significant 
public health impact, and attention has turned to gene-environment interactions in the 
etiology of complex diseases. A number of common gene variants have been associated 
with common, complex diseases such as cardiovascular disease and lung cancer. This 
raises the possibility of genetic testing for susceptibility to complex diseases and the 
identification of high-risk individuals. In the next chapter I will discuss the issues raised 
by testing individuals for single-gene and complex diseases, as the implications of 
testing for the two different types of disease are different and have led to recent 
controversy over how these emergent tests should be evaluated and regulated.
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CHAPTER 2 
Genetic testing: from diagnostics to predictions
1. What is genetic testing?
Genetic testing is most often defined as “the analysis of a specific gene, its product or 
function, or other DNA and chromosome analysis, to detect or exclude an alteration 
likely to be associated with a genetic disorder” (Harper, 1997), although at its most 
simple it can be thought of as any procedure which tests for the presence or absence of 
genetic variation. In the UK, the Advisory Committee on Genetic Testing (ACGT), in 
its Report on Genetic Testing fo r  Late Onset Disorder (ACGT, 1997), defined genetic 
testing simply as:
“testing to detect the presence or absence of, or alteration in, a particular gene, 
chromosome or gene product”
and the US Task Force on Genetic Testing, in Promoting Safe and Effective Genetic 
Testing in the United States” (US Task Force, 1997, www.genome.gov/10001733 
accessed 25 April 2005), as “the analysis of human DNA, RNA, chromosomes, proteins, 
and certain metabolites in order to detect heritable disease related genotypes, mutations, 
phenotypes or karyotypes for clinical purposes”. A more recent definition, “a procedure 
to detect the presence or absence of, or change in, a particular gene or chromosome, 
including an indirect test for a gene product or other specific metabolite that is primarily 
indicative of a specific gene change”, was agreed upon by a majority of the 190 Member 
States of the United Nations Educational, Scientific and Cultural Organisation 
(UNESCO, 2003) in the International Declaration on Human Genetic Data, and so is 
probably the best reflection of a recent internationally consensual definition.
Many definitions include not only DNA tests but tests of its products and function as 
well. Tests of DNA are called direct tests, whereas tests which involve looking at 
markers co-inherited with a disease causing gene (linkage testing), assaying certain 
metabolites (biochemical testing), or examining the cytochromes (cytogenetic testing),
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are called indirect tests (GeneTests, accessed 2004). In addition to two of those shown 
above (Harper, 1997; US Task Force, 1997), a number of other definitions have also 
included both direct and indirect testing (Secretary’s Advisory Committee on Genetic 
Testing, 2000; Medical Research Council, 2001; Department of Health, 2003). This is 
not always the case though, as shown in the ACGT definition above which was also used 
in the Code o f Practice and Guidance on Human Genetic Testing Services Supplied 
Direct to the Public (ACGT, 1997). Whilst some definitions have specified that the 
genetic variation being examined is ‘in relation to a genetic disorder’ (Harper, 1997; 
ACGT, 1998; MRC, 2001; Stewart et al, 2002); ‘to detect heritable disease-related 
genotypes for clinical purposes’ (US Task Force, 1997); and ‘to detect heritable or 
acquired genotypes... that cause or are likely to cause a specific disease or condition’ 
(SACGT, 2000), this raises questions as to what qualifies as ‘genetic disorder’ and 
‘clinical purposes’ (for a detailed conceptual exploration of genetic testing see Zimmem,
1999).
For the purposes of this thesis, the term genetic testing is usually restricted to direct 
testing only, and is applied to all human diseases, from single-gene disorders to complex 
diseases. One added complication which has not yet been fully resolved is the point at 
which a genetic test moves from research status to clinical status. The US Task Force 
(1997) explicitly states that its definition of genetic testing “excludes tests conducted 
purely for research”, and yet the line between research tests and clinical tests is not as 
well defined as it first seems. I shall explore this issue in the following sections, because 
it is relevant to the subsequent consideration of the importance of the social and 
psychological issues raised by genetic tests.
2. The continuum from research to clinical genetic tests
According to some classifications, genetic tests can be classified as investigational, 
research or clinical, depending on where they fall along the research-clinical application 
continuum. Investigational tests test for genetic variants which are deemed to be of 
value but not yet scientifically valid or generally accepted by the medical community as 
accurate and useful. Research tests are similar, but the genetic variations are better 
understood, and specimens are examined for the purpose of understanding a condition 
better, or developing a clinical test. Clinical tests are used to examine genetic variations
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the results of which are reported to health care providers or patients for the purpose of 
diagnosis, prevention or treatment in the care of individual patients. There are currently 
328 research and investigational genetic tests, and 765 clinical genetic tests, available or 
in use in genetic testing laboratories3 (GeneTests, 2004).
3. Genetic test evaluation: when does a research test become a clinical test?
For a genetic test to move from research status to clinical status it must be shown to 
improve health outcomes (SACGT, 2000). Determining whether genetic testing can 
improve health outcomes requires careful assessment of two main areas: (i) the validity 
of the testing process, and (ii) the utility of the test information, based on the availability 
of safe and effective interventions to reduce risk. The associated ethical, legal and social 
issues should also be considered (Haga, Khoury & Burke, 2003). The validity of the 
testing process can be measured in terms of analytic validity and clinical validity.
Analytic validity refers to how well a test measures the property or characteristic it is 
intended to measure and can be defined as the sensitivity, specificity and reproducibility 
of a particular gene variant (SACGT, 2000; Expert Working Group, 2000; Burke et al, 
2002; Haga, Khoury & Burke, 2003). Sample type and quality, testing protocol, 
reagents and equipment, and personnel are among the many factors that can influence 
analytic validity (Haga, Khoury & Burke, 2003).
Clinical validity refers to the accuracy with which a test predicts the presence or absence 
of a certain disease or predisposition (SACGT, 2000; Burke et al, 2002). It measures 
how well an allele-positive result identifies people who will develop the disease and how 
well an allele-negative result identifies those who will not develop the disease 
(Holtzman et al, 1997; Yang et al, 2000; Yang et al, 2003). It has also been described as 
the degree to which the sequence variant detected is a good predictor of clinical disorder 
(i.e. penetrance). Clinical validity data ideally should be based on strong epidemiologic 
study design and may be presented as the sensitivity, specificity or positive and negative 
predictive value of a test for a particular clinical outcome (Haga, Khoury & Burke, 
2003) (note the overlap with analytic validity here). Many genetic tests have uncertain
3 As of November 2004
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clinical validity because of limited and potentially biased study populations, low 
genotype penetrance, variable expressivity, lack of understanding of phenotypic 
modifiers and multiple or ambiguous clinical end points (Burke et al, 2002).
Clinical utility refers to the likelihood that use of a test will result in improved health 
outcomes (SACGT, 2000; Burke et al, 2002). The clinical utility of a test will depend on 
the availability, safety and effectiveness of preventive or therapeutic measures offered to 
individuals with positive test results (Haga, Khoury & Burke, 2003). According to 
Burke, Pinsky & Press (2001), with tests which have limited clinical validity but an 
effective intervention available, the key questions are the balance between the potential 
for adverse effects of labelling (or medical treatment) and the potential for improved 
health outcome. Factors to be weighed include the nature of the condition, its potential 
for stigma, and the nature and effectiveness of the treatment. Tests with low predictive 
value may be acceptable when the label carries little emotional weight. Burke et al 
(2001) suggest that this may prove to be the case for some common disease risk factors 
identified by genetic testing, such as heart disease susceptibility. They also state that a 
simple, relatively safe treatment may also generate a stronger rationale for testing than 
an intervention that involves significant risk, but that when tests have limited predictive 
value, a careful consideration of both medical and social outcomes is needed to provide 
clinicians and policy-makers with the information they need to determine appropriate 
test use. This highlights the point that social outcomes become more important and also 
more ambiguous as genetic tests emerge which are for common variants of low 
penetrance.
4. Genetic testing for single-gene disorders: diagnosis and prediction
The majority of clinical genetic tests in use at the present time, i.e. which have been 
deemed to be of clinical validity and/or utility, are for single-gene disorders, and can be 
mainly classified as diagnostic tests or presymptomatic tests. Diagnostic testing (or 
confirmatory testing) identifies or confirms the diagnosis of a given disease or condition. 
Diagnostic tests are used prenatally to diagnose diseases and conditions in developing 
fetuses, and to diagnose or classify diseases in children and adults. Used in children and 
adults, genetic tests can help determine how a disease will progress and what treatment 
choices should be made. A special case of diagnostic testing is preimplantation genetic
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diagnosis (PGD), which is used following in vitro fertilization of an egg to diagnose a 
disease or condition in a preimplantation embryo (Braude, Pickering, Flinter & Ogilvie,
2002). Carrier testing is a subtype of diagnostic testing and is performed to determine 
whether an individual carries one copy of an altered gene for an inherited recessive 
disorder. Carrier tests for recessive diseases such as cystic fibrosis first became 
available in the 1980s.
Presymptomatic testing is a predictive test carried out for genetic mutations associated 
with dominantly inherited conditions where having the mutation inevitably leads to the 
disease, such as Huntington’s or familial adenomatous polyposis. Presymptomatic 
testing for Huntington’s disease became available in the mid 1980s, shortly after the 
disease-associated gene was located.
4.1. Human rights and genetic counseling
Article 12 of the convention of human rights and biomedicine (Council of Europe, 1997) 
states that, “tests which are predictive of genetic diseases or which serve either to 
identify to subject as a carrier of a gene responsible for a disease or to detect a genetic 
predisposition or susceptibility to a disease may be performed only for health purposes 
or for scientific research linked to health purposes, and subject to appropriate genetic 
counseling”. This sentiment is repeated in the International Declaration on Human 
Genetic Data (UNESCO, 2003):
Article 11: Genetic counseling. It is ethically imperative that when genetic 
testing that may have significant implications for a person’s health is being 
considered, genetic counseling should be made available in an appropriate 
manner. Genetic counseling should be non-directive, culturally adapted and 
consistent with the best interest of the person concerned.
UNESCO, Paris, 2003.
Note that there is ambiguity in this definition: what ‘implications’ would be considered 
‘significant’? What exactly does ‘in an appropriate manner’ mean? Genetic counseling 
is a two-way communication between a counselor and a client, and may take place 
before and after genetic testing. Genetic counseling is defined in the Declaration as, “a
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procedure to explain the possible implications of the findings of genetic testing or 
screening, its advantages and risks and where applicable to assist the individual in the 
long-term handling of the consequences: it takes place before and after genetic testing 
and screening”. Genetic testing is the act of taking the test itself. Together, genetic 
testing and genetic counseling comprise the current clinical ‘genetic service’ (Wang et 
al, 2004). However, genetic counseling and genetic testing are not always offered 
together: genetic counseling does not always lead to genetic testing; genetic testing is not 
always preceded by genetic counseling (Wang et al, 2004).
The goals of genetic counseling have been defined as: 1) to educate and inform 
individuals of the genetic condition for which they may be at risk; 2) to provide support 
and help them cope (psychological, social e.g. support to families, referral to appropriate 
support services); and 3) to facilitate informed decision making about both testing and 
subsequent options (Wang et al, 2004). Outcomes that may be considered indicative of 
counseling ‘effectiveness’ include educational variables such as knowledge acquisition 
and risk comprehension, anxiety levels, reproductive decisions, decisions to undergo 
genetic testing and, more recently, adherence to breast cancer screening behaviours 
(Braithwaite et al, 2004; Wang et al, 2004). In comparison, the goals for genetic testing 
are poorly defined.
Genetic counseling is believed to be a crucial part of the genetic service for single-gene 
disorders, both before testing -  in order to aid the individual in deciding whether they 
want to take the test or not -  and after -  to help them to adjust to their new risk status. 
Genetic testing for Huntington’s disease for example is always accompanied by the 
availability of genetic testing, and it is possible that catastrophic effects of the test results 
have been limited by the protective effect of counseling (Marteau & Croyle, 1998). 
There is consensus about the fact that genetic tests for single-gene disorders should 
never be taken without the offer of genetic counseling, and it is generally accepted now 
that genetic testing even for single-gene disorders does not have a catastrophic 
psychological impact on the individual as long as counseling is part of the testing 
process (Marteau & Croyle, 1998; Lerman et al, 2002). The impact of genetic testing for 
single-gene disorders without genetic counseling is not known.
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5. Genetic testing for complex disease susceptibility: current tests for rare 
mutations
A handful of genetic tests are clinically available for complex diseases associated with 
rare genetic mutations, primarily the familial cancers. These tests can be defined as 
“genetic susceptibility tests”, i.e. predictive tests carried out for gene mutations that 
confer an increased risk but not a certainty of developing a disease. BRCA1/BRCA2 
testing accompanied by genetic counseling is now widely available in clinical settings 
across the UK and the US, and demand for tests from concerned women is almost 
overwhelmingly high in the UK (where testing is free at the point of delivery, unlike in 
the US). In both the UK and the US, genetic tests for BRCA1 and BRCA2 are also 
commercially available, and marketed direct to the public. Clinical genetic tests for 
hereditary non-polyposis colorectal cancer (HNPCC) are now also more widespread in 
clinical practice. An example of a genetic test which is in the process of moving from 
investigational status to clinical status, is the test for prostate cancer risk, which is 
currently performed only in the context of research investigations, but it is predicted that 
these tests will soon become clinically available.
5.1. Genetic counseling and risk-reducing strategies
As with single-gene disorders, there is general consensus that genetic testing for rare 
highly penetrant mutations associated with complex diseases should always be 
accompanied by the availability of genetic counseling. The main interventions available 
at the present time to reduce risk for breast and colon cancer in individuals who test 
positive, are rather severe and intrusive, such as prophylactic surgery (mastectomy or 
oophorectomy) for breast/ovarian cancer, or high levels of surveillance and regular 
removal of polyps for hereditary nonpolyposis colon cancer.
6. Genetic testing for common variants associated with complex disease 
susceptibility: new promises, pitfalls and challenges
Genetic tests for common variants are still in the research phase and are not yet available 
clinically via health care providers. A search of GeneTests for ‘cancer’ and ‘coronary’ 
and ‘heart’ (disease) exemplifies this. Clinical genetic tests are available from 
laboratories listed on GeneTests for the single-gene and highly penetrant forms of cancer
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and heart disease: BRCA1/BRCA2 hereditary breast/ovarian cancer, familial
adenomatous polyposis (FAP), hereditary nonpolyposis colon cancer (HNPCC), familial 
pancreatic cancer, hereditary diffuse gastric cancer, angiotensin I converting enzyme 1, 
angiotensin II receptor Type I, angiotensin, heart and hand syndrome (Holt-Oran 
Syndrome) and isolated nonsyndromic congenital heart disease. Research genetic tests 
are available, according to GeneTests, for esophageal cancer, familial thyroid cancer, 
lung cancer, prostate cancer, nasopharyngeal cancer, and premature coronary heart 
disease. Whereas the majority of the 700 or so clinical genetic tests are for single-gene 
disorders, many of the research genetic tests are for complex diseases, including many 
common genetic variants.
6.1. The promises: new risk-reducing strategies
The Advisory Committee on Genetic Testing (1998) listed four potential beneficial 
consequences of genetic testing for complex disease susceptibility:
1) greater understanding of disease mechanisms and increased possibility of 
separating broad disease categories into more specific groups, which may be 
relevant to therapeutic interventions
2) identification of genetic susceptibility to particular drugs could become important 
in drug choice and dosage
3) identifying genetic susceptibility to infectious diseases could be relevant in 
targeting immunization and related programmes
4) those identified as being at high risk for common chronic disorders could adjust 
their diet, lifestyle and other factors to reduce the risk of developing the disorder.
These four consequences can be collapsed into two main applications of genetic 
susceptibility testing. Firstly, disease susceptibility genes polymorphisms which provide 
information about risk may be used in diet, exercise, and lifestyle management, as well 
as medical interventions. Although not yet in clinical use, one of the main promises of 
the increasing discovery of common variants that affect risk for complex diseases, is that 
the information could be used in individualized preventive medicine or interventions -  
including diet, exercise, lifestyle, and pharmaceutical interventions -  to maximize the
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likelihood of staying well (Collins et al, 2003). It has been suggested that genetic tests 
for complex disease susceptibility may be used clinically in the future to identify and 
target people at increased risk of complex diseases (Bell, 1998; Day & Wilson, 2001), 
much in the way that risk factors such as blood pressure or cholesterol are used today 
(Department of Health, 2003). Secondly, pharmacogenetic profiles for polymorphisms 
in drug-metabolizing enzymes and drug target genes or abbreviated SNP profiling can be 
used to determine drug choices in the treatment or prevention of disease (Roses, 2000). 
The two applications have distinct ethical, legal and social implications, which are 
discussed in the following sections.
6.1.1. Pharmacogenomics
Allen Roses argues that the ELSI issues are more relevant in the case of disease genetics 
than for pharmacogenetics applications of genetic tests. Part of the reason for this is that 
pharmacogenetics is not, despite prior claims, going to be ‘personalised to the 
individual’. The physician, doctor, or health professional will simply have more 
information on which to base their choice of drug treatment for an individual. The key 
point is that the individual may not be informed, or desire to know, what their genotype 
is in this scenario. The alternative scenario, however, in which genetic tests are used to 
make lifestyle or medical changes, is much more dependant on how the individual 
interprets and responds to the genetic risk information. Many experts now believe that 
disease susceptibility gene polymorphisms which provide information about risk will 
become useful for pharmacogenomic applications before applications which consist of 
tailoring lifestyle advice to the individual (Roses, 2000; Goldstein et al, 2003). 
However, as will be discussed shortly, this has not prevented commercial companies 
utilising genetics information in precisely this way.
6.1.2. Lifestyle interventions
The view that finding complex disease genes raises the possibility of identifying 
individuals who are at high risk of developing disease in the future is, in fact, repeatedly 
reported in the literature (Bell, 1998; Bartsch, 1999; Whittemore & Nelson, 1999; Perera 
& Weinstein, 2000; Yang et al, 2000; Garte, 2001; Bouchardy et al, 2001; Mathew, 
2001; Peto, 2001; Pharoah et al, 2002; Austin, 2004; Balmain, Gray & Ponder, 2003; 
Yang et al, 2003; Wu et al, 2004). Specific examples include Ellsworth et al (1999) who
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stated that “a primary goal of genetic research on the epidemiology and pathophysiology 
of coronary heart disease is to identify persons or populations at increased risk so that 
action may be taken to reduce disease risk” and Houlston & Tomlinson (2000) who 
stated that, “the identification of common, moderate or low penetrance genes for cancer 
is potentially of great benefit, because it allows screening to be targeted to those at 
greatest risk”. In particular, as already mentioned, in 1998 the Advisory Committee on 
Genetic Testing wrote:
“One of the advantages of genetic susceptibility tests will be that they will allow 
people identified as ‘higher risk’ to make appropriate lifestyle changes in order to 
reduce their risk.” (ACGT, 1998)
In 1999, Francis Collins predicted that at least a dozen of these types of genetic tests 
would be in regular clinical use in this way by the year 2010. He presented a scenario in 
which John, a 23-year-old college graduate, undergoes genetic testing, on the advice of 
his physician, for a number of complex diseases, and is informed that he has a reduced 
risk of prostate cancer and Alzheimer’s disease, but an increased risk of coronary artery 
disease, colon cancer and lung cancer (see Box 2.1).
Box 2.1. A prediction for future genetic test results for complex diseases
Results of genetic testing in a hypothetical patient in 2010
Condition Hypothetical genes 
involved
Relative
risk
Lifetime 
risk (%)
Reduced risk
Prostate cancer HPC1, HPC2, HPC3 0.4 7%
Alzheimer’s disease APOE, FAD3, XAD 0.3 10%
Elevated risk
Coronary artery disease APOB, CETP 2.5 70%
Colon cancer FCC4, APC 4 23%
Lung cancer NAT2 6 40%
Source: Collins (1999)
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In Collins’ scenario, a pharmacogenomic drug regimen based on the knowledge of 
John’s personal genetic data can be precisely prescribed to reduce his cholesterol level 
and the risk of coronary artery disease to normal levels, and his risk of colon cancer is 
addressed with annual colonoscopy. He continues: “John is sobered by the evidence of 
his increased risks of contracting coronary artery disease, colon cancer and lung cancer. 
Confronted with the reality of his own genetic data, he arrives at that ‘teachable 
moment’ when a lifelong change in health-related behaviour, focused on reducing 
specific risks, is possible... His substantial risk of contracting lung cancer provides the 
key motivation for him to join a support group of persons at genetically high risk for 
serious complications of smoking, and he successfully kicks the habit” (Collins, 1999).
Many commentators are skeptical of this vision, and certainly people have become 
slightly more conservative in their estimation of the timescale and the number of years it 
will take for this type of scenario to become a reality. Nonetheless, a very similar 
scenario was presented more recently by the Department of Health in 2003 (see Box 
2.2). An important feature of this scenario is the implicit assumption that informing 
individuals of their increased susceptibility to disease will automatically motivate them 
to change and improve their behaviour.
6.1.3. Commercially available tests for common genetic variants
Despite reservations about the clinical uses of genetic tests for common variants at the 
present time, the fact is that, should they wish, doctors and consumers can already order 
personalized genomic profiles to promote healthy lifestyles or guide preventive care 
(Haga et al, 2003). A number of companies in the UK and the US offer genomic profiles 
direct to the public, such as Oxidative Stress Profile, Oxidative Stress for Skin Health 
and Ageing Profile, Obesity Susceptibility Profile, CardioGenomic Profile, 
DetoxiGenomic Profile, Immuno Genomic Profile, Tissue Repair Screen and Alcohol 
Metabolism Screen (see http://www.genovations.com. http://www.sciona.com and 
http://bankdna.com for more information). The combination of specific gene variants 
screened in these profiles is not always disclosed on their websites or advertisements. 
This lack of disclosure is important because the scientific and clinical data on which 
genomic profiling is currently based are questionable (Haga et al, 2003).
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The commercial sector claims that, because the implications of genetic testing for 
complex diseases are so much less severe than for monogenic diseases, counseling may 
not always be necessary. Whilst it is certainly true that the risks conferred by testing 
positive for a complex disease are small relative to presymptomatic tests for 
Huntington’s disease, there is still concern that these tests could cause psychological 
harm if people misinterpret the information being provided in the absence of adequate 
information or counseling. In response to the developments in the commercial sector, 
the UK Government’s independent advisory body on human genetics, the Human 
Genetics Commission (HGC), advised an overhaul of the regulation of genetic 
tests provided direct to the public in its document Genes Direct: Ensuring the Effective 
Oversight o f Genetic Tests Supplied Directly to the Public (HGC, 2003: 
www.hRc.gov.uk, accessed 25 April, 2005). The HGC recognizes that genetic testing is 
developing against a background which increasingly encourages people to take 
responsibility for their own health, and notes that public demand, coupled with 
commercial pressures, may lead to tests being offered direct to consumers before they 
are available clinically.
6.2. The pitfalls
These developments highlight how the question of what constitutes ‘accurate’ and 
‘useful’ is not as straightforward as it first seems. There is considerable ambiguity 
regarding the issue of when, and for what reasons, a genetic susceptibility test moves 
from ‘research’ through ‘investigational’ to ‘clinical’ status. In addition, in contrast to 
the consensus on diagnostic and presymptomatic genetic testing, there is debate and 
disagreement about whether susceptibility testing should always be accompanied by 
counseling, due in large part to uncertainty about the potential positive and negative 
psychological and behavioural effects of genetic testing for common variants.
In addition, the type of scenario presented by the Department of Health (Box 3.2) has 
been criticized by some lobby groups for raising unrealistic expectations 
(http://www.genewatch.org/publications/briefs/brief26.pdf. accessed 4 March, 2005), 
and others have agreed that it is too early to say whether ‘patients who have heart 
attacks’ would really be more motivated to take preventive action if they know they are 
at increased genetic risk for coronary heart disease; whether future genetic tests will add
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an appreciable degree of precision to current risk estimates based on biochemical or 
lifestyle factors; or even whether existing interventions will be of greater or lesser effect 
in genetically predisposed individuals (Stewart & Zimmem, 2003).
There is also considerable concern about the possibility of people perceiving genetic 
risks as definitive (Senior, Marteau & Peters, 1999). It is suggested that this ‘genetic 
exceptionalism’ or fatalism may impact on perceptions about the disease and subsequent 
health decisions through some individuals interpreting a positive test result as a ‘death 
sentence’, i.e. that the disease cannot be treated or prevented (Senior, Marteau & 
Weinman, 2000). Conversely, a negative result may be interpreted as a guarantee 
against developing the disease (Axworthy, Brock, Bobrow & Marteau, 1996; Hopwood, 
1997). It has been suggested that either interpretation could have a negative impact on 
adopting preventive behaviours.
In 2001, Marteau & Lerman interpreted the then current evidence to suggest that 
“providing people with DNA derived information about risks to their health does not 
increase motivation to change behaviour beyond that achieved with non-genetic 
information” and that “for some people genetic information may even reduce motivation 
to change behaviour” [p i058]. This is now a widely held belief, that “current data 
suggest little reason for optimism concerning the potential for genetic test results to 
motivate behavioural change” (Haga et al, 2003). The concerns that the results of 
susceptibility tests may be misinterpreted, causing undue psychological distress to some 
in the high risk group, and complacency or false beliefs that people are ‘safe’ from 
disease in the other, are particularly relevant in the case of genetic testing for complex 
diseases which are linked to smoking. Although smokers who receive personalized 
‘higher’ genetic risk information may be more motivated to quit smoking, they may also 
experience excessively high levels of fear and concern. Smokers who receive 
personalized Tower’ genetic risk information could become complacent and less 
motivated to quit smoking.
Another concern, stated by the Human Genetics Commission (2003), is that 
“misinterpreted or erroneous predictive health information which overstates the role of 
genetics in developing common diseases may result in delays in seeking proper medical 
advice (or seeking unnecessary medical treatment) or making expensive and unproven
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dietary or lifestyle changes” [p7]. Central to all of these issues is the fact that the 
clinical validity and utility of genetic tests for common gene variants has not yet been 
established.
Box 2.2. A prediction for the future use of genetic risk information 
Coronary heart disease
A patient today: Ali has a heart attack and is lucky to survive. After returning from 
hospital, his doctor explains that coronary heart disease (CHD), which can lead to 
heart attacks and strokes, is one of the commonest causes of premature death in the 
UK, but action can be taken to reduce the chances of another attack.
Ali is prescribed tablets for high blood pressure and high cholesterol. He resolves to 
try harder to lose weight, eat more healthily and take more exercise. Secretly, he 
wishes he had taken these things seriously before.
In the future: Primary care teams are able to identify people at genetic risk before 
they develop heart disease. When Ali moves house and registers at a new practice, 
the nurse uses a genetic test to assess his risk of CHD. Although Ali does not yet 
have any symptoms, and his blood pressure is normal, the test shows him to be at 
high risk because of his genetic make-up. Ali and his GP are then able to make 
more personalized decisions on lifestyle changes or drug therapy to reduce his 
likelihood of developing heart disease.
Source: D epartm en t o f  H ealth  (2003)
6.3. The challenges
6.3.1. Establishing clinical validity
The clinical validity, i.e. the accuracy with which a test predicts disease, of almost all 
genetic tests for common variants is uncertain at the present time (Haga et al, 2003). 
Many genetic tests have uncertain clinical validity because of limited and potentially 
biased study populations, low genotype penetrance, variable expressivity, lack of 
understanding of phenotyping modifiers and multiple or ambiguous clinical endpoints 
(Burke et al, 2002).
The clinical validity of testing for multiple common gene variants together (sometimes 
called ‘genomic profiles’) is particularly difficult to assess. In the case of ‘genomic 
profiles’ currently offered direct to the public, some laboratories have elected not to
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disclose which gene variants are included in their profiles, which means that it is not 
possible to evaluate the clinical validity of their tests (Haga et al, 2003).
The validity of these ‘genomic profiles’ will need to be based on well designed 
epidemiologic studies on genotype-disease associations and gene-gene and gene- 
environment interactions. To make sense of genotype-disease associations, 
epidemiologic methods and principles need to be applied to the design of such studies. 
These include a large sampling base for cases, representativeness of controls, adequate 
sample sizes and proper adjustment for population stratification and other forms of 
confounding, including assessment of gene-gene and gene-environment interaction 
(Khoury, 2002; Little et al, 2002). Replication of studies is also important: a gene- 
disease association should be validated across studies and should not be considered 
proven until is has been adequately replicated (Ioannidis et al, 2001; Hirschhom et al, 
2002).
A question that remains unanswered and largely unaddressed is, at what point of 
predictive power is a test deemed to be a ‘good predictor’ of clinical disorder? This 
question notwithstanding, recent studies have suggested that evaluating multiple variants 
concurrently (e.g. through the use of a panel of genetic tests) substantially increases the 
predictive value of the disease (Yang et al, 2003). Yang and colleagues showed that 
using a panel of genetic tests can substantially improve the ability to predict the risk of 
developing a multi factorial disease, compared with using just one test.
6.3.2. Establishing clinical utility
The clinical utility, i.e. the likelihood of improved health outcomes, of genetic tests for 
common variants is very poorly understood at the present time. Burke et al (2002) 
define clinical utility as ‘whether the clinical prediction enabled by the test is useful and 
valued by the patient’. But although the clinical utility of a test “will depend on the 
availability, safety and effectiveness of preventive or therapeutic measures offered to 
individuals with positive test results” (Haga et al, 2003: p348), this leaves considerable 
room for ambiguity in the case of genetic testing for complex disease. This is because 
there is no guidance as to what counts as a ‘useful’ and/or ‘valued’ application of the 
test. Does lifestyle change count as a valid and effective intervention?
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Whether a genetic test is ‘safe’ or not, is equally difficult to define. For example, 
determining the physical risks of genetic testing are minimal, because most genetic tests 
are performed on blood samples or cells obtained by swabbing the lining of the cheek 
(SACGT, 2000). But the risks of genetic testing for complex diseases are primarily 
social and psychological, which could indirectly or directly lead to physical or mental 
harm, not immediate physical risks. For example, ‘knowledge about disease risk may 
prove burdensome because of uncertainty about the efficacy of preventative measures 
are constantly changing, as occurs during controversies about dietary interventions or the 
use of hormone replacement therapy in preventing heart disease’ (SACGT, 2000).
Assessing and quantifying social and psychological harm is more complex and difficult 
than assessing physical harm. Haga et al (2003) propose that when a gene variant 
predicts greater risk that could be ameliorated through a change in lifestyle, three 
questions must be addressed to determine the clinical utility of the test:
(i) Will people with a positive test result make the indicated lifestyle changes 
that lead to improved health outcomes?
(ii) Will people with a negative test result have less motivation to pursue healthy 
lifestyles?
(iii) Are lifestyle recommendations dependant on the genotype information?
The last point refers to the proposition that, “if all would benefit from a healthy diet, 
exercise, smoking cessation or prudent alcohol intake, regardless of genotype, the added 
value of the test is unclear unless it can be shown to motivate compliance in those who 
test positive without reducing compliance in those who test negative”. As usual, Haga 
and colleagues, like others, rely on Theresa Marteau and Caryn Lerman’s B M Jreview of 
the available evidence as an indicator that “current data suggest little reason for 
optimism concerning the potential for genetic test results to motivate behavioural 
change” (Marteau & Lerman, 2001; Haga et al, 2003).
To confirm the utility of a test, carefully controlled trials need to be designed with 
definitive and measurable clinical endpoints (Gollust, Hull & Wilfond, 2002). Ideally, 
the endpoints measured in such trials would include subjective factors, such as sense of
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well-being, as well as conventional medical outcomes. Haga et al (2003) suggest that 
these types of studies would be longitudinal by nature and probably costly, and that 
because some of the products of recommended preventive strategies, such as greater 
intake of vitamins or supplements in the case of commercial ‘genomic profiles’, are not 
subject to regulatory review, the commercial incentive for conducting such studies may 
be low. They suggest that, even as more evidence accumulates, few genomic profiles 
are likely to be assessed in well designed randomized controlled trials [p349]. Rather 
than the collection of empirical data addressing these questions, they therefore propose 
‘consensus procedures’ used for evaluating preventive care (e.g. 
http:I/www.hta.nhsweb.nlis.uk) could be adapted to the evaluation of genomic profiling. 
Haga et al (2003) suggest that, in the absence of empirical data and randomized 
controlled trials, careful thought needs to be given to the level of evidence that justifies 
clinical use of genomic profiling, taking into account the strength of the observational 
data, the plausibility of clinical benefit and the potential for harm. Because, they say, 
‘experts may disagree in the evaluation of a particular body of evidence’, the public and 
the clinical community will be best served by a consensus process that incorporates well 
defined procedures for evaluating evidence and reaching conclusions and includes the 
participation of clinicians, health care payers and consumers (Haga et al, 2003). Table 
2.1 summarises some of the factors that contribute to the potential validity and utility of 
genetic tests for a range of conditions.
6.3.3. The collection of empirical data on clinical utility
Haga and colleagues may be hasty in their assumption that empirical data and 
appropriately randomized controlled trials either need not or will not be conducted to 
address the clinical utility of genetic testing for complex diseases. There is doubtless a 
major role for public participation and consensus procedures in developing policy 
around the regulation of these tests, but this should be complemented by empirical 
research in which the outcomes of such testing are evaluated both in terms of lifestyle 
change and psychological wellbeing. This is not going to be easy, given the limited 
clinical validity of these tests at the present time. However, some genetic variants have 
repeatedly been found to be associated with complex diseases, such as the modest but 
significant association between the GSTM1 null allele and lung cancer susceptibility,
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and empirical research may therefore be conducted, albeit cautiously, investigating the 
impact of informing individuals of their genotype for this type of common variants.
Ensuring the effective oversight and appropriate level of regulation for genetic tests, 
however, requires policy that takes account of the benefits and risks posed by each test 
in advance of it becoming clinically or commercially available. One of the main 
challenges set for researchers in the new millennium is “to investigate how genetic risk 
information is conveyed in clinical settings, how that information influences health 
strategies and behaviours, and how these affect health outcomes and costs” (Collins et al, 
2003: see Table 2.2). Health psychologists and health behaviour researchers are 
therefore ideally placed to play a central role in the evaluation of emergent genetic 
technologies (Patenaude, Guttmacher & Collins, 2002; Collins et al, 2003).
The debate on the future evaluation and regulation of genetic testing for complex 
diseases has been almost completely uninformed by empirical evidence on the harms 
and benefits of the tests, which whilst understandable given the remaining uncertainties 
over clinical validity, is regrettable. Genetic test evaluation undoubtedly poses new 
dilemmas for policy makers and researchers because the traditional criteria by which 
medical devices, technologies and pharmaceutical medicines are evaluated do not 
sufficiently encompass the outcomes relevant to genetic tests for complex diseases. 
There is an urgent need for impartial, empirical evidence on the possible impact of 
genetic testing for susceptibility using the types of genetic variations being used by the 
commercial companies. Only once this is achieved will there be real consensus on how 
genetic susceptibility tests should be evaluated and regulated. The challenge posed by 
genetic tests for complex diseases for researchers in the fields of psychology, public 
health, and health behaviour are (i) how to conduct empirical research on psychological 
aspects of genetic tests for gene variants of uncertain validity and predictive power and
(ii) how to evaluate genetic tests for complex disease susceptibility and collect 
meaningful and useful data in an ethically sound manner that protects the interests and 
wellbeing of research participants.
34
Chapter 2: Genetic testing
Table 2.1. Clinical validity, utility and related characteristics o f  selected adult-onset conditions and predictive genetic tests
Type of disease Penetrance of variant
Type of 
condition Type of test
Clinical
validity
Population
frequency
GeneTest
status
Risk-
reducing
strategies?
Consensus 
re value?
Clinical
utility
Huntington’s disease Complete,100%
Single­
gene,
Mendelian
Predictive,
presymptomatic High Low, rare Clinical No Yes Moderate
Familial
hypercholesterolemia
Complete,
100%
Single­
gene,
Mendelian
Predictive or 
diagnostic* High
Low, rare 
(1/500) Clinical Yes Yes
Moderate-
High
FAP colon cancer Complete,100%
Single­
gene,
Mendelian
Predictive,
presymptomatic High Low, rare Clinical Yes Yes
Moderate-
high
BRCA1/2 breast cancer
Incomplete, 
high, 35- 
85%
Complex Predictive,susceptibility Moderate Low, rare Clinical Yes Yes
Moderate-
high
HNPCC colon cancer Incomplete,high Complex
Predictive,
susceptibility
Moderate-
high Low, rare Clinical Yes Yes
Moderate-
High
APC prostate cancer Incomplete,high Complex
Predictive,
susceptibility
Moderate-
high Low, rare
Research-
clinical Yes Yes
Moderate-
High
Lung cancer Incomplete, low, 1-2% Complex
Predictive,
susceptibility Low
High (1/10 
smokers) Research Yes No Unknown
Cardiovascular
function
Incomplete,
low Complex
Predictive,
susceptibility Low High Research Yes No Unknown
‘Genomic profiling' of 
multiple health-related 
genetic variants
Incomplete,
low Complex
Predictive,
susceptibility Low High** Research*** Yes No Unknown
*depends on disease status of individual being tested. If individual is already showing symptoms, then diagnostic. If individual is asymptomatic, then 
presymptomatic.
**potentially high, actually depends on specific condition or combination of commen gene variants being tested.
***’Genomic profiles’ as such are not listed on GeneTests as the term refers to the testing of multiple genetic variations. However, each individual variation that 
they are testing for is listed on GeneTests (as far as is known on the available data), and these are all variants which are currently listed as ‘research’.
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Table 2.2. The “Grand Challenges” for future genomics research4
1. Genom ics to biology: Elucidating the structure and function o f genom es
Grand Challenge 
1-1
Comprehensively identify the structural and functional components encoded in the 
human genome
Grand Challenge 
1-2
Elucidate the organization of genetic networks and protein pathways and establish how 
they contribute to cellular and organismal phenotypes
Grand Challenge 
1-3
Develop a detailed understanding of the heritable variation in the human genome
Grand Challenge 
1-4
Understand evolutionary variation across species and the mechanisms underlying it
Grand Challenge 
1-5
Develop policy and options that facilitate the widespread use of genome information in 
both research and clinical settings
2. Genom ics to health: Translating genom e-based knowledge into health benefits
Grand Challenge 
II-1
Develop robust strategies for identifying the genetic contributions to disease and drug 
response
Grand Challenge 
II-2
Develop strategies to identify gene variants that contribute to good health and 
resistance to disease
Grand Challenge 
II-3
Develop genome-based approaches to prediction of disease susceptibility and drug 
response, early detection of illness, and molecular taxonomy of disease states
Grand Challenge 
II-4
Use new understanding of genes and pathways to develop powerful new therapeutic 
approaches to disease
Grand Challenge 
II-5
Investigate how genetic risk information is conveyed in clinical settings, how that 
information influences health strategies and behaviours, and how these affect health 
outcomes and costs
Grand Challenge 
II-6
Develop genome-based tools that improve health for all
3. Genom ics to society: Prom oting the use o f genom ics to m axim ize benefits and m inim ize harms
Grand Challenge 
III-l
Develop policy options for the uses of genomics in medical and non-medical settings
Grand Challenge 
III-2
Understand the relationships between genomics, race and ethnicity, and the 
consequences of uncovering these relationships
Grand Challenge 
III-3
Understand the consequences of uncovering the genomic contributions to human traits 
and behaviour
Grand Challenge 
III-4
Assess how to define the ethical boundaries for uses of genomics
4 Source: Collins, Green, Guttmacher, Guyer et al (2003)
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7. Evaluating the clinical utility of genetic tests for complex disease susceptibility: a 
framework that rises to the challenge
Despite the pessimistic views of some commentators, providing empirical data on the 
clinical utility of genetic tests for complex disease susceptibility, i.e. whether they lead 
to changes in lifestyle and psychological wellbeing, will be difficult, but certainly not 
impossible. It has been proposed that behavioural interventions should be rigorously 
evaluated using randomized controlled trials in the same way as pharmacological 
interventions (Friedli & King, 1998; Stephenson & Imrie, 1998), and the gold standard is 
to conduct randomized controlled trials in which the impact of genetic risk information 
is evaluated over time.
Some argue that the validity and predictive power of genetic tests for common variants 
is too uncertain and their empirical evaluation is premature. This must be overcome 
given the existing availability of genomic profiling direct to the public, which 
desperately needs sound empirical data to inform policy making about whether and to 
what extent regulatory decisions must be taken. Nonetheless, the concerns about the 
potential impact of the genetic risk information on the individual must be taken 
seriously, and a cautious framework is therefore needed within which to conduct 
empirical research in this field. One such framework that fits the bill was provided in a 
paper by the UK Medical Research Council (www.mrc.ac.uk/complex_packages.html). 
The guidelines are neatly summarized by Campbell et al (2000) in the British Medical 
Journal, in a paper titled, “Framework for design and evaluation of complex 
interventions to improve health”. The proposed framework is based on the premise that 
randomized controlled trials are the most widely accepted and most reliable method of 
determining the effectiveness of interventions to improve health, but that studies 
addressing more complex interventions than a single drug face particular challenges in 
implementing such an approach. Providing individuals with genetic risk information to 
improve their health is typical of a complex intervention, because the information is 
given within the context of an intervention design which is “made up of various 
interconnecting parts”. There are specific difficulties in defining, developing, 
documenting, and reproducing complex interventions, because they are subject to more 
variation than a drug. In the case of genetic susceptibility testing, there is considerable 
variation in the technical specificity and sensitivity of a genetic test itself.
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In addition to the characteristics of the genetic test itself, numerous additional factors 
may also influence the outcome. For example, a trial investigating the impact of genetic 
susceptibility testing on health behaviours needs to consider not only the technical 
aspects of the test, but also the expertise of the various health professionals 
implementing the intervention (e.g. what is an appropriate level of training?), the 
characteristics of the participants (is there variation in how individuals interpret genetic 
test results?), and the way in which the genetic risk information is presented (Should 
written feedback be given? Is it appropriate to provide the information through the 
post?). All these factors and more need to be taken into account, and this means that the 
design, development, interpretation, evaluation, and comparisons of interventions are 
complicated. In addition, great care must be taken to protect the interests and wellbeing 
of the individuals participating in the research.
Table 2.3. The five phases of the MRC framework for the design and evaluation of 
complex interventions to improve health
Preclinical 
(theoretical) phase
Includes a review of the theoretical basis for the intervention and of any 
relevant previous empirical evidence. The aim of this phase is to identify the 
evidence that the intervention might have the desired effect.
Phase I Uses preliminary surveys, qualitative interviews, focus groups, or case studies 
to: a) improve understanding of the components of the intervention and their 
interrelationships; b) help define the relevant components; and c) show how the 
intervention works and to find potential barriers to change in trials that seek to 
alter patient behaviour.
Phase II This is the ‘exploratory phase’, which aims to: a) test acceptability and 
feasibility for providers and patients; b) define outcome measures and other 
variables; c) using an appropriately controlled and randomized small, 
exploratory trial design.
Phase III Main randomized controlled trial.
Phase IV Examine the implementation of the intervention into practice, examining uptake, 
stability, broadening of subject groups, and adverse effects.
Source: Campbell et a (2000)
Campbell et al (2000) suggest that it is useful to consider the process of development 
and evaluation of such interventions as having several distinct phases. These can be 
compared with the sequential phases of drug development or may be seen as more 
iterative. Either way, a phased approach separates the different questions being asked.
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One of the advantages of this approach is that the identification of which stage of 
development has been reached in specifying the intervention and outcome measures 
gives researchers and funding bodies reasonable confidence that an appropriately 
designed and relevant study is being proposed. The five phases are outlined in Table
2.3. This phased, iterative approach provides precisely the cautious framework that is 
needed for the evaluation of emerging genetic susceptibility tests. In this thesis I shall 
describe how the first three phases of the framework were implemented to address the 
complicated psychological issues surrounding genetic susceptibility testing, and the 
implications of the work for future Phase III and IV research studies. The methods used 
were two quantitative surveys, pilot qualitative interviews, and an exploratory trial 
which employed a randomized and controlled approach.
8. Summary
Genetic tests are introduced into clinical practice when they are evaluated as being of 
high clinical validity (i.e. high association between gene and disease) and clinical utility 
(i.e. of value to the patient). Tests for common genetic variants are not at present 
deemed to be of sufficient validity or utility to be used clinically. However, unregulated 
tests for multiple common gene variants (‘genomic profiles’) are being marketed direct 
to health care professionals and the public via commercial companies and the internet. 
There is consensus that genetic tests for mutations of complete or high penetrance should 
always be regulated and accompanied by genetic counseling, but debate and 
disagreement about the extent to which regulation and genetic counseling should be 
insisted upon for multiple genetic tests for common variants of low penetrance, or 
genomic profiles. The question of whether genetic testing leads to changes in 
motivation to engage in healthy behaviours and lifestyles is particularly important as this 
is the claim most often used to justify the introduction of genomic profiles. Health 
psychologists and health behaviour researchers therefore have a central role to play in 
evaluating the clinical utility of these genetic tests, and the MRC phased framework for 
designing and evaluating complex interventions provides a useful framework within 
which to conduct this empirical research. In the next chapter I shall consider the 
evidence on psychological issues around genetic testing as these issues play an important 
but controversial role in determining the potential utility of genetic tests.
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CHAPTER 3 
Psychological issues raised by genetic testing
1. Overview
The first psychological questions that have always been addressed for each new type of 
genetic test have been, what is the degree o f interest in genetic testing amongst the relevant 
groups, and what factors influence whether individuals decide to have a genetic test? 
(Salkovskis & Rimes, 1997; Croyle, Achilles & Lerman, 1997; Hop wood, 1997; Bowen, 
Patenaude & Vernon, 1999; Evers-Kiebooms et al, 2000; Holtzman & Marteau, 2000; 
Lerman, Croyle, Tercyak & Hamann, 2002; Patenaude, Guttmacher & Collins, 2002). The 
second question that has been relevant to most emergent types of genetic test has been, 
what is the psychological impact o f genetic testing? (Croyle, Achilles & Lerman, 1997; 
Evers-Kiebooms et al, 2000; Lerman, Croyle, Tercyak & Hamann, 2002). A third question 
that has become more relevant with the advent of genetic susceptibility test for adult-onset 
complex diseases is, what is the impact o f genetic testing on health-related behaviour? 
(Croyle, Achilles & Lerman, 1997; Marteau, 1999; Marteau & Lerman, 2001; Lerman, 
Croyle, Tercyak & Hamann, 2002). The specific issues addressed in the psychological 
literature have evolved alongside the advances in genetics research and advances in 
biotechnology: since prenatal testing and carrier testing were among the first genetic tests 
offered clinically, early psychological research focused more on decision making in the 
reproductive area; as genetic testing is increasingly applied to detect personal susceptibility 
to disease, psychological research efforts are increasingly focusing on the behavioural 
impact in terms of the potential for implementing individual risk-reducing strategies 
(Lerman, Croyle, Tercyak & Hamann, 2002).
In this chapter, I review the literature addressing each of these questions (interest in genetic 
testing, psychological impact of genetic testing, and behavioural impact of genetic testing), 
concerning predictive genetic testing for adult-onset disorders. It is impossible to provide 
an exhaustive review of this vast literature (Lerman, Croyle, Tercyak & Hamnan, 2002),
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and so for each section I focus on the area of the literature that sheds most light on the 
question, including evidence from complex diseases associated with rare genetic mutations 
of complete or high penetrance, complex diseases associated with common genetic variants 
of low penetrance, and occasionally single-gene disorders. In Section 2 the evidence on 
interest in genetic testing is considered, focusing on examples in Huntington’s disease and 
cancer. In Section 3, the psychological impact of genetic testing is examined using 
examples from Huntington’s disease and the familial cancers (breast-ovarian, FAP, and 
HNPCC). Section 4 examines the literature on the behavioural impact of genetic testing. 
This literature covers the limited evidence from the clinical experience to date with breast 
and ovarian cancer and HNPCC, and the emergent area of research looking at the 
behavioural impact of genetic testing for common genetic variants and complex diseases, 
including two randomised controlled trials examining variants associated with lung cancer, 
observational and analogue studies for a range of conditions, including obesity, heart 
disease, and nicotine addiction, and the recent experience with familial 
hypercholesterolemia (FH). FH is included here because, although it is strictly speaking an 
autosomal dominant disease, the association between FH and actual coronary heart disease 
is incomplete, and the risk of disease can be reduced with behavioural interventions 
including medication and lifestyle changes. Finally, I address the outstanding research 
needs and define my research questions.
2. Interest in genetic testing
2.1. Single-gene disorders: Huntington’s disease
Although Huntington’s disease is a single-gene disorder and the genetic test is therefore a 
presymptomatic test rather than a susceptibility test, it is nonetheless useful to consider the 
experience with genetic testing for Huntington’s, because it was the first genetic test to 
become available which gave adults information about their risk of developing a disease in 
the future. Since 1986, presymptomatic DNA testing using genetic linkage analysis has 
made it possible for risk carriers to have their risk modified to approximately 98% or 2%. 
After identification of the HD mutation in 1993, CAG repeat size analysis of the 
Huntington gene allowed complete certainty of either having or not having Huntington’s
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disease in the future (Huntington’s Disease Collaborative Research Group, 1993). The 
tests for Huntington’s disease are an example of genetic testing where the clinical validity 
of the test is extremely high (i.e. the genetic mutation is completely predictive of the 
disease) but the clinical utility is low or non-existent because there are no risk-reducing 
strategies available. The test may still fulfil the criterion for clinical utility however, if at- 
risk individuals want the test available to them, and if at least some of them find the risk 
information of value, despite the lack of interventions available.
In studies conducted before Huntington’s disease genetic testing was widely available, 
between 50% and 80% of surveyed at-risk individuals expressed interest in Huntington’s 
disease testing (Mastromauro et al, 1987; Babul et al, 1993). However, subsequent 
research on test uptake revealed significant discrepancies between genetic-testing 
intentions and actual decision making (Salkovskis & Rimes, 1997). The proportion of 
tested individuals was much smaller than expected based on intentions and attitudes before 
the availability of the test, with actual uptake rates varying between 5% and 20% (Crauford 
et al, 1989; Quaid & Morris, 1993; Evers-Kiebooms, Welkenhuysen, Claes, Decruyenaere 
& Denayer, 2000). For example, in one early study (Crauford et al, 1989), 110 adults at 
risk of Huntington’s disease were offered genetic testing and a further 91 individuals 
spontaneously sought testing. Although acceptance rates were high (87%) amongst the 
individuals who spontaneously sought testing, only 16% of the 110 invited to consider 
genetic testing accepted the offer; many expressed an interest in testing, then withdrew. 
These findings may suggest that individuals are more interested in a potentially available 
predictive test than one that is immediately available (Lerman, Croyle, Tercyak & Hamann, 
2002).
The evidence suggests that demographic variables play little part in the decision of whether 
to be tested for Huntington’s disease or not (Evers-Kiebooms, Welkenhuysen et al, 2000). 
Perceived susceptibility and particularly perceived severity are also rather similar in tested 
and untested individuals (Evers-Kiebooms & Decruyenaere, 1998). The most cited reasons 
for undergoing Huntington’s disease genetic testing are reducing uncertainty and making 
decisions for the future (Tibben et al, 1997; Lerman, Croyle, Tercyak & Hamann, 2002).
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In addition, personality profile and individual coping styles seem to be factors in the 
decision to be tested (Decruyenaere et al, 1996).
The literature on Huntington’s disease has particularly highlighted the importance of 
psychological “robustness” in determining whether or not people choose to put themselves 
forward for genetic testing. In one early study, test acceptors were less likely to endorse 
concerns about emotional reactions than those who had chosen not to be tested (Codori, 
Hanson & Brandt, 1994). In another study, test decliners reported a more pessimistic 
outlook for the future and higher levels of depression prior to counselling than those in the 
tested group (van der Steenstraten, Tibben et al, 1994). They were also more likely to 
expect to be carriers and anticipated more negative effects from a positive result.
Several additional studies have also provided evidence that people who choose to be tested 
have psychological characteristics that predict a more favourable response to genetic 
testing. Psychometric testing in a pre-test period (Decruyenaere, Evers-Kiebooms, 
Boogaerts et al, 1995) indicated that test participants were a self-selected group with a 
higher ego strength and with significantly better coping strategies than the general 
population. People who anticipated feeling depressed or reported being at risk of suicide 
should the result be positive were less likely to want to test (Mastromauro et al, 1987; 
Evers-Kieboom, Swerts, Cassiman & Van Den Berghe, 1989). The most commonly 
reported reasons for choosing not to have the test also related to the psychological 
consequences of a positive test result (Babul et al, 1993), such as anticipating being unable 
to cope with a bad result (Decruyenaere, Evers-Kiebooms, Boogaerst, Cloostermans et al, 
1997). Studies of the interest of lay people in the general public about predictive genetic 
testing or any other late onset neurodegenerative diseases are scarce. It is tempting to 
conclude from the collective findings amongst individuals at-risk for Huntington’s disease 
that there is a strong tendency for people to self-select themselves in or out of testing for 
mutations of complete penetrance depending on their ability to cope, regardless of the test 
result itself.
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2.2. Complex diseases: cancer
Surveys of individuals identified as high-risk on the basis of their either having had cancer 
themselves or having a first degree relative with cancer, have tended to find high levels of 
interest in genetic testing, typically around 80% -90% (Struewing et al, 1995; Lerman et al, 
1996; Petersen et al, 1999). For example, 87% of African-American men from the African 
American Hereditary Prostate Cancer Study and the South Carolina Prostate Cancer 
Education and Screening Study indicated interest in genetic testing for prostate cancer 
susceptibility (Weinrich et al, 2002).
In the case of breast cancer, after the BRCA1 gene had been identified, but before clinical 
genetic testing for the gene had been introduced, Struewing, Lerman, Rase, Giambarresi 
and Tucker (1995) studied anticipated uptake of, or interest in, testing for mutations in this 
gene in members of high-risk families. They also looked at anticipated reactions. They 
surveyed 91 female and 49 male subjects using a structured interview by study nurses. All 
subjects were members of inherited breast-ovarian cancer families participating in a genetic 
linkage study at the National Cancer Institute in the US. 79% of subjects indicated that 
they would “definitely” want to be tested, and 16% would “probably” want to be tested for 
mutations in the BRCA1 gene. Subjects with a high self-perceived risk of having an 
altered BRCA1 gene were more likely to want testing, while estimated true genetic risk did 
not predict interest in the test. Women were significantly more likely to want testing, but 
also had a significantly greater mean anticipated negative-impact score compared to men.
Initial studies have indicated that actual uptake of genetic testing for cancer susceptibility 
has been higher than in the case of Huntington’s disease, although not as high as predicted 
based on studies of interest in testing (Bowen, Patenaude & Vernon, 1999). Studies which 
examine actual uptake of genetic testing for cancer susceptibility typically report uptake 
amongst high-risk individuals to be around 40%. For example, uptake rates amongst 
members of hereditary breast cancer families have been reported to be 43% (Lerman et al, 
1996) and 36% (Geller et al, 1999), and similarly 43% amongst members of hereditary 
colon cancer families (Lerman et al, 1999).
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Because of the widening availability of genetic tests, surveys have also been conducted 
which have examined interest in genetic testing amongst general populations. These 
studies have also reported high levels of interest in genetic testing. For example, in one 
random digit-dialling survey in the US, 83% said they would be “somewhat” or “very” 
interested in predictive genetic testing for colon cancer (Croyle & Lerman, 1993); in 
another, 87% expressed interest in genetic testing for general cancer susceptibility and 93% 
of women expressed interest in genetic testing for breast cancer susceptibility 
(Andrykowski et al, 1996). Interest in genetic testing for prostate cancer susceptibility was 
similarly high amongst African-American male patients at a University Health Service in 
Chicago who did not have a personal history of prostate cancer (Myers et al, 2000).
One of the advantages of population-based surveys of interest in genetic testing is that they 
allow the demographic characteristics of interested and non-interested persons to be 
examined, away from the clinical, high-risk context. It will increasingly be important to 
understand these factors, as genetic tests become available commercially to members of the 
general public. In particular, differences between socioeconomic groups need to be 
addressed to ensure that genetic test availability does not contribute to existing inequalities 
in health. If genetic tests that are commercially available cause psychological harm, it is 
important that people with lower levels of education are not more susceptible to 
unscrupulous marketing of the tests. On the other hand, if such tests prove to be helpful in 
improving health outcomes, then a social gradient in uptake, with lower socioeconomic 
groups having lower uptake, could contribute to existing social inequalities further.
Studies have tended to find that people with higher levels of education and income are 
more likely to express interest in genetic testing or attend genetic counselling for breast 
cancer (Lerman et al, 1996; Geller et al, 1999) and colon cancer (Glanz et al, 1999; Lerman 
et al, 1999; Vernon et al, 1999), with the exception of one study in prostate cancer, in 
which there was no association between education and interest in genetic testing (Weinrich 
et al, 2002). In the US, having health insurance has also been associated with higher 
interest (Lerman et al, 1996), which is obviously likely to be linked to income. All of these 
studies have been conducted in the US and, given the differences between the US and the
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UK in terms of health care provision, as well as other cultural differences, it is necessary to 
determine whether the same relationship between education and interest will be found in 
the UK.
In addition to socioeconomic status, other demographic variables which have been 
examined have been gender, age, ethnicity and marital status, although not to the same 
extent. In one study the only significant demographic predictor of interest was marital 
status, with married men being significantly more likely to express interest in genetic 
testing for prostate cancer than unmarried men (Weinrich et al, 2002). Glanz et al (1999) 
found that interest in genetic counselling amongst first-degree relatives of colorectal 
patients was associated with Hawaiian ethnicity, and that interest to undergo genetic testing 
was also associated with Japanese ethnicity. On the other hand, another study found that 
interest in learning about or undergoing genetic testing for prostate cancer did not vary by 
race (Miesfeldt et al, 2000). There is also uncertainty regarding the effect of age on interest 
in genetic testing. Older men have been reported to have higher levels of interest in genetic 
testing for prostate cancer than younger men in some studies (Myers et al, 2000), but not in 
others. Weinrich et al (2002) for example, found no association between age and interest in 
genetic testing for prostate cancer.
There has been slightly more consensus with regard to the effects of gender on interest. 
Women have generally been found to be more likely to express interest in genetic testing 
for breast cancer than men (Struewing et al, 1995; Lerman et al, 1996) for obvious reasons, 
but they have also been more likely to express interest in genetic testing for Huntington’s 
disease (Tibben et al, 1993; Holloway et al, 1994). This has been linked to the fact that 
women are often more knowledgeable about health threats than men, and that men cope 
with adverse information about their health in a more avoidant manner women (Marteau, 
Dundas & Axworthy, 1997). It is also possible that women take more interest in genetics 
because of their heightened perceived investment in their offspring (Richards, 1996). 
However, few studies of interest in genetic testing for colon cancer have reported gender 
differences, and there is a need for further clarification of gender differences in interest, 
especially with regard to other diseases that may be perceived as more ‘male’, such as heart
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disease. There is no clear pattern at the present time in terms of the association between 
interest in genetic testing for cancer susceptibility and demographic characteristics (see 
Table 3.1 for examples of studies reporting positive, negative, or no associations between 
demographics and interest). Another clear caveat is that, even when there is consensus, 
such as that for gender, none of the representative population-based surveys have been 
conducted in the UK.
In order to examine the effect of family history, some studies have specifically compared 
women selected for having or not having a family history of breast cancer. In one study, 
levels of interest in genetic testing were 90% and 74% respectively (Lipkus et al, 1999). In 
another study, 72% of women diagnosed with breast cancer were interested in genetic 
testing compared with 46% overall including general population women (Cappelli et al, 
1999). Similarly, 68% of women with at least one blood relative with breast cancer were 
interested in genetic testing compared to 45% of women (Cappelli et al, 2001). Some 
prostate cancer studies have failed to find any association between family history and 
interest in genetic testing (Miesfeldt et al, 2000; Weinrich et al, 2002). These findings 
suggest that, although family history is a predictor of interest in genetic testing, the 
association is not as strong as might be expected. Far stronger is the association between 
perceived risk, rather than ‘objective’ risk (Lerman, Croyle, Tercyak & Hamann, 2002).
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Table 3.1. Socio-demographic correlates of interest in genetic testing for susceptibility to
cancer
Socio-demographic variable Cancer type Association Study
Female gender
Non-specific 0 Andrykowski et al, 1996
Breast + Lerman et al, 1996
Breast + Struewing et al, 1995
Older age
Non-specific 0 Andrykowski et al, 1996
Breast - Armstrong et al, 2002
Breast - Tamboretal, 1997
Breast 0 Andrykowski et al, 1996
Colon + Glanz et al, 1999
Prostate - Myers et al, 2000
Prostate 0 Weinrich et al, 2002
Education
Non-specific - Bosompra et al, 2000
Non-specific + Andrykowski et al, 1996
Breast + Geller et al, 1999
Breast + Tamboretal, 1997
Breast + Lerman et al, 1996
Breast + Andrykowski et al, 1996
Colon + Glanz et al, 1999
Colon + Lerman et al, 1999
Prostate - Weinrich et al, 2002
Income
Non-specific 0 Andrykowski et al, 1996
Non-specific 0 Bosompra et al, 2000
Breast 0 Andrykowski et al, 1996
Colon + Vernon et al, 1999
Colon + Smith & Croyle, 1995
Non-white ethnicity
Non-specific 0 Andrykowski et al, 1996
Breast - Andrykowski et al, 1996
Breast - Tambor et al, 1997
Prostate 0 Miesfeldt et al, 2000
Being married
Prostate + Weinrich et al, 2002
Personal history o f cancer Breast + Lerman et al, 1999
Breast + Cappelli et al, 1999
Family history o f cancer
Non-specific + Bosompra et al, 2000
Breast + Lipkus et al, 1999
Breast + Cappelli et al, 2001
Breast - Armstrong et al, 2002
Breast - Welkenhuysen et al, 2001
Colon + Petersen et al, 1999
Prostate 0 Weinrich et al, 2002
Prostate 0 Miesfeldt et al, 2000
+ positive association; - negative association; 0 no association
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Perceived risk, or perceived susceptibility, has received a lot of attention in the literature, 
and has been found to be strongly associated with interest in genetic testing for both breast 
cancer (Struewing et al, 1995; Lipkus et al, 1999; Durfy et al, 1999; Geller et al, 1999; 
Cappelli et al, 2001) and colon cancer (Croyle & Lerman, 1993; Smith & Croyle, 1995; 
Codori et al, 1999; Glanz et al, 1999). As mentioned above, the association between 
perceived risk and interest is often stronger than that between actual high risk status 
(determined by family history and own history).
This fits with social cognition models of behavioural intentions, such as the health belief 
model (HBM: Rosenstock, 1974), which state that perceived susceptibility to a disease is 
one of the predictors of engaging in a behaviour believed to reduce risk of developing that 
disease. A number of studies have examined the relationship between other social 
cognition model variables and interest in testing, and used these models as frameworks for 
the design of their surveys. For example, a number of studies have found that interest is 
associated with other components of the HBM, primarily perceived benefits and barriers to 
engaging in testing: greater perceived benefits of testing (Cappelli et al, 1999; Vernon et al, 
1999; Cappelli et al, 2001); fewer perceived barriers or ‘costs’ either or testing or of 
learning of results (Cappelli et al, 1999; Vernon et al, 1999; Cappelli et al, 2001); 
perceiving more disadvantages of not getting tested and more advantages of getting tested 
(Helmes, 2002); and believing that genetic counselling is too much trouble relative to the 
benefits (Vernon et al, 1999), have all been found to be associated with interest. In 
addition, attitudes and subjective norms as defined by the theory of planned behaviour 
(TPB: Ajzen, 1985) have also been found to correlate with interest in genetic testing 
(Braithwaite et al, 2002). Similarly, some studies report that people are motivated by their 
beliefs and concerns regarding the health of their families, which fit with the anticipated 
outcomes construct of Bandura’s social cognitive theory (Bandura, 1977; 1986) and the 
health action process approach (HAPA: Schwarzer, 1992). For example, increased interest 
in genetic testing has been associated with: believing that regular mammograms could 
benefit family members (Tambor et al, 1997); concern about the risk of relatives 
developing breast cancer (Cappelli et al, 1999); believing that being tested will help family 
members prevent cancer (Cappelli et al, 1999); perceiving advantages of informing
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relatives about test results (Vernon et al, 1999); and obtaining information about the risk 
for offspring (Esplen et al, 2001). Perceived control has also been associated with interest, 
in that being fatalistic about prostate cancer prevention has been negatively associated with 
intention to have genetic testing (Myers et al, 2000). As with Huntington’s disease, these 
studies suggest that the relationship between interest and anticipated outcomes or reactions 
might warrant further investigation in the general population.
There is therefore strong evidence to support that social cognition model (SCM) variables 
such as perceived susceptibility and benefits and barriers to testing are associated with 
interest (see first part of Table 3.2). However, Braithwaite et al (2002) recently showed 
that attitude toward uncertainty, as in Huntington’s disease, was a stronger predictor of 
intention to undergo genetic testing for colon cancer and breast cancer than the variables 
that were included based on the theory of planned behaviour (see second part of Table 3.2). 
In addition, Geller et al (1999) reported that the reasons for attending genetic counselling 
and testing for breast cancer that were rated as “very important” were to learn about the test 
(80%), to have the test (43%), and to help research (38%).
In this study, an altruistic desire to help research was in fact a greater motivation for 
participation in this research than interest in being tested.
One particularly interesting area of investigation that has recently been examined, is that of 
understanding of genetic testing. Investigators have started to suspect that people may be 
motivated to undergo genetic testing by a misunderstanding of what it is exactly that 
genetic testing can offer. Some authors have noted that there has been a high level of 
confusion between cancer susceptibility testing and cancer screening amongst respondents 
to their surveys (Weinrich et al, 2002), while another study reported that a significant 
proportion (28%) of their respondents failed to demonstrate an adequate understanding of 
the concept of ‘inherited tendency’ (Miesfeldt et al, 2000). Although in the second of these 
studies an interest in learning about or undergoing genetic testing did not vary by 
demonstrated understanding of the concept of inherited risk, it may be that the discrepancy 
between anticipated interest and actual uptake can be accounted for at least in part by a
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diminishing interest as people learn more about the limitations and realities of the uncertain 
information that genetic tests provide. These findings suggest that understanding of genetic 
testing may be a particularly important area for future research, especially as genetic tests 
move out of the clinical field and into the general population where there is less structured 
information provided. These findings also suggest that it would be interesting to 
investigate whether attempts to influence understanding of genetic testing by, for example, 
including written information materials with surveys, affect interest.
Finally, whereas disease-specific distress appears to deter genetic testing for Huntington’s 
disease (van der Steenstraten et al, 1994), studies suggest that cancer worries and cancer- 
specific distress may motivate cancer genetic test use. In studies of genetic testing for 
cancer susceptibility, worry about the disease or about carrying an altered gene is often 
positively associated with interest (Lerman et al, 1997; Lipkus et al, 1999; Durfy et al, 
1999; Vernon et al, 1999; Glanz et al, 1999; Helmes, 2002) and again, the extent to which 
an individual is worried or concerned is often more predictive of their interest in testing 
than their actual risk status. This is not surprising when one considers that there are no 
options available for preventing or treating Huntington’s disease, while the potential for 
cancer risk reduction exists, albeit often involving drastic measures such as prophylactic 
surgery. On the other hand, general distress appears to reduce the likelihood of testing for 
cancer susceptibility. In the case of colon cancer, the presence of global depressive 
symptoms has been associated with lower rates of genetic test use, particularly among 
females (Lerman et al, 1999), and having lower perceived confidence in the ability to cope 
with unfavourable genetic information has been associated with lower interest and uptake 
(Codori et al, 1999). This suggests that even when risk reduction is possible, global 
distress symptoms may promote feelings of fatalism that prevent engagement with genetic 
testing (Lerman, Croyle, Tercyak & Hamann, 2002).
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Table 3.2. Psychological correlates of interest in genetic testing for cancer susceptibility
Psychological variable Cancer type Association Study
Perceived susceptibility Breast + Struewing et al, 1995
Breast + Lipkus et al, 1999
Breast + Durfy et al, 1999
Breast + Geller et al, 1999
Breast + Cappelli et al, 2001
Breast + Helmes et al, 2002
Colon + Croyle & Lerman, 1993
Colon + Smith & Croyle, 1995
Colon + Glanz et al, 1999
Colon + Codori et al, 1999
Colon + Myers et al, 1998
Prostate - Myers et al, 2000
Cancer-specific worry
Non-specific 0 Andrykowski et al, 1996
Breast 0 Andrykowski et al, 1996
Breast + Lerman et al, 1997
Breast + Lipkus et al, 1999
Breast + Durfy et al, 1999
Breast + Helmes et al, 2002
Colon + Glanz et al, 1999
Colon + Codori et al, 1999
Colon + Vemon et al, 1999
Perceived benefits o f testing
Non-specific + Bosompra et al, 2000
Breast + Tambor et al, 1997
Breast + Cappelli et al, 1999
Breast + Cappelli et al, 2001
Breast + Helmes et al, 2002
Colon + Vemon et al, 1999
Perceived barriers to testing
Non-specific - Bosompra et al, 2000
Breast - Cappelli et al, 1999
Breast - Cappelli et al, 2001
Breast - Helmes, 2002
Colon - Vemon et al, 1999
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Psychological variable Cancer type Association Study
Knowledge of genetic testing
Breast + Lerman et al, 1997
Attitude/decreasing uncertainty
Breast + Braithwaite et al, 2002
Colon + Braithwaite et al, 2002
Colon + Esplen et al, 1999
Depression/pessimism
Non-specific + Bosompra et al, 2000
Non-specific 0 Andrykowski et al, 1996
Breast 0 Andrykowski et al, 1996
Colon + Lerman et al, 1999
Colon 0 Croyle & Lerman, 1993
Ability to cope with result
Colon + Codori et al, 1999
Colon + Vemon et al, 1999
Belief that useful for relatives
Colon + Vemon et al, 1999
Colon + Esplen et al, 2001
Understanding o f genetic risks
Non-specific 0 Andrykowski et al, 1996
Breast 0 Andrykowski et al, 1996
Prostate 0 Miesfeldt et al, 2000
Engaging in other health behaviours
Non-specific + Andrykowski et al, 1996
Breast + Andrykowski et al, 1996
Colon + Myers et al, 1998
Prostate - Myers et al, 2000
Question framing
Colon 0 Croyle &  Lerman, 1993
+ positive association; - negative association; 0 no association 
Highlighted studies are those in which two diseases were examined at once.
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2.3. Interest: summary and critique
The literature on interest and Huntington’s disease suggests three main things. First, actual 
uptake of genetic testing is invariably lower at around 10% than initial surveys of interest 
amongst high-risk individuals predict, initial stated interest being around 80% 
(Mastromauro et al, 1987; Crauford et al, 1989; Salkovskis & Rimes, 1997; Lerman, 
Croyle, Tercyak & Hamann, 2002). Second, demographic variables and perceived 
susceptibility and severity are poor predictors of interest, whilst the most cited reasons for 
interest are reduction of uncertainty and planning for the future (Tibben et al, 1997; Evers- 
Kieboom & Decruyenaere, 1998; Evers-Kieboom, Welkenhuysen et al, 2000; Lerman, 
Croyle, Tercyak & Hamann, 2002). Third, there is a strong tendency for people to self­
select themselves out of testing depending on their beliefs about anticipated outcomes, 
global distress, and disease-specific distress (Codori, Hanson & Brandt, 1994; van der 
Steenstraten, Tibben et al, 1994; Mastromauro et al, 1987; Evers-Kieboom, Swerts et al, 
1989; Decruyenaere, Evers-Kieboom, Boogaerst, Cloostermans et al, 1997).
The evidence from the clinical cancer genetics literature also suggests a discrepancy 
between initial interest and actual uptake, although actual uptake is higher for familial 
cancers than it is for Huntington’s disease; interest amongst high risk families is usually 
around 80% and actual uptake around 40% (Struewing et al, 1995; Lerman et al, 1996; 
Petersen et al, 1999; Geller et al, 1999; Lerman et al, 1999; Bowen, Patenaude & Vemon, 
1999). Most of the literature has focused on clinical, high-risk samples, but there have 
been some surveys of interest in genetic testing for cancer susceptibility in the general 
population, and these have found high levels of interest too, typically ranging between 50- 
80% (Croyle & Lerman, 1993; Andrykowski et al, 1996; Myers et al, 2000). Part of the 
discrepancy between initial interest and ultimate uptake may be attributable in part to a 
poor initial understanding of what genetic testing is (Miesfeldt et al, 2000; Weinrich et al, 
2002).
Demographic factors have been more important correlates of interest in the cancer genetics 
literature than the Huntington’s disease literature; interest and uptake of genetic testing for 
cancer susceptibility have been higher amongst women and people with higher levels of
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education, whilst the association with age has been inconsistent (Struewing et al, 1995; 
Lerman et al, 1996a; Lerman et al, 1996b; Glanz et al, 1999; Lerman et al, 1999; Vemon et 
al, 1999; Myers et al, 2000; Weinrich et al, 2002). People with a family history of cancer 
have higher levels of interest than those without, but the association is not particularly 
strong, and perceived, rather than objective, risk is a far stronger predictor of interest than 
family history (Lipkus et al, 1999; Cappelli et al, 1999; Cappelli et al, 2001; Struewing et 
al, 1995; Geller et al, 1999; Codori et al, 1999; Glanz et al, 1999; Lerman, Croyle, Tercyak 
& Hamann, 2002). Global distress and pessimism reduce interest (Lerman et al, 1999; 
Codori et al, 1999), but unlike in Huntington’s, disease-specific distress increases rather 
than decreases interest in genetic testing for cancer susceptibility (Lerman et al, 1997; 
Lipkus et al, 1999; Durfy et al, 1999; Vemon et al, 1999; Glanz et al, 1999; Helmes, 2002).
Although there is consensus on some of the correlates of interest, there still remains much 
doubt, such as the relationship with age. Part of this is due to a wide range of 
methodologies being employed, and a wide range of study populations. Methodologies 
include surveys of interest amongst high-risk populations, surveys of interest amongst the 
general population, comparisons of interest between high-risk and general-risk populations, 
and actual uptake amongst high-risk populations (see Table 3.3 for examples 
of studies employing each approach). Bowen, Patenaude and Vemon (1999) discuss this in 
terms of the composition of the study populations showing considerable variation in cancer 
risk; investigators have studied patients with cancer, individuals with strong family 
histories, first degree relatives of cancer patients, invitees to a high-risk clinic, and groups 
recruited from the general population. Also, data collection methods have included mailed 
surveys, telephone surveys, interviews, and self-administered questionnaire surveys. 
Although the sources of recruitment have been diverse, the overwhelming focus of studies 
on higher risk populations is a reflection of the fact that genetic testing has primarily been 
offered within the clinical context to date. As genetic tests move into the wider social 
sphere, there is a need to better understand the determinants of interest in the general 
population. There is also a lack of evidence on any complex diseases other than cancer, 
such as heart disease, and a lack of understanding about the impact of the information that 
accompanies the survey instruments.
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Table 3.3. Studies examining interest in genetic testing for cancer and heart disease susceptibility: methodologies and examples
Disease type Interest M ethod No. Country Participants
Actual uptake amongst high-risk populations
Lerman et al (1996) Breast 43% Test result uptake 279 US Members of hereditary breast cancer families
Nash et al (1999) Breast 35% Test result uptake Members of hereditary breast cancer families
Geller et al (1999) Breast 10%, 25% Test utilization 132 US Women at increased risk, ‘clinical’ and ‘registry’
Culver et al (2001) Breast 52% Counselling uptake 97 us Women with a family history of breast cancer
Schwartz et al (2000) Breast 82% Test result uptake 290 us Women with familial breast cancer
Lerman et al (1999) Colon 43% Test result uptake 208 us Members of hereditary colon cancer families
Esplen et al (2001) Colon n/a Retrospective 50 Individuals engaged in genetic testing process
Codori et al (1999) Colon n/a Retrospective 258 77 test acceptors; 181 test decliners
Surveys o f interest amongst high-risk populations
Struewing et al (1995) Breast 95% Interviews 150 us Members of hereditary breast cancer families
Durfy et al (1999) Breast 83%-90% RCT baseline survey 543 us Women at increased risk (white,lesbian,AA,Ashkenazi)
Bowen et al (1999) Breast not reported Telephone survey 588 us Women with a family history of breast cancer
Meiser et al (2000) Breast 92% Mailed survey 461 Australia Unaffected women with a family history of breast cancer
Kinney et al (2001) Breast 82% Interviews 95 US Male and female African-American kindred members
Lerman et al (1996) Colon 86% Interviews 45 US First-degree relatives of colon cancer patients
Glanz et al (1999) Colon 45% Mailed survey 426 US First-degree relatives of colon cancer patients
Vemon et al (1999) Colon 90% Intention to learn result 342 US Colorectal cancer patients
Petersen et al (1999) Colon 92% Mailed survey 1,373 US Individuals with >1 family member with colon cancer
Bratt et al (2000) Prostate 94% Mailed survey 110 Sweden Unaffected men in families with hereditary prost. cancer
Diefenbach et al (2000) Prostate 74% Mailed survey 126 US Men treated for prostate cancer & advert respondents
(continued overleaf)
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Surveys of interest amongst the general population
Andrykowski et al (1996) Cancer 87% Telephone survey 347 US General population women
Bosompra et al (2000) Cancer 20% Telephone survey 622 US General population
Aro et al (1997) Cancer not reported Mailed survey 1,169 Finland General population
Aro et al (1997) Heart disease not reported Mailed survey 1,169 Finland General population
Andrykowski et al (1996) Breast 93% Telephone survey 649 US General population
Tambor et al (1997) Breast 69% Telephone survey 473 US General population
Welkenhuysen et al (2001) Breast 66% Self-admin survey 318 Belgium Students at the Institute for Family Sciences
Braithwaite et al (2002) Breast 72% Postal survey 124 UK General population
Armstrong et al (2002) Breast 58% Mailed survey 242 US General population women
Helmes (2002) Breast not reported Mailed survey 330 US Women at low to moderate risk, physician network
Miesfeldt et al (2000) Prostate 89% Self-admin survey 342 US Self-selected men presenting for prostate cancer screening
Myers et al (2000) Prostate 86% Telephone survey 413 US Men at a Uni. Health Service, no family history
Weinrich et al (2002) Prostate 87% Survey (type unknown) 320 US African-American men from two prostate cancer studies
Croyle & Lerman (1993) Colon 83% Telephone survey 401 US General population
Smith & Croyle (1995) Colon 84% Survey (type unknown) 383 US General population
Myers et al (1998) Colon 58% Mailed survey 2,693 US While male employees
Braithwaite et al (2002) Colon 72% Mailed survey 168 UK General population
Bunn et al (2002) Colon 51% Telephone survey 1,836 US General population
Comparison of interest amongst high- vs. general-risk populations
Lipkus et al (1999) Breast 89% vs. 74% Telephone survey266 US Women with and without family history
Cappelli et al (1999) Breast 72%vs. 46% Postal survey 110 Canada 60 women with breast cancer; 50 general population
Cappelli et al (2001) Breast 68% vs. 45% Survey (type unknown) 108 Canada 58 women >1 family member; 50 general population
Bottorff et al (2002) Breast 31% vs. 29% Telephone survey 1,021 Canada Women with and without breast cancer
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3. Psychological impact of genetic testing
3.1. Single-gene disorders
3.1.1. Huntington’s disease
Before genetic testing for Huntington’s disease was introduced, there was considerable 
concern that the definitive nature of the information could cause catastrophic 
psychological reactions amongst individuals receiving unfavourable results, even suicide. 
However, these dire predictions have not been fulfilled (Evers-Kiebooms & 
Decruyenaere, 1998). The first longitudinal study (Wiggins, Whyte, Huggins et al, 1993) 
investigating the impact of genetic testing for Huntington’s, in fact suggested that there 
were potential benefits for the psychological health of the people taking the tests 
regardless of whether the result indicated a favourable or unfavourable result. The 135 
participants in the Canadian program were followed prospectively in three groups 
according to their test results: increased-risk (n=37), decreased-risk (n=58), and no­
change (n=40). 32 of those in the no-change group didn’t receive risk-altering
information because they declined testing, the other 17 were told that testing would not 
be informative for them. At each follow-up assessment (7 days, 6 months and 12 
months), the decreased-risk group had lower scores for distress (on the General Severity 
Index of the Symptom Check List 90-R) than before testing. The increased-risk group 
showed no significant change on any follow-up measure, including the Beck Depression 
Inventory. The no-change group had scores lower than at baseline on the index of 
general well-being (on the General Well-Being Scale) at each follow-up. At the 12- 
month follow-up, both the increased-risk group and the decreased-risk group had lower 
scores for depression and higher scores for well-being than the no-change group. This 
supports the evidence from other studies, that one of the benefits of genetic testing for 
Huntington’s, and a reason people often give for opting for testing, is the reduction of 
uncertainty (Lerman, Croyle, Tercyak & Hamann, 2002).
Around the same time, 29 individuals with increased risk and 44 with decreased risk were
followed up, 6 months after receiving their test results, in the Dutch presymptomatic
genetic testing program for Huntington’s disease (Tibben, Duivenvoorden et al, 1993).
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As in the Canadian study, most individuals with increased risk seemed to cope well. 
Moreover, Tibben and colleagues attempted to develop a prognostic model aimed at 
identifying individuals at risk for psychological maladjustment, using a battery of 
measures, including the Impact of Event Scale, the Beck Hopelessness Scale, the General 
Health Questionnaire, and the Social Support Questionnaire. They found that the test 
result itself had far less impact on psychological functioning at follow-up than 
psychological functioning prior to testing. For example, the more that both individuals 
with increased risk results and those with decreased risk results were pessimistic about 
their future prior to the test, the greater the probability that they reported feeling 
depressed six months after the test. Similarly, Codori, Slavney, Young et al (1997) 
examined psychological adjustment in 52 individuals who tested positive for the 
Huntington’s disease mutation, and 108 who tested negative for the mutation, and found 
that hopelessness and depression at 3, 6, 9 and 12 months after testing was within normal 
limits for both groups. Baseline depression was a strong predictor of follow-up 
depression scores, and hopelessness at baseline was a strong predictor of follow-up 
hopelessness, whereas genetic status, or test result, was only marginally predictive of 
follow-up depression and was not predictive at all of follow-up hopelessness. Another 
study (Tibben, Timman, Bannink et al, 1997), this time of 20 carriers of the Huntington’s 
disease gene and 29 noncarriers, with a three-year follow-up, found that one week after 
receiving their results carriers had increased and noncarriers had decreased levels of 
hopelessness, but the effects disappeared after 6 months and did not recur.
The evidence on Huntington’s disease genetic testing suggest that, even when the test is 
100% predictive of the disease and when there are no risk-reducing strategies available, 
people who test positive for the gene mutation experience no more psychological 
problems in the long-term than those who test negative (Evers-Kiebooms, Welkenhuysen, 
Claes et al, 2000; Meiser & Dunn, 2000; Duisterhof, Trijsburg et al, 2001; Lerman, 
Croyle, Tercyak & Hamann, 2002). As discussed in the previous section on interest, 
there is strong evidence to suggest that people who choose to be tested are 
psychologically selected for a favourable response to testing (Meiser & Dunn, 2000), that 
those who believe they would have a poor psychological response to genetic testing do 
not opt for testing in the first place, and that many people opt for testing because
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reduction of uncertainty is important to them (Lerman, Croyle, Tercyak & Hamann, 
2002). The few that report being distressed before testing, but nonetheless have the test 
and receive the result, most often have problems in adapting to the test result, regardless 
of what that result is (Duisterhof, Trijsburg et al, 2001). In addition to self-selection, the 
rarity of adverse psychological outcomes is likely to be attributable to the careful genetics 
counselling and education protocols adhered to in clinical practice (Bundey, 1997; 
Lerman, Croyle et al, 2002). The psychological impact of genetic testing for single-gene 
disorders of complete penetrance without counselling is unknown, and would be 
unethical at the present time due to the seriousness of the information potentially being 
imparted.
3.1.2. Familial adenomatous polyposis (FAP)
A study by Codori, Petersen, Boyd et al (1996) addressed the psychological effects of 
genetic testing for FAP, which is first characterised by the formation of hundreds of 
polyps in adolescence and early adulthood. They surveyed 41 tested children and their 
parents before and 3 months after testing. Children’s depression levels remained in the 
normal ranges after testing, although mutation-positive children with affected mothers 
had significantly higher follow-up depression scores. Michie, Bobrow & Marteau (2001) 
invested the emotional impact of genetic testing for FAP in 148 adults and 60 children. 
In children receiving positive results, mean scores for anxiety and depression were within 
the normal range, although there was a trend for them to be more anxious and depressed 
than those receiving negative results. In adults, mean scores of anxiety were within the 
normal range for those receiving negative results, but were in the clinical range for those 
receiving positive results, with 43% of the latter having scores in this range. Regardless 
of test results, adults were more likely to be clinically anxious at follow-up if they were 
low in optimism or self-esteem.
3.2. Complex diseases: rare mutations of high penetrance
3.2.1. Breast and ovarian cancer
A few large-scale longitudinal studies, and some smaller, less controlled studies, have 
begun to yield data on the psychological effects of genetic testing for cancer
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susceptibility, with most data on breast and ovarian cancer. In one of the very first 
studies, Croyle, Smith, Botkin et al (1997) reported on the short-term psychological 
effects of BRCA1 testing amongst 60 Utah-based members of the largest family at that 
time to be identified with a pattern of heritable breast and ovarian cancer (the protocol for 
which was described in Botkin, Croyle, Smith et al, 1996). They examined levels of 
general distress (anxiety) and specific test-related distress (thoughts and feelings about 
the test results) 1-2 weeks after the women had received their test results during an in- 
person visit with a genetic counsellor and a psychological counsellor. In a follow-up 
telephone interview, the average level of general distress reported by the group of women 
was not high (a few individuals did report high distress, however). Noncarriers, on 
average, showed some decline in general distress compared with the anxiety reported 
before genetic counselling and testing in the baseline interview. Carriers showed no 
significant change in general distress after receiving their results.
In the second early, and much larger study, psychological reactions to genetic test results 
were examined in 279 members of hereditary breast cancer families at one month follow- 
up. Noncarriers of BRCA1 mutations reported significant reductions in depressive 
symptoms (as defined by the CES-D scale) and functional impairment (as measured by 
two scales from the Medical Outcomes Study), compared with carriers and those who 
chose not to be tested. However, individuals identified as mutation carriers did not 
exhibit increases in depression and functional impairment (Lerman, Narod, Schulman et 
al, 1996). In another study, this time of 181 individuals from hereditary breast and 
ovarian cancer families, 80% of those who tested negative for the BRCA1 mutation 
reported emotional relief, whilst over one-third of those who tested positive reported 
sadness, anger, or guilt (Lynch, Lemon, Durham et al, 1997).
Some studies have tried to identify subgroups of individuals that might be more 
psychologically vulnerable to negative psychological reactions to genetic test results. 
Lerman, Hughes, Lemon et al (1998) classified their hereditary breast cancer family 
members into low-moderate (two lowest tertiles) and high-stress (highest tertile) 
categories based on their scores on an intrusion scale at baseline. The highest levels of 
depression symptoms one month after testing (based on the CES-D) were reported by
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individuals with high stress at baseline who decided not to get tested. In this subgroup, 
26% reported symptoms consistent with depression at baseline, and by one month this 
number had increased to 47%. More recently, Dorval, Patenaude, Schneider et al (2000) 
examined the ability of individuals undergoing genetic testing for cancer susceptibility in 
two structured research protocols to accurately anticipate emotional reactions to 
disclosure of their test results. Data from 65 individuals were analyzed; 24 members of 
Li-Fraumeni cancer syndrome females were tested for p53 mutations (all 24 were 
unaffected), and 41 subjects with hereditary breast-ovarian cancer susceptibility were 
tested for BRCA1 mutations (34 were unaffected and 7 were affected). Overall, mean 
levels of emotional reactions after receiving test results were not different from those 
anticipated before result disclosure, although affected BRCA1 carriers did experience 
higher levels of anger and worry than they had anticipated. One small recent study of 23 
breast-ovarian or colorectal cancer patients who had received carrier genetic test results, 
found that 5% were classified as being depressed, and 29% as abnormally anxious six 
weeks after they received a positive carrier result for being a mutation carrier (Bonadona, 
Saltel, Desseigne et al, 2002), but interpretation of this study is limited due to the lack of 
comparison groups. A larger better controlled study recently examined changes in 
psychological distress following cancer genetic counselling (Bish, Sutton, Jacobs et al 
(2002). Women attending a family cancer clinic completed questionnaires before their 
appointment and at various follow-ups over the following year. Women received a low 
risk result (n=26), a moderate risk result (n=76), or a high risk result (n=46), and 46 had 
previously had breast or ovarian cancer. General psychological distress did not change 
over the course of the study, and the groups did not differ on these measures. Worry 
about developing breast cancer and perceptions of the likelihood of carrying a genetic 
mutation significantly decreased following genetic counselling.
3.2.2. Hereditary nonpolyposis colon cancer (HNPCC)
In one early study, Lerman, Marshall et al (1996) conducted interviews with 45 male and 
female first-degree relatives of colorectal cancer patients. The aim of the study was to 
provide information useful in the education and counselling of individuals considering 
genetic testing, in the face of new genetic tests for colon cancer susceptibility becoming 
commercially available at that time. Most participants anticipated that they would
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become depressed and anxious if they tested positive for a mutation, while many would 
feel guilty and still worry if they tested negative. Importantly, roughly half of the 
respondents expected that they would decrease their use of screening tests and make 
fewer attempts to reduce dietary fat if they tested negative. Lerman and colleagues 
proposed that the potential for false reassurance following a negative test result should be 
addressed by emphasizing the residual risks of cancer among non-carriers of predisposing 
mutations. This raises the important question of what should be done with people whose 
genetic test results indicate a decreased susceptibility to a behaviour-related disease 
(discussed further below).
In another small study (Esplen, Madlensky, Butler et al, 2001) of 56 individuals on 
familial cancer registries who had taken an HNPCC genetic test, depression and anxiety 
were highest amongst people who had not yet received their results; people who were 
waiting for their genetic test results showed higher levels of anxiety than mutation 
noncarriers. Claes, Denayer, Evers-Kieboom et al (2004) described the short-term 
psychological impact of predictive genetic testing for HNPCC using a semi-structured 
interview and self-report questionnaires. Distress was within normal ranges. Distress 
decreased significantly from pre- to post-test in non-carriers and did not in carriers. It 
also decreased in individuals for whom ‘reducing uncertainty’ was a very important 
motive for the test, not in the others. Although some of the carriers did not have 
colonoscopies, all carriers intended to have regular colonoscopies in the future. Henning 
Brodersen, Sutton, Goff et al (2004) investigated anticipated emotional and behavioural 
reactions to genetic testing amongst 437 asymptomatic individuals from families with a 
history of colon cancer. More women than men anticipated feeling worried, regretful, 
and angry if tested positive. People at lower-risk anticipated more surprise and disbelief 
than those at higher-risk. People anticipated feeling more guilt, regret and less relief if 
they were not tested than if they were. High-risk results were anticipated to increase 
depression and worry. Most people still wanted screening if at low risk, anticipated 
leading healthier lifestyles whatever the result, and would make more plans for the future 
if they were at high risk.
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3.3. Psychological impact: summary and critique
Genetic test results have consistently had less influence on emotional distress 
(depression, anxiety, or disease-specific concern) than initially expected (Lerman, 
Croyle, Tercyak & Hamann, 2002). The literature on predictive genetic tests already in 
clinical use (Huntington’s disease, breast cancer and colon cancer) provides little support 
for adverse psychological effects of testing. The few longitudinal studies that have been 
conducted show reductions in distress among noncarriers and minimal changes in distress 
among carriers (Broadstock, Michie & Marteau, 2000; Meiser & Halliday, 2002; 
Braithwaite, Emery, Walter et al, 2004). The occasional increases in distress that have 
been observed in carriers tend to be transient and not clinically significant, rarely lasting 
beyond one month following testing.
An important caveat in the literature is that most research studies have used optimal 
models of genetic counselling that may have more beneficial outcomes than more 
minimal approaches used in experimental studies and commercially provided genetic 
testing contexts. The fact that specific genetic-testing research protocols that include 
comprehensive genetics education and counselling have been adhered to in most research 
studies to date, means that the results of these studies could underestimate rates of 
psychological distress amongst people outside of the clinical genetic counselling context 
(Lerman, Croyle et al, 2002). Few studies have experimentally manipulated the amount 
or type of counselling provided, and the relationship between counseling and emotional 
outcome is therefore unclear and awaits empirical study (Broadstock, Michie & Marteau, 
2000).
Another limitation of the data collected to date is that it is not generalisable to the general 
population. All of the clinical studies have examined the psychological impact of genetic 
test results amongst individuals and populations who were already identified as high risk, 
and most of whom came from hereditary disease research families and research registries. 
This has implications for interpretation of the findings. For example, the extent to which 
reduction of uncertainty about personal risk is important to the individual has emerged as 
a major factor in the literature so far, but may be less important for individuals who do
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not come from families with a history of disease and amongst whom baseline risk may be 
lower in the first place.
Another consideration is that, whereas test result has rarely been found to predict 
psychological outcomes, pre-test emotional state has consistently been a strong predictor 
of emotional reactions to genetic test results, although the range of reactions has almost 
always been within the normal range anyway. As discussed in the previous section, this 
strongly suggests that self-selection plays a major part in the lack of adverse 
psychological outcomes reported to date, with individuals being more likely to opt for 
genetic testing when they believe they will be able to cope with the test result, regardless 
of what the result itself actually is. However, it is worth noting that, even if self-selection 
is in action, there are a significant minority of individuals who opt for testing despite 
having high levels of distress at baseline, and this therefore indicates a degree of caution 
when offering genetic tests to people.
4. Behavioural impact of genetic testing 
4.1. Complex diseases: rare variants of high penetrance
4.1.1. Breast and ovarian cancer
The limited recent findings on the effects of genetic testing on surveillance and
prophylactic surgery behaviours are mixed. A study of women from families with
hereditary breast-ovarian cancer examined one-year follow-up rates of mammogram,
transvaginal ultrasound and prophylactic mastectomy and oophorectomy following
BRCA1/BRCA2 genetic testing (Lerman et al, 2000). Women who are unaffected
carriers did not significantly increase their compliance with mammogram and ultrasound
recommendations. Rates for both tests remained low even after subjects received the
genetic test results; 68% were adherent to mammography recommendations before
BRCA1/2 testing and 68% reported adherence one year after receiving positive test
results. On the other hand, this was compared to a rate of 44% of the noncarriers. Less
than 15% of BRCA1/2 carriers had the recommended ovarian cancer screening. Only a
very small percentage of women underwent prophylactic surgeries to reduce their risk: 1
of 29 (3%) unaffected female carriers had prophylactic mastectomy within one year after
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receiving genetic test results and 13% had a prophylactic oophorectomy. Similar rates 
were found in women with negative test results.
In contrast, Botkin et al (2003) demonstrated a marked difference between carriers and 
non-carriers in women’s utilization of mastectomy and oophorectomy as risk-reducing 
measures for breast-ovarian cancer. In this study, mammography utilization increased 
significantly from 22% and 30% at baseline amongst carriers and non-carriers to 62%and 
53% at one-year follow-up, but the difference between the two groups was not 
significant. Breast self-ex am also significantly increased amongst both carriers and non­
carriers, but neither group increased their use of clinical breast-exam. Prophylactic 
options were discussed at length with women who had undergone genetic testing. They 
were advised that the current evidence for the efficacy of mastectomy was limited, but 
that oophorectomy may be an efficacious option for women over 40 who did not want 
any more children. None of the women in either group obtained a mastectomy during the 
two-year follow-up, but 46% of carriers had had oophorectomies during the same time, 
compared to 4% of non-carriers. When broken down by age, 80% of carriers vs. 5% of 
non-carriers over 40yrs of age had had oophorectomies. The equivalent figures were 
29% vs. 3% of women under 40yrs.
Different findings were obtained in Dutch populations. Following BRCA1/2 testing, 
Meijers-Heijboer et al (2000) found that 55% of carriers had a mastectomy by two years 
following testing and 60% had a prophylactic oophorectomy. Kauf et al (2002) 
prospectively followed 170 BRCA1/2 carriers and found that 58% chose risk-reducing 
oophorectomy.
4.1.2. Hereditary nonpolyposis colon cancer (HNPCC)
Amongst HNPCC colon cancer mutation carriers, 69% (11/16) of individuals in one 
study indicated that they had increased the frequency of medical screening tests such as 
colonoscopy, but equivalent figures were not reported in the small sample of non-carriers 
(n=7) by way of comparison (Esplen et al, 2001). Lynch, Watson, Shaw et al (1999) 
reported that, amongst relatives of colon cancer patients who were offered HNPCC 
genetic testing, 67 out of 140 (48%) had been given screening recommendations by their
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personal health care providers, which included colonoscopy and flexible sigmoidoscopy 
and, more importantly, recommendations about when to initiate screening and what 
screening intervals were appropriate varied widely.
4.2. Complex diseases: common variants of low penetrance
The genes which are tested for at present in the clinical context are highly penetrant, and 
the diseases are difficult to prevent even once high risk has been established. In contrast, 
future genetic susceptibility tests for complex diseases such as common forms of cancer 
and heart disease, may be more preventable via health behaviour change. There has been 
particular interest in the potential for genetic testing to motivation smoking cessation 
amongst smokers (Lerman et al, 1997; Ostroff et al, 1999), but the concept that 
personalised risk information may be an effective strategy to increase motivation and 
promote behaviour change is not new.
Perceived susceptibility, or perceived risk, is a central component of many social 
cognition models of health behaviour change. The health belief model, health decision 
model, protection motivation theory, theory of reasoned action, and dual process model 
all suggest that behaviour change is in part induced by one’s perceived susceptibility to 
disease and a desire to avoid this outcome (Weinstein, 1993; McClure, 2002). For 
example, according to the health belief model (HBM: Rosenstock, 1974), smokers will 
quit smoking when they perceive the benefits of quitting to outweigh the barriers, when 
they perceive the consequences of smoking to be severe, when they perceive themselves 
to be at high risk of those consequences, and when they have high levels of health 
motivation. Informing smokers that their genetic susceptibility to a smoking-related 
disease is higher than average, could therefore directly influence their motivation to quit 
smoking via the perceived susceptibility pathway. Protection motivation theory (PTM: 
Rogers, 1975; 1983) similarly contains within it the idea of threat appraisals (perceived 
severity and perceived susceptibility) and the health action process approach (HAPA: 
Schwarzer, 1992) incorporates perceived risk as the precursor to an individual forming an 
intention to change behaviour in the motivation phase of the model. There is therefore 
some theoretical basis for suggesting that providing people with genetic test results that
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indicate they have an increased risk of personally developing a behaviour-related disease 
may lead to behaviour change.
4.2.1. Lung cancer and CYP2D6
This hypothesis was empirically tested by Caryn Lerman and colleagues in a randomized 
trial investigating the impact of incorporating genetic testing into a minimal-contact quit- 
smoking counselling intervention (Lerman, Gold, Audrain et al, 1997). 427 smokers 
were randomised to either a counselling control group, a carbon monoxide feedback 
group, or a CYP2D genetic testing group. The genetic testing treatment produced 
significantly greater effects on perceived risk, perceived quitting benefits and fear arousal 
than either the control group or the carbon monoxide group in the immediate impact 
assessment. For example, immediate impact measures showed that 76% of smokers in 
the control group perceived their risk as much greater than nonsmokers, and 72% of 
smokers who received carbon monoxide feedback perceived their risk as much greater. 
In contrast, 94% of smokers who received genetic risk feedback perceived their risk as 
greater. At two month follow-up, there were no significant effects of the interventions on 
quitting behaviour on any of the measures. Among participants who reported continued 
smoking at the two month follow-up, linear regression analysis was performed to 
examine the effects of treatment on follow-up smoking rate while controlling for baseline 
smoking rate. On average, participants smoked 23 cigarettes per day at baseline and 15 
per day at two month follow-up. At baseline, the numbers of cigarettes smoked per day 
amongst smokers who were not in the ‘preparation’ stage of change, or readiness to quit, 
were 23 24 and 22 in the genetic testing, carbon monoxide, and control groups 
respectively. This reduced to 17, 17, and 14 at two month follow-up respectively. 
Amongst smokers in the ‘preparation’ stage, baseline number of cigarettes per day were 
22, 22 and 21 respectively. These figures dropped to 11 per day in the genetic testing 
group, and 10 per day in the carbon monoxide group, but only to 15 per day in the control 
group at two month follow-up. A repeated-measures analysis of variance was used to test 
the main and interacting effects of baseline stage of change and intervention in the 
number of cigarettes smoked per day. There was a significant main effect of stage and a 
significant stage x treatment interaction effect. Among the smokers in the preparation 
stage, post hoc analyses (Fisher’s least significant difference tests) indicated that the
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control group versus genetic testing group, and the control group versus the carbon 
monoxide group comparisons were both significant (p<.05).
Baseline depression symptoms (CES-D scale) in this study population were higher than 
in the general population. Depression scores amongst smokers in the genetic feedback 
group at two month follow-up were found to be significantly higher than the standard 
care control group (p=.04) and marginally different from the carbon monoxide feedback 
group (p=.056). The actual changes from baseline to 2-month follow-up in the genetic 
feedback, carbon monoxide feedback, and control groups were +0.2, -2.1 and -2.4 
respectively, from an overall mean of 14.6 (sd=9.8). Smokers in the control group and 
carbon monoxide group showed reductions in depressive symptoms by two months, but 
smokers in the genetic testing group did not. 25% of smokers who received high genetic 
risk feedback said that the information was ‘very frightening’, compared to 11% in the 
carbon monoxide feedback group and 7% in the standard care group (p<.001).
Lerman and colleagues referred to the fact that the genetic testing group showed 
increases in fear and depression at two month follow-up as being a particular concern 
given evidence for a propensity toward depressive symptoms and affective disorders 
among smokers (Glassman et al, 1988; Lerman, Audrain et al, 1996). They speculated 
that if excessive distress or fear is generated, yet self-efficacy is not sufficiently high, 
genetic susceptibility feedback could backfire. Distress could lead some smokers to deny 
or to underestimate their smoking problem, which would increase resistance to behaviour 
change (Weinstein & Klein, 1995). Distress could also promote smoking to achieve the 
mood-enhancing effects of nicotine (Lerman, Audrain et al, 1996). They therefore 
looked in more detail at the issues of depression and self-efficacy when they followed the 
participants up one year later.
At one year follow-up, the initial observed increase in depression amongst the genetic 
testing group was not maintained (Audrain, Boyd, Roth, Main, Caporasso & Lerman, 
1997). The group given the genetic risk feedback were more motivated to quit at one 
year follow-up, and had made more quit attempts, than controls, but there were no 
differences on actual cessation rates. 85% of those in the genetic testing group reported
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trying to quit compared with 81% of smokers in the carbon monoxide group and 73% of 
smokers in the control group. This time, they also examined baseline self-efficacy, or 
quitting confidence, using the item, “How confident are you that you could quit smoking 
for good?”. They reported that neither stage of change nor baseline self-efficacy 
moderated the relations between treatment and smoking cessation at one year follow-up 
(they did not report changes in self-efficacy over time). The authors had hypothesised 
smokers with high levels of self-efficacy would respond better to motivational feedback 
about genetic susceptibility than smokers with low levels of self-efficacy. They 
speculated that the lack of significant moderation by self-efficacy, and thus the lack of 
evidence for this hypothesis, indicated that the failure of genetic feedback to promote 
cessation was not related to a motivational deficit but rather to an inability to overcome 
the addiction. This was because their smokers were highly addicted and because the 
intervention only involved minimal counselling, and so they suspected that more 
intensive counselling would be needed to help these smokers overcome their addiction. 
They also acknowledged that counselling interventions are more effective when 
supplemented with nicotine replacement therapy [p749].
Although this study did not find any evidence of a moderating effect of self-efficacy, it is 
worth considering the relationships between efficacy, genetic testing and smoking 
cessation in a bit more detail, because there may be other, equally plausible explanations 
for the findings. The extended parallel process model (EPPM: Witte, 1992), which is the 
most recent adaptation of the fear-appeal model and protection motivation theory (PMT), 
states that threat appraisal (susceptibility and severity) plus coping appraisal (response- 
efficacy and self-efficacy) lead to adaptive (protection motivation) or maladaptive 
(avoidance) behavioural responses. Thus, increasing perceived threat (susceptibility) 
would only lead to engaging in a health-protective behaviour such as quitting smoking if 
the individual believed that the behaviour change would reduce that risk (response- 
efficacy) and that the behaviour change was under their control (self-efficacy). If threat 
is increased under circumstances where an individual has low coping appraisal, the 
outcome could be an increase in fear and a maladaptive avoidant behavioural response. 
The model also allows for ‘no response’ as an outcome, if no threat is perceived. 
Perceived behavioural control is also incorporated in the theory of planned behaviour as a
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predictor of behavioural intentions in addition to attitudes and subjective norms (TPB: 
Ajzen, 1985; Conner & Sparks, 1995). All of this is in line with the predictions made by 
Lerman et al (1997) and Audrain et al (1997), that smokers with high self-efficacy should 
be more likely to be motivated to quit in response to genetic risk information that 
indicates susceptibility to smoking-related disease.
However, although Lerman and colleagues speculated that their lack of evidence to 
support this hypothesis was due to the counselling not being intensive enough, the above 
models suggest at least two alternative explanations for the lack of association between 
efficacy and reaction to test result. The first hypothesis is based on the re-framing of the 
question, what factors predict quitting behaviour in response to genetic susceptibility 
feedback?, to what factors predict interest in genetic testing for smoking-related 
diseases? Essentially, this is replacing ‘intention to quit’ as the outcome variable with 
‘intention to undergo genetic testing for a behaviour-related disease’. Doing this, the 
health belief model predicts that people will engage in genetic testing for a behaviour- 
related disease such as smoking-related lung cancer, if they believe not only that lung 
cancer is severe and that they are susceptible to lung cancer, but also if they hold more 
beneficial than barrier beliefs about genetic testing for lung cancer. Similarly, protection 
motivation theory and the extended parallel process model also predict that people will 
take genetic tests for lung cancer susceptibility if they have high severity and 
susceptibility beliefs, but also that they will only take up genetic testing if they hold 
certain efficacy beliefs. In addition to self-efficacy, the ‘response efficacy’ component 
stipulates that they must believe that engaging in genetic testing will be efficacious in 
reducing their risk of developing lung cancer, e.g. by helping them to quit smoking, 
possibly by increasing their motivation and acting as a motivational tool. So, the lack of 
association between self-efficacy and reaction to genetic susceptibility testing could be 
due to self-selection -  those with very low efficacy beliefs about their ability to quit, or 
with very low efficacy beliefs about the genetic test being able to help them to quit 
smoking, have self-selected themselves out and may not have opted to participate in 
genetic testing in the first place, leading to a limited range of within-sample responses.
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A second hypothesis is that smokers did not actually quit in response to their genetic 
susceptibility feedback not because the counselling was not powerful enough, but 
because the risk information itself was not powerful enough. They may not have quit 
because of their attitudes, beliefs and understanding regarding the genetic test, and even 
their beliefs about genetics more generally, not only their attitudes and beliefs regarding 
the disease and their smoking behaviour. For example, if they correctly perceived that 
the risk information only gave them a small increase in risk, albeit one that led to a 
statistically significant increase in risk detected compared to the other two groups, this 
may not have been enough to lead to actual quitting. It is conceivable that tests for panels 
of multiple genes in the future would produce stronger results.
4.2.2. Lung cancer and GSTM1
The trial conducted by Caryn Lerman and colleagues threw up some interesting 
hypotheses, but the use of a CYP2D6 polymorphism meant that 92% of the sample was 
categorised as ‘high risk’. This meant that the impact of ‘non-susceptible’ status on 
affect, motivation and cessation could not be evaluated. The questions of whether 
feedback of increased genetic susceptibility would lead to greater increases in perceived 
risk, negative affect and cessation rates than feedback of non-susceptibility were posed in 
a trial by Colleen McBride and colleagues (McBride et al, 2002). They used the GSTM1 
genotype; 50% of the population has the null genotype and so this makes it more suited 
for use in randomised controlled trials. Of the 869 African American smokers referred 
for recruitment in to the study, 307 were ineligible, 5 refused to take part in the study. 
487 completed the preintervention assessment. A total of 185 smokers were randomised 
to the control group, and 372 were randomised to the genetic testing group. Among those 
randomised to the genetic testing group, 83% (n=308) agreed to have their blood tested 
for the GSTM1 enzyme. There were no differences in age, gender, amount smoked, 
perceived risk, or worry related to lung cancer for those who accepted or declined the test 
(n=64). There were no differences between the control group and genetic testing group 
in use of nicotine patches (46% vs. 48% respectively), although helpfulness of the 
nicotine patches was rated significantly greater among smokers in the genetic testing 
group (p=.01). The authors did not report if there were differences between GSTM1 
missing and GSTM1 present smokers on use of nicotine patches. There were no
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differences in use of GSTM1 booklet between those who had a GSTM1 missing and 
those who had a GSTM1 present result, although the authors do not define how they 
measured ‘use’. Only 50% of the smokers reported having read the test result booklet. 
Compared with those with the enzyme present, those in the GSTM1 missing group were 
significantly more likely to say that, based on their test result, it was likely that they 
would get lung cancer in their lifetime (23% vs. 53% respectively, p<.001). However, 
the authors do not describe whether there were differences on a standardized assessment 
of perceived risk.
Among those in the genetic testing group, 13% could not be reached for any of the calls, 
87% participated in at least one counselling call, 76% in two calls, 64% in three calls, and 
only 38% in all four calls. This suggests that four counselling calls may not be necessary 
or effective. Efforts to biochemically confirm self-reported cessation were unsuccessful. 
Only 39% (24 of 61) of those who reported abstinence and agreed to provide a saliva 
sample returned one. Rates of return did not differ between the two arms. The trial 
outcomes were therefore based on self-reported cessation. This suggests that self- 
reported cessation is probably better for use in this kind of trial than attempting to 
validate self-reports with cotinine.
At six month follow-up, 19% of the genetic testing group had quit compared to 10% of 
the control group (p<.001). The difference was not maintained at one year follow-up. 
There were no differences between GSTM1 missing smokers and GSTM1 present 
smokers on cessation. At six month follow-up, 17% of the GSTM1 missing group had 
quit compared to 23% of the GSTM1 present group. At one year follow-up, 18% of the 
GSTM1 missing group had quit and 15% of GSTM1 present group had quit. Among 
those who declined the test, 11% had quit at 6 month and 1 year follow-ups (n=64). It is 
worth noting that there were no differences in gender, age, amount smoked, perceived 
risk, or worry related to lung cancer for those who accepted or declined the test, but the 
authors do not say whether there were other important differences, such as education, 
attitudes towards genetics, income, or understanding of genetics.
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Given that a primary research question in this study was, “Would feedback o f increased 
genetic susceptibility result in greater increases in perceived risk, negative affect, and 
cessation rates than feedback o f non-susceptibility? ", there is a surprising lack of results 
presented in this paper comparing the GSTM1 missing with the GSTM1 present smokers. 
In fact, the authors don’t even say whether there were differences between the two 
genetic testing groups on depression, a primary outcome variable (although they do bring 
it up briefly in the discussion). The vast majority of the results presented compare the 
control group with the genetic testing group overall, but these comparisons are extremely 
uninformative about the impact of genetic testing because of the vastly differing levels of 
support provided to the two groups (support was almost non-existent in the control group 
other than NRT, whereas the genetic testing group had NRT plus a tailored booklet 
intervention plus four telephone counselling calls).
Instead of looking at risk, worry and depression between the GSTM1 missing and the 
GSTM1 present group, the authors compare these three primary outcome variables 
between the control group and the genetic testing group. One can only assume that the 
authors were influenced by the relatively hostile atmosphere in the US towards human 
genetics research at the time the paper was published. When they initiated their study in 
1996 there was less concern about human genetics research in humans than there were six 
years later in 2002; in particular, there was significantly more discussion and debate 
about the potential harms caused to subjects involved in genetics research protocols 
(Colleen McBride, personal communication).
Anyway, with regard to the results that the authors did present, there were no time x 
group interactions (group being ‘control group’ or ‘genetic testing group’) for changes in 
perceived risk of lung cancer or depression. Between baseline and 1 year follow up, the 
proportion who perceived lung cancer risk to be likely, and level of depression, decreased 
steadily among smokers in both groups. However, for worry, the time x group 
interaction was marginally significant (p=.06). The proportion who were worried about 
lung cancer levelled off among those in the genetic testing group and steadily declined in 
the control group. One of the major limitations of this study was that the design did not
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allow them to disentangle the independent contribution of the genetic testing from the 
telephone counselling.
In their discussion, the authors comment on the fact that feedback of increased 
susceptibility to lung cancer was not associated with significant increases in smoking 
cessation, risk perceptions, or levels of depression in the short or long term (note that not 
all of these findings were presented in their results section and so these statements are not 
all supported by data), and also that feedback of not being susceptible did not seem to 
undermine success at smoking cessation. The authors hypothesise that the reason that 
increased susceptibility was not a powerful inducement to quit may have been attributed 
to characteristics of the participants and ceiling effects, the majority of whom already 
were experiencing health effects of their smoking and had high levels of perceived risk 
for lung cancer and high motivation to quit.
In the results section, the authors had reported that smokers in the two test result groups 
were “equally likely to accurately interpret the meaning of the test result” [p525]. 
However, the authors’ definition of ‘accurate interpretation’ is dubious. Although it is 
difficult to discern from the way the information is present in the paper exactly how this 
was assessed, they appear to have assessed it as, in the GSTM1 present group, “having 
the GSTM1 enzyme present indicated that their risk for lung cancer was equal to other 
smokers”. In the GSTM1 missing group, “missing the GSTM1 enzyme indicated their 
risk was greater compared with other smokers”. Using this criteria, 53% and 56% 
‘accurately interpreted’ their test results. They went on to discuss the opinion that 
feedback of genetic susceptibility did not have a powerful impact because 45% of the 
smokers did not fully understand their result. There is reason to approach their 
discussion of this issue with extreme caution.
The way the authors themselves defined what was accurate and inaccurate is wrong. 
When there are only two genotypes possible, as in the case of GSTM1 (gene present 
versus gene missing), if one genotype is accepted as conferring an increased risk of 
disease, the opposite genotype has to mean that the individual has a decreased risk of 
disease, relative to those who have the gene present, not ‘equal to other smokers’ (this
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reference to average risk being meaningless if 50% has one genotype and 50% has the
other genotype). It is understandable that they did not want to inform smokers with the
GSTM1 present genotype that they were at decreased risk of developing lung cancer,
given the concerns about causing complacency in this group, but it is not fair to say that
smokers that did not concur with these definitions of test results were inaccurately
interpreted their results. The issue of understanding is likely to be an important
consideration in determining how people react to genetic risk information, but not
necessarily for the reasons presented by these authors.
*
4.2.3. Obesity, heart disease, and nicotine addiction
A handful of observational and hypothetical scenario studies have examined the impact 
of positive and negative genetic test results for other conditions, primarily obesity, heart 
disease, and nicotine addiction. In one small observational study (Harvey-Berino et al, 
2001), 30 obese women underwent genetic testing for the b3-adrenergic reception gene, a 
gene variant thought to influence weight gain and energy expenditure. Subjects were 
asked a number of questions before and after testing, including a question on the degree 
to which they were confident they could control overeating and lose weight. There were 
no group by time differences in eating self-efficacy or confidence in the ability to lose 
weight. Thus, groups did not differ in their attitudinal variables on feedback about their 
genetic status. There were time differences, with both groups reporting increased 
confidence in their ability to lose weight after gene status was revealed. These findings 
provide no evidence either for genetic risk information increasing or decreasing 
confidence in ability to change behaviour, although could possible suggest genetic testing 
per se leads to changes in self-efficacy. However, the lack of a control group in this 
study means that this is conjecture only.
In anticipation of genetic tests for complex diseases becoming more widely available, a 
handful of studies have been conducted using hypothetical scenarios amongst individuals 
in the general population. Hicken and Tucker (2002) randomly assigned 90 adults to 
receive risk estimates based on a positive family history, a positive genetic test result, or 
a negative genetic test result. Although people were led to believe they were taking a real 
genetic test, it was in fact fake, and the disease -  despite having the characteristics similar
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to hemochromatosis -  was made up. Participants rated their perceived risk for 
developing ‘Asch Syndrome’ on a number of measures after receiving their risk results. 
Unsurprisingly, those who received a high risk result perceived themselves to be at higher 
risk than those who received a low risk result (3.0 vs 1.5 on a scale of 0 to 8). Those who 
received a positive genetic test result were not more likely to perceive high risk than 
those who received a positive family history result (3.3 vs 2.6 on the same 0 to 8 scale). 
No differences were found on intention to consume fat or soy between low genetic risk, 
high genetic risk, and high family-history based risk groups. People given the high-risk 
genetic feedback were more likely to intend to get screening than those in the low-risk 
genetic feedback group (p<.01). However, there were no differences between those who 
received high genetic risk feedback and high family history-based feedback (Hicken & 
Tucker, 2002). The ethical problem with this study design is clear: deliberately 
misleading people into believing that they are at risk of developing any disease, even if 
they were informed shortly after completing the study that the disease, and their risk, was 
completely fictional, is highly questionable.
A second approach that has been used is the ‘analogue’ study. Senior et al (2000) used 
this analogue approach by asking 212 students to imagine that they had recently taken a 
test that informed them that they were at high risk of developing heart disease. Half of 
the participants were asked to imagine that it was a ‘genetic test’ and the other half that it 
was a non-specified ‘test’. The participants with risk based on the genetic test rated heart 
disease as less preventable than did the other participants. In addition, the provision of 
genetic risk information resulted in lower magnitude ratings of attributions to the 
behavioural factors of lifestyle and diet than when risk information of an unspecified 
nature was provided.
In another experimental analog study (Wright, Weinman & Marteau, 2004), the impact 
on perceived control of testing for genetic vulnerability to nicotine addiction was 
examined. Smokers who were asked to imagine that they had tested positive for a 
mutation that confers an inherited predisposition to nicotine addiction did not perceive 
themselves as having less control over smoking. They were, however, more likely to 
select the use of a pharmacological agent as effective in assisting quitting and less likely
77
Chapter 5: Psychoiopjeai issue
to select the use of willpower. The authors suggested that this was concerning, because it 
raised the possibility that genetic testing will reinforce biologically based ways of 
reducing risk when behavioural or environmental change is equally if not more effective.
4.2.4. Familial hypercholesterolemia
Theresa Marteau and colleagues have pursued this issue of control using clinical studies 
of individuals and families being given information about the inherited condition, familial 
hypercholesterolemia (FH). They suggested that finding a mutation that confirms a 
clinical diagnosis reduces perceptions of control over the disease and adherence to risk- 
reducing behaviours. The first empirical study on which they based this hypothesis was 
an interview study with parents of 24 children who had received a positive screening 
result informing them that their child was at-risk for having FH (Senior et al, 1999). 
When parents perceived the test as detecting raised cholesterol the condition was 
perceived as familiar, dietary in origin, controllable, and less threatening. When the test 
was seen as detecting a genetic problem, the condition was perceived as uncontrollable 
and, hence, more threatening. They suggested that these pilot data raised questions about 
the extent to which assessing disease risks by DNA analysis may result in a sense of 
fatalism, adversely affecting motivation to change behaviour and to reduce risks.
Given that there may be a common perception that genetic risks are uncontrollable (Hunt 
et al, 2000; Shiloh et al, 2002), this hypothesis is supported by protection motivation 
theory, which states that changes in motivation and behaviour are largely determined by 
the perceptions that a recommended behaviour is both effective in achieving risk 
reduction and personally controllable. Thus, using genetic tests to predict disease could 
potentially decrease motivation to engage in risk-reducing behaviours, by strengthening 
beliefs that a disease is neither preventable nor controllable (Marteau et al, 2004).
Whilst this hypothesis is theoretically plausible, the findings from the small, non­
controlled interview study of 24 parents of newborn infants (Senior et al, 1999), have 
been used time and again in the past to support the argument that positive genetic test 
results of all kinds may lead to a sense of fatalism based on the belief that genetically 
conferred risks are serious and immutable (Marteau & Lerman, 2001). They have
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repeatedly been cited to support the view that genetic testing for complex diseases is 
unlikely to increase motivation to change behaviour because of the common perception 
that genetic factors are uncontrollable (Haga et al, 2003). In the paper, Senior and 
colleagues suggest that if providing people with genetic risk information leads them to 
become fatalistic, they may be less likely to act in ways which reduce their risks such as 
changing their diet or quitting smoking. However, the wisdom of extrapolating to any 
great extent from diagnostic testing of newborn babies to genetic susceptibility testing in 
adults is questionable, given the different implications of the two types of test for the 
individual concerned.
Accordingly, Marteau and colleagues designed a randomised controlled trial to test the 
fatalism hypothesis in adults by assessing the impact of confirming or making a clinical 
diagnosis of FH using genetic testing (Marteau et al, 2004). The study comprised 
families with a known predisposition to heart disease, and were thus already aware of 
their genetic vulnerability to heart disease. 341 FH probands and 128 adult relatives were 
randomly assigned to one of two groups: routine clinical diagnosis or routine clinical 
diagnosis plus confirming genetic testing. The findings were in direct contrast to the 
hypothesis that increasing perceptions of genetic cause decreases perceived control over 
the disease: people who received a genetic diagnosis perceived more control, not less, 
over heart disease and FH than people in whom no mutation was found (p=.03 and 
p=.01). In addition, perceived fatalism was no different in people who received an FH 
carrier genetic test result than either those who received an FH non-carrier result or who 
received their diagnosis non-genetically. The study did find some short term 
psychological effects of receiving a positive genetic test result for FH; mutation carriers 
were more depressed than non-carriers at one-week follow-up (p=.04) but the effects 
were reduced at 6 month follow-up (p=.07) and there were no differences in anxiety 
levels between mutation carriers and non-carriers at either time point. Those in whom an 
FH mutation was found were less anxious than those for whom the diagnosis was non- 
genetically confirmed one week after the diagnostic assessment (p=.03), but again, not at 
6 months. They found that there were no differences on medication adherence between 
carriers, non-carriers and non-genetic diagnosis patients at follow-up. Total fat intake 
and unsaturated fat intake also did not differ between groups, nor did exercise levels, nor
79
Chapter 3: PsycbokHiK'ni issues
did smoking. Thus on the one hand, the study found no evidence for a motivational 
effect of being informed of FH carrier status, nor on the other hand was there evidence 
for a de-motivational effect of either a carrier or a non-carrier status. However, the 
population studied was aware of their higher risk status already due to family history, and 
had better baseline health behaviours than the general population, so the study may not 
have detected differences due to ceiling effects at baseline.
Although cited less often than Marteau’s work, it is useful also to consider the experience 
in the Netherlands, where a nationwide screening and genetic testing program for the 
identification of individuals with FH was initialised in 1994 (Umans-Eckenhausen et al, 
2001). When the 747 patients diagnosed with FH using genetic testing in this study were 
followed up two years later, only 14 (2%) communicated a negative opinion and regretted 
taking the test. 624 patients with FH (85%) reported a positive attitude toward the FH 
program, and 95 (13%) expressed a neutral opinion. However, the possibility of self­
selection is again raised here.
The percentage of FH carriers treated with cholesterol-lowering medication rose from 
38% to 85% after two years (Umans-Eckenhausen et al, 2003). This is quite a striking 
increase although the lack of a control group limits the conclusions we can draw on the 
basis of this increase. However, the authors challenged the often-quoted assertion of 
Marteau and Lerman (2001) that behavioural change after identification of a genetic risk 
was difficult to achieve, claiming instead that “in contrast, the results of this study, such 
as the significant increase in treatment levels and overall positive attitude toward the 
screening program, do not support their findings”. We might tentatively conclude from 
the limited evidence available in FH, that a small minority of individuals who choose to 
take a genetic test for FH regret their decision once they have received their result, and 
that there are short term but not long term effects on depression. We may speculate that 
self-selection earlier in the process meant that people who would have regretted taking 
the test in the Netherlands did not agree to be tested.
Although we can speculate on the implications of these FH studies, it is difficult to draw 
any strong conclusions from them because of, for example, the small sample size in
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Senior et al (1999) and the lack of control group in the Netherlands study. However, 
none of the studies provide evidence of major psychological harm, either in terms of 
lasting depression or anxiety in the positive genetic test result group, nor in terms of false 
reassurance in terms of behaviours. Extrapolating from the study by Marteau et al (2004) 
to genetic testing for common variants in general population samples is difficult, since all 
the individuals in this study already knew that they had hereditary heart disease (or a 
close family member did) and were therefore at high risk of future heart events regardless 
of whether or not an FH mutation was found.
4.3. Behavioural impact: summary and critique
Despite repeated claims that genetic testing will lead to reduced disease burden by 
motivating individuals to make health-protective behaviour changes (Bell, 1998; Collins, 
1999; Garte, 2001; Mathew, 2001; Pharoah et al, 2002; Balmain, Gray & Ponder, 2002; 
Department of Health, 2003), very little is known about the actual ways in which genetic 
testing influences behaviour (Lerman, Croyle, Tercyak & Hamann, 2002). The few 
studies examining behaviours relevant to breast and ovarian cancer, such as prophylactic 
surgery, have reported mixed findings. The proportion of carriers opting for mastectomy 
has ranged from 0% (Botkin et al, 2003) and 3% (Lerman et al, 2000) in the US, up to 
55% (Meijers-Heijboer et al, 2000) in the Netherlands. Decisions amongst carriers to opt 
for oophorectomy have been similarly varied, ranging from 13% (Lerman et al, 2000) up 
to 46% (Botkin et al, 2003), and higher in the Netherlands at 58-60% (Kauf et al, 2002; 
Meijers-Heijboer et al, 2000). Differences in the content of the information and 
recommendations provided may explain in part the mixed findings between studies in this 
area. Similarly, some of the differences in terms of use of prophylactic surgery between 
US studies and Dutch studies may be cultural, and the differences between all studies 
may have something to do with the exact nature of the information that the women are 
given, and the advice that they receive.
The question of whether genetic testing will lead to health behaviour change becomes
ever more important as common genetic variants are identified which confer an increased
or decreased susceptibility to complex diseases which are more strongly linked to
behaviour than the familial cancers associated with rare, highly penetrant mutations.
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There is growing recognition that health education and health behaviour researchers will 
play a central role in evaluating the benefits and risks of new genetic tests for common 
genetic variants associated with complex diseases as they emerge (Marteau, 1999; 
Collins, Green, Guttmacher & Guyer, 2003). The assumption that individuals identified 
as being at increased risk of developing a complex, behaviour-related disease, such as 
lung cancer or heart disease, may be able to considerably reduce their risk by making 
lifestyle changes (Bell, 1998; Day & Wilson, 2001), such as quitting smoking, is 
supported by the fact that perceived disease susceptibility is a central component of many 
social cognition models of health behaviour change such as the Health Belief Model 
(HBM: Rosenstock, 1974, Protection Motivation Theory (PMT: Rogers, 1975; 1983) and 
the Health Action Process Approach (HAPA: Schwarzer, 1992). However, it also 
follows that informing smokers that they are not genetically susceptible could decrease 
their motivation to quit, and there is the danger that people who are not found to be at 
increased risk could develop a false sense of reassurance, feeling invulnerable to the 
adverse effects of their risky behaviour (Marteau & Lerman, 2001).
Two randomized controlled trials have evaluated the impact of feedback on common 
genetic variants associated with smoking-related disease susceptibility (Lerman et al, 
1997; McBride et al, 2002). In both, smokers were randomly assigned either to a 
smoking cessation intervention which included personalized genetic risk information on 
the basis of genetic testing for a common genetic variant, or to a control group. Lerman 
et al (1997) used the CYP2D6 gene, and McBride et al (2002) used the GSTM1 gene, 
both of which are polymorphic and may contribute to lung cancer susceptibility (El Zein, 
1997; Rostami-Hodjegan et al, 1998; McWillians et al, 1995; Houlston et al, 1999; Vineis 
et al, 1999; Benhamou et al, 2002).
Lerman et al (1997) found no differences between groups on smoking variables at 2- 
month follow-up, but did find that the group given genetic risk information were more 
motivated to quit and had made more quit attempts than the control group at one year 
follow-up. However, there were no differences in actual cessation rates at either follow- 
up. They found that the genetic risk information had short-term (two month), but not 
long-term (one year) effects on depression and fear relative to controls (for one-year
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follow-up data see Audrain et al, 1997). In this study, the authors suggest that the 
minimal contact counselling intervention may not have provided enough support for the 
participants to overcome their nicotine addiction, despite their increased motivation.
McBride et al (2002) found that smokers given the genetic risk information were twice as 
likely to have actually quit at six month follow-up than controls (19% vs. 10%), but there 
were no differences between those who received a positive (‘higher risk’) genetic test 
result and those who received a negative (‘not higher risk’) genetic test result. They 
found no effect of genetic testing on perceived risk or depression. In this study, those 
receiving genetic risk information received considerably more support than the control 
group, so disentangling the different components of the intervention is difficult. The 
relative impact of negative genetic test results versus positive genetic test results for 
complex, behaviour-related diseases therefore remains to be seen. In addition, the 
smokers who participated in these studies were more motivated to quit and more addicted 
to nicotine than those in the general population.
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Table 3.4. Studies examining the impact of genetic testing for cancer and heart disease: examples of randomized and non-randomized 
study designs
Study
Botkin et al (2003)
Lerman et al (2000)
Bonadona et al (2002)
Esplen et al (2001)
Marteau et al (2004)
Umans-Eckenhausen et al (2003)
Hicken & Tucker (2004)
Lerman/Audrain et al (1997)
McBride et al (2000)
McBride et al (2002)
Disease Sample size Sample characteristics and groups
breast-ovarian 189 High risk sample, all offered genetic test.
carriers vs. non-carriers
breast-ovarian 216 High risk sample, all offered genetic testing._________________________
carriers vs. non-carriers vs. test decliners
BRCA/HNPCC 23 Cancer patients, all taken genetic test and received a positive carrier result.
genetic testing, no comparison group
HNPCC 50 High risk sample, all taken genetic test._________________________________
carriers vs. non-carriers vs. waiting for result
FH 469 High risk sample o f FH probands and relatives, randomized to genetic testing or not.
genetic test, mutation vs. genetic test, no mutation vs. non-genetic
diagnosis
FH 747 high risk patients, all received positive FH mutation genetic test results
genetic testing, no comparison group
TAA (fake) 90 General population randomized to genetic testing or not.
genetic test vs. genetic test vs. family history based
high risk result low risk result high risk result
lung cancer 426 General population smokers, randomized to genetic test, C 20, or not.
CYP2D6 _______________
genetic test vs. C 20 control vs. standard care
high risk result group control group
lung cancer 144 General population smokers, all tested, randomized to counseling method.
GSTM1
genetic testing______________________________________________________
lung cancer 557 General population smokers, randomized to genetic testing or not.
GSTM1
genetic testing______ vs.______ standard care___________________________
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Table 3.5. Outcomes included in studies examining the behavioural and psychological
impact of genetic testing for susceptibility to cancer
Outcome/study Disease (gene or type) Country Study design
Psychological impact outcomes
Depression
Bonadona et al (2002) 
Esplen et al (2001) 
McBride et al (2000) 
McBride et al (2002) 
Lerman et al (1997) 
Audrain et al (1997)
Breast-ovarian or colon (HNPCC) 
Colon cancer (HNPCC)
Lung cancer (GSTM1)
Lung cancer (GSTM1)
Lung cancer (CYP2D6)
Lung cancer (CYP2D6)
France
Canada
US
US
US
us
Qualitative
Prospective
Experimental
Experimental
Experimental
Experimental
Perceived risk
Esplen et al (2001) 
Lerman et al (1997) 
McBride et al (2000) 
McBride et al (2002)
Colon cancer (HNPCC) 
Lung cancer (CYP2D6) 
Lung cancer (GSTM1) 
Lung cancer (GSTM1)
Canada
US
US
US
Prospective
Experimental
Experimental
Experimental
Disease-specific worry
Botkin et al (2003) 
Lerman et al (2000) 
Esplen et al (2001) 
McBride et al (2002) 
McBride et al (2000) 
Lerman et al (1997)
Breast cancer (BRCA1/2) 
Breast-ovarian cancer (BRCA1/2) 
Colon cancer (HNPCC)
Lung cancer (GSTM 1)
Lung cancer (GSTM 1)
Lung cancer (CYP2D6)
US
US
Canada
US
US
US
Prospective
Prospective
Prospective
Experimental
Experimental
Experimental
Anxiety
Bonadona et al (2002) 
Esplen et al (2001)
Breast-ovarian or colon (HNPCC) 
Colon cancer (HNPCC)
France
Canada
Qualitative
Prospective
Reduced uncertainty
Esplen et al (2001) Colon cancer (HNPCC) Canada Prospective
Behavioural impact outcomes
Smoking
McBride et al (2002) 
McBride et al (2000) 
Lerman et al (1997) 
Audrain et al (1997)
Lung cancer (GSTM1) 
Lung cancer (GSTM1) 
Lung cancer (CYP2D6) 
Lung cancer (CYP2D6)
US
US
us
us
Experimental
Experimental
Experimental
Experimental
Disease surveillance
Botkin et al (2003) 
Lerman et al (2000) 
Esplen et al (2001)
Breast cancer (BRCA1/2) 
Breast-ovarian cancer (BRCA1/2) 
Colon cancer (HNPCC)
us
us
Canada
Prospective
Prospective
Prospective
Prophylactic surgery
Botkin et al (2003) 
Lerman et al (2000)
Breast cancer (BRCA1/2) 
Breast-ovarian cancer (BRCA1/2)
US
US
Prospective
Prospective
Diet
Esplen et al (2001) Colon cancer (HNPCC) Canada Prospective
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5. Discussion and research needs
5.1. Interest in genetic testing
The clinical utility of the new genetic tests for complex diseases as they emerge will 
depend in part on whether people believe the tests to be of potential personal value 
(Burke et al, 2002). The first step towards evaluating this is to ask what demand might 
be amongst the relevant groups. In the case of genetic tests for common genetic variants 
the relevant group is initially the whole of the general population. Therefore, interest at 
the population level needs to be examined. Much of the literature on interest in genetic 
testing comes from clinical genetics, and of the studies examining interest at a 
representative population level, none have been conducted in the UK. The first research 
need, therefore, is to examine initial interest in genetic testing for complex diseases in a 
UK representative general population sample.
The second research need is for surveys of interest in genetic tests for complex diseases 
other than cancer, such as heart disease, because most of the literature so far has focused 
on cancer genetics. There is also a need for surveys of interest which examine more than 
one disease at a time, since at present it is difficult to establish whether general 
population attitudes are specific to cancer genetic testing, or generalizable to other 
equally widespread conditions such as heart disease.
Examination of the correlates of interest in genetic testing suggests that demographic 
variables warrant further investigation, partly because there is not yet consensus on how 
some of these variables relate to interest, and also because factors such as socioeconomic 
status and education may be more important as genetic tests move into the general 
population and away from the specialised clinical context. The relationship with family 
history also warrants further consideration because, until now, this has been an important 
factor in determining the appropriateness of genetic testing for an individual, whereas in 
the future this is likely to be less the case.
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Finally, initial studies have been criticized for using hypothetical vignettes to assess 
interest in testing and correlates of interest, since assessments of intentions have been 
made following brief, relatively uninformative statements about the tests. Studies have 
provided limited information to participants about the potential risks of testing, such as 
insurance discrimination and adverse psychological effects (Lerman, Croyle, Tercyak & 
Hamann, 2002). There is therefore a need to consider whether people who are given 
more information of this kind express different attitudes and levels of interest compared 
to those who receive more basic information.
5.2. Psychological impact of genetic testing
Although the clinical literature suggests there are short term, but not long term adverse 
psychological effects of genetic testing, all of the research to date has been conducted 
within the clinical context and with the availability of extensive counselling. Genetic 
tests are already being marketed direct to the public by commercial companies without 
this level of support, and almost nothing is known about the potential level of harm that 
this could cause. Whether genetic counselling will be necessary for all forms of genetic 
tests in the future is debatable and remains to be seen. So, the first research need is to 
examine reactions amongst a general population sample to see if there is the potential for 
adverse psychological reactions, such as depression, to unfavourable genetic test results 
for complex disease susceptibility, away from the clinical counselling context. This 
raises ethical difficulties, because one doesn’t want to risk causing harm by giving people 
genetic test results which might cause psychological distress in the absence of extensive 
counselling.
A starting point is to look at anticipated psychological reactions to determine how people 
believe they might respond and to determine the characteristics of those who may be 
vulnerable to having more adverse psychological reactions. A second research need is 
therefore to examine the characteristics of people in the general population who may be 
vulnerable to adverse psychological reactions. This information can then be used to 
make decisions about the appropriateness and design of research protocols in which 
actual reactions are potentially examined.
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With regard to correlates of psychological impact, the clinical literature suggests that 
people with higher levels of pessimism have worse reactions. Public understanding of 
genetics has received less attention in the literature on psychological impact of genetic 
testing, but will be of increasing importance as a broader range of people in the general 
population increasingly have access to genetic tests. A third research need is therefore to 
examine the relationship between understanding of genetic testing and anticipated 
psychological reactions to genetic test results and, as with interest, to consider whether 
the provision of additional information modifies this relationship.
Finally, a fourth research need is to test the self-selection hypothesis in a general 
population sample. Individuals vulnerable to having adverse psychological reactions 
may not choose to take the test in the first place, and the relationship between anticipated 
psychological reactions and interest in testing therefore warrants further investigation.
5.3. Behavioural impact of genetic testing
There is an urgent need for research evaluating the behavioural impact of genetic tests for 
common genetic variants because of the unregulated commercial availability of these 
tests. There is also a need for health psychologists and health behaviour researchers to 
have a better understanding of how these tests impact on behavioural change in order to 
determine whether future tests may be viable components of interventions such as 
smoking cessation programmes or individual risk assessments for diseases such as heart 
disease. Ideally, further empirical research is needed which evaluates the impact of 
genetic testing for common variants using randomised controlled trials (RCTs) (Friedli & 
King, 1998; Stephenson & Imrie, 1998), such as those conducted by Caryn Lerman 
(Lerman et al, 1997) and Colleen McBride (McBride et al, 2002) (see Table 3.4 for 
examples of randomized and non-randomized studies).
A number of outcomes could be examined, such as changes in dietary fat intake, reduced 
BMI, smoking cessation, changes in motivation to quit smoking, intention to quit 
smoking, increased activity levels, changes in disease perceptions, perceived control, or 
willingness to use pharmacological interventions versus willingness to make lifestyle 
changes (see Table 3.5 for examples of psychological and behavioural outcomes studied
to date). At present, probably the best outcomes to examine empirically are those that are 
smoking-related, due to the relatively robust association of one particular common 
variant, GSTM1, with smoking-related cancers, particularly lung cancer (see Chapter 1). 
Also, two RCTs have already generated some data in this field (Lerman et al, 1997; 
McBride et al, 2002), although they leave a number of research questions still to be 
answered. The first research need is to examine the impact of receiving a GSTM1- 
present genetic test result (conferring decreased susceptibility to lung cancer) versus a 
GSTM 1-missing genetic test result (conferring an increased susceptibility to lung cancer) 
on depression, motivation to quit, and perceived risk. Although one previous study posed 
these questions (McBride et al, 2002), the design and reporting of the study did not allow 
for a full examination of these outcomes.
The second research need is for surveys and other pilot studies to improve understanding 
of the circumstances under which genetic testing for smoking-related disease might lead 
either to positive outcomes such as increased motivation to quit smoking or to 
undesirable outcomes such as depression or complacency. One way to do this is to 
compare the characteristics of smokers in the general population who do and do not 
anticipate each of these outcomes. As before, there is also a research need to make 
comparisons between different diseases, such as cancer versus heart disease, as this has 
been neglected in all areas of the psychological literature on genetic testing to date.
6. Research questions
At the beginning of this chapter I outlined three broad research questions relating to 
psychological issues around genetic testing: 1) what is the degree o f interest in genetic 
testing amongst the relevant groups, and what factors influence whether individuals 
decide to have a genetic test? 2) what is the psychological impact o f genetic testing? and 
3) what is the impact o f genetic testing on health-related behaviour? The literature 
reviewed in this chapter demonstrates that most of what is known regarding these three 
questions comes from experience with clinical genetic tests for rare genetic mutations and 
high-risk populations but, as discussed in Chapters 1 and 2, genetic testing is moving out 
of the clinical context and into the general public sphere as more genetic tests for
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complex diseases and common genetic variants are introduced. A number of specific 
research questions identified from the literature are therefore suggested which focus more 
specifically on genetic testing for common genetic variants associated with complex 
diseases amongst the general population. These are listed below under the heading of 
each of the three broad research questions.
What is the degree o f interest in genetic testing for complex diseases in the general 
population, and what factors influence whether individuals decide to have a genetic 
test?
Specifically, what is the level of interest in genetic testing for complex diseases in the 
UK? Is the level of interest the same for heart disease as it is for cancer, and do the same 
factors predict interest in genetic testing for the different diseases? What are the 
relationships between demographics and family history with interest? And does the 
amount and type of information that accompanies surveys influence interest?
What is the psychological impact o f genetic testing for complex diseases in the general 
population?
What are the anticipated and actual psychological reactions to genetic testing for common 
diseases such as cancer and heart disease amongst people not selected for being at high 
genetic risk? Do individual characteristics such as understanding of genetic testing 
influence adverse anticipated reactions? Is there evidence to support the hypothesis that 
individuals in the general population will self-select themselves in and out of testing?
What is the impact of genetic testing for complex diseases on health-related behaviour 
in the general population?
Specifically, what are the characteristics of smokers who anticipate finding genetic 
testing motivational and therefore might benefit from testing? What are the 
characteristics of smokers who anticipate responding complacently or with adverse 
psychological reactions and therefore might be susceptible to harm by genetic testing? 
Will GSTM 1-missing results lead to increased motivation to quit smoking or depression? 
And will GSTM 1-present results lead to decreased motivation and complacency?
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7. Overview of studies
In this thesis I describe three studies which addressed these research questions; two 
population-based surveys and one exploratory randomised controlled trial.
Study 1 examined the degree of interest in genetic testing amongst a UK representative 
sample (n= 1,960) recruited through the Office for National Statistics Omnibus Survey. 
Demographic and family history correlates of interest were examined, and comparisons 
were made between interest in genetic testing for susceptibility to cancer versus heart 
disease.
Study 2 was a postal population-based questionnaire survey of people recruited through a 
GP practice in Oxfordshire (n= 1,024), in which half respondents received a genetics 
information leaflet with the survey. The results of this study are presented in three parts, 
Studies 2a, 2b, and 2c.
Study 2a examined the effects of the information leaflet on respondents’ interest in 
genetic testing. Also examined were people’s anticipated psychological reactions to 
genetic test results, and their subjective understanding of genetic testing, and the impact 
that the leaflet had on these outcomes.
Study 2b examined the correlates of anticipated psychological reactions, and looked 
particularly at the relationships between anticipated reactions and interest to test the self­
selection hypothesis.
Study 2c examined the anticipated behavioural impact of genetic testing amongst a 
subset of smokers. Specifically, the characteristics of smokers who anticipated having 
motivated, complacent and depressed reactions to genetic test results were examined, in 
anticipation of giving actual genetic risk feedback to smokers in Study 3.
Study 3 was a small randomized controlled trial (n=61) in which smokers were randomly 
assigned to a control group or a GSTM1 genetic testing group, and followed up for two 
months. Comparisons were made between the controls, the GSTM 1-missing group, and 
the GSTM 1-present group on perceived risk of lung cancer, depression and anxiety, and 
motivation to quit smoking.
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CHAPTER 4
Study 1: Interest in genetic testing for cancer and heart disease amongst 
a representative population-based sample5
1. Introduction
The aim of this study was to examine the degree of interest in genetic testing for complex 
diseases in a sample representative of the UK general population. Whilst there is an 
abundance of literature on interest in genetic testing for cancer susceptibility, much of it 
has been in high-risk samples, and none of the population-based surveys that have been 
conducted have been in the UK. Moreover, much less is known about interest in genetic 
testing for other complex diseases, such as heart disease. The fact that most studies 
examining interest amongst general populations have examined cancer makes it difficult 
to determine on the current evidence the extent to which people are interested in genetic 
testing per se, or whether there are significant differences in levels of interest in genetic 
testing for different common diseases.
Genetic factors associated with heart disease have been established for many years: as 
early as 1974 the candidate gene approach led to the detection of a strong association 
between genetically determined Lp(a)lipoprotein and premature coronary heart disease 
(CHD) (Stephens & Humphries, 2003), and more recently polymorphic genes have been 
associated with heart disease, such as APOE (Humphries et al, 2001). It was suggested 
as early as 1989 that ‘such variants should become useful tools in predictive genetic 
testing for CHD risk’ (Berg, 1989), and yet there has been a paucity of research 
investigating the psychological and social aspects of genetic testing for heart disease.
It is generally assumed that people are more fearful of cancer than they are of heart 
disease, and believe it to be less preventable. There is some evidence that people who 
have high levels of disease concern are more likely to opt for cancer genetic testing, as
5 A version of this chapter has been published in Preventive Medicine (Sanderson, Wardle, Jarvis & 
Humphries, 2004: see Appendix A)
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are people who believe they are at higher risk of developing the disease (Bosompra et al, 
2000), and in addition there is some limited evidence to suggest that people think 
differently about their personal risks of developing heart disease compared to cancer. In 
one study, 23% of 112 participants believed they were less likely to develop heart disease 
than other people of their age, whereas only 10% believed they were less likely to 
develop cancer than other people (Ponder et al, 1996). This could suggest that people 
might be more interested in genetic testing for cancer than heart disease, were it not for 
the finding in some studies that people believe cancer to be less preventable than heart 
disease. Given that interest in genetic testing tends to be higher when people believe the 
disease is preventable or that action can be taken to reduce risk, then we might 
hypothesise that interest will be higher for genetic testing for heart disease than cancer 
susceptibility.
Previous studies have found interest and uptake of genetic testing for cancer 
susceptibility to be higher amongst women and people with higher levels of education, 
whilst the association with age has been inconsistent (Struewing et al, 1995; Lerman et al, 
1996; Glanz et al, 1999; Myers et al, 2000; Weinrich et al, 2002). People with a family 
history of cancer have higher levels of interest than those without, but the association is 
not as strong as might be expected (Lipkus et al, 1999; Capelli et al, 2001; Lerman, 
Croyle, Tercyak & Hamann, 2002). It remains to be seen whether the same patterns of 
correlates will emerge for heart disease.
Part of the reason for some of the inconsistencies such as the association with family 
history may be due in part to differences in the characteristics and source of the 
population being studied. Another reason for addressing both cancer and heart disease 
within one study is therefore to examine whether people respond differently to questions 
of genetic testing for different diseases when the same data collection methodology is 
used. One of the limitations of studies to date is that a range of levels of interest in 
genetic testing have been reported (albeit within the higher range of interest), but the 
studies have a) addressed different diseases (e.g. Huntington’s or breast cancer or colon 
cancer); b) used different methodologies (e.g. postal, telephone or face-to-face surveys); 
and c) adopted different question formats (Bowen, Patenaude & Vernon, 1999).
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Addressing two diseases within one survey might help shed light on whether people 
answer differently for different diseases. This is an important issue to address because 
policy decisions draw on this kind of research, and yet cancer is not necessarily 
representative of other diseases.
A further reason for the present study was to address how individuals in the general 
population feel about taking genetic tests for complex diseases when given minimal 
information. Some population-based surveys have been criticized for providing too little 
information to participants concerning the limitations of testing (Lerman, Croyle, 
Tercyak & Hamann, 2002). Undoubtedly, as the literature on Huntington’s disease and 
breast cancer has shown, actual uptake is invariably lower than initial interest 
(Mastromauro et al, 1987; Salkovskis & Rimes, 1997). Part of the reason for diminishing 
interest may be due to some people who show an initial interest later deciding against it 
once they learn, for example, that the tests cannot give them a definitive, yes or no, 
answer. However, it is important to know about the public’s interest without detailed 
information, because it may reflect the reality that commercial companies currently 
providing these tests do not necessarily provide extensive, or reliable, information about 
testing.
The aim of the present study was therefore to assess interest in genetic testing using a 
survey sample that was representative of the UK general population, and that had not 
received detailed information about genetic tests prior to decision-making. The cross- 
sectional study was designed to be able to compare levels of interest in genetic testing for 
heart disease and cancer within individuals, and to examine the relationships between 
interest and gender, age, education, and family history. It was hypothesized that people 
would be more interested in genetic testing for heart disease than for cancer, on the basis 
that heart disease tends to be regarded as more controllable and less terrifying than 
cancer. It was also hypothesized that interest in genetic testing for cancer susceptibility 
would be higher amongst women, people with lower education and people with a family 
history of the disease, and that the same factors would be associated with interest in 
genetic testing for heart disease.
94
Chapter 4: Study !: ONS survev
2. Method
2.1. Participants and procedure
A series of questions on genetic testing were included in the September 2002 Omnibus 
Survey. The Omnibus Survey is a monthly multi-purpose survey developed by the Office 
for National Statistics for use by Government and non-profit making organisations, and 
uses a stratified random probability sample. The surveys are conducted by interviewers 
with hand-held computers in people’s homes. Previous Omnibus surveys have addressed 
a range of health-related issues, including obesity (Wardle et al, 2001), oral health (Grath 
et al, 2000), and health status (Bowling & Windsor, 1997). Of the 3,000 addresses that 
were selected in September 2002, 224 (7%) were ineligible on the basis that they were 
not occupied homes, i.e. they were business addresses or new or empty properties. From 
the remaining 2,776 eligible addresses, 586 (21%) of the people contacted did not wish to 
take part, and 230 (8%) were uncontactable, giving a response rate of 71%. As a 
preamble to the genetic testing section of the interview, respondents were told that 
‘Nowadays, it is possible to predict whether or not a person is likely to develop certain 
diseases by analysing their genes. This is called genetic testing. Genetic testing is 
currently available for a limited number o f diseases, but it may be available for more 
diseases in the future. ’ See Appendix D for survey instrument.
2.2. Measures
2.2.1. Interest in genetic testing measures
Interest in genetic testing was then measured using the items: 'I f  it were available, would 
you, in the next 6 months, have a genetic test to see ifyou are at risk o f developing heart 
disease [cancer] in the future?’. Response options were: ‘yes definitely’; ‘yes 
probably’; ‘no probably not’; and ‘no definitely not’. This item were adapted from 
previous research (Bunn et al, 2002; Bosompra et al, 2000), and was chosen on the basis 
that the six month time frame made the hypothetical question more concrete; it has been 
suggested that six months is about as far into the future as most people plan a specific 
behaviour change (Prochaska et al, 1994).
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2.2.2. Demographic measures
The Omnibus survey includes questions on gender, age and ethnicity. Educational level 
was classified into four groups: ‘degree or equivalent’, ‘A-levels or equivalent’ 
(examinations taken at age 18 in England), ‘GCSEs or equivalent’ (examinations taken at 
age 16 in England), and ‘no formal qualifications (or ‘none’)’.
2.2.3. Family history measures
Family history was assessed with the questions ‘do any o f your close family members 
(e.g. parents, children, brothers, sisters, grandparents) have, or have had, heart disease 
[cancer]?\ A dichotomous ‘yes’ or ‘no’ response was required. This item was designed 
to measure the respondents’ subjective belief about whether or not they had the disease in 
their family, rather than an objective assessment of family history-based risk. The 
interviewer was also given the following instructions: “Include immediate blood relatives 
only, not cousins or spouse/partner”. Although it was not explicitly asked, if respondents 
spontaneously responded that they themselves had heart disease or cancer, the 
interviewer was briefed not to ask any further questions about family history or interest in 
genetic testing for that disease. This was because the interviewers were not trained to 
deal with the issues that might be raised, and there was no mechanism in place whereby 
respondents could be referred for further support.
2.3. Statistical analysis
Statistical analyses were carried out using SPSS for Windows v 10.0. Interest in the two 
types of testing was compared using a paired t-test. Univariate associations between 
interest in genetic testing and age, gender, ethnicity, education, and family history were 
examined using a series of chi-square tests. Pearson’s chi-square tests were calculated 
for all of the predictor variables, and linear-by-linear associations were also reported 
when the variable contained more than two categories. The linear-by-linear test is a form 
of chi-square available on SPSS-10 which allows the explicit examination of linear 
associations between the predictor variable and the output variable. Multiple logistic 
regression was used to examine the independent associations between interest in testing 
and the predictor variables when controlling for all other predictor variables. Analyses
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on predictors of interest in genetic testing were conducted having dichotomised the four 
response options for ‘interest in genetic testing’ into ‘interested’ (responding ‘yes, 
probably’ or ‘yes, definitely’) and ‘not interested’ (responding ‘no, probably not’ or ‘no, 
definitely not’).
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3. Results
3.1. Characteristics of respondents
The 1,960 respondents ranged in age from 16 to 96 with a mean age of 47 years 
(SD=18.2yrs). Just over half (51%) were female, and the majority (94%) were White 
British. Table 4.1 shows the demographic characteristics of the sample: 32% had no 
formal qualifications; 27% had GCSEs or equivalent; 29% had A-levels or equivalent; 
and 13% had a degree or equivalent. When asked whether they had any close family 
members with heart disease: 42% (830) said ‘yes’; 52% (1,017) said ‘no’; 2% (41) said 
‘don’t know’; and 4% (72) volunteered that they had heart disease themselves. When 
asked whether they had any close family members with cancer: 55% (1,070) said ‘yes’; 
42% (812) said ‘no’; 1% (24) said ‘don’t know’; and 3% (53) volunteered that they had 
cancer themselves.
Table 4.1. Characteristics of respondents
% n
Gender
Male 49% 961
Female 51% 999
Age group
16-30 21% 412
31-45 30% 584
46-60 24% 478
61-75 17% 333
76+ 8% 152
Education
Degree 13% 247
A-levels 29% 559
GCSEs 27% 524
No formal qualifications 32% 629
Ethnicity
White-British 94% 1843
Non White-British 6% 112
Family history of heart disease
Respondent has heart disease 4% 72
No (no family members with heart disease) 52% 1017
Don’t know 2% 41
Yes (at least 1 family member with heart disease) 42% 830
Family history o f cancer
Respondent has cancer 3% 57
No (no family members with cancer) 42% 819
Don’t know 1% 21
Yes (at least 1 family member with cancer) 54% 1061
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3.2. Interest in genetic testing: cancer vs. heart disease
Of the 1,960 respondents who were asked about their interest in genetic testing for cancer 
risk, 64% (1,202) said that they would ‘definitely’ or ‘probably’ take the test: 39% (725) said 
‘yes, definitely’, 26% (477) said ‘yes, probably’, 16% (296) said ‘no, probably not’, 20% 
(372) said ‘no, definitely not’, and 2% (36) refused to answer the question or said ‘don’t 
know’.
Of the 1,888 respondents asked whether they would take a genetic test for heart disease, 69% 
(1,297) said that they would ‘definitely’ or ‘probably’ take the test: 42% (785) of
respondents said ‘yes, definitely’ and 28% (512) said ‘yes, probably’. 14% (253) said ‘no, 
probably not’, 17% (307) said ‘no, definitely not’, and 2% (32) said that they ‘didn’t know’ 
or refused to answer the question (these respondents were not included in subsequent 
analyses). Table 4.2 shows the frequencies of responses.
Table 4.2. Interest in genetic testing: frequencies and comparison between cancer and heart 
disease
Cancer Heart
disease
Sig.*
If it were available now, would you have a
genetic test for [cancer] [heart disease] risk
in the next 6 months? No, definitely not 20% 17%
No, probably not 16% 14% p<.001
Yes, probably 26% 28%
Yes, definitely 39% 42%
A paired t-test (with interest scored from 1-4, with 4 being definitely interested) showed that 
people were more likely (p<.001) to express interest in genetic testing for heart disease 
(mean 2.95, 95% Cl 2.91:3.01) than for cancer (2.83, 95% Cl 2.78:2.88), but the absolute 
differences were not large (see Figure 4.1).
99
Chapter 4: Study 1: ONS survey
Figure 4.1. Proportions of respondents expressing 
interest in genetic testing for susceptibility to cancer 
and heart disease
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3.3. Correlates of interest in genetic testing
3.3.1. Genetic testing for susceptibility to cancer
Contrary to the hypothesis, chi-square analyses showed that men were more interested than 
women in having a genetic test for cancer risk than were women (67% vs. 62%, p=.019). 
Interest was lowest in the oldest adults at 51%, and highest in the mid-life adults (aged 46- 
60yrs, 69% were interested, p=.001). Interest in testing for cancer was lowest in people 
educated to degree level, and among those with no formal qualifications, and higher in 
people with middling levels of education (p=.028). There were no differences between 
White British and Non-White British respondents (p=.982). There was no association 
between family history and interest: the proportions interested were 63% of those with no 
family history, 66% of those with a family history, and 52% of those who didn’t know about 
their family history (p=.244). When all the variables were put into a multiple logistic 
regression analysis, the effects of gender, age and education were maintained.
3.3.2. Genetic testing for susceptibility to heart disease
The univariate associations with gender, age, education and ethnicity were the same for heart 
disease risk as for cancer risk. Men were slightly more likely than women to say that they
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would ‘definitely’ or ‘probably’ take a genetic test for heart disease risk (72% vs. 68% 
respectively; p=029), and age was strongly associated with interest (p<.001), with highest 
interest in people in later middle age (78%) and lowest in the older age group (49%). There 
were significant differences between educational groups (p<.001), with lowest interest in 
those with the highest level of education (62%). Among the remaining groups, interest was 
lower among those with no formal qualifications (64%), and slightly higher in those with 
school-based qualifications (74% GCSEs and 75% A-levels). Interest was slightly, but not 
significantly (p=.159), higher in non-White British (76%) than British respondents (69%). 
Respondents who said that they had at least one close family member with heart disease were 
more likely to express interest than respondents who didn’t know about their family 
members, who in turn were more likely to express interest than those with no close family 
members with heart disease (74%, 70% and 67% respectively; p=.005).
When all the variables were put into a multiple logistic regression analysis, the associations 
between interest and gender, age, education and family history were all maintained. Figures
4.2. and 4.3 illustrate the seemingly curivilinear relationships between interest and age 
(Figure 4.2) and between interest and education (Figure 4.3) for both cancer and heart 
disease. The results of all the analyses are summarised in Table 4.3.
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Figure 4.2. Association between age and
interest in genetic testing for susceptibility
to cancer and heart disease
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Figure 4.3. Association between education and 
interest in genetic testing for susceptibility to cancer 
and heart disease
100%
60%
20%
c
D.
0%o.
None GCSEs A-levels Degree
■  Cancer 
□  Heart disease
102
Table 4.3. Correlates of interest in genetic testing for susceptibility to heart disease and cancer: demographics and family history
Variable Response categories 
Gender
Male (n=961)
Female (n=999)
Age
16-30 (n=412)
31-45 (n=584)
46-60 (n=478)
61-75 (n=333)
76+(n -152)
Education
Degree (n=247)
A-levels (n=559)
GCSEs (n=524)
No formal qualifications (n=629)
Ethnicity
White-British (n=1843)
Non White-British (n=l 12)
Family history
No (n=1017 heart; n=812 cancer) 
Don’t know (n=41 heart; n=24 cancer) 
Yes (n=830 heart; n=1070 cancer)
HEART DISEASE
Interesta Univariate Multivariate odds
(%) sig. ratio (95% Cl)
72 .029 1.0
68 0.79 (0.65:0.97)*
67 <.001 (chi) 1.0
73 .008 (linear chi) 1.43(1.08:1.90)*
78 1.99 (1.45:2.75)***
65 1.09(0.77:1.56)
49 0.61 (0.39:0.94)*
62 <.001 (chi) 1.0
75 .256 (linear chi) 1.99(1.43:2.79)***
74 1.90(1.35:2.66)***
64 1.30(0.92:1.84)
69 .159 1.0
76 1.47(0.91:2.36)
67 .005 1.0
70 1.20 (0.59:2.43)
74 1.36(1.09:1.66)**
*p<0.05, **p<0.01, ***p<0.001
a Proportion of respondents who would ‘definitely’ or ‘probably’ take a genetic test on a 4-point scale
CANCER
Interesta Univariate Multivariate odds
(%) sig. ratio (95% Cl)
67 .019 1.0
62 0.79 (0.65:0.95)*
61 .001 (chi) 1.0
66 .282 (linear chi) 1.27(0.97:1.66)
69 1.44(1.07:1.94)*
64 1.11 (0.79:1.55)
51 0.69(0.45:1.05)
57 .028 (chi) 1.0
66 .359 (linear chi) 1.61(1.17:2.21)**
67 1.66(1.21:2.30)**
63 1.45(1.07:2.07)*
64 .982 1.0
64 1.09(0.71:1.67)
63 .244 1.0
52 0.64(0.28:1.48)
66 1.11 (0.91:1.36)
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4. Discussion
This study adds to the literature by building on what is known about public interest in 
genetic testing for cancer risk and extending it to heart disease. The absolute degrees of 
interest of 64% for cancer and 69% for heart disease are within the range of levels 
reported by previous studies, which have reported between 50-80% interest (Croyle & 
Lerman, 1993; Myers et al, 2000) for cancer. It could be said that the proportion of 64% 
for interest in cancer risk genetic testing is actually slightly lower than many previous 
studies, which have tended to report more towards the higher end of the range, around 
80% (Croyle & Lerman, 1993; Andrykowski et al, 1996). Given that this was the first 
survey of its kind in the UK, this could reflect differences between the health care 
systems of the UK in comparison to the US, where much of the previous research has 
been conducted. Because the US does not have a health care service that is free at the 
point of delivery, unlike the British National Health Service, some of the previous US 
surveys have sometimes include information such as the relative cheapness of the tests. 
Another possibility is that it reflects cultural differences such as different attitudes 
towards the purchasing and use of medical technologies and novel health care products.
As expected, interest in genetic testing for susceptibility to heart disease was slightly 
higher than for cancer (69% vs. 64%, p<.001). This fits with the idea that people are 
more interested in genetic testing when they believe that there is something they can do 
to reduce their risk of developing the disease. Heart disease has tended to be more 
associated with controllable lifestyle factors such as diet, exercise, stress and smoking, 
whereas cancer has been viewed as more of a mystery and thus more threatening in many 
ways. However, as epidemiologic evidence starts to uncover the ways in which these 
same factors, especially diet, contribute to individual risks of cancer, this may change. 
Public health messages are already starting to incorporate the evidence for the impact of 
lifestyle on cancer risk, and we may see a substantial shift in public attitudes as a 
consequence over the next few years. It will be interesting to see how this plays out in 
the field of cancer and heart disease genetics.
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Although there was higher interest in genetic testing for heart disease than cancer in this 
study, the absolute difference was not large. One possible hypothesis for this is that 
interest as stated in this context is more of a reflection of more general attitudes to 
genetics than towards the disease itself or, as previous studies have suggested, a 
reflection of information-seeking personality type more globally.
A major advantage of this study was that the questions were asked regarding both 
diseases to all respondents, and so the comparative levels of interest are within- 
individuals. This means that people weren’t biased in responding to the survey because 
they had a particularly personal interest in the disease due to it running in their family, for 
example. Somewhat surprisingly, perhaps, we found an association between family 
history of heart disease and interest in genetic testing for heart disease, but no such 
relationship between family history of cancer and interest in cancer genetic testing. It is 
possible that this is because ‘heart disease’ is arguably a more homogeneous set of 
conditions, whereas the non-specific term ‘cancer’ used in this study encompassed the 
whole wide range of different types of cancer. In the case of heart disease, the observed 
relationship fits with the hypothesis that people who have heightened perceived 
susceptibility are more likely to want to know their risk (Bosompra et al, 2000). In the 
case of cancer, previous studies on the links between interest and having one or more 
family member have produced mixed results (Bottorff et al, 2002; Miesfeldt et al, 2000; 
Armstrong et al, 2002). Given the stronger association found in many studies between 
perceived rather than objective risk, emotional factors, and personality traits such as 
global depression or worry, this may not be surprising (Struewing et al, 1995; Glanz et al, 
1999). It was a shortcoming of the present study that these variables were not assessed, 
but it was not possible to include a large battery of measures due to the expense of 
including questions in the ONS Omnibus survey. Family history was the only predictor 
that differed between the two diseases.
For both cancer and heart disease, men were more interested in testing than women, and 
there appeared to be a curvilinear relationship with age and education, with those in the 
middle-age and with intermediate levels of education being more interested than those at 
either end of the spectrums. Given that this was the first study to look at public interest
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in heart disease testing, the relationship with gender may not be surprising; previous 
studies have found perceived susceptibility to be a strong predictor of interest in genetic 
testing and so this gender difference may be due to men correctly perceiving their risk of 
heart disease to be higher than that of women. The finding was unexpected however in 
the case of cancer. Previous studies have found women to be more interested than men in 
genetic testing for cancer (Evans et al, 1997), and other diseases (Tibben et al, 1993; 
Holloway et al, 1994), which has been linked to the proposal that men cope with adverse 
information about their health in a more avoidant manner than women (Marteau, Dundas 
& Axworthy, 1997). It is also possible that women take more interest in genetics because 
of their heightened perceived investment in their offspring (Richards, 1996), although the 
present findings may challenge this view. One possible reason for the present finding, is 
that women have been found to be less likely than men to regard heart attacks and cancer 
as more preventable (Smith et al, 1999), and so given the link between perceived 
preventability of disease and interest this could possibly account for the finding.
Previous studies have reported conflicting results regarding the relationship between age 
and interest (Myers et al, 2000; Weinrich et al, 2002). In the present study, interest was 
lowest in older adults but also low among young adults. The fact that the relationship 
appears to be curvilinear could mean that studies which have less of an age range in their 
sample, or which are not as representative of the general population, or which do not 
have enough categories of age groups, could produce biased results in this area. With 
regard to older people in our study, they may be more concerned about their age as a risk 
factor than about a possible genetic predisposition. Adolescents are often reported to be 
optimistically biased about their risk of disease, especially when the disease is linked to 
their health behaviours (Arnett, 2000), so they may see little reason for being interested in 
tests which make predictions about their future health status. People in their mid-life on 
the other hand are increasingly coming into contact with others suffering from heart 
disease and cancer, and are more concerned about being healthy and taking up health 
screening interventions than younger people (Turk-Charles et al, 1997). They are also 
more likely to seek out medical information (Mills et al, 2002), which would explain the 
high levels of interest in this age group.
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Whereas previous have tended to find that people with higher levels of education show 
higher levels of interest or uptake of genetic testing (Lerman et al, 1996; Lerman et al, 
1999; Vernon et al, 1999), in the present study the relationship appears to be curvilinear, 
with the people at the highest and lowest ends of the educational spectrum expressing the 
least interest in testing. Again, some studies may not pick up the curvilinear association 
if the samples are at all biased. Previous studies have found that people at the lowest 
education levels tend to be the least informed but the most willing to accept routine 
medical procedures (Press & Browner, 1997; Ray et al, 1997), but this is not strictly what 
we found in this study. The lower interest in the most educated people could be because 
they have access to, and attend to, more sources of information regarding advances in 
genetic technology, and so may have a more realistic understanding of the predictive 
capabilities of genetic testing than those in the education group immediately below them. 
The lower interest in the least educated groups could be due to differences in attitudes 
towards genetics generally, or a reflection of differences in attitudes towards preventive 
health care, or having more barriers to engaging in testing, such as the hassle of taking 
the test being more of an issue than the benefits of receiving the risk information.
This study was limited by being cross-sectional, addressing interest rather than actual 
uptake, and providing only limited information about genetic testing prior to decision­
making, and a number of additional variables were not addressed, such as personality 
traits and perceived susceptibility. Also, the inclusion of a question about personal 
history of cancer and heart disease may have produced a slightly more homogeneous 
sample than would otherwise have been obtained. A strength of the study was that the 
sample was recruited from across the country and represented a broad range of the 
sociodeomographic spectrum. In addition, the genetic questions were asked as part of an 
established survey of a wide range of issues, and agreement to participate or not in the 
survey could not therefore have been influenced by any knowledge about the inclusion of 
questions addressing these issues.
Although it is interesting to know how people respond initially and instinctively to 
questions on genetic testing their responses in this study were not informed to any great 
extent by detailed information. It is likely that their responses could alter over time, or
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with more detailed information about genetic testing. In particular, it’s possible that 
people misunderstood the meaning of ‘genetic testing’, and there may have been 
confusion between disease susceptibility testing and disease screening (Weinrich et al, 
2002). The issues of understanding and information provision therefore warrant further 
investigation.
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CHAPTER 5
Study 2a: The effects of a genetics information leaflet on interest and 
anticipated reactions to genetic testing for cancer and heart disease
susceptibility6
1. Introduction
1.1. Study 2: overview of design and rationale
In order to be able to include a larger battery of measures than it was possible to include 
in the ONS survey described in the last chapter, a second survey study was designed 
which utilized a postal questionnaire survey design. The first aim of this questionnaire 
study was to be able to look in more detail at the psychosocial correlates of interest in 
genetic testing for susceptibility to complex diseases in a general population sample. In 
order to do this, a large number of respondents were needed, but it was also necessary to 
be able to include lots of questions. It was decided that respondents would be recruited 
using a GP patient list in Oxfordshire, and an 8-page questionnaire was developed for use 
in the study which examined attitudes towards genetic testing for susceptibility to cancer.
However, as in Study 1, it seemed appropriate to address more than one disease, but 
because the survey instrument was already eight pages long only it was difficult to 
incorporate any further questions into the same instrument. It was therefore decided that 
two versions of the questionnaire would be sent out: one which asked questions about 
genetic testing for cancer, and one which asked about genetic testing for heart disease. 
This had the advantage that although the same respondents would not be asked about 
both cancer and heart disease, other sources of variation would be reduced by recruiting 
people from the same geographic area, using the same methodology (i.e. postal survey) 
and survey instrument (with the exception of the word ‘cancer’ being replaced each time 
by the word ‘heart disease’), and being conducted at the same moment in time.
6 A version of this chapter has been published in Public Understanding o f Science (Sanderson, Wardle & 
Michie, 2005: see Appendix A).
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In addition, the ONS survey had the disadvantage that it was only possible to provide 
minimal information about genetic testing to accompany the survey. A genetics 
information leaflet was therefore developed to accompany the postal survey used in 
Study 2. Given that little is known about the impact of genetics information leaflets on 
attitudes, the leaflet was only included with half of the surveys in order to see whether 
this increased understanding and whether it influenced respondents’ responses.
This resulted in a 2x2 study design: leaflet condition (leaflet vs. no leaflet) x disease 
condition (cancer vs. heart disease). In addition, there were three main outcome that 
linked to the three research themes discussed in Chapter 2; interest, psychological impact, 
and behavioural impact. Because this design produced a number of different ways in 
which the data could be analysed, the results are presented in three parts, Studies 2a, 2b 
and 2c. In the present chapter I describe Study 2a, in which the effects of the leaflet on 
these outcomes are examined. In Study 2b (Chapter 6), the differences between disease 
conditions, some of the correlates of interest and anticipated reactions, and the 
relationship between anticipated psychological reactions and interest, will be examined. 
In Study 2c (Chapter 7), I look specifically at responses amongst the subset of smokers 
within the survey sample, in anticipation of giving smokers actual genetic risk feedback 
in Study 3 (Chapter 8).
1.2. Rationale for examination of the effects of an information leaflet on interest
The advantage of Study 1 was that the use of the ONS Omnibus Survey meant that the 
sample was representative of the general population and that a good response rate of 71 % 
was achieved. However, the disadvantage of being able to use this source of respondents 
was that it was not possible to include a large battery of measures in the survey, which 
includes questions from many different organizations and is costly. This meant that 
many of the more interesting psychological questions around interest and impact of 
genetic testing were not able to be addressed. In this chapter, I describe a study designed 
to redress some of these issues. The aim of the present study was again to address 
interest and other psychological issues around genetic testing in the public domain, but 
this time to look at the impact of providing some respondents with additional 
information, to look at the relationships with subjective understanding and attitudes more
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generally, and to begin to address the question of anticipated psychological reactions to 
genetic testing in the general population.
As in Study 1, questions on interest in genetic testing for complex disease susceptibility 
were included in a survey (this time an 8-page questionnaire), but respondents were 
randomly allocated to either receive a standard information sheet about the study, or the 
standard information sheet plus an additional genetics information leaflet. As discussed 
in the previous chapter, surveys of interest have been criticized for not including 
substantial information about the pros and cons of genetic testing (Lerman, Croyle, 
Tercyak & Hamann, 2002), and there is a possibility that people misunderstood ‘genetic 
testing’ to mean ‘screening for the presence of disease’ (Weinrich et al, 2002). I was 
therefore interested to see whether more detailed information about genetics and about 
the pros and cons of testing would affect how people responded to questions on interest.
A recent focus of research in the area of BRCA1/2 genetic testing has been to try to
reduce inappropriately high levels of interest amongst women who are not appropriate
candidates for testing, and it has been suggested that written information materials could
influence interest. For example, Schwarz et al (2001) randomly assigned women to
receive either genetic testing educational print materials (n=195) or general breast cancer
education control materials (n=196). They found that, relative to the control materials,
the genetic testing education materials led to decreased interest in obtaining a
BRCA1/BRCA2 mutation test, which was the desired outcome. The aim of their written
materials was to educate low risk women about genetic testing and reduce inappropriate
demand and interest in testing. Their results suggested that written leaflets could have
such an effect. In addition, they found that the group who received the genetic education
leaflets also showed increases in knowledge about genetic testing, and increased
perception of the risks and limitations of genetic testing. I was therefore also interested
to see whether the inclusion of information not only about the benefits and risks of
genetic testing influenced interest, but also whether information more generally about
genetics would influence responses, possibly by increasing understanding of genetics or
genetic testing. There tends to be an assumption that the public’s understanding of
genetics and genetic testing is limited (Henderson & Maguire, 1998; Singer et al, 1998),
111
and I therefore wanted to look at whether giving people an information leaflet would 
increase their understanding.
There is a considerable body of literature on the relationship between understanding and 
attitudes towards science more generally which suggests that understanding of science is 
related, albeit sometimes weakly, to holding more positive attitudes towards science 
(Evans & Durant, 1995; Wroe & Salkovskis, 1999; Sturgis & Allum, 2004). At the same 
time, there is evidence that as people gain more knowledge about some specific human 
genetic technologies such as cloning, they in fact have more arguments against the 
technology (Wellcome Trust, 1998). This is possibly consistent with the observation that 
people who are more knowledgeable about science hold more positive attitudes generally, 
but have more developed arguments against specific technologies (Evans & Durant,
1995). I was therefore also interested to look at the relationships between understanding 
and attitudes towards genetics more generally.
In addition, evidence from clinical genetics suggests that information that is intended to 
be nondirective could unintentionally influence attitudes. Wroe & Salkovskis (1999) for 
example, showed that information about genetics and breast cancer given to people prior 
to making a decision about opting for genetic testing, influenced both their testing 
decisions and their ratings of the severity of breast cancer, which challenges the notion 
that apparently nondirective information is neutral. It is possible that efforts to increase 
understanding of genetics in order to enable people to make informed responses to survey 
questions could have the unintended effect of shifting attitudes in a more positive 
direction. I was therefore keen to use information materials that were widely available 
and accessible to the general public, and that were designed to give neutral and impartial 
information about genetic testing, such as the information sheet on the website of the 
American Academy of Family Physicians, “Genetic Testing: What You Should Know ” 
(see http ://familydoctor. org/handouts/462.html).
Another reason for assessing the impact of genetics information on public attitudes is 
because of the current focus on ‘gauging public opinion’ in the human genetics 
regulatory framework: the UK Government’s advisory body on human genetics, recently
112
C h a p t e r  5: S t u c k  2a;  L ea f l e t
stated that it was ‘not [their] job to offer detailed regulatory advice’, but rather to ‘gauge 
public opinion and offer suggestions about what the regulation of genetic tests might look 
like (Human Genetics Commission, http://www.hgc.gov.uk/genesdirect, accessed 1 
August 2003). This focus on gauging public opinion highlights the weight given to 
public consultation in the governance of human genetics in the UK at the present time, 
and suggests that the results from social surveys of public attitudes may have a very real 
influence on the regulation of human genetics technologies. It is important that such 
surveys represent the public’s views as accurately as possible, as well as that they 
consider possible factors that could -  deliberately or inadvertently -  influence public 
opinion. An additional reason for these analyses was to consider whether providing 
people with general genetic information, rather than genetic risk information, has an 
impact on their attitudes towards genetics and genetic testing. This could help in 
interpreting the results of studies which find differences between genetic testing groups 
and controls, but not between subgroups that receive different test results within the 
genetic testing group.
1.3. Rationale for examination of an information leaflet on anticipated reactions
A second aim of the present study was to move on to begin to consider questions around
the potential psychological impact of genetic testing in general population samples as
well as interest. Shaw et al (1999) identified five studies that had used experimental
designs to determine the effect upon mood of an intervention before testing, when
presenting test results, or after results had been presented. All reported significant
positive effects of the intervention for those receiving positive results. Two of the studies
(Stewart et al, 1993; Wilkinson et al, 1990) randomly allocated women who had received
a positive cervical smear result to either ‘information leaflet’ or ‘no information leaflet’.
Those in the ‘information leaflet’ condition showed significantly lower levels of distress
and anxiety than those in the ‘no information leaflet’ condition. These findings suggest
that written information materials could, in addition to influencing interest in genetic
testing, have an influence on reactions to genetic test results. This could be important
given that commercial companies already provide genetic test results through the post
and away from the clinical counseling context, and with written rather than verbal
information. In the present survey, I therefore asked whether the genetic information
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leaflet influenced anticipated psychological reactions to genetic testing results. I also 
looked at the impact of the leaflet on anticipated behavioural reactions in the subsample 
of smokers.
1.4. Research questions
This study examined whether the inclusion of an information leaflet in a postal survey 
influenced interest in genetic testing for complex diseases and also whether it influenced 
anticipated psychological reactions to genetic test results, and attitudes towards genetics 
generally. The research questions were, does providing people with a genetics 
information leaflet influence a) interest in genetic testing? b) anticipated reactions to 
genetic testing? c) understanding o f genetic testing? and d) attitudes towards genetics 
generally?
It was hypothesized that, on the basis that the information included risks of genetic 
testing, and that previous research had seen decreases in interest in a leaflet group 
(Schwarz et al, 2001) we might see lower levels of interest in genetic testing in the leaflet 
group than the no leaflet group. The leaflet was developed with the intention of 
increasing subjective understanding of genetic testing and was intended to give the 
information in a neutral way. We hypothesized that the leaflet group would therefore 
show higher levels of subjective understanding than the no leaflet group, and that there 
would be a corresponding decrease in anticipated adverse psychological reactions to 
higher risk genetic test results. There was no intended effect on attitudes towards 
genetics generally, but it was hypothesized that, if an increase in understanding was 
observed, there could be a corresponding increase in positive attitudes towards genetics. 
This also raised an alternative hypothesis regarding interest in testing, that people in the 
leaflet group would show higher, not lower, levels of interest, due to the change in 
attitudes towards genetics more generally.
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2. Method
2.1. Design
Two thousand adults, aged 18 to 75 years, were selected randomly from a general 
practice register. Materials included an 8-page postal survey and a genetics information 
leaflet. People were randomly allocated to receive either the survey alone or the survey 
plus the information leaflet. Half of the survey instruments asked questions in relation to 
genetics and cancer whilst the other half asked questions in relation to genetics and heart 
disease, in a 2x2 experimental survey design (leaflet vs. no leaflet; cancer vs. heart 
disease). Pilot work was conducted prior to the main survey data collection procedure to 
inform the design and development of the questionnaire and additional materials. Ethical 
approval for the survey was sought from the UCL Ethics Committee and Central Oxford 
NHS Research Ethics Committee (OxREC). Ethical approval was granted by UCL on 
July 9, and by OxREC on November 26. See Appendix B for letter of approval and 
related correspondence.
2.2. Pilot work
Exploratory pilot interviews (n=8) were conducted between January and June 2001 to 
develop the area of focus, and identify relevant themes and questions. The interviews 
addressed smoking (addiction, initiation, cessation), cancer, genetics, and interest in 
genetic testing. All were tape-recorded and transcribed. A first draft of the questionnaire 
was developed and piloted April to June. The pilot work included completion of the 
developing questionnaire by work colleagues, friends and acquaintances (n=51). I also 
sat in the Oxford GP waiting room for a morning, and the second draft of the 
questionnaire was completed by patients there (n=9), to see how well people in a general 
population understood the questionnaire, and to check whether there were any particular 
problems of interpretation. Their comments were typed up. This led to some minor 
changes and the expulsion of a number of items, as well as the re-wording of some 
further items. In particular, further explanation was given about what a ‘positive’ and 
what a ‘negative’ genetic test result actually meant every time this was referred to in a 
question. This was because it was clear from this and the previous interviews that people
115
C h a p t e r  5:  S t u d v  2a :  Le a f l e t .
had very little understanding of genetics, and few had come into contact with the concept 
of genetic testing, let alone knew what it was. The revised version of the questionnaire 
was then given to 100 people in a legal publishing office, as a final check for wording 
(n=71, RR=71%). Respondents were also asked to indicate how long it had taken them 
to fill in the questionnaire (mean 10±4 minutes, range 3-30mins). Some items were 
ejected on the basis of comments. A sub-sample of the office workers were invited to 
participate in a lunch-time focus group (n=9). They were asked to comment on the 
questionnaire first, which people found generally easy to fill in. The one item regarded 
as confusing was taken out. The questionnaire was 8 pages long and contained 81 items, 
plus a ‘further comments’ section (see Appendix E for full questionnaire).
2.3. Procedure
The study took place in a General Practice in Oxfordshire in January 2002. The
participating practice covered a population of around 11,000 of whom roughly 8,000
were between 18 and 75 years old. A cross-sectional quantitative survey design was
used, using two versions of the questionnaire, one of which addressed genetic testing for
susceptibility to cancer and the other, heart disease. The only inclusion criteria was that
patients should be aged between 18 and 75. Patients were excluded prior to selection if
their GP had reason to believe that they should not be contacted in relation to the study,
such as people with a terminal illness, a learning disability or who were unable to give
informed consent. After these exclusions, two thousand patient details were randomly
selected from the patient register using a random number generation procedure, and a
questionnaire was sent in the post to the 2,000 selected adults. Each of the selected
patients were sent a pack containing (see Appendix E): a letter signed by their GP
informing them that their practice was involved in a research study and inviting them to
take part; a Study Information Sheet; a questionnaire (on cancer or heart disease); and a
pre-paid return envelope. In addition, a genetics information leaflet was included with
half of the questionnaires in each disease group, the results of which will be reported in a
separate analysis (see Chapter 6). Reminder packs were sent after three weeks to patients
who had not yet responded. The Study Information Sheet -  which all respondents
received -  included the following information about genetic testing: “A genetic test
informs a person about their risk o f getting a disease in the future, on the basis o f their
116
Chapte? 5; S tuih 2;?; Leaflet
genetic makeup. A genetic test does not give a simple “yes ” or “no ” answer. It will tell 
a person i f  they have a high risk o f getting a disease, but it will not tell them definitely i f  
or when the disease will develop. ”
2.4. Information leaflet
The content of the information leaflet used in this study was adapted from a two-page 
handout on the website of the American Academy of Family Physicians called “Genetic 
Testing: What You Should Know” (http://fami 1 vdoctor. or g/handouts/4 62.html). This 
information source was chosen after consideration of a number of sources because it was 
deemed to be the most suitable for members of the general population, much of the 
information literature available being targeted more to individuals and families who have 
been identified as being at high risk of developing ‘genetic diseases’. It was also clear 
and concise, and was a credible and widely available source of information. The leaflet 
was piloted with 71 individuals, a focus group, a lay representative of the Patient 
Involvement Group at the general practice at which the study was conducted, and a UK 
genetics specialist. The aim of this pilot work was to develop the content and appearance 
of the information to make it as accessible, easy to read, and balanced as possible. The 
final version of the leaflet was double-sided, A5, colour and glossy. It was titled 
“Genetics and Health: A Brief Introduction”, with the subheadings “The Genetics and 
Health Survey” and “University of London”. The first half of the leaflet provided 
background information about genetics under the subheadings: “What is genetic 
testing?,” “What does a positive test result mean?”, “What does a negative test result 
mean?”, and “What are the advantages and disadvantages of genetic testing?”. In 
response to pilot work a small amount of information was added under the subheading 
“What diseases are genetic tests currently available for?”, adapted from the 
“Understanding Gene Testing” pages of the National Cancer Institute website 
(http.v/press2.nci.nih.gov/sciencebehind/genetesting/genetesting01.htmL A copy of the 
final information leaflet used in this study can be found in Appendix E.
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2.5.Measures
2.5.1. Socio-demographics
The questionnaire included items to assess gender; age; marital status (single, married, 
cohabiting/living with partner, divorced/separated, widowed)', number of children (none, 
one, two, three, more than three), ethnic group (white, black, asian, other, do not wish to 
answer)', housing tenure (rent from local authority, rent from private landlord, own 
home, other)', employment status (employed full-time, employed part-time, unemployed, 
full-time homemaker, retired, student, disabled or too ill to work)’, educational attainment 
(GCSE/O-level/CSE, vocational qualifications (e.g. NVQ1+2, A-level or equivalent (e.g. 
NVQ3, Bachelor degree or equivalent (e.g. NVQ4), Masters/PhD or equivalent, other, no 
formal qualifications, still studying)', car ownership (no, yes one, yes more than one)’, 
internet use (yes, no, don’t know)', and religious influence (not at all, a little, quite a lot, 
completely, not applicable).
2.5.2. Health status
Respondents’ general health status was measured using two items, a self-rated health 
item and number of GP visits in the past three months. Self-rated, or subjective, health 
was measured using an item taken from the Health Survey for England (1996): “In 
general, would you say that your health is... excellent, good, fair, poor”. GP visits were 
measured by asking respondents how many times they had visited the GP in the past 
three months, with the response options, “I  haven’t been”, “once”, “twice”, “three or 
more times ”. Respondents were also asked to indicate whether they personally had ever 
had cancer (in the cancer questionnaire) or heart disease (in the heart disease 
questionnaire), with response options “yes ” or “no ”.
2.5.3. Interest in genetic testing
A similar item to that used in the ONS survey (Study 1) was used to assess interest in 
genetic testing: “I f  it were available now, would you have a genetic test fo r cancer [heart 
disease] risk in the next six months? ”. This item was adapted from an existing measure 
(Bosompra et al, 2000) and again, was chosen on the basis that the six month time frame 
made the hypothetical question more concrete (Prochaska et al, 1994). In addition,
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because it has been suggested that different question framings may influence responses, 
three alternative items were also included. These were: 1) Suppose you had inherited 
something from your parents which made you more likely to develop cancer [heart 
disease] than other people, would you want to be told this? 2) Would you have a genetic 
test for cancer [heart disease] risk i f  your doctor recommended it? and 3) Would you 
have a genetic test for cancer [heart disease] risk i f  your doctor recommended it? Four 
response options were given for each question ( “no, definitely not ”, “no, probably not ”, 
“yes, probably”, “yes, definitely”). When the items were combined, they loaded on to 
one factor in principal components analysis, and had a Cronbach’s alpha coefficient of 
0.90. However, in order to be able to make comparisons with Study 1, and for ease of 
interpretation, the single item of interest will be reported here ( “if  it were available, 
would you have a genetic test for cancer [heart disease] risk in the next six months? ”).
2.5.4. Understanding of genetic testing
Understanding of genetic testing was measured using a self-report item, “I  have a clear 
picture o f what genetic testing is ”(strongly disagree, disagree, not sure, agree, strongly 
agree), which was taken from the Illness Perception Questionnaire (Weinman et al,
1996). We elected to use a self-report measure of subjective understanding of genetic 
testing rather than a multi-item measure of “objective” understanding, so that respondents 
were not deterred from replying by feeling that they were being “tested”. Measuring 
actual knowledge would also have been difficult given that this was a postal survey, and 
so respondents could have referred to the leaflet or additional sources of information (e.g. 
books or relatives) when answering the questions.
2.5.5. Attitudes towards genetics
2.5.5.i. 12-item attitudes checklist
The survey included questions on general attitudes towards genetics and genetic testing. 
‘Attitudes toward genetics’ were measured using a 12-item attitude checklist, as well as 
four attitude statements. The checklist was adapted from an existing measure (Michie et 
al, 1995), and contained four positive words (excited, enthusiastic, optimistic, and 
hopeful)', four negative words (worried, concerned, pessimistic, and horrified); and four
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mixed-neutral words {cautious, indifferent, mixed feelings, and confused). Participants 
were asked to indicate which of the words described their feelings about genetics, by 
endorsing as many or as few of the words as they liked. The attitude checklist was used 
in two ways. First, analyses were conducted on individual attitude words. Second, two 
attitude scales were created using data reduction techniques, and analyses were conducted 
on these two scales. In order to create the two scales, we first of all conducted a principle 
components analysis with varimax rotation to see how the words best loaded together 
(alpha coefficients were inappropriate because of the checklist structure of the measure). 
This produced two factors accounting for 30% of the variance. The words enthusiastic, 
optimistic, hopeful and excited all loaded on Factor 1 with values over .50. Cautious, 
horrified, concerned, pessimistic, and worried all loaded on Factor 2 with values over .40. 
Factor 1 was therefore labeled ‘Positive Attitude Score’ and Factor 2 was labeled 
‘Negative Attitude Score’. The remainder of the mixed-neutral words had low loadings 
(between .178 and -.480) on both factors, but appeared to have negative connotations, 
loading negatively on Factor 1, and positively on Factor 2. See Table 5.1 for factor 
loadings.
Table 5.1. Factor analysis of attitude towards genetics items: 
rotated component matrix_____________________________
Component
1 2
Positive attitude score negative attitude score
Enthusiastic .663 .000
Indifferent -.178 .000
Cautious -.238 .435
Optimistic .622 .000
Horrified .142 .582
Confused -.211 .351
Hopeful .518 .000
Concerned .000 .573
Mixed feelings -.480 .331
Excited .611 .211
Pessimistic .000 .421
Worried .000 .663
Extraction Method: Principal Component Analysis. Rotation
Method: Varimax with Kaiser Normalization. Rotation converged 
in 3 iterations.
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2.5.5.ii. Four attitude statements
The following four measures of attitudes towards genetics were also included: 1) “All 
research into genetics is messing with nature and is therefore wrong”; 2) “Genetic 
research will bring cures for many diseases 3) “Research into cloning is messing with 
nature and is therefore wrong 4) “Genetics are a big part o f our lives and we should 
all take an interest ”.
2.5.6. Anticipated psychological reactions to genetic test results
A series of questions were included in the survey asking respondents what they believed 
their emotional reactions would be to receiving genetic test results. The questions asked 
about anticipated emotional reactions in response to 1) anticipated emotional reactions to 
receiving a positive genetic test result for [cancer] [heart disease] risk, and 2) anticipated 
emotional reactions to receiving a negative genetic test result for [cancer] [heart disease] 
risk. A positive test result was defined as follows: “A positive test result means you may 
be more likely to get [cancer] [heart disease] than other people”. A negative result was 
defined as: “A negative test result means that you’re not at higher risk of getting [cancer] 
[heart disease] than other people.” Respondents were asked to indicate the extent to 
which they agreed or disagreed with nine statements which pertained to different 
emotional reactions to receiving a positive genetic test result, and seven statements which 
pertained to emotional reactions to receiving a negative genetic test result. The 
statements were chosen having reviewed the literature on the impact of genetic testing, 
and were informed by pilot interviews. The seven items that were included for both 
positive and negative genetic test results were:
I f  I  received a positive [negative] genetic test result, I  would...
... be concerned 
.. .regret having had the test 
...feel depressed 
.. .be glad that I knew of my risk
...want to discuss my test result with a health professional (e.g. doctor, counselor or 
nurse)
...feel I was definitely [definitely NOT] going to get that cancer [heart disease] in the 
future
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...feel that I could provide my family with useful information about their risk of cancer 
[heart disease]
The additional two questions that were included for the positive genetic test result only 
were:
.. .worry that it may cause problems with life insurance 
.. .worry that it may cause problems with employers
2.5.7. Anticipated behavioural reactions to genetic test results (smokers only)
Current smokers in the samples were asked six questions on anticipated behavioural 
reactions to genetic test results with regard to their smoking. As before, they were asked 
whether they would intend to quit smoking in response to the same two outcome 
scenarios -  receiving a positive result and receiving a negative result. They were asked 
to indicate, using a five-point scale, whether they thought that they would definitely quit 
smoking if they received a positive genetic test result and if they received a negative 
genetic test result. The main outcome variable was intention to quit smoking in response 
to a positive genetic test result. The item used to assess this was: “I f  I  received a positive 
genetic test result I  would definitely quit smoking. ” By way of comparison, quitting 
intention following a negative genetic test result was also examined, using the item “I f  I  
received a negative genetic test result I  would definitely quit smoking. ” The secondary 
outcome variable was anticipated complacency following a negative genetic test result. 
Respondents were asked to indicate, again on the same five-point scale, whether they felt 
that they would think it was safe for them to smoke if they received a negative genetic 
test result. The item used was: “I f  I  received a negative genetic test result I  would feel 
that it was safe for me to carry on smoking”. This was conceptualized as “anticipated 
complacency following a negative genetic test result”. Two additional items were 
included which were “I f  I  received a positive genetic test result, it would increase my 
desire to quit smoking ”, and “I f  I  received a negative genetic test result, it would 
increase my desire to quit smoking ”.
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2.5.8. Experience/family history of disease
Experience of the disease and family history was measured using three questions. The 
first question addressed whether the respondent had any first degree relatives with cancer 
or heart disease, using the measure, “Has anyone in your close family had cancer [heart 
disease] (e.g. parents, brothers, sisters)?, with response options “yes” or “no”. The 
second item measured self-reported, or subjective, family history. The question used 
was: “In your opinion, does cancer [heart disease] run in your family? ”, with response 
options, “yes”, “no”, and “don't know”. Finally, respondents were also asked to 
indicate whether they had a family history of any other diseases or conditions, again 
response options were “yes ”, “no ”, and “don’t know ”.
2.5.9. Dispositional optimism and pessimism
Dispositional optimism and pessimism were measured using the six items from the short 
version of the revised Life Orientation Test (LOT-R: Sheier & Carver, 1985; Scheier, 
Carver & Bridges, 1994). The items are: “I f  something can go wrong for me, it will”,
“I  hardly ever expect things to go my way ”, “I  rarely count on good things to happen to 
me”, “In uncertain times, I  usually expect the best”, “I ’m always optimistic about my 
future”, and “Overall, I  expect more good things to happen to me than bad”. Response 
options were: “strongly disagree”, “disagree”, “not sure”, “agree”, and “strongly 
agree ”.
2.5.10. Disease representations
The measures that were included were disease specific worry, perceived risk, 
understanding of the disease, perceived control, and perceived curability.
2.5.10.i. Disease-specific worry
Disease-specific worry was measured with the item: “How often do you worry about 
cancer [heart disease]? ” Never, not very often, some o f the time, quite often, all the time.
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2.5.10.ii. Perceived susceptibility
Perceived susceptibility was measured using the item: “Compared with other people o f 
your age and sex, do you think your chances o f getting cancer [heart disease] at some 
point in your life are: much lower, lower, about the same, higher, much higher”). This 
item was adapted from Sutton et al (1994).
2.5.10.iii. Understanding of the disease
Understanding of the disease was measured using the item: “I  have a clear picture o f 
what cancer [heart disease] is” (strongly disagree”, “disagree”, “not sure”, “agree”, 
and “strongly agree”). This item was taken from the Illness Perception Questionnaire 
(Weinman et al, 1996). There were originally more understanding items from the IPQ 
when were discarded after piloting.
2.5.10.iv. Perceived control
Perceived control was measured with: “There are things I  can do to control whether I  get 
cancer or not” (strongly disagree”, “disagree”, “not sure”, “agree”, and “strongly 
agree ”).
2.5.10.V. Percieved curability
Perceived curability was measured with: “When found early, cancer [heart disease] can 
be cured” (strongly disagree”, “disagree”, “not sure”, “agree”, and “strongly agree”).
2.5.11. Smoking measures
2.5.1 l.i. Smoking status (all respondents)
All respondents were asked, “Have you ever smoked a cigarette, even a puff? ” (response 
options “yes ” or “no ”). They were then asked, “Do you ever smoke cigarettes now? ” 
(again, “yes ” or “no ” responses).
2.5.1 l.ii. Motivation to quit smoking (smokers only)
Motivation to quit smoking was measured with two items. The first was, “How much do 
you want to give up smoking all together?” (not at all, slightly, moderately, quite 
strongly, very strongly). This measure of motivation, or desire to quit, is used in the
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Office for National Statistics assessment of smoking-related behaviours and attitudes in 
the UK (Lader & Goddard, 2002). The second item pertained to intention to quit, and 
was “Are you intending to give up smoking within the next 6 months? ” (no definitely not, 
no probably not, possibly, yes probably, yes definitely).
2.5.1 l.iii. Addiction to nicotine (smokers only)
Addiction to nicotine was measured using three items. These were: “How soon after 
waking do you smoke your first cigarette o f the day? ” (less than 5 minutes, between 5 
and 15 minutes, between 15 and 30 minutes, between 30 min and 1 hour, between 1 and 2 
hours, longer than 2 hours); “How many cigarettes do you usually smoke per day? 
“How easy or difficult would you find it to go without smoking for a whole day? ” (very 
easy, fairy easy, fairly difficult, very difficult). The first two items were taken from one 
of the most frequently used instruments to measure nicotine dependence, the 6-item 
Fagerstrom Test for Nicotine Dependence (FTND: Heatherton et al, 1991). The third 
item is an assessment of cigarette dependence (Russell, 1971).
2.5.12. Questionnaire evaluation
Finally, respondents were asked, “Did you find completing this questionnaire... very 
easy, quite easy, quite difficult, very difficult ”.
2.6. Statistical analyses
Statistical analyses for Study 2a were carried out using SPSS for Windows v.10.0. 
Demographic characteristics (including gender, age and education) of the sample overall 
were examined using frequency tables. A series of cross-tabulations and chi-squares 
were conducted first with ‘leaflet condition’ as the predictor variable and ‘sample 
characteristics’ as the outcome variables, to check that the two groups were similar. The 
analyses were then repeated with ‘disease type’ as the predictor variable. Frequencies of 
responses to the ‘interest’ items were examined in the sample as a whole using frequency 
tables, and responses were compared between educational attainment groups using linear 
regressions. The effect of the leaflet on interest in genetic testing was assessed using 
linear regression analysis, and was re-run including gender, age, education and
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employment status as independent variables. The effects of the leaflet on anticipated 
psychological reactions to genetic test results using the Kruskall Wallis //te st for three or 
more unrelated samples. The effects of the leaflet on attitudes and understanding were 
assessed using linear regressions. In order to test whether any effect on positive and 
negative attitude was attributable to the effect on understanding, the size of the regression 
coefficient was compared in models including or not including the score on 
understanding. If the attitude effect was mediated by understanding, then including 
understanding in the regression equation should reduce the apparent effect of the leaflet 
on attitudes.
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3. Results
3.1. Sample characteristics
1,024 (51% response rate) survey questionnaires were returned, with similar numbers in 
the two groups (517 in leaflet group, 507 in no leaflet group) and for each disease focus 
(512 where genetic testing questions alluded to cancer, and 512 for heart disease). 
Demographic characteristics of the whole sample are presented in Table 5.2.
Table 5.2. Demograp lie characteristics of the sample
n=l,024 N Percent (%)
Sex Male 455 44
Female 568 56
Age 18-35 yrs 222 22
36-55 yrs 465 47
56-75 yrs 309 31
Marital status Single 222 22
Married or cohabiting 798 78
Children 0 246 24
1 152 15
2 396 39
3 166 16
More than 3 58 6
Ethnic group White British 1004 98
Non-White British 7 1
Housing tenure Rent from local authority 76 8
Rent from private landlord 73 7
Own home 798 78
Other 72 7
Employment status Employed 731 72
Not employed 106 11
Retired 177 18
Education None 167 17
GCSEs 367 37
A-levels 131 13
Degree 320 33
There were lower proportions of Non-White British respondents than in the general UK 
population, which is probably partly due to the geographical location of the study, but 
there were no demographic differences between the leaflet group and no-leaflet group, 
nor differences on health status or disposition. Smokers in the leaflet group were more 
likely to say that they would find it difficult to go without smoking for a whole day than
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smokers in the no-leaflet group (66% vs. 49%, p=.022), but there were no other 
differences between the two groups on any other variables. The only variable that 
differed between the cancer group and the heart disease group was the item, ‘‘Do any 
other conditions or illnesses run in your family? Respondents in the cancer sample 
were more likely to answer ‘no’ and less likely to answer ‘not sure’ than respondents in 
the heart disease sample. There were no differences on any of the measures of health 
status, socio-demographics, disposition, smoking characteristics, or experience of genetic 
conditions.
3.2. Interest in genetic testing
In response to the item, ‘‘I f  it were available now, would you have a genetic test for 
cancer [heart disease] risk in the next 6 months?”, 79% (806) of the sample overall 
reported that they would ‘definitely’ or ‘probably’ take a genetic test. Interest in genetic 
testing was higher amongst those with lower levels of educational attainment (90% with 
no formal qualifications; 81% with GCSEs; 78% with A-levels; 75% with degrees, 
p<.001). In the leaflet group, 81% (418) said that they would definitely or probably take 
a genetic test: 39% (200) said yes definitely, 42% (218) said yes probably, 17% (85) said 
no probably not, and 2% (11) said no definitely not.
77% (388) of the no-leaflet group said that they would definitely or probably take a 
genetic test: 34% (170) said yes definitely, 43% (218) said yes definitely, 20% (98) said 
no probably not, and 3% (16) said no definitely not. Linear regression analysis showed 
that the difference in interest between the two groups was statistically significant, with 
interest higher in the leaflet group than the no-leaflet group (t[l]=2.03, p=.043).
There was no difference on interest between the cancer condition and heart disease 
condition (78% vs. 80% respectively: y?[\]=0.76, p=.384) (the relationships between 
disease type and outcomes are explored more fully in Chapter 6), and so the two disease 
groups were combined. Table 5.3 shows the distributions of responses for the main 
‘interest’ outcome variable, as well as the three additional interest items and the 
composite scale means. Overall, the mean interest scale score was 3.3+0.6 (on a range of 
1 to 4, where 4=high interest).
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The effect of the leaflet on interest using the single-item measure was maintained when 
adjusted for gender, age, educational attainment and employment status (see Table 5.4). 
Although interest in genetic testing was higher in the leaflet group than in the no-leaflet 
group, the absolute differences were not large (see Figure 5.1).
Table 5.3. Interest in taking a genetic test: leaflet vs. no leaflet
Leaflet No leaflet Sig.*
If it were available now, would you have a 
genetic test for [cancer] [heart disease] risk in 
the next 6 months? No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
2% (11) 
17% (85) 
42% (218) 
39% (200)
3% (16) 
20% (98) 
43% (218) 
34% (170)
t[l]=2.03, p=.043
Would you have a genetic test for [cancer] 
[heart disease] risk if  your doctor 
recommended it? No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
1% (4)
3% (13) 
38% (196) 
59% (300)
1%(5)
4% (22) 
44% (220) 
51% (256)
t[l]=2.58, p=.010
Suppose you had inherited something from 
your parents which made you more likely to 
develop [cancer] [heart disease] than other 
people; would you want to be told this? No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
1% (5)
9% (45) 
47% (237) 
44% (223)
2% (8) 
12% (61) 
48% (242) 
38% (193)
t[l ]=2.27, p=.024
Would you be interested in taking a genetic 
test for [cancer] [heart disease] risk?
No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
3% (14) 
11% (57) 
48% (244) 
39% (197)
2% (12) 
15% (73) 
50% (253) 
33% (164)
t[ 1 ]= 1.82, p=.069
Interest scale (composite o f four items) Mean (sd) 3.31 (0.62) 3.22 (0.64) t[l ]=2.34, p=.020
*Significance values are unadjusted and were calculated using linear regression analyses
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Figure 5.1. Interest in genetic testing using different measures: leaflet vs. no leaflet
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Table 5.4. Effect of leaflet on interest in genetic testing using 4-item composite scale
T Sig-
Leaflet 2.30 p =.022
Sex 1.18 p=.239
Age 2.26 p = .024
Educational attainment 3.09 p =.002
Employment status 4.78 p<.001
a Dependent Variable: Interest scale score (mean of the four interest items) 
Linear regression
3.3. Anticipated psychological reactions
In response to receiving a positive (higher risk) genetic test result in the hypothetical
scenario, most respondents felt that they would want to discuss their test result with a
health professional, regardless of whether they were in the leaflet group or the no-leaflet
group (97% vs. 94% respectively: p=.058). Within the leaflet group, 93% agreed or
strongly agreed that they would be concerned; 82% felt that they would be able to
provide their family with useful information; 79% would be glad to know of their risk;
32% would feel depressed; 41% would worry that it may cause problems with life
insurance; 24% would worry that it may cause problems with employers; 17% would feel
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that they were definitely going to get cancer [heart disease]; and 7% would regret having 
taken the test. In response to receiving a negative (not higher risk) genetic test result, 
83% of the leaflet group felt that they would be glad that they knew of their risk; 71% felt 
that it would provide their family with useful information about their own risk; 51% 
would want to discuss the test result with a health professional; 12% would feel they 
were definitely going to get cancer [heart disease]; 10% would be concerned; 5% would 
regret having had the test; and 3% would feel depressed. The figures were similar for 
those in the no-leaflet group.
The differences between the two groups were assessed using the Kruskall Wallis H  test 
for three or more unrelated samples. People in the leaflet group were less likely to 
believe that a negative result would make them feel like they were definitely not going to 
get the disease than those in the no-leaflet group (12% vs. 16%: x2[2]=8.04, p=.005). 
People in the leaflet group were also more likely to feel that receiving a positive result 
would provide their family with useful information (82% vs. 76%: x2[2]=5.66, p=.017), 
and to believe that a negative result would provide their family with useful information 
(71% vs. 62%: x2[2]=6.95, p=.008). There were no other differences between the leaflet 
and no-leaflet groups in terms of anticipated psychological reactions (see Table 5.5).
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TABLE 5.5. Anticipated psychological reactions to genetic test results: leaflet vs. no leaflet
Disagree
Leaflet 
Not sure Agree Disagree
No leaflet 
Not sure Agree Sig.
If I received a positive genetic test result, I w ould...
Want to discuss my test result with health professional 2 0% 15 3% 494 97% 7 1% 22 4% 472 94% X2[2 ]= 3 .6 0 ,p = .0 5 8
Be concerned 7 1% 28 6% 469 93% 11 2% 35 7% 451 91% X2[2 ]= 1 .8 3 ,p = .1 7 6
Feel could provide family with useful information 16 3% 75 15% 404 82% 24 5% 95 20% 366 76% X2 [21=5.66, p= .0 1 7
Be glad that I knew of my risk 21 4% 86 17% 402 79% 23 5% 104 21% 364 74% X2[2 ]= 3 .1 2 ,p = 0 7 7
Feel depressed 103 21% 235 47% 160 32% 88 18% 215 44% 183 38% X2[2 ]= 3 .2 3 ,p = 0 7 2
Worry that it may cause problems with life insurance 140 29% 152 31% 200 41% 125 26% 154 32% 203 42% X2[2]= 0 .54 , p= . 463
Worry that it may cause problems with employers 255 54% 106 22% 115 24% 212 46% 132 28% 120 26% X2[2 ]= 3 .8 2 ,p = 0 5 1
Feel was definitely going to get cancer/heart disease 211 42% 206 41% 84 17% 178 36% 225 46% 88 18% X2[2]= 2 .69 , p =  101
Regret having had the test 329 66% 134 27% 35 7% 301 62% 140 29% 48 10% X2[2]= 2 .72 , p=  099
If I received a negative genetic test result, I w ould...
Be glad that I knew of my risk 34 7% 54 11% 414 83% 36 7% 56 11% 398 81% X2[2]= 0 .26 , p=. 608
Feel could provide family with useful information 42 9% 102 21% 345 71% 50 10% 134 28% 303 62% X 2 [2 [=6.95, p= .0 0 8
Want to discuss my test result with health professional 147 29% 97 19% 256 51% 147 30% 80 17% 258 53% X2[2]= 0 .08 , p = .773
Feel was not going to get cancer/heart disease 292 58% 146 29% 62 12% 242 49% 170 35% 78 16% X 2 [21=8.04, p= .005
Be concerned 281 77% 62 13% 39 10% 367 76% 77 16% 38 8% X2[2]= 0 .07 , p = .797
Regret having had the test 430 87% 42 9% 22 5% 408 85% 53 11% 21 4% X2[2 ]= 1 .0 4 ,p = 3 0 9
Feel depressed 439 89% 41 8% 15 3% 417 87% 48 10% 13 3% X2[2 ]= 0 .4 3 ,p = 5 1 2
Significance values were calculated using the Kruskal Wallis // te s t  for three or more unrelated samples
132
( 'hapk-! Sm d\ 2a: fo a flc
3.4. Anticipated behavioural reactions (smokers only)
Smokers in the leaflet group did not anticipate reacting differently to those in the no- 
leaflet group on any of the behavioural items (see Table 5.6).
Table 5.6. Anticipated behavioural reactions to genetic test results: leaflet vs. no leaflet
Leaflet (n=80) No leaflet (n=106) Sig.
If I received a positive genetic 
test result...
I would definitely quit smoking Strongly-disagree- 
not sure-agree (1-4) 
Strongly agree (5)
62% 49 
38% 30
61% 65 
39% 41
X2[l 1=0.01, 
p=.922
It would increase my desire to 
quit smoking Strongly-disagree- not sure-agree (1-4) 
Strongly agree (5)
52% 43 
48% 40
48% 51 
52% 55
X2[l 1=0.25, 
p=.614
I would feel that it was safe for 
me to carry on smoking Strongly disagree (1) 
disagree- not sure- 
agree-strongly (2-5)
49% 39 
51% 41
43% 46 
57% 60
X2[l]=0.53,
p=.468
If I received a negative genetic 
test result...
I would definitely quit smoking Strongly-disagree- 
not sure-agree (1 -4) 
Strongly agree (5)
90% 71 
10% 8
91% 96 
9% 10
X2[l]=0.03,
p=.875
It would increase my desire to 
quit smoking Strongly-disagree- not sure-agree (1-4) 
Strongly agree (5)
86% 70 
14% 11
91% 95 
10% 10
X2[l]=0.75,
p=.386
I would feel that it was safe for 
me to carry on smoking Strongly disagree (1) 
disagree -not sure- 
agree-strongly (2-5)
25% 20 
75% 60
19% 20 
81% 86
X2[l 1=1.02, 
p=.314
3.5. Understanding of genetic testing
Overall, 61% of the sample self-reported that they had an understanding of genetic 
testing. Self-reported understanding did not vary by age or gender, but individuals with 
higher educational attainment reported higher levels of understanding than those with 
lower levels of educational attainment: 39% with no formal qualifications, 58% with 
GCSEs, 66% with A-levels, and 74% with degrees felt they had a clear understanding of 
what genetic testing was (p<.001). Univariate chi-square analysis showed that the leaflet
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group reported significantly more understanding of genetic testing (68% vs. 53%, 
pc.001) than the no-leaflet group in the univariate analysis (see Table 5.7).
Table 5.7. Understanding of genetic testing: leaflet vs. no leaflet
Measure Response Leaflet No leaflet Sig.
I have a clear picture of what 
genetic testing is
Strongly-disagree- 
not sure (1-3) 
Agree-strongly 
agree (4-5)
32% 162 
68% 346
47% 236 
53% 264
X!m =24.72,
p<.001
Given the finding that understanding was lower in the lower educational groups, I was 
interested to see whether the leaflet reduced the differences between the higher and lower 
groups. So in order to determine whether the information leaflet affected the strength of 
the association between education and understanding, two linear regressions were 
conducted. The first model had understanding as a continuous outcome variable, and 
education, gender and age as dependent variables. The second model included the 
information leaflet as a dependent variable. There was no difference in beta weights, i.e. 
the strength of the associations, between demographic factors (gender, age, education) 
and understanding in the two models. This suggested that the effect of the leaflet on 
understanding of genetic testing did not vary between different demographic groups, and 
that the leaflet did not reduce the educational gradient in understanding of genetic testing 
(see Table 5.8).
Table 5.8. Regression analyses of associations between demographic characteristics, 
self-reported understanding of genetic testing, with and without information leaflet
Dependent variable Beta weight Sig.
U nderstanding of genetic 
testing
Model 1 G ender (m=0,f=1) .044 .174
Age .045 .179
Education .204 <.001
Model 2 G ender (m=0,f=1) .043 .176
Age .042 .197
Education .215 <.001
Leaflet (no leaflet=0, leaflet=1) .192 <.001
Although the above analyses suggested that the leaflet did not successfully reduce 
socioeconomic differences in understanding of genetic testing, a more careful 
examination of the data suggests that there was some interaction between leaflet and
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educational level. I re-ran the chi-square analyses of understanding by leaflet condition, 
but this time on each socioeconomic group one at a time. The leaflet had no impact 
amongst people who had ‘no formal qualifications’: 40% of the leaflet group and 38% of 
the no-leaflet group understood what genetic testing was (x2[l]=0.09, p=.768). However, 
the leaflet did have a significant effect on understanding amongst people with 
intermediate levels of education. Amongst respondents who were educated to GCSE 
level, 72% of the leaflet group felt that they understood what genetic testing was, 
compared to only 43% in the no-leaflet group (x2[l]=30.89, p<.001), and the impact was 
similar amongst respondents with A-levels or equivalent (% [1]=5.64, p=.018). There 
was a lesser effect of the leaflet amongst people educated to Degree level or above (79% 
vs. 70%: % 2[1]=3 .33, p=068). These data are summarized in Table 5.9 and illustrated in 
Figure 5.2.
Table 5.9. Understanding of genetic testing: leaflet condition by socioeconomic group
No formal 
qualifications GCSEs A-levels Degree
Leaflet 40% (33/82) 72% (138/193) 75% (54/72) 79% (111/141)
No leaflet 38% (30/79) 43% (71/167) 55% (32/58) 70% (124/178)
Sig. X2[l ]=0.09, p=.768 X 2 [ l  1=30.89, p<.001 X2|11=5.64,p=.018 X2[l]=3.33,p= .068
3.6. Attitudes towards genetics
Attitudes towards genetics tended to be a mixture of positive and mixed-neutral words: 
43% said that they were cautious about genetics, 37% were hopeful, 33% had mixed 
feelings, 32% were optimistic and 17% were enthusiastic. There was less of a tendency 
to report negative attitudes towards genetics: 7% were worried, 3% were pessimistic and 
2% were horrified. The method used to calculate the attitude scales produced a 
standardized mean score of zero overall for both the positive attitude scale and the 
negative attitude scale. People with higher levels of education held more positive 
attitudes (i.e. scored more highly on the positive attitude scale) than those with lower 
levels of education (p=.026), but there was no association of education with negative 
attitude scale scores (p=.438). Respondents in the leaflet group were more enthusiastic 
(21% vs. 12%), more optimistic (35% vs. 28%), and less cautious (39% vs. 47%),
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concerned (14% vs. 21%), and worried (5% vs. 9%) about genetics than those in the 
control group. Figure 5.3 shows the differences between the two groups for all of the 
attitude words.
Figure 5.2. Subjective understanding of genetic testing: leaflet condition by 
socioeconomic group
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Overall, the leaflet group reported more positive attitudes towards genetics (0.11 +_1.05 
vs. -0.11 :L0.93, p=.001), and less negative attitudes (-0.10 + 0.91 vs. 0.10+1.11, p=.001) 
than those in the control group (Table 5.10).
The linear regression with positive attitude as the dependent variable, and gender, age, 
and education as control variables (see Table 5.11), showed that the effect was 
independent of demographic effects (beta=-.123, p<001). To test whether this effect on 
attitudes was attributable to the increased understanding, the understanding score was 
included in the regression model. The beta weight associated with the leaflet was very 
little reduced (beta=-.090, p=.005), indicating that the effect on attitudes was largely 
independent of the effect on understanding.
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Figure 5.3. Attitudes towards genetics compared between leaflet conditions
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Table 5.10. Attitudes towards genetics: leaflet vs. no leaflet
Leaflet No leaflet Sig.
Attitudes towards genetics: checklist 
composite-items scales
Positive attitudes 
Negative attitudes
mean (standard 
deviation) 
mean (standard 
deviation)
0.11 (0.93) 
-0.10 (0.91)
-0.11 (0.93) 
0.10 (1.08)
F[l]=11.96,
p=.001
F[1J=10.46,
p=.001
Attitudes towards genetics: statements
All research into genetics is messing with 
nature and is therefore wrong
Strongly-disagree
(1-2)
not sure-agree- 
strongly (3-5)
81% 411 
19% 99
79% 392 
21% 107
X2[l ]=0.64, p=.424
Genetic research will bring cures for 
many diseases
Strongly- 
disagree-not sure 
(1-3)
Agree-strongly 
agree (4-5)
27% 138 
73% 375
30% 150 
70% 352
X2[l]= l.ll ,p = .2 9 2
Research into cloning is messing with 
nature and is therefore wrong
Strongly-disagree
(1-2)
not sure-agree- 
strongly (3-5)
30% 152 
70% 359
28% 139 
72% 363
X2[ 1 ]=0.52, p=.470
Genetics are a big part o f our lives and 
we should all take an interest
Strongly- 
disagree-not sure 
(1-3)
Agree-strongly 
agree (4-5)
23% 116 
77% 398
26% 129 
74% 373
X2[l 1=1 -36, p=.244
□  No leaflet (n=502)
□  Leaflet (n=516)
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Table 5.11. Regression analyses of the independence of the effect of the information leaflet on
positive and negative attitudes towards genetics
Dependent variable Beta weight Significance
Positive attitude
Model 1
Gender (m=0, f=l) -.063 .050
Age .035 .289
Education .098 .003
Model 2
Gender (m=0, f=l) -.064 .046
Age .049 .140
Education .108 .001
Leaflet (no leaflet=0, leaflet=l) .126 <.001
Model 3
Gender (m=0, f=l) -.065 .043
Age .047 .155
Education .068 .042
Leaflet (no leaflet=0, leaflet=l) .090 .024
Understanding .170 <.001
Negative attitude
Model 1
Gender (m=0, f=l) .029 .375
Age -.145 <.001
Education -.030 .336
Model 2
Gender (m=0, f=l) .035 .279
Age -.131 <.001
Education -.032 .337
Leaflet -.101 .002
Model 3
Gender (m=0, f=l) .037 .257
Age -.130 <.001
Education -.017 .612
Leaflet (no leaflet=0, leaflet=l) -.084 .011
Understanding -.059 .076
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4. Discussion
This study builds on the ONS survey (Study 1) by supporting the hypothesis based on 
evidence from the clinical literature (Schwarz et al, 2001), that interest in genetic testing 
amongst a general population sample could be influenced by written information 
materials about genetics and genetic testing. However, the direction of the effect was 
found to be opposite to that reported by Schwarz and colleagues. Whereas they found 
that interest was lower amongst women who received a genetics information leaflet, the 
present study found interest to be higher in the leaflet group, at 81% compared to 77% in 
the no-leaflet group (p=.043). This is likely to be partly due to the reasons for which the 
written information materials were developed in the two studies. The specific aims of the 
written materials used by Schwarz et al (2001) were to educate low risk women about 
genetic testing and reduce inappropriate demand for testing. Thus the content of their 
leaflet focused very much on the risks and limitations of genetic testing for 
BRCA1/BRCA2 mutations. In contrast, the written information leaflet used in the 
present study was based largely on a much more general information sheet provided by 
the American Association of Family Physicians called, “Genetic Testing: What You 
Should Know”, and contained only a small proportion of information about the potential 
risks, or disadvantages, of genetic testing. It was assumed that the aim of this leaflet was 
to impart information to a lay audience about genetics and genetic testing, in a short, 
clear and concise way, so that people might be slightly more informed about genetic 
testing at a general population level.
The aim of including an adapted version of this leaflet in the present survey was to 
increase understanding of genetic testing so that people felt more informed and better 
able to express their views about genetics and genetic testing in the survey. As hoped, 
the people in the present survey who received the leaflet did report higher levels of 
understanding of genetic testing than those in the no-leaflet group (68% vs. 53%,
p<.001).
In addition, I was interested to see whether the information leaflet might also influence 
people’s anticipated reactions to genetic test results. It was hypothesized that it might, 
because in previous studies women receiving adverse test results were significantly less
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likely to show distress and anxiety if they received a written information leaflet than if 
they received no leaflet (Stewart et al, 1993; Wilkinson et al, 1990). This seemed 
relevant to the present debate about whether genetic testing should always be 
accompanied by genetic counseling, the goals of which are to 1) educate and inform, 2) 
provide psychological support, and 3) facilitate informed decision making (Wang et al, 
2004). Some commercial companies are sending test results through the post
(www.genewatch.org, accessed March 2005), which means that they are reliant on 
written information materials to do the job of genetic counseling.
However, the present study did not provide strong support for the notion that written 
information materials might significantly influence reactions to test results, or at least, 
anticipated reactions. For example, although people in the leaflet group were slightly less 
likely than those in the no-leaflet group to agree with the statement, “I f  I  received a 
positive genetic test result for cancer [heart disease], I  would feel depressed”, the 
difference was not significant (32% vs. 38%: x2[2]=3.23, p=.072). On the other hand, 
one of the concerns about genetic testing is that people are fatalistic about genetic risks, 
and might interpret a positive test result as a ‘death sentence’ (Senior, Marteau & 
Weinman, 2000) and a negative result as a guarantee against disease (Axworthy, Brock, 
Bobrow & Marteau, 1996; Hopwood, 1997). In the present study, only 17% and 18% of 
the leaflet and no-leaflet groups agreed with the statement “I f  I  received a positive 
genetic test result for cancer [heart disease] risk, I  would feel I  was definitely going to 
get the disease in the future ”. Moreover, people in the leaflet group were less likely to 
agree with the statement, “I f  I  received a negative genetic test result, I  would feel I  was
'y
definitely not going to get the disease” (12% vs. 16%, % [2]=8.04, p=.005). This might 
suggest that written information materials could be effective in reducing fatalistic beliefs 
about genetic risks. However, multiple comparisons were made and only a few 
significant differences were found, and so these results should be interpreted with 
extreme caution. They may however suggest testable hypotheses for future research.
In addition to the primary outcome variables (interest and anticipated reactions), 
understanding of genetic testing and attitudes towards genetics more generally were also 
examined in a bit more detail. There was a strong social gradient in terms of
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understanding of genetic testing, with only 39% of respondents with no formal 
qualifications feeling that they had a clear picture of what genetic testing was, compared 
to 74% of those with degrees or above. Given the concerns about misinterpretation of 
genetic test results leading to adverse psychological outcomes (Senior, Marteau & 
Weinman, 2000), it will be important to try to reduce the gradient whereby lower 
socioeconomic (SES) groups have poorer understanding than higher SES groups. The 
findings were mixed. On the one hand, the linear regression analysis suggested that the 
leaflet did not reduce the association between educational attainment and understanding 
of genetic testing. In addition, there was no difference within the group with no formal 
qualifications between those who received the leaflet and those who did not (40% vs. 
38%: x2[1]=0.09, p=.768). On the other hand, amongst people education to GCSE level, 
72% of those who received the leaflet felt that they had a clear picture of what genetic 
testing was, compared to only 43% of those who did not receive the leaflet (x2[l]=30.89, 
p<.001). Similarly, amongst people with A-levels, 75% of the leaflet group compared to 
55% of the no-leaflet group had an understanding of genetic testing (x2[l]=5.64, p=.018). 
Understanding was high in the Degree and above group and was little affected by the 
leaflet. Again, this might have implications as genetic testing moves out of the clinical 
context and into the wider social sphere, in that it suggests that it may be worth pursuing 
the value of written information materials to ‘inform and educate’ (Wang et al, 2004) 
individuals taking genetic tests away from the heavily supported clinical environment. 
However, it is a shame that the leaflet did not influence understanding in the lowest SES 
group, and further work is needed to investigate why this was.
A somewhat unexpected finding was that, although positive attitudes towards genetics 
generally were more prevalent in the leaflet group than in the no-leaflet group as 
hypothesized, this attitudinal difference between groups did not appear to be due to the 
difference in levels of understanding. Although we had hypothesized that more 
understanding would lead to more acceptance and positive attitudes (Evans & Durant,
1995), the results of the regression analyses suggested that the effect of the leaflet on 
attitudes was independent of the effect on understanding. This suggests an alternative 
hypothesis which is, rather than the content of the information leading to the changes in 
attitude, it was something about the appearance of the leaflet that affected attitudes.
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Efforts were deliberately made to make the appearance of the leaflet attractive so that 
people would be more likely to read it and attend to it, but this could also inadvertently 
have influenced attitudes. The Elaboration Likelihood Model (ELM) proposes, for 
example, that under some circumstances people form their attitudes in response to 
peripheral cues such as the attractiveness and source of the information provided (Petty & 
Cacioppo, 1986), so it’s possible that people in the leaflet group may have become more 
positive in response to the fact that the information leaflet was glossy and colourful. 
Also, the leaflet came from the University of London, and previous studies have found 
that universities and scientists are rated more positively and as more trustworthy sources 
of information about genetics than the government or commercial companies (Frewer et 
al, 1999).
Alternatively, Wroe & Salkovskis (2000) suggested that people may become more 
positive and accepting of genetic technologies when they have been encouraged, or 
‘prompted’, to focus on the positive aspects of genetics. Given that people are more 
positive towards genetics in the context of treating or preventing disease, it is possible 
that the focus of the leaflet on genetic testing and disease, and the title “Genetics and 
Health: A Brief Introduction ”, could also have positively influenced attitudes.
We recently addressed these possibilities in a series of four studies which examined 
different aspects of the leaflet (Michie et al, 2004).7 The first two investigated 
presentation of the leaflet (the original glossy A5 version vs. a plain black and white A4 
version), and method of reading (read only vs. read followed by probing questions). The 
second two investigated content, using “think aloud”, “card sort”, and delayed recall 
tasks. We found that those receiving the glossy leaflet expressed more positive attitudes 
and more interest in undergoing testing than those receiving a black and white leaflet, 
which does suggest that the appearance of the leaflet could have had a significant impact. 
However, whether people in the glossy condition also attended to the information more, 
processed it more, and had higher understanding of genetics, was not assessed.
7 These studies were conducted by three UCL undergraduate psychology students, under the supervision of 
Dr Susan Michie. The results were published in Michie, Di Lorenzo, Lane, Armstrong & Sanderson (2004) 
in Genetics in Medicine 6: 219-225.
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On a methodological note, the finding in the present study that there were at least two 
dimensions to attitudes when measured using a multiple adjective checklist approach, 
could have implications for survey methodologies. Measures of attitudes towards 
genetics have been criticized by Pardo & Calvo (2002) for being weak and subject to 
misinterpretation, particularly the attitude statements which are commonly used. In 
particular, the single dimension produced by attitude statements disallows the possibility 
of individuals holding both positive and negative views. The factor analysis reported in 
the present study demonstrated that at the very least people hold these two sets (positive 
and negative) of views independently of one another, which suggests that attitude scales 
should be developed which measure at least these two separate constructs.
There were a number of limitations to this study. One major limitation was that the 
measures used were ad hoc, especially those used to look at anticipated reactions to 
genetic test results. Another major limitation was that the response rate was only 51%, 
and that it was a cross-sectional survey, and so it was not possible to examine whether the 
effects held or changed over time. A further limitation was that a self-report measure of 
understanding of genetic testing was used rather than a more objective measure. A ‘true’ 
knowledge test was not used partly because of the difficulty in obtaining objective 
measures of understanding. However, it is important to find out whether these types of 
written information materials do increase real knowledge or only induce an illusion of 
understanding. Obviously a significant limitation was that the interest and impact 
outcome variables were all hypothetical rather than actual measures of uptake and 
impact.
However, the results are helpful in the context of the MRC framework for the 
development of complex interventions, which states that preliminary surveys should be 
used to help define the relevant components of interventions and find potential problems 
and barriers (Campbell et al, 2000: see Chapter 2). In considering the feasibility and 
appropriateness of providing people in the general population with genetic test results for 
common genetic variants, one possibility was to give people their genetic test results 
through the post, as had been done by McBride et al (2002). However, the present 
findings advised caution in doing this. The fact that over 90% of respondents wanted to
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talk about a positive result with a health professional suggested that it might be more 
appropriate to provide genetic test results in person, face-to-face, rather than in the post. 
Also, only 61% of respondents overall felt that they had a clear understanding of genetic 
testing, and whilst the leaflet went some way to improving understanding, it did not do so 
in the lowest SES and possibly most vulnerable group. In addition, the leaflet had no 
considerable influence on anticipated psychological reactions to genetic test results. All 
of these findings suggested that it might be more advisable to give genetic test results in 
person than rely on written information materials. On the other hand, the finding that the 
leaflet did have some impact on understanding suggested that it might be a good idea to 
develop clear and easily understandable written and visual information materials to 
complement the verbal information and support provided in the randomized controlled 
trial.
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CHAPTER 6
Study 2b: Anticipated psychological reactions to genetic susceptibility 
testing and their relationship with interest
1. Introduction 
1.1. Overview of Study 2b
This study builds on the previous two studies by examining the correlates of interest in 
genetic testing and of anticipated psychological reactions in more detail. Also, the self­
selection hypothesis is tested in this general population sample by examining the 
relationships between anticipated psychological reactions and interest in undergoing 
genetic testing. The present study makes use of the same postal questionnaire survey 
dataset described in Study 2a (Chapter 5).
1.2. Rationale for examination of the correlates of interest
Study 1 suggested that people in the general population were slightly more interested in 
genetic testing or susceptibility to heart disease than they were for cancer; that men were 
more interested in genetic testing for susceptibility to both heart disease and cancer than 
women; and that people in the mid-life age group and with intermediate educational 
qualifications were more interested in genetic testing for both diseases than those at either 
end of the spectrums. There was a relationship between having a family history of heart 
disease and being interested in genetic testing for heart disease susceptibility, but there 
was no such relationship for cancer. This observation of a different relationship between 
family history and heart disease compared to cancer suggests that it should not be 
assumed that the same factors that predict interest in genetic testing for cancer also 
predict interest in other complex diseases.
The findings from Study 2a suggested that subtle differences in methodology such as 
question framing and accompanying information could also influence interest, but that 
anticipated reactions to genetic test results were less easily influenced. Study 2a also
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raised the issue of understanding, and showed a strong social gradient in terms of 
understanding of genetic testing. In the present analyses (Study 2b), I looked in more 
detail at the psychosocial correlates of interest in genetic testing for complex disease 
susceptibility in the same general population sample.
Previous research has shown that interest in genetic testing for cancer susceptibility is 
associated with lower levels of global distress or pessimism (Lerman et al, 1999; Codori 
et al, 1999), higher levels of disease-specific worry (Lerman et al, 1997; Lipkus et al, 
1999; Vernon et al, 1999; Helmes, 2002), higher levels of perceived susceptibility 
(Croyle & Lerman, 1993; Struewing et al, 1995; Durfy et al, 1999; Cappelli et al, 2001), 
and holding more beliefs that the results could benefit family members (Tambor et al, 
1997; Cappelli et al, 1999; Vernon et al, 1999; Esplen et al, 2001). In addition, it is 
starting to be suspected that initial interest in genetic testing is motivated by a 
misunderstanding of what genetic testing actually is and of the type of information that it 
can provide individuals with (Miesfeldt et al, 2000; Weinrich et al, 2002). Although 
there is a considerable body of literature examining correlates of interest in cancer 
genetic testing, little is known about the extent to which these findings can be 
extrapolated to other complex diseases, such as heart disease. Therefore, the first aim of 
the present study, Study 2b, was to examine the relationships between psychosocial 
correlates outlined above and interest in genetic testing for both cancer and heart disease 
susceptibility in a UK population-based sample.
Previous research, especially in the field of Huntington’s disease genetic testing, has 
shown that there is a strong tendency for people to self-select themselves out of testing on 
their beliefs about anticipated outcomes (Codori et al, 1994; Mastromauro et al, 1987; 
Decruyenaere et al, 1997), and a few recent studies have started to investigate the 
relationship between anticipated reactions and interest in genetic testing for cancer 
susceptibility in high-risk populations (Doukas et al, 2004). It is important to determine 
whether this will also be the case for common, complex diseases and amongst the general 
population, as genetic testing moves away from the clinical realm. Some of the main 
concerns about genetic testing for complex disease susceptibility revolve around the 
possibility that they may cause harm to vulnerable individuals by causing depression and
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worry. However, the harmful consequences of genetic testing could be reduced if people 
who believe that they would respond negatively to genetic test results do not opt for 
genetic testing in the first place, effectively self-selecting themselves out of testing. 
Whilst this certainly appears to be the case in clinical genetics to a large degree, it 
remains to be seen whether it will also be true in the general population. The issue of 
self-selection is rarely mentioned in current discussions about the future utility of genetic 
tests for complex traits, nor in current discussion about how commercial genetic tests 
should be regulated, and yet this seems to be an important point and relevant to these 
debates.
1.3. Rationale for examination of the correlates of anticipated psychological 
reactions to genetic test results
Although the research to date has provided little support for long term adverse 
psychological effects of genetic testing (Broadstock, Michie & Marteau, 2000; Meiser & 
Halliday, 2002; Braithwaite, Emery, Walter et al, 2004), all of the research has been 
conducted within the clinical counselling context and could therefore underestimate rates 
of psychological distress amongst general population samples away from the clinical 
genetics counselling environment (Lerman, Croyle et al, 2002). In addition, 
psychological reactions have not differed hugely between people receiving high risk and 
low risk genetic risk results (Bish, Sutton, Jacobs et al, 2002; Evers-Kiebooms et al, 
2000; Meiser & Dunn, 2000; Duisterhof et al, 2001; Lerman, Croyle et al, 2002), 
although in one study of anticipated reactions high risk results were anticipated to 
increase depression and worry whereas low risk results were not (Brodersen, Sutton, Goff 
et al, 2004). The second aim of the present study was therefore to examine the 
proportions of people in a general population sample who anticipated having adverse 
psychological reactions to genetic test results for complex diseases such as depression, 
concern, and regret about having taken the test, and to make comparisons between 
anticipated reactions to positive versus negative results.
It was decided to look at anticipated psychological reactions in a non-clinical population 
prior to looking at actual psychological reactions in order to conform with the MRC 
framework for developing complex interventions (Campbell et al, 2000). An advantage
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of adopting this phased approach was that it allowed us to gain insight into whether there 
was the potential for harm in a general population sample and to design the randomised 
controlled trial accordingly, taking these findings into consideration. In addition, when 
this work was initiated in 2000, it was far from certain that it would be ethical and 
feasible to conduct a study in which general population individuals were given 
information about their genotype for a common genetic variant, and so again this was 
further reason for being cautious and looking at anticipated reactions before actual 
reactions.
Previous research has suggested that people who have higher levels of distress prior to 
testing are more likely to have problems in adapting to test results than others (Duisterhof 
et al, 2001), and that a person’s mood before testing is a better indication of how they 
react to their test result than is the result itself (Tibben et al, 1997; Decruyenaere et al,
1996). Prior studies have reported few demographic associations with psychological 
impact in terms of age or education, although associations with gender have been 
observed; women have shown higher levels of both actual distress (Tibben et al, 1993) 
and anticipated worry, regret, and anger (Brodersen et al, 2004). Previous studies have 
reported fewer distressed reactions amongst people with a lower perceived risk based on 
family history prior to testing (Marteau & Anionwu, 1996). The authors suggested that 
people who do not have a family history may find a positive result more distressing than 
people who do have a family history, due to being less psychologically prepared for the 
higher risk information. This clearly has implications for genetic testing in the general 
population, in that people are less likely to have considered themselves at risk of the 
disease in question prior to testing than those in clinical settings.
Given that one of the concerns is that people are assumed to be fatalistic about genetic 
risks and could therefore have adverse psychological reactions (Senior, Marteau & 
Weinman, 2000; Axworthy et al, 1996; Hopwood, 1997; Senior et al, 1999), surprisingly 
few studies have included understanding of genetic testing in any examination of factors 
associated with having harmful psychological reactions to receiving genetic test results. 
This is particularly important given the outstanding question of whether genetic 
counselling is necessary to a) improve understanding and b) thus reduce adverse
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psychological effects (Wang et al, 2004). Furthermore, few studies have looked at 
whether having fatalistic beliefs, such as the individual believing that a positive result 
would mean they were definitely going to get the disease, increases the likelihood of 
having a negative emotional reaction to the test result. This is despite the hypothesis 
proposed by Senior et al (1999) that genetic testing for complex disease susceptibility 
could cause psychological distress because people may misinterpret test results as 
meaning that they will definitely get the disease in question.
1.4. Research questions
The research questions addressed in the present study were 1) what are the 
characteristics o f people in the general population who express interest in genetic testing 
for complex diseases? and 2) what are the characteristics o f people in the general 
population who anticipate having depressed reactions to adverse genetic test results? It 
was hypothesised that interest in genetic testing for cancer susceptibility would be higher 
amongst people with lower levels of dispositional pessimism, higher levels of perceived 
family history, lower levels of understanding of genetic testing, and fewer anticipated 
adverse psychological reactions to positive (higher risk) genetic test results. As in Study 
1, it was hypothesised that the same factors that predict interest in testing for cancer 
susceptibility would predict interest in testing for heart disease susceptibility, that interest 
would be higher for heart disease susceptibility than for cancer, and that interest would be 
higher in people with lower education and amongst women. The hypothesis regarding 
gender was based on the bulk of the previous literature, but bearing in mind that in Study 
1 interest in genetic testing for both cancer and heart disease was higher in men, an 
alternative hypothesis was that the opposite association between gender and interest 
could also be observed in the present study.
It was hypothesised that anticipating having a depressed reaction to a positive (higher 
risk) result for cancer susceptibility would be associated with higher levels of 
dispositional pessimism, not having a perceived family history of cancer, being female, 
having a lower understanding of genetic testing and higher level of fatalism about a 
positive genetic test result. As before, it was hypothesised in the absence of any other 
empirical evidence that the same factors that predicted interest in testing for cancer would
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also predict interest in heart disease genetic testing. Comparisons were also made on all 
the anticipated reaction variables between cancer and heart disease, and between positive 
and negative test results. It was hypothesised that more adverse reactions would be 
anticipated in response to receiving a positive genetic test result for cancer than for heart 
disease on the basis that cancer is more feared than heart disease, and that more adverse 
reactions would be anticipated for positive than for negative results.
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2. Method
2.1. Design
The study design and measures for these analyses are described in full in Chapter 5. In 
brief, a cross-sectional quantitative survey was used, in a 2x2 experimental design (leaflet 
vs. no leaflet; cancer vs. heart disease). 1,024 survey questionnaires were returned with 
similar numbers of respondents in each group.
2.2. Measures
The measures (all described in full in Chapter 5, see also Appendix E) used in the present 
study were as follows:
2.2.1. Demographics
Gender, age, education.
2.2.2. Interest in genetic testing
“If it were available now, would you have a genetic test for cancer [heart disease] risk in 
the next six months?” (Bosompra et al, 2000) (response options: no definitely not, no 
probably not, yes probably, yes definitely).
2.2.3. Anticipated psychological reactions
See Chapter 5.
2.2.4. Understanding of genetic testing
“I have a clear picture of what genetic testing is” (strongly disagree, disagree, not sure, 
agree, strongly agree) (Weinman et al, 1996).
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2.2.5. Experience/family history of disease
“Has anyone in your close family had cancer [heart disease] (e.g. parents, brothers, 
sisters)?” with response options yes or not, and “In your opinion, does cancer [heart 
disease] run in your family?”, with response options yes, no, and don’t know.
2.2.6. Disease representations
Disease-specific worry, perceived risk, understanding of the disease, perceived control, 
perceived curability (see Chapter 5).
2.2.7. Smoking status
See Chapter 5.
2.3. Statistical analyses
In order to check that the respondents in the cancer sample and the respondents in the 
heart disease sample were similar demographically, a series of cross-tabulations and chi- 
square analyses were conducted first, with ‘disease type’ as the predictor variable and 
‘sample characteristics’ as the outcome variables. Interest in genetic testing for cancer 
risk was compared to interest in genetic testing for heart disease risk using chi squares. 
Anticipated psychological reactions to positive and negative genetic test results were 
described separately for the cancer sample and the heart disease sample using frequency 
tables. Differences between anticipated reactions to genetic test results for cancer versus 
heart disease were examined using chi-squares. Differences between anticipated 
reactions to a positive result versus a negative result were compared using paired samples 
t-tests (separately for the cancer sample and the heart disease sample). Factors associated 
with anticipating a depressed emotional reaction to receiving a positive genetic test result 
for cancer were examined using a series of univariate linear regressions with depression 
as the continuous outcome variable, and with the predictor variables being categorised in 
order to reduce the skew of the distributions. The predictor variables that emerged as 
being significantly associated with depressed anticipated reaction were entered into a 
multivariate linear regression analysis, to determine whether the associations held when
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the other significant variables were controlled for. These linear regressions were then 
repeated on the heart disease sample.
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3. Results
3.1. Sample characteristics
The first aim of these analyses was to check that the respondents in the cancer sample and 
the respondents in the heart disease sample were similar demographically. 1,024 (51% 
response rate) survey forms were returned with similar numbers for each disease focus 
(512 where the questions alluded to cancer, and 512 for heart disease). Table 6.1 (below) 
shows the results of a series of cross-tabulations and chi-square analyses with ‘disease 
type’ as the predictor variable and ‘sample characteristics’ as the outcome variables. 
There were no differences between the two samples on gender, age, education, or any 
other socio-demographic variables. The only variable that differed significantly between 
the two groups was the item ‘do any other conditions or illnesses run in your family?’. 
Respondents in the cancer sample were more likely to answer ‘no’ and less likely to 
answer ‘not sure’ than respondents in the heart disease sample (p=.030). There were no 
differences on any of the measures of health status, psychological state, smoking 
characteristics, or experience of genetic conditions and tests.
Table 6.1. Sample characteristics
n - 1,024 Cancer Heart
disease
Sig.
Socio-demographics
Sex Male 45% 44% x2[i]=o.oi,
Female 55% 56% p=928
Age 18-35yrs 22% 23% X2[2]=0.39,
36-55yrs 46% 47% p=825
56-75yrs 32% 30%
Marital status Single 22% 22% X2[l]=0.01,
Married or cohabiting 78% 78% p=.905
Children 0 26% 23%
1 13% 17% X2[4]= 3.85,
2 40% 38% p=.426
3 16% 17%
More than 3 6% 6%
Ethnic group White British 99% 98% X2[l]=3.73,
Non-White British 1% 1% p=.155
Housing tenure Rent from local authority 7% 8%
Rent from private landlord 9% 6% X2[3]=3.53,
Own home 77% 79% p=.317
Other 7% 7%
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Table 6.1. (cont)
Employment status Employed 53% 46% X2[2]=5.70,
Not employed 24% 26% p=.058
Retired 22% 28%
Education None 17% 17%
GCSEs 37% 38% X2[3]=2.87,
A-levels 12% 15% p=.412
Degree 35% 30%
Car ownership No 4% 5% X2[2M -99,
Yes, one 37% 33% p=.369
Yes, more than one 59% 62%
Internet use Yes 65% 67% X2[l]=0.57,
No 36% 33% p-,450
Religious influence None 54% 55%
A little 28% 28% X2[3]=1.55,
Quite a lot 17% 15% p=.671
Completely 3% 2%
Health status
Self-reported health status Excellent 22% 22%
Good 63% 63% X2[3]=0.38,
Fair 14% 13% p=945
Poor 2% 2%
Number of GP visits Haven’t been 48% 47%
Once 32% 31% X2[3]=0.81,
Twice 13% 14% p=.847
Three or more times 8% 8%
Personal history of disease Yes 4% 6% X2[l]=l-33,
No 96% 94% p=248
First degree relative with disease Yes 56% 57% X2[l]=0.15,
No 44% 43% p=.703
Self-reported family history of cancer/heart Yes 17% 18%
disease No 57% 54% X2[2]=0.80,
Not sure 26% 28% p=671
Family history of any other conditions or Yes 39% 37%
illnesses No 38% 33% X2[2 ]= 7 .0 1 ,
Not sure 23% 30% p=.030
Smoking status
Ever smoked a cigarette, even a puff Yes 76% 76% X2[l]=0.02,
No 24% 24% p=.880
Currently smoke Yes 20% 16% X2[l]=2.71,
No 80% 84% p=. 113
Self-reported smoking status Never/non-smoker 54% 55%
Ex-smoker 26% 29% X2[3]=4.79
Social smoker 7% 1% p=. 188
Smoker 14% 10%
Experience o f genetic conditions / tests
Personally diagnosed with a genetic illness Yes 3% 3% X2[ l ]= 0 .0 2
No / not sure 97% 97% p=882
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Table 6.1. (cont)
Family member diagnosed with 
genetic illness
Yes
No / not sure
10%
90%
11%
89%
X2[l]=0.04, 
p= 834
Personally taken a genetic test Yes
No / not sure
3%
97%
3%
97%
X2[l 1=0.51, 
p=.475
Friends or family taken genetic test Yes
No / not sure
4%
96%
6%
94%
X2[l]=1.63,
p=.202
Psychological state (LOT-R)
Dispositional optimism 
Dispositional pessimism
Mean (sd) 
Mean (sd)
2.44 (0.82) 
3.51 (0.72)
2.49 (0.83) 
3.51 (0.71)
F[l]=0.79,
p=.373
F[1]=0.00,
p=.979
Smoking characteristics (smokers 
only)
Addiction to nicotine
How soon after waking do you 
smoke your first cigarette of the day? Less than 30mins (1-3) 
30mins to 2hrs (4-5) 
More than 2hrs (6)
36%
31%
34%
36%
34%
30%
X2[l]=0.31,
p=.855
How many cigarettes do you usually 
smoke per day? Mean 14.0 13.4
F[1 ]=0.26, 
p=614
How easy or difficult would you find 
it to go without smoking for a whole 
day? Easy (1-2) 
Difficult (3-4)
49%
52%
37%
63%
X2[l]=2.34,
p=.126
M otivation to quit smoking
How much do you want to give up 
smoking all together?
Not at all-slightly- 
moderately (1-3)
Quite strongly-very 
strongly (4-5)
47%
53%
58%
42%
X2[l]=2.13,
p=.145
Are you intending to give up 
smoking within the next 6 months? No (1-2) 
Possibly (3) 
Yes (4-5)
31%
28%
41%
35%
39%
27%
X2[2]=4.52, 
p=. 104
3.2. Interest in genetic testing
3.2.1. Cancer vs. heart disease
Levels of interest in genetic testing for cancer versus heart disease were compared using 
each of the four measures of interest. Using the measure used in Study 1, “I f  it were 
available now, would you take a genetic test for cancer [heart disease] risk in the next six 
months?, 78% of respondents said yes definitely or probably for cancer, and 80% said yes 
definitely or probably for heart disease (see Table 6.2). These figures were higher than 
the levels of interest expressed by the ONS sample in Study 1, which were 65% and 70% 
respectively.
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Table 6.2. Interest in genetic testing: frequencies
Cancer Heart
disease
If it were available now, would you have a 
genetic test for [cancer] [heart disease] risk 
in the next 6 months? No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
3% (15) 
19% (95) 
44% (221) 
35% (174)
2% (12) 
17% (88) 
42% (215) 
38% (196)
Would you have a genetic test for [cancer] 
[heart disease] risk if your doctor 
recommended it? No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
1% (6)
4% (20) 
44% (224) 
51% (255)
1% (3)
3% (15) 
38% (192) 
59% (301)
Would you be interested in taking a genetic 
test for [cancer] [heart disease] risk? No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
3% (16) 
15% (77) 
49% (246) 
33% (166)
2% (10) 
10% (53) 
49% (251) 
38% (195)
Suppose you had inherited something from 
your parents which made you more likely to 
develop [cancer] [heart disease] than other 
people; would you want to be told this? No, definitely not 
No, probably not 
Yes, probably 
Yes, definitely
1 % (6) 
14% (69) 
48% (241) 
38% (190)
1 % (7)
7% (37) 
47% (238) 
45% (226)
In the present study, three additional measures of interest were included. Almost all of 
the respondents said that they would take a genetic test for cancer (95%) or heart disease 
(97%) if their doctor recommended it {‘‘Would you have a genetic test for [cancer] [heart 
disease] risk i f  your doctor recommended it?”)', 82% for cancer and 88% for heart 
disease said yes in response to the item, “Wouldyou be interested in taking a genetic test 
for [cancer] [heart disease] risk?”, and 85% and 91% respectively said yes in response 
to the item, “Suppose you had inherited something from your parents which made you 
more likely to develop [cancer] [heart disease] than other people; would you want to be 
told this? ”.
There was no difference between interest in cancer genetic testing compared to heart 
disease testing using the first two measures of interest in genetic testing (see Table 6.3 
below). However, interest in genetic testing was lower in the cancer sample than in the 
heart disease sample using the less specific item, ‘would you be interested in taking a 
genetic test for cancer/heart disease risk?’ (82% vs. 88% respectively: x2[l]=7.10,
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p=.008). Interest was also significantly lower in the cancer sample compared to the heart 
disease sample using the item ‘suppose you had inherited something from your parents 
which made you more likely to develop cancer/heart disease than other people; would 
you want to be told this? ’ (85% vs. 91%: y?[\]=9.29, p=.002).
Table 6.3. Interest in taking a genetic test using dichotomized individual items: cancer
vs. heart disease
Cancer Heart
disease
Sig.*
If it were available now, would you have a 
genetic test for [cancer] [heart disease] risk 
in the next 6 months? No (1-2) 
Yes (3-4)
22%
78%
20%
80%
X2m=0.76, p=.384
Would you have a genetic test for [cancer] 
[heart disease] risk if your doctor 
recommended it? No (1-2) 
Yes (3-4)
5%
95%
4%
97%
X2[l]=1.62,p=.203
Would you be interested in taking a genetic 
test for [cancer] [heart disease] risk? No (1-2) 
Yes (3-4)
18%
82%
12%
88%
X2H l=7.10 ,p = .008
Suppose you had inherited something from 
your parents which made you more likely to 
develop [cancer] [heart disease] than other 
people; would you want to be told this? No (1-2) 
Yes (3-4)
15%
85%
9%
91%
X2|ll= 9 .2 9 , p=.002
Interest scale (composite of four items) Mean (sd) 3.21
(0.65)
3.32
(0.60)
F |ll= 7 .7 2 , p=.006
* Significance values calculated using cross-tabulations and chi-square analyses
When the items were combined, the items loaded on to one factor in principal 
components analysis, and had a Cronbach’s alpha coefficient of 0.90. As expected, using 
this composite measure (range 1-4, with 4 being most interested), interest in genetic 
testing was lower for cancer than for heart disease (3.21 vs. 3.32: F[l]=7.72, p=.006). 
However, in order to be able to make comparisons with Study 1, the single item of 
interest will be reported here ( “I f  it were available now, would you have a genetic test for  
[cancer] [heart disease] risk in the next 6 months? ”).
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3.2.2. Correlates of interest in genetic testing
3.2.2.i. Dispositional pessimism
Cancer: The association between interest in genetic testing for cancer risk and 
dispositional pessimism was not significant (x [2]=4.79, p=.091), but there was a trend 
with people with lower levels of dispositional pessimism being less interested in genetic 
testing than those with medium or higher levels of dispositional pessimism (76%: 86%: 
84%; linear-by-linear x2[2]=3.63, p= 057).
Heart disease: People with lower levels of dispositional pessimism were less interested in 
genetic testing than those with medium or higher levels of pessimism (78%: 82%: 95%; 
linear-by-linear x2[2]=6.98, p=.008).
3.2.2.ii. Understanding of genetic testing
Cancer: People who felt that they did not have an understanding of genetic testing were 
less interested in taking a genetic test for cancer risk than those who either were not sure 
or who felt that they did not understand (62%: 81%: 79%: x2[2]=5.87, p=.057).
Heart disease: As with cancer, people who felt that they did not have an understanding 
of genetic testing were also less interested in taking a genetic test for heart disease risk 
than those who were not sure or who did not understand (69%: 87%: 78%: x2[2]=8.46, 
p=.015).
3.2.2.iii. Perceived family history
Cancer: People who had a close family member with cancer were more interested in 
genetic testing than those who did not (85% vs. 73%: x2[l]=9.29, p=.002). Similarly, 
people who believed that cancer ‘runs in their family’ were more interested in genetic 
testing than those who did not believe that (91% vs. 75%: x,2[l]=10.18, p=.001).
Heart disease: People who had a close family member with heart disease were more 
interested (87% vs. 75%: %2[\]=\0.69, p=.001), and people who believed that heart 
disease ‘runs in their family’ were more interested in genetic testing than those who did 
not (90% vs. 78%: x2[l]=7.36, p=.007).
159
( ' h a p k / r  o :  S n i d y  2 b :  S e l l - s e l e c t i o n
3.2.2.iv. Demographics
Cancer: These analyses examined the relationships between interest in genetic testing 
and demographic characteristics, in part so that comparisons could be made with the 
findings of Study 1. In the present study, there was no significant difference between 
men and women in terms of interest in genetic testing for cancer, although there was a 
trend, with men being more interested in testing than women (82% vs. 76%: x2[l]=2.67, 
p=.102). There was also no significant effect of education using a straightforward chi- 
square test, but again there was a trend: people with lower levels of education appeared to 
be more interested in testing than those with higher levels of education (88%; 79%; 79%; 
75%: x2[3]=5.46, p=.141), and the linear-by-linear association was significant (linear-by- 
linear x2[3]=4.13, p=.042). Younger adults (18-35yrs) were less interested than mid-life 
adults (36-55yrs) and older adults (56-75yrs) (69%; 80%; 82%: x2[2]=7.10, p=.029). 
Heart disease: Men were no more or less interested in genetic testing for heart disease 
risk than women (81% vs. 80%: x2[l]=0.25, p=.617). As with cancer, younger adults 
were less interested in genetic testing for heart disease (65%; 81%; 90%: x2[2]=24.93, 
p<.001), and people with lower educational attainment were more interested (91%; 83%; 
77%; 74%: x2[3]=12.13, p=.007).
3.2.2.V. Anticipated psychological reactions
Cancer: All of the ‘anticipated reaction’ items were associated with interest in genetic 
testing. Interest in genetic testing was higher amongst people who would want to discuss 
their positive (higher risk) genetic test result with a health professional (x2[2]=15.83,
'y
p<.001); who would not be concerned about the result (x [2]=5.73, p=.057); who thought 
that the information would provide their family with useful information about their own 
risk (x2[2]=45.98, p<.001); who would be glad to know of their risk (x2[2]=121.00, 
p<.001); who would not be depressed about the result (x [2]=19.58, p<.001); who would 
not worry about life insurance (x [2]=5.84, p=.054) or about employment (x [2]=12.09, 
p=.002); who would not feel that they were definitely going to get cancer (x2[2]=10.05, 
p=.007); and who would not regret having taken the test (x2[2]=60.65, p<.001).
Heart disease: Interest in genetic testing for heart disease risk was higher amongst
individuals who would want to discuss a positive (higher risk) genetic test result with a
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health professional (x2[2]=8.23, p=.016); who felt that the result would provide useful 
information for their family (x2[2]=55.87, p<.001); who would be glad to know of their 
risk (x2[2]=55.65, p<.001); who would not be depressed by the result (%2[2]=8.71, 
p=.013); who would not be worried about life insurance (x [2]=6.34, p=.042) and to a 
less degree employment (x2[2]=5.00, p= 082); and who would not regret having taken the 
test (x2[2]=33.15, p<.001). However, there was no association with anticipated concern 
(X2[2]=1.84, p=.399) or with anticipating feeling that the test result would mean they 
were definitely going to get heart disease (x2[2]=0.48, p=.785).
3.2.2.vi. Multivariate analyses
Cancer: A binary logistic regression was conducted with all of the predictor variables 
from the univariate analyses entered, and with interest in genetic testing for cancer risk as 
the outcome variable. The effects of gender, education, believing that cancer ‘runs in the 
family’, dispositional pessimism, and the anticipated reactions to a positive (higher risk 
result) being glad to know and not being regretful, were all maintained in the multivariate 
analysis. The effects of age, understanding of genetic testing, having a close family 
member with cancer, and the other anticipated reactions were not maintained (see Table 
6.4).
Heart disease: When the binary logistic regression was repeated for interest in genetic 
testing for heart disease risk, the effects of age, understanding of genetic testing, 
dispositional pessimism, and the anticipated reactions being glad to know of risk, feeling 
that the information would be useful for family members, and not regretting having taken 
the test, were maintained. The associations with gender, education, having a close family 
member with heart disease, believing that heart disease ran in the family, and the other 
anticipated reactions were not maintained (see Table 6.5).
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Table 6.4. Correlates of interest in genetic testing for susceptibility to cancer
Interested Univariate sig. Multivariate sig.
Socio-demographics
Gender Male 82% (185/227) X [l]-2 .67 , p=.102 1
Female 76% (209/277) 0.51 [0.23-1.00]*
Age 18-35yrs 69% (76/110) 1
36-55yrs 80% (181/226) X2[2]=7.10, p=.029 0.89 [0.41-1.97]
56-75yrs 82% (127/155) 0.94 [0.36-2.48]
Education None 88% (72/82) 1
GCSEs 79% (139/177) X2[3]=5.46, p=. 141 0.30 [0.07-1.33]
A-levels 79% (44/56) 0.25 [0.04-1.48]
Degree 75% (126/168) 0.17 [0.04-0.86J*
Close family member with cancer No 73% (203/277) X2 [11=9.29, p=.002 1
Yes 85% (187/221) 1.69 [0.84-3.39]
Belief that cancer ‘runs in the family’ No-n/s 75% (309/411) X2[l 1=10.18, p=.001 1
Yes 91% (79/87) 5.70 [1.66-19.58]**
Dispositional pessimism Low 76% (265/349) 1
Medium 86% (77/90) X2[2]=4.79,p=.091 3.35 [1.10-10.26J*
High 84% (41/49) 1.77 [0.53-5.93]
Understanding of genetic testing Disagree 62% (21/34) 1
Not sure 81% (120/149) X2 [21=5.87, p=.053 2.45 [0.67-8.98]
Agree 79% (247/314) 2.66 [0.83-8.54]
Anticipated emotional reactions to positive results
If I received a positive genetic test result, I would...
disagree 43% (3/7) 1
Want to discuss result with professional not sure 50% (10/20) X 2 [21=15.83, p<.001 1.43 [0.04-46.39]
Agree 80% (379/472) 9.55 [0.41-221.13]
disagree 55% (6/11) 1
Be concerned not sure 69% (25/36) X2[21=5.73, p=.057 1.17 [0.11-12.42]
Agree 80% (358/450) 3.29 [0.41-26.71]
disagree 60% (12/20) 1
Feel could give family useful information not sure 57% (55/97) X 2 [21=45.98, p<.001 0.45 [0.10-2.01]
Agree 86% (317/367) 0.96 [0.24-3.89]
disagree 22% (6/27) 1
Be glad that I knew o f my risk not sure 54% (62/114) X2[2J=121.00, p<.001 3.61 [0.88-14.73]
Agree 91% (320/353) 19.32 [4.63-80.63J***
disagree 84% (52/62) 1
Feel depressed not sure 86% (185/215) X 2 [21=19.58, p<.001 1.58 [0.46-5.49]
Agree 69% (147/213) 0.73 [0.21-2.56]
disagree 84% (114/135) 1
Worry about life insurance not sure 80% (116/145) X 2121=5.84, p=.054 0.84 [0.29-2.43]
Agree 74% (145/197) 0.67 [0.23-1.97]
disagree 85% (209/247) 1
Worry about employers not sure 74% (83/112) X 2[2]=12.09, p=.002 0.79 [0.32-1.98]
Agree 69% (72/104) 1.06 [0.39-2.87]
disagree 84% (161/192) 1
Feel I was definitely going to get cancer not sure 78% (164/211) X2[2]=10.05, p=.007 0.71 [0.31-1.62]
Agree 67% (59/88) 0.91 [0.33-2.50]
disagree 89% (266/298) 1
Regret having taken the test not sure 68% (98/144) x2 [21=60.65, p<.001 0.59 [0.27-1.31]
Agree 46% (22/48) 0.18 [0.06-0.551**
*p<.05, **p<.01, ***p<.001; ‘Interested’ indicates the proportion o f respondents who would ‘definitely’ or ‘probably’ 
take a genetic test, using a single item measure (If it were available now, would you have a genetic test for cancer risk?)
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Table 6.5. Correlates of interest in genetic testing for susceptibility to heart disease
Interested Univariate sig. Multivariate sig.
Socio-dem ographics
Gender Male 81% (184/226) X. [ 1 ]=0.25, p=.617 1
Female 80% (227/285) 1.22 [0.67-2.20]
Age 18-35yrs 65% (73/112) 1
36-55yrs 81% (190/235) X2{21=24.93, p< .001 2 .09  [1 .06-4.111*
56-75yrs 90% (135/150) 3 .20  [1 .20 -8 .55 ]*
Education None 92% (78/85) 1
GCSEs 83% (154/186) X2[3 ]= 1 2 .1 3 ,p = .0 0 7 0.87 [0.25-3.00]
A-levels 77% (56/73) 0.73 [0.19-2.79]
Degree 74% (112/151) 1.09 [0.30-3.89]
Close family member with heart disease No 75% (217/288) X2[l]= 1 0 .6 9 , p= .001 1
Yes 87% (188/216) 1.31 [0.65-2.68]
Belief that heart disease ‘runs in the family’ No 78% (321/412) X2[l]= 7 .3 6 ,p = .0 0 7 1
Yes 90% (84/93) 2.21 [0.82-5.92]
Dispositional pessim ism Low 78% (274/352) 1
Medium 82% (88/107) X2I2 ]= 7 .7 5 ,p = .0 2 1 2 .04 10.91-4.58]*
High 95% (41/43) 6.58 [1.24-34.93]
Understanding o f genetic testing Disagree 69% (29/42) 1
Not sure 87% (148/171) X21 2 ]= 8 .4 6 ,p = .0 1 5 3 .11 [1 .07-9 .03]*
Agree 78% (228/292) 1.89 [0.72-4.98]
Anticipated em otional reactions to positive results
If I received a positive genetic test result, I would...
disagree 0% (0/2) 1
Want to discuss result with professional not sure 82% (14/17) X 2 [21=8.23, p = .0 1 6 6938.71 #0 in cell#
Agree 81% (394/489) 5606.39 #0 in cell#
disagree 100% (7/7) 1
Be concerned not sure 82% (22/27) X2[2]=1.84, p=.399 0.01 #0 in cell#
Agree 80% (370/465) 0.01 #0 in cell#
disagree 45% (9/20) 1
Feel could give family useful information not sure 53% (37/70) X 2 [21=55.87, p< .001 1.54 [0.39-6.09]
Agree 86% (345/401) 5 .37  [1 .54-18 .73]**
disagree 38% (6/16) 1
Be glad that I knew o f my risk not sure 57% (43/75) X 2 [21=55.65, p< .001 3.58 [0.73-17.51]
Agree 87% (356/410) 8.01 11.80-35.64]**
disagree 85% (109/128) 1
Feel depressed not sure 82% (190/232) X2121=8.71, p = .0 1 3 1.32 [0.62-2.80]
Agree 71% (92/129) 1.01 [0.43-2.36]
disagree 82% (106/130) 1
Worry about life insurance not sure 85% (135/159) X2[21=6.34, p = .042 2.46 [0.91-6.66]
Agree 75% (152/204) 1.01 [0.40-2.54]
disagree 83% (181/218) 1
Worry about employers not sure 78% (97/125) X2[2]=5.00, p=.082 0.55 [0.24-1.28]
Agree 73% (95/130) 0.84 [0.36-1.95]
Feel I was definitely going to get heart disagree 79% (153/195) 1
disease not sure 81% (177/218) X2[2]=0.48, p=.785 1.63 [0.83-3.19]
Agree 80% (66/83) 1.31 [0.47-3.62]
disagree 87% (289/331) 1
Regret having taken the test not sure 65% (82 /1 2 6 ) X2[21=33.15, p< .001 0 .29  [0 .14-0 .60]**
Agree 66% (23/35) 0.49 [0.13-1.89]
‘Interested’ indicates the proportion o f respondents who would ‘definitely’ or ‘probably’ take a genetic test, using a 
single item measure (If it were available now, would you have a genetic test for heart disease risk?)
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3.3. Anticipated psychological reactions to genetic test results
3.3.1. Cancer vs. heart disease
If the genetic test result was positive i.e. indicative of higher risk of disease, the majority 
of people felt that they would be concerned regardless of whether it was for cancer (91%) 
or for heart disease (93%). Respondents in the cancer sample were more likely than the 
heart disease sample to feel depressed (43% vs. 26%: x2[2]=43.65, p<.001) and to regret 
having taken the test (10% vs. 7%: x2[2]=5.05, p=.025), but less likely to worry about 
problems with employers (22% vs. 28%: x2[2]=5.68, p=.017). 41% of the cancer sample 
and 42% of the heart disease sample would worry about possible problems with life 
insurance. 18% of the cancer sample and 17% of the heart disease sample would feel 
they were definitely going to get the disease if they received a positive result. Fewer 
people in the cancer sample felt that they would be glad to know of their risk than in the 
heart disease sample (72% vs. 82%: x2[2]=14.65, p<.001). 76% of respondents felt that a 
positive genetic test result for cancer would provide their family with useful information 
about their own risk, which was lower than the 82% who felt that a positive genetic test 
result for cancer would be useful for their family (x [2]=4.61, p=.032). The majority felt 
that they would want to discuss their test result with a health professional (95% cancer: 
96% heart disease).
If the genetic test result was negative, the majority of respondents felt that they would be 
glad that they knew of their risk (81% cancer: 83% heart disease). Respondents were less 
likely to feel that they could provide their family with useful information about their own 
risk if the test result was for cancer than for heart disease (63% vs. 70%: x2[2]=4.78, 
p=.029), and more likely to want to discuss their test result with a health professional 
(55% vs. 49%: x2[2]=5.17, p=.023). 15% of the cancer sample and 14% of the heart 
disease sample anticipated that they would feel they were definitely not going to get the 
disease if they received a negative genetic test result. Few people felt that they would be 
concerned (11% cancer: 7% heart disease), regretful (5% cancer: 4% heart disease) or 
depressed (3% cancer: 3% heart disease). These results are shown in Table 6.6.
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Table 6.6. Anticipated psychological reactions to genetic test results: cancer versus heart disease
Disagree
Cancer
Not sure Agree Disagree
Heart disease
Not sure Agree Sig.
If I received a positive genetic test result, I w ould...
Want to discuss my test result with health professional 7 1% 20 4% 476 95% 2 0% 17 3% 490 96% X![2]=1.62,p=204
Be concerned 11 2% 36 7% 695 91% 7 1% 27 5% 466 93% X2 [2]=2.27,p=. 132
Feel could provide family with useful information 20 4% 99 20% 369 76% 16 3% 76 15% 410 82% X! [2]=4.61, p=.032
Be glad that I knew of my risk 28 6% 114 23% 356 72% 20 4% 71 14% 401 82% X2 [21=14.65, p<.001
Feel depressed 63 13% 17 44% 214 43% 128 26% 233 48% 129 26% X2 [2]=43.65, p<.001
Worry that it may cause problems with life insurance 135 28% 147 31% 198 41% 130 26% 159 32% 205 42% X2 [2]=0.13, p=.721
Worry that it may cause problems with employers 249 53% 113 24% 104 22% 218 46% 125 26% 131 28% X2 [2]=5.68, p=.017
Feel was definitely going to get cancer/heart disease 194 39% 212 43% 89 18% 195 39% 219 44% 83 17% X2 [2]=0.06,p=810
Regret having had the test 99 61% 47 30% 48 10% 331 67% 127 26% 35 7% X2 [21=5.05, p=.025
If I received a negative genetic test result, I w ould...
Be glad that I knew of my risk 33 7% 63 13% 397 81% 37 7% 47 9% 415 83% X2 [2]=0.89, p=,345
Feel could provide family with useful information 46 10% 135 28% 304 63% 46 9% 101 21% 344 70% X2 [21=4.78, p=.029
Want to discuss my test result with health professional 129 26% 89 18% 270 55% 165 33% 88 18% 244 49% X2 [21=5.17, p=.023
Feel was not going to get cancer/heart disease 270 55% 153 31% 72 15% 264 53% 163 33% 68 14% X2 [2]=0.04, p=.839
Be concerned 365 75% 69 14% 53 11% 383 79% 70 14% 34 7% X2 [2]=2.45, p=. 118
Regret having had the test 409 85% 50 10% 25 5% 429 87% 45 9% 18 4% X2 [2]=1.55, p=.213
Feel depressed 422 87% 46 10% 15 3% 434 89% 43 9% 13 3% X2 [2]=0.34, p=.559
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3.3.2. Positive test results vs. negative test results
A series of paired sample t-tests were conducted to compare people’s anticipated 
reactions to positive versus negative genetic test results. For cancer, respondents were 
more likely to want to discuss their test result with a health professional if it was positive 
than if it was negative (mean positive test result score [on scale from 1 to 5] 4.44+0.66: 
mean negative test result score 3.37+1.14; t[486]=-20.32, p<.001). They were also more 
likely to anticipate being concerned (positive 4.28+0.70: negative 2.16+0.96; t[486]=- 
35.70, p<.001), more likely to feel that they could provide their family with useful 
information (positive 3.88+0.77: negative 3.63+0.90; t[479]=-7.27, p<.001), less likely to 
be glad to know of their risk (positive 3.80+0.80: negative 3.92+8.64; t[487]=2.97), more 
likely to feel depressed (positive 3.37+0.92: negative 1.86+0.73; t[480]=-29.32, p<.001), 
and more likely to regret having taken the test (positive 2.33+0.93: negative 1.90+0.81; 
t[482]=-9.69). Figure 6.1 illustrates these data graphically. The figure highlights that 
whilst most people would be concerned about a positive genetic test result, only half of 
those felt that they would be depressed, and moreover very few would regret having 
taken the test. In contrast, the majority would be glad to know of their risk, even if the 
test result was positive.
The pattern was similar for heart disease, with respondents being more likely to want to 
discuss their test result with a health professional if it was positive than if it was negative 
(4.46+0.58 vs. 3.19+1.18: t[496]=-23.69, p<.001), as well as more concerned (4.23+0.65 
vs. 2.03+0.85: t[481]=-42.93, p<.001), more likely to feel that they could provide their 
family with useful information (3.97+0.75 vs. 3.72+0.86: t[483]=-7.43, p<.001), more 
depressed (2.98+0.92 vs. 1.81+0.71: t[482]=-24.37, p<.001), and more regretful 
(2.21+0.89 vs. 1.85+0.74: t[485]=-9.17, p<.001). However, people in the heart disease 
sample were no less likely to anticipate feeling glad to know of their risk in response to a 
positive test result than to a negative test result (3.98+0.72 vs. 3.95+0.86: t[490]=-0.91, 
p=.362). Table 5.9 shows the results for heart disease and cancer having dichotomized 
people into either ‘strongly-agree’ or ‘strongly-disagree-not sure’.
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Figure 6.1. Anticipated psychological reactions to positive
and negative genetic test results for susceptibility to cancer
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Table 6.7. Anticipated reactions to genetic testing: comparisons between positive
and negative test results
Result
Cancer 
Agree-strongly agree (4-5)
% n
Heart disease 
Agree-strongly agree (4-
5)
% N
Discuss result Positive 95%** 476 96%** 490
Negative 55% 270 49% 244
Concerned Positive 91%** 454 93%** 466
Negative 11% 53 7% 34
Useful information Positive 76%** 369 82%** 401
Negative 63% 304 70% 344
Glad to know Positive 72%* 356 82% 410
Negative 81% 397 83% 415
Depressed Positive 43%** 214 26%** 129
Negative 3% 15 3% 13
Feel definitely/not get disease Positive 18%** 89 17%** 83
Negative 15% 72 14% 68
Regretful Positive 10%** 48 7%** 35
' Negative 5% 25 4% 18
*p<.05, **p<.001
□  Positive result
□  Negative result
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3.3.3. Correlates of anticipated depressed reaction to a positive genetic test result
3.3.3.i. Dispositional pessimism
Cancer: In order to examine the correlates of anticipated depressed reaction, a series of 
univariate linear regressions were conducted with the item, "If I  received a positive 
genetic test result for cancer risk, I  would feel depressed ” , as the continuous outcome 
variable. The item was normally distributed: 3% responded ‘strongly disagree’, 10% 
‘disagree’, 44% ‘not sure’, 33% ‘agree’, and 11% ‘strongly agree’. The aim of these 
analyses was to identify groups of people in the general population at high risk of having 
adverse psychological reactions to unfavourable genetic test results for complex disease 
susceptibility. People with high levels of dispositional pessimism were more likely to 
anticipate having a depressed reaction than those with medium or low levels of 
dispositional pessimism (P=0.28, p<.001).
Heart disease: A univariate linear regression with the item "If I  received a positive 
genetic test result for heart disease risk, I  would feel depressed” as the continuous 
outcome variable and dispositional pessimism as the predictor variable showed that 
people with low levels of dispositional pessimism were less likely to anticipate 
depression than those with higher levels of pessimism ((3=.222, p=.001).
3.3.3.ii. Understanding of genetic testing
Cancer: Subjective understanding of genetic testing was measured with the item "I have 
a clear picture o f what genetic testing is Because of skewed responses, respondents 
were dichotomised into two groups, ‘do not understand’ (strongly disagree, disagree, not 
sure) and ‘understand’ (agree or strongly agree). Respondents who had a subjective 
understanding of genetic testing on this item were less likely to anticipate feeling 
depressed in response to a positive genetic test result than respondents who did not feel 
that they understood what genetic testing was (41% vs. 47%: p=0.20, p=.017).
Heart disease: People with higher subjective understanding of genetic testing were less 
likely to anticipate feeling depressed in response to receiving a positive genetic test result 
for heart disease susceptibility than those with a lower understanding (34% vs. 21%: (3=- 
.353, p<.001).
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3.3.3.iii. Perceived family history
Cancer: There was no relationship between perceived family history of cancer and
anticipated depression (p=-.l 10, p=.321).
Heart disease: Similarly, there was no relationship between family history of heart
disease and anticipated depression (P=.096, p=.374).
3.3.3.iv. Demographics
Cancer: There was no association between educational attainment and anticipated
depression (p==.016, p=.671). However, there was a relationship with age and gender. 
As hypothesised, women were more likely to anticipate feeling depressed in response to a 
positive result than men (47% vs. 39%: (3=-.204, p=.017). In addition, 56% 18-35yr olds 
anticipated feeling depressed, which was significantly higher than the 36-55yr olds (38% 
of whom anticipated feeling depressed) and the 56-75yr olds (of whom 42% anticipated 
feeling depressed (P—.136, p=.017). See Table 6.8 for summary of univariate 
associations for cancer.
Heart disease: The same pattern of results was obtained as for cancer. There was no 
relationship between educational attainment and anticipated depression but, as predicted, 
women were more likely to anticipate feeling depressed than were men (29% vs. 23%: 
p=-.353, p<.001). Also, younger adults were more likely to anticipate feeling depressed 
than mid-life or older adults (39% vs. 25% vs. 20%: p=-.209, p<.001). See Table 6.9 for 
a summary of the univariate associations for heart disease.
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Table 6.8. Correlates of anticipating a depressed reaction to receiving a positive genetic
test result for cancer risk: univariate linear regressions
Depressed response to 
positive cancer result*
Univariate regression  
linear sig.
Understanding o f genetics
Understanding of genetic testing
Yes (4-5) 41% P=-.204, p=.017
No (1-3) 47%
Positive result would mean
definitely get the disease
Disagree (1-2) 30% P=.532, p<.001
Not sure (3) 45%
Agree (4-5) 70%
Psychological state
Dispostional pessimism
Low (1-2) 39% P=.281, p<.001
Medium (3) 48%
High (4-5) 68%
Disease representations
Not worried
Disease-specific worry (1-2) 35% P=.329, p<.001
Worried (3-5) 50%
Perceived risk of disease
Lower (1-2) 34% P=.020, p=.786
Same (3) 47%
Higher(4-5) 35%
Understanding of disease Yes (4-5) 43% p=.095, p-.335
No (1-3) 43%
Perceived control over disease Yes (5) 41% P=-.159, p=.072
No (1-4) 49%
Perceived curability of disease Yes (5) 41% P=-.154, p=.085
No (1-4) 49%
Demographics
Smoking status
Smoker 39% P=.071, p=.490
Non-smoker 45%
Gender
Male 39% P=-.204, p = 017
Female 47%
Age
18-35 56% P=-.136, p=.017
36-55 38%
56-75 42%
None 45%
GCSEs 43%
A-levels 39%
Educational qualifications Degree 43% p=.016, p=.671
Yes 37%
Perceived family history- Don’t know 40% p=-. 110, p=.321
based risk No 47%
Leaflet Leaflet 47% p=.027, p=.742
No leaflet 45%
*The figures are shown for the percentage of respondents within each predictor variable group who 
‘agreed’ or ‘strongly agreed’ with the item "If I  received a positive genetic test result for cancer risk I  
would depressed”
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Table 6.9. Correlates of anticipating a depressed reaction to receiving a positive genetic
test result for heart disease risk ____________________________________
Depressed response to 
positive heart disease result*
Univariate linear 
regression sig.
Understanding o f genetics
Understanding Yes (4-5) 
No (1-3)
21%
34%
P=-.353, p<.001
Positive result would mean
definitely get the disease Disagree (1-2) 
Not sure (3) 
Agree (4-5)
16%
27%
48%
P=.432, p<.001
Psychological state
Dispostional pessimism Low (1-2) 
Medium (3) 
High (4-5)
25%
31%
29%
P=.222, p=.001
Disease representations
Not worried
Disease-specific worry (1-2)
Worried (3-5)
26%
27%
P=.148, p=.086
Perceived risk of disease
Lower (1-2) 26% P=.095, p=. 141
Same (3) 26%
Higher(4-5) 29%
Understanding of disease
Yes (4-5) 
No (1-3)
26%
28%
P=-.219, p=.012
Perceived control over
disease Yes (5) 
No (1-4)
27%
18%
P=.096, p=.428
Perceived curability Yes (5) 
No (1-4)
27%
26%
P=-.063, p=.458
Demographics
Gender Male
Female
23%
29%
P=-.353, p<.001
Age
18-35
36-55
56-75
39%
25%
20%
P=-.209, p<.001
Educational qualifications
None 20%
GCSEs 24% P-.020, p=. 608
A-levels 29%
Degree 31%
Smoking status
Smoker 27% P=.0l9, p-.863
Non-smoker 26%
Perceived family history- 
based risk Yes 26%
Don’t know 24% P=.096, p=.374
No 28%
Leaflet
Leaflet 42% P=.151,p=.072
No leaflet 45%
*The figures are shown for the percentage of respondents within each predictor variable group who 
‘agreed’ or ‘strongly agreed’ with the item “I f  I received a positive genetic test result for cancer risk I  
would depressed ”
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3.3.3.V. Multivariate analyses
Cancer: The variables that were significantly associated with anticipated depression in 
the univariate analyses were entered into a multiple linear regression. These included 
dispositional pessimism, understanding of genetic testing (as well as the fatalism item “I f  
I  received a positive genetic test result, I  would feel I  was definitely going to get 
cancer”), gender, and age. Two additional variables were also included, understanding 
of cancer and disease-specific worry, as they also emerged as predictive either for cancer 
or for heart disease. In the multiple linear regression, the associations between 
anticipated depression and pessimism, fatalism, age, and disease-specific worry were 
maintained. The effects of understanding of genetic testing, understanding of cancer, and 
gender were not maintained.
Heart disease: Pessimism, understanding of genetic testing, fatalism, disease-specific 
worry, gender, age, and understanding of heart disease were then entered into a second 
multivariate linear regression, this time with anticipated depression in response to a 
positive heart disease genetic test result as the outcome variable. Understanding of 
genetic testing, genetic fatalism, age, and gender, all remained significantly associated 
with anticipated depression. Understanding of heart disease, dispositional pessimism and 
disease-specific worry did not (see Table 6.10 for summary of multiple linear regression 
analyses).
Table 6.10. Multiple linear regressions on anticipated depressed reaction 
to positive genetic test results for cancer and heart disease
Cancer
Sig.
Heart disease 
Sig.
Understanding of genetic testing P=.069, p-.447 P=-.308, p<.001
Positive result would mean definitely cancer P=.480, p<.001 P=.366, p<.001
Understanding of cancer P=.021,p=.842 P=-.089, p=.308
Dispositional pessimism P=.150, p=.020 P=.096,p=. 152
Disease-specific worry P=.235, p=.004 P=. 134, p= 119
Age P=-.139, p=.012 P=-.211, p<.001
Gender P=.071,p=379 P=.211, p=.010
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4. Discussion
The findings in this study go some way to supporting the self-selection hypothesis that 
people in the general population who anticipate having adverse psychological reactions to 
genetic test results are less likely to opt for genetic testing than those who think they 
would benefit from the process. For example, 46% of people who anticipated regretting 
having taken the test if the result was unfavourable reported being interested in taking a 
genetic test for cancer susceptibility, compared to 89% of people who felt that they would 
not regret having taken the test. Similarly, 86% of people who felt that a positive result 
would provide their family with useful information about their own risks were interested 
in testing for cancer susceptibility compared to 60% of people who did not feel that way. 
Putting this into the context of the MRC framework for designing complex interventions 
(Campbell et al, 2000), these associations between anticipated outcomes and interest 
could suggest that offering general population people genetic risk information may not 
cause substantial harm, given that those people who would have the most adverse 
reactions would not participate or opt for testing in the first place. However, although the 
findings do support that there is a relationship between anticipated outcomes and interest, 
they also show that, in absolute terms, large numbers of people who anticipated adverse 
outcomes would nonetheless take the tests. For example, although there was an 
association between anticipated depression and interest in genetic testing for cancer 
susceptibility (x2[2]=19.58, p<.001), 69% of people who anticipated feeling depressed 
were still interested in taking the test. These findings therefore present a mixed message: 
on the one hand, vulnerable people will probably self-select themselves out of testing to 
some degree; on the other hand, there is still reason to be concerned that some people 
could have adverse psychological reactions to positive genetic test results. This therefore 
supports the need for consideration of who might be most at risk for adverse reactions. In 
the present study, I attempted to address this question by looking at some of the correlates 
of anticipated depression in response to positive genetic test results.
As hypothesised on the basis of previous research (Duisterhof et al, 2001; Tibben et al, 
1991; Decruyenaere et al, 1996), dispositional pessimism was associated with anticipated 
depression in response to genetic testing for both cancer and heart disease susceptibility.
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Although this is not altogether surprising, it does highlight that it is important to assess 
the psychological state of individuals prior to offering them genetic risk information. In 
the present context, this finding made me feel that it would be best to have a stringent 
exclusion criterion in the randomised controlled trial. It made me more sure that it would 
be better to be safe than sorry at this stage and not offer genetic testing for a common 
genetic variant to anyone who had had a diagnosis of any psychiatric condition in the past 
or who was currently being treated for depression. Whilst this in fact led to the exclusion 
of a considerable proportion of people, given that this was to be only the third RCT of its 
kind to be conducted and that there were therefore a large number of unknown quantities, 
I felt that a cautious approach to this issue was the best one for the time being.
The findings regarding understanding of genetic testing and fatalism also had 
implications for the design of intervention studies incorporating actual genetic risk 
feedback. In the present study, people with lower subjective understanding of genetic 
testing were more likely to anticipate feeling depressed in reaction to receiving positive 
genetic test results for both cancer and heart disease. Possibly more importantly, 70% of 
people who agreed with the statement “I f  I  received a positive genetic test result for  
cancer risk, I  would feel I  was definitely going to get cancer in the future ” anticipated 
feeling depressed, compared to only 30% of people who disagreed with this statement. 
These findings highlight the importance of ensuring that people really understand the 
genetic risk information they are being given. The implication for the design of an 
intervention study in which we were considering giving people actual genetic risk 
information, was that it was clearly very important to try to ensure that people understood 
that the genetic test results were in no way definitive, and that people should have as 
good an understanding as possible, not only to be able to make an informed decision 
about whether to undergo testing, but also to minimize adverse psychological reactions to 
genetic test results.
More generally, these findings support the hypothesis that people who are more fatalistic 
about genetic risks are more vulnerable to having adverse psychological reactions 
(Senior, Marteau & Weinman, 2000). The present findings also supported previous 
research which suggested that women would be more vulnerable to depressed reactions
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than men (Tibben et al, 1993; Brodersen et al, 2004), and in addition suggested that 
younger people are more vulnerable to having depressed reactions than older people. 
These findings suggested that we should be aware in the implementing of a genetic 
testing study that younger adults and women could be potentially more at risk of being 
harmed psychologically by their results than older adults and men.
The overall levels of anticipated concern and depression reported by respondents in this 
study provides some evidence to support the suggestions that people in the general 
population may find positive genetic test results for complex diseases distressing but, on 
the other hand, very few people anticipated regretting having taken the test, and most 
would be glad that they knew of their risk. This suggests that concerns about people 
experiencing some negative emotional reactions to genetic test results may be justified, 
but equally that some people may nonetheless wish to know and be glad to know of their 
risk.
One major limiting factor in this kind of survey work is that, whilst there is an abundance 
of evidence showing that intentions predict behaviour (albeit with only about 30% 
accuracy; Marteau & Lerman, 2001), interest in genetic testing could nonetheless be 
construed simply as another facet of global attitudes towards either genetics or risk. The 
majority of people interviewed in the pilot development of the survey had almost no idea 
whatsoever as to what genetic testing was, and it therefore seems possible that the vast 
majority of people in the general population and in this survey were answering the 
questions having made almost no considered judgements about their responses. In which 
case, both interest and anticipated reactions could simply be reflections of attitudes in 
general towards genetics, medical interventions, or cancer or heart disease. This 
highlights the limitations of this kind of survey work and supports the need for trials in 
which actual genetic risk feedback about common genetic variants is given.
In conclusion, bearing the above caveats in mind, this study found that high levels of 
people in the general population anticipate feeling depressed or concerned about genetic 
test results, and would want the option of talking to a health professional, but would not 
regret having taken the test, regardless of the result. Genetic testing for susceptibility to
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complex diseases may cause psychological distress, but people are particularly prone to 
distress if they do not understand the meaning of genetic tests and genetic risk 
information. The implications of these findings are that it may be feasible to conduct 
genetic testing for complex disease susceptibility, but care must be taken to ensure that 
people taking the tests understand the results as well as is possible, and that they are 
given the option of talking to a health professional about their results.
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CHAPTER 7
Study 2c: Depressed, motivated or complacent? Anticipated reactions 
to genetic testing in a survey sample of smokers 8
1. Introduction 
1.1. Overview of Study 2c
In the previous three chapters I focused on interest in genetic testing and anticipated 
psychological reactions to genetic testing in two general population-based survey 
samples. In the present study I move on to consider anticipated behavioural reactions 
amongst smokers in the general population. Again, the postal questionnaire survey 
sample is used.
1.2. Rationale for examination of anticipated behavioural reactions amongst 
smokers
There is growing recognition that health behaviour researchers will play a central role in 
evaluating the benefits and risks of genetic tests for common genetic variants associated 
with complex diseases as they emerge (Marteau, 1999; Collins, Green, Guttmacher & 
Guyer, 2003). The question of whether genetic testing will lead to health behaviour 
change becomes ever more important as common genetic variants are identified which 
confer an increased or decreased susceptibility to complex, behaviour-related diseases. 
Although there have been concerns about the psychological impact of genetic test results 
since genetic testing was first introduced, it is only in the past few years that genes 
associated with increased susceptibility to complex, behaviour-related diseases have 
begun to be identified, and the behavioural implications of genetic test results have 
therefore only recently begun to be investigated. This is especially true of lifestyle
8 A version of this chapter was an invited paper presented at the Genomics and Health Symposium in 
Michigan, October 2004, and is due for publication in Health Education and Behavior (Sanderson & 
Wardle, in press). See Appendix A.
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behaviours such as dietary choices, physical activity levels, and smoking cessation. 
Hereditary breast and colon cancer studies have started to examine behavioural reactions 
to genetic testing such as medication adherence, screening adherence and prophylactic 
surgery behaviours (Lerman et al, 2000; Botkin et al, 2003; Kauf et al, 2002; Esplen et al, 
2001), but the extent to which these studies may be extrapolated to a) the general public, 
and b) lifestyle-related behaviours, remains unclear. Given that one of the hypothesized 
advantages of genetic susceptibility testing at a policy level is that it will “allow people 
identified as ‘higher risk’ to make appropriate lifestyle changes in order to reduce their 
risk” (Advisory Committee on Genetic Testing, 1998), this is an area that needs further 
investigation.
The assumption that individuals identified as being at increased risk of developing a 
complex, behaviour-related disease, such as lung cancer or heart disease, may be able to 
considerably reduce their risk by making lifestyle changes (Bell, 1998; ACGT, 1998; Day 
& Wilson, 2001) is supported by the fact that perceived disease susceptibility is a central 
component of many social cognition models of health behaviour change such as the 
Health Belief Model (HBM: Rosenstock, 1974), Protection Motivation Theory (PMT: 
Rogers, 1975; 1983) and the Health Action Process Approach (HAPA: Schwarzer, 1992). 
In the case of smoking cessation, these models suggest that informing smokers that they 
are genetically susceptible to the harmful effects of smoking could increase their 
motivation to quit smoking. However, some fear-appeal models, such as the PMT and 
the Extended Parallel Process Model (EPPM: Witte, 1994; Witte & Allen, 2000), suggest 
that increasing fear amongst individuals who have low self-efficacy could actually 
undermine their motivation to quit smoking, and even ‘deny their smoking problem’ 
(Wang et al, 2004). It also follows that informing smokers that they are not genetically 
susceptible could decrease their motivation to quit, and there is the danger that people 
who are found not to be at increased risk could develop a false sense of reassurance, 
feeling invulnerable to the adverse effects of their risk behaviour (Marteau & Lerman, 
2001).
As genetic tests become available for diseases associated with smoking, it will be 
important to determine whether smokers are particularly prone to having depressed
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responses. Smokers are thought to be a relatively vulnerable group, in that they are 
already more liable to be depressed or anxious than non-smokers (Lerman et al, 1997). It 
is therefore important to consider whether they will be particularly prone to have negative 
responses to genetic test results that inform them they are at high risk of a disease that is 
linked to a behaviour they may feel is beyond their control. Two randomized controlled 
trials have evaluated the impact of feedback on common genetic variants associated with 
smoking-related disease (Lerman et al, 1997; McBride et al, 2002). In both, smokers 
were randomly assigned to either a smoking cessation intervention which included 
personalized genetic risk information on the basis of genetic testing or to a control group. 
The findings in relation to motivation to quit and depression were mixed. In one study, 
motivation to quit increased in the genetic testing group but actual cessation did not 
(Lerman et al, 1997), whereas in the other, actual cessation in the genetic test group was 
twice as high as that in the control group (McBride et al, 2002). A possibly surprising 
finding in the second of these studies was that there was no difference between the 
subgroup that received higher genetic risk information and the subgroup that received 
lower genetic risk information. The first study (Lerman et al, 1997) only gave higher risk 
information. Neither study found lasting effects on depression. The relative impact of 
negative genetic test results versus positive genetic test results for complex, behaviour- 
related diseases remains to be seen. In addition, the smokers who participated in these 
studies were likely to be more motivated to quit and more addicted to nicotine than those 
in the general population.
In line with Phase II of the MRC framework for complex intervention development 
(Campbell et al, 2000), these questions were addressed in the postal survey study before 
attempting to actually offer smokers genetic test results indicating increased or decreased 
susceptibility to a smoking-related disease. The aim of the present study was to advance 
understanding of the circumstances under which genetic testing for smoking-related 
disease risk might lead either to positive outcomes such as increased motivation to quit 
smoking or undesirable outcomes such as depression or complacency, by comparing the 
characteristics of smokers in the general population who did and did not anticipate each 
of these outcomes. The use of the two different complex diseases in the survey sample, 
cancer and heart disease, was relevant because one single behaviour change can
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effectively reduce an individual’s risk of multiple common diseases. The use of the 
quantitative survey also enabled us to compare anticipated reactions with actual reactions 
in the final study.
1.3. Research questions
The primary research question addressed in this study was: How do smokers anticipate 
responding to genetic risk information for smoking-related diseases? The three 
secondary research questions were: What are the characteristics o f smokers who would i) 
be motivated to quit in response to receiving a positive genetic test result for  
susceptibility to smoking-related disease, ii) believe that a negative genetic test result 
would mean that it was safe for them to carry on smoking (i.e. would be de-motivated or 
complacent), and Hi) be at risk o f having a depressed reaction to receiving a positive 
genetic test result. The association between anticipated reactions and subjective 
understanding of genetic testing was also examined partly because it has been suggested 
that understanding has an impact on smokers’ reactions to genetic test results (Lipkus et 
al, 2004). Comparisons were made between cancer and heart disease, and between 
positive and negative genetic test results. In addition, I looked again at the self-selection 
issue by looking briefly at the relationship in these smokers between anticipated reactions 
and interest in testing. It was predicted that smokers would anticipate being more likely 
to quit smoking if they received a positive result than if they received a negative result.
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2. Method
2.1. Design
Again, the study design and measures for these analyses are described in full in Chapter 
5, and materials can be found in Appendix E. In brief, a cross-sectional quantitative 
survey was used, in a 2x2 experimental design (leaflet vs. no leaflet; cancer vs. heart 
disease). 1,024 survey questionnaires were returned with similar numbers of respondents 
in each group. 186 respondents were smokers.
2.2. Measures
As before, the measures used in this study were described in full in Chapter 5. Those 
included in the present analyses were:
2.2.1. Demographics
Gender, age, and education.
2.2.2. Perceived family history
Perceived (subjective or self-reported) family history was measured with the question, 
“In your opinion, does cancer [heart disease] run in your family?”, with response options, 
“yes”, “no”, and “don’t know”.
2.2.3. Dispositional pessimism
Dispositional pessimism was measured using the three items from the short version of the 
revised Life Orientation Test (LOT-R: Scheier & Carver, 1985; Carver & Bridges,
1994): “If something can go wrong for me, it will”, “I hardly ever expect things to go my 
way”, and “I rarely count on good things to happen to me”. Response options were 
strongly disagree, disagree, not sure, agree, and strongly agree.
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2.2.4. Desire to quit smoking
All respondents were asked the dichotomous, yes or no, question, “Do you ever smoke 
cigarettes now?”. Desire to quit was measured with item: “How much do you want to 
give up smoking all together?” (not at all, slightly, moderately, quite strongly, very 
strongly). This measure of desire to quit smoking, or motivation, is used in the annual 
Office for National Statistics assessment of smoking-related behaviours and attitudes in 
the UK (Lader & Goddard, 2002).
2.2.5. Level of nicotine addiction
See Chapter 5.
2.2.6. Understanding of genetic testing
See Chapter 5.
2.2.7. Anticipated reactions to positive and negative genetic test results
See Chapter 5.
2.3. Statistical analyses
Anticipated reactions to positive and negative genetic test results were described 
separately for the cancer sample and the heart disease sample using frequency tables. 
Differences between anticipated reactions to genetic test results for cancer versus heart 
disease were examined using Pearson’s chi-square analyses. Differences between 
anticipated reactions to a positive result versus a negative result were compared using 
paired samples t-tests. Further analyses were conducted having collapsed the two disease 
samples into one, due to the small number of subjects in each sample. In order to 
examine the characteristics of smokers who believed that they would be motivated to quit 
smoking by receiving a positive genetic test result, chi-square analyses were conducted 
with the item “I f  I  received a positive genetic test result, I  would definitely quit 
smoking”, having dichotomized responses into ‘motivated’ (agree or strongly agree) 
versus ‘not motivated’ (not sure, disagree, or strongly disagree). The predictor variables 
that were significantly associated with anticipated motivated reaction in the univariate
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analysis, were entered into a binary logistic regression, with the dichotomized ‘motivated 
reaction’ item as the outcome variable. Univariate associations between anticipated de­
motivated reaction (not sure, agree, or strongly agree with the item, “I f  I  received a 
negative genetic test result, I  would feel that it was safe for me to carry on smoking ”) and 
the predictor variables was examined using a series of Pearson’s chi-square tests. As 
before, the predictor variables that were significantly associated with anticipated de­
motivated reaction in the univariate analysis were entered into a binary logistic 
regression. The univariate and multivariate analyses were then repeated a further time 
with anticipated depression (agree or strongly agree with “I f  I  received a positive genetic 
test result, I  would feel depressed”) as the outcome variable.
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3. Results
3.1. Sample characteristics
Demographic characteristics of the whole survey sample were reported in Chapters 5 and 
6. In response to the question, “Do you ever smoke cigarettes now?”, 102 (20%) of the 
cancer sample, and 84 (16%) of the heart disease sample, responded ‘yes’. This was a 
total sample size of 186 (18% of the whole sample) when the two survey samples were 
combined. The figure of 18% is somewhat lower than the UK population of whom about 
25% are smokers. There were no significant differences between the cancer sample and 
the heart disease sample on socio-demographic or smoking variables (see Table 7.1).
Table 7.1. Characteristics of surveyed smokers
C ancer
(n=102)
H eart disease 
(n=84)
Sig.
Dem ographics
Gender Male
Female
51 (50%) 
51 (50%)
41 (49%) 
43 (51%)
X2[l]=0.03, 
p=. 884
Age 18-35yrs
36-55yrs
56-75yrs
37 (37%) 
39 (39%) 
24 (24%)
29 (36%) 
37 (46%) 
15(19%)
X2[2]=L12,
p=.572
Educational qualifications No formal qualifications
GCSEs
A-levels
Degree
20 (20%) 
40(41% ) 
16(16% ) 
22 (22%)
15 (18%) 
32 (39%) 
15 (18%) 
20 (24%)
X2[3]=--0.31,
p=.958
Perceived fam ily history
In your opinion, does cancer/heart disease 
run in your family? Yes
No-not sure
22 (22%) 
80 (78%)
21 (26%) 
61 (74%)
X2[l]=0-42,
p=.520
Dispositional pessim ism
Mean o f 3-item composite LOT-R scale Low
Medium
High
67 (67%) 
17(17% ) 
16 (16%)
53 (64%) 
20 (24%) 
10(12%)
X2[2]=1.70,
p=428
Sm oking variables
Desire to quit smoking: How much do you 
want to give up smoking all together?
Weak desire: Not at all­
moderate 1 y (1-3)
Strong desire: Quite-very strongly 
(4-5)
48 (47%) 
54 (53%)
48 (58%) 
35 (42%)
X2[l]=2-13, 
p=. 145
Level of nicotine addiction: How easy or 
difficult would you find it to go without 
smoking for a whole day?
High addiction: difficult (3-4) 
Low addiction: easy (1-2)
53 (52%) 
50 (49%)
52 (63%) 
31 (37%)
X2[l]=2.34,
p=. 126
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Table 7.1. (cont)
U nderstanding o f genetic testing
Understanding o f genetic testing: I have a 
clear picture o f what genetic testing is
Disagree-not sure (1 -3) 
Agree (4-5)
45 (45%) 
55 (55%)
37 (45%) 
46 (55%)
z 2[i ]=o.oo, 
p=954
Fatalistic belief about genetic testing: If I 
received a positive genetic test result, I 
would feel I was definitely going to get 
cancer/heart disease in the future
Disagree (1-2)
Not sure-agree (3-5)
30 (30%) 
69 (70%)
27 (33%) 
54 (67%)
Z2[ 11=0.19, 
p=664
Younger adults were twice as likely as older adults to be smokers (32% 18-35yrs olds), 
17% 36-55yr olds, and 13% 56-75yr olds, p<.001). Respondents with lower levels of 
education were more likely to be smokers than those with higher levels of education 
(p<.001) (see Table 7.2). Smokers were less likely to classify themselves as being in 
excellent or good health (p=.010), but were no more likely to have visited the GP in the 
past three months. There was no difference between smokers and non-smokers on the 
measures of dispositional pessimism and optimism (see Table 7.3).
Table 7.2. Proportion of smokers within demographic groups
n= 1,024 %
smokers
(n=191)*
Sig.
Demographics
Sex Male 21% X2[l]=2.09, p=.148
Female 17%
Age 18-35yrs 32%
36-55yrs 17% X2[21=31.07,
p<.001
56-75yrs 13%
Education None 21%
GCSEs 20% X2[31=8.05, p=.045
A-levels 24%
Degree 14%
Housing tenure Own home 15%
Rent from private 29% X2[3]=39.95,
landlord p<.001
Other 35%
Rent from local 36%
authority
*Note: 8 people didn’t respond to the smoking question. Also, 5 people who identified themselves as 
smokers didn’t go on to answer the smoking-specific questions, which is why the total n of smokers is 186 
throughout the other analyses
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Table 7.3. Health status and psychological state: comparisons between smokers and non-
smokers
Smokers
(n=191)
Non-
smokers
(n=825)
Sig.
Health status
Self-reported health status Excellent 14% 23% X2[3]=11.29,
Good 67% 62% p=.010
Fair 18% 13%
Poor 1% 2%
Number of GP visits in past 3 Haven’t been 51% 47%
months Once 25% 33% X2[3]=6.15,p=.104
Twice 14% 13%
Three or more 11% 7%
times
Psychological state (LOT-R)
Dispositional optimism Mean (sd) 3.46 (0.80) 3.52 (0.69) F[l]=0.83,p=.361
Dispositional pessimism Mean (sd) 2.56 (0.93) 2.45 (0.80) F[l]=2.91, p=.089
3.2.Interest in genetic testing and its relationship with motivation to quit smoking
One hypothesis is that smokers who are strongly motivated to quit smoking will be more 
likely to opt to take genetic tests for complex, smoking-related diseases, possibly because 
they are more willing to try interventions that they believe might help them quit. In order 
to test this hypothesis, a chi-square was conducted on level of motivation to quit (not at 
all to moderately [1-3] vs. strongly [4-5]) and interest in taking a genetic test (not 
interested [1-2] vs. interested [3-4]). The results of this analysis did not suggest that the 
two were associated: 77% (73/95) un-motivated smokers expressed interest in genetic 
testing compared to 83% (74/89) of strongly motivated smokers (x2[l]=1.14, p=.286). 
However, the analyses were re-run having dichotomized interest into ‘not interested’ [1-
3] vs. ‘definitely interested’ [4]. This time there was an association, with 52% (46/89) 
strongly motivated smokers saying that they would ‘definitely’ take a genetic test, 
compared to 31% (29/95) un-motivated smokers (%2[1]=8.52, p=.004). A multiple 
binary logistic regression showed that the effect of motivation to quit smoking on interest
186
Chapter'?: Studs 2c: Smokers' anticipated reactions
in genetic testing was independent of gender, age, education, family history/experience, 
understanding of genetic testing, and pessimism (OR=2.17 [95% Cl: 1.09-4.31]).
3.3. Anticipated reactions to genetic test results
3.3.1. Cancer vs. heart disease
Overall, 65% (121) of smokers said that they would definitely quit smoking (i.e. agreed 
or strongly agreed with the statement) following a positive genetic test result, slightly 
more when the disease in question was cancer (70% agreed or strongly agreed) than heart 
disease (60% agreed or strongly agreed), but the difference was not significant 
(X2[ 1]=1 -77, p=.183). The pattern was similar for believing that receiving a positive 
genetic test result would increase their desire to quit smoking. 40% (70) said they might 
think that it was safe for them to smoke if they received a negative genetic test result (i.e. 
responded with ‘strongly agree’, ‘agree’, or ‘not sure’ to the statement), which was taken 
as a ‘de-motivated’ reaction to receiving a negative genetic test result. Responses did not 
differ by disease (35% in the cancer group had a de-motivated reaction vs. 37% in the 
heart disease group: x2[l]=0.05, p=.634). 24% (45) anticipated that they would definitely 
quit smoking if they received a negative genetic test result. As before, this did not differ 
by disease (26% in the cancer group vs. 22% in the heart disease group: x2[l]=0.05, 
p=.502). Thus there were no significant differences between cancer and heart disease on 
any of the anticipated behavioral reaction items. However, there was a difference in 
terms of anticipated depressed reaction: smokers were more likely to anticipate having a 
depressed reaction to a positive genetic test result for cancer than for heart disease (40% 
vs. 24%: x2[1]=5.16, p=.023) (see Table 7.4).
Table 7.4. Smokers’ anticipated reactions to genetic test results: cancer versus heart disease
Cancer
(n=102)
Heart
disease
(n=84)
Sig.
If I received a positive [higher 
risk] genetic test resu lt...
1 would definitely quit smoking Strongly-disagree-not sure (1-3) 
Agree-strongly agree (4-5)
30% 31 
70% 71
40% 33 
60% 50
X2D H -7 7
p=.183
It would increase my desire to 
quit smoking Strongly-disagree-not sure (1-3) 
Agree-strongly agree (4-5)
13% 13 
87% 90
16% 14 
84% 72
X2[l]=0.51
p=474
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Table 7.4. (cont)
I would feel that it was safe for 
me to carry on smoking Strongly-disagree (1 -2) 
not sure-agree-strongly (3-5)
81% 83 
19% 19
86% 72 
14% 12
X2[l]=0.63
p=429
I would feel depressed Strongly-disagree-not sure (1-3) 
Agree-strongly agree (4-5)
60% 59 
40% 39
76% 61 
24% 19
X! |l]= 5 .16
p=.023
I f  I received a negative [lower 
risk] genetic test resu lt...
I would definitely quit smoking Strongly-disagree-not sure (1-3) 
Agree-strongly agree (4-5)
74% 76 
26% 27
78% 64 
22% 18
X2[1H>.45 
p=. 502
It would increase my desire to 
quit smoking Strongly-disagree-not sure (1-3) 
Agree-strongly agree (4-5)
65% 66 
35% 36
63% 53 
37% 31
*2[1]=0.05
p=. 820
I would feel that it was safe for 
me to carry on smoking Strongly-disagree (1-2) 
not sure-agree-strongly (3-5)
65% 66 
35% 36
63% 52 
37% 31
X2[l]=0.23
p=.634
I would feel depressed Strongly-disagree-not sure (1-3) 
Agree-strongly agree (4-5)
95% 93 
5% 5
100% 79 
0% 0
(X2[l]=4.15, 
p =.042)*
*Note: 1 cell has less than 5 values in it and is not therefore valid for statistical analysis
3.3.2. Positive test results vs. negative test results
Because there were no differences between cancer and heart disease responses on the 
primary outcome variable, anticipated motivated reaction, and because of the small 
numbers of respondents in each disease group, the two groups were combined for the 
remainder of the analyses. Paired sample t-tests showed that smokers were more likely to 
believe that they would find a positive result motivating than a negative result; 65% said 
that they would definitely quit if it was positive compared to 24% if it was negative 
(p<.001), and 86% said that a positive result would increase their desire to quit smoking 
compared to 36% for a negative result (p<.001, see Table 7.5). They were less likely to 
believe that a positive result would mean that it was safe to smoke (i.e. be de-motivated) 
compared to a negative result (17% vs. 39%, p<.001), and more likely to be depressed by 
a positive result than a negative result (31% vs. 3%, p<.001).
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Table 7.5. Proportions of smokers anticipating having motivated, de-
motivated, and depressed reactions: positive versus negative results_____
Result % ** N
I would definitely quit sm oking
Positive
Negative
Sig.*
65% 121 
24% 45
t[183]=11.22, p<.001
It would increase my desire to quit 
smoking
Positive
Negative
Sig. *
86% 162 
36% 67
t[1851=13.18, p<.001
I would feel it was safe for me to 
carry  on smoking
Positive
Negative
Sig.*
17% 31 
39% 73
t | l 841=6.75, p<.001
I would feel depressed
Positive
Negative
Sig.*
31% 58 
3% 5
t|1751=15.44, p<.001
*Results o f paired samples t-tests on continuous variables 
♦♦Percent (%) who responded ‘agree’ or ‘strongly agree’
3.3.3. Correlates of anticipated motivated reaction to a positive result
Smokers who had a strong desire to quit were more motivated by a positive result than 
smokers who had a weak desire to quit (78% vs. 55%, p=.001), and smokers who had a 
lower level of nicotine addiction were also more motivated to quit by a positive result 
than those with a higher level of nicotine addiction (78% vs. 55%, p=.001). None of the 
other predictor variables emerged as significantly associated with having a motivated 
reaction to a positive test result. The two predictor variables that were significantly 
associated with anticipated motivated reaction in the univariate analysis, were entered 
into a multiple binary logistic regression, with the dichotomized ‘motivated reaction’ 
item (agree or strongly agree with “I f  I  received a positive genetic test result, I  would 
definitely quit smoking”) as the outcome variable. Desire to quit was maintained as a 
significant predictor of anticipating a motivated reaction (OR 3.28: 95% Cl 1.66-6.46; 
p=.001), as was nicotine addiction (OR 3.34: 95% Cl 1.67-6.67; p=.001) (see Tables 7.6 
and 7.7).
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Table 7.6. Factors associated with smokers anticipating a motivated reaction to a positive genetic
test result: unadjusted chi-squares______ __________________ _____________ _________________
n=186 M otivated* Sig.
Dem ographics
Gender
Male
Female
64% (58/90) 
65% (59/91)
X2[l 1=0.87, p=.624
Age
18-35
36-55
56-75
68% (44/66) 
65% (47/74) 
65% (24/37)
X2[2]=0.18, p=.916
Educational qualifications
No formal
qualifications
GCSEs
A-levels
Degree
59% (19/32) 
70% (49/71) 
55% (17/31) 
70% (28/41)
X2[3]=3.05, p=.385
Perceived family history
Yes
No-not sure
71% (30/42) 
62% (86/138)
X2[l]=1.17,p=.280
Dispositional pessim ism
Mean of 3-item composite LOT-R scale Low (1-2) 
Medium (3) 
High (4-5)
66% (77/117) 
70% (25/36) 
56% (14/26)
X2[2]—1 -76, p=.415
Smoking variables
Desire to quit smoking
Weak desire (1-3) 
Strong desire (4-5)
54% (51/95) 
78% (66/85)
X2[l]=11.67,p=001
Level of nicotine addiction
High addiction (3-4) 
Low addiction (1-2)
55% (55/101) 
78% (62/80)
X2[ll=10.37, p=.001
Understanding of genetic testing
Understanding of genetic testing
Disagree-not sure (1-3) 
Agree (4-5)
65% (52/80) 
65% (64/99)
X2[l]=0.00, p=.961
Fatalistic belief about genetic testing
Disagree (1-2)
Not sure-agree (3-5)
62% (34/55) 
66% (80/122)
X2[21=0.23, p-.629
Leaflet
Leaflet 
No leaflet
61% (47/77) 
68% (70/104)
X2[l 1=0-76, p=.383
Disease
Cancer 
Heart disease
70% (70/101) 
60% (47/80)
X2[l 1=1 -77, p=. 183
* Motivated = ‘agree’ or ‘strongly agree’ with the item “I f  I  received a positive genetic test result, I  would definitely quit 
smoking ’’
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Table 7.7. Factors associated with smokers anticipating a motivated reaction to a
positive genetic test result: multiple logistic regression _____________ _______
M otivated M ultivariate odds 
ratio  (95%  C l)
Desire to quit smoking
Weak desire (1-3) 
Strong desire (4-5)
54% (51/95) 
78% (66/85)
1.0
3.28 [1.66-6.46]**
Level o f nicotine addiction
High addiction (3-4) 
Low addiction (1 -2)
55% (62/80) 
78% (55/101)
1.0
3.34 [1.67-6.671**
**p=.001
3.3.4. Correlates of anticipated motivated reaction to a negative result
Smokers who anticipated being de-motivated by a negative genetic test result (i.e. who 
thought that a negative result would mean that it was safe for them to carry on smoking) 
had fewer educational qualifications (x [3]=10.53, p=.015) (see Figure 7.1) and a lower 
understanding of genetic testing (26% vs. 55%: (x [1]=16.85, p<.001) than smokers who 
did not anticipate being de-motivated. They also had a lower desire to quit (48% vs. 
31%: (x [1]=5.15, p=.023), and were less likely to fall into the middle-life age category 
(X [2]=12.36, p=.002). The predictor variables that were significantly associated with 
anticipated de-motivated reaction in the univariate analysis (desire to quit, understanding 
of genetic testing, age, and education) were entered into a multiple binary logistic 
regression: the effects of age and education were maintained in the multivariate analysis, 
whereas the effects of desire to quit and understanding of genetic testing, were not (see 
Tables 7.8 and 7.9).
Table 7.8. Factors associated with smokers anticipating a de-motivated reaction to a
negative genetic test result: unadjusted chi-squares
n=186 De­
motivated* Sig.
Dem ographics
Gender Male 37% X2[l]=0.40,p=527
Female 42%
Age 18-35 47%
36-55 24% X2[2]=12.36, p=.002
56-75 53%
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Table 7.8. (cont)
Educational qualifications
No formal
qualifications
GCSEs
A-levels
Degree
61%
34%
36%
26%
X2[3]=10.53, p=.015
Perceived family history
Yes
No-not sure
48%
34%
X2[2]=2.23, p=.328
Dispositional pessimism
Low (1-2) 
Medium (3) 
High (4-5)
34%
46%
52%
X2[2]=3.80, p=. 150
Smoking variables
Desire to quit smoking
Weak desire (1-3) 
Strong desire (4-5)
48%
31%
X2[l]=5.15, p=.023
Level of nicotine addiction
High addiction (3-4) 
Low addiction (1-2)
44%
35%
X2[l]=1.72,p=. 190
Understanding o f genetic testing
Understanding of genetic testing
Disagree-not sure (4-5) 
Agree (1-3)
26%
55%
X2[l]=16.85, p<.001
Fatalistic belief about genetic testing
Disagree (1-2)
Not sure-agree (3-5)
29% (16/55) 
43% (53/123)
X2[l]=3.14,p=077
Leaflet
Leaflet 
No leaflet
40%
39%
X2[l]=0.03,p=. 855
Disease
Cancer 
Heart disease
41%
37%
X2[ 1 ]=0.23, p=.634
*De-motivated = ‘agree’ or ‘strongly agree’ with the item “I f  I  received a negative genetic test result, I  
would feel it was safe for me to carry on smoking”
Table 7.9. Factors associated with smokers anticipating a de-motivated reaction to 
a negative genetic test result: multiple logistic regression _____________ _____
De-motivated M ultivariate odds 
ratio  (95%  Cl)
Age
18-35 47% (32/68) 1.0
36-55 24% (18/76) 0.33 [0.15-0.75]**
56-75 53% (20/38) 0.59 [0.21-1.63]
Educational qualifications
No formal qualifications 61% (20/33) 1.0
GCSEs 34% (25/73) 0.41 [0.15-1.14]
A-levels 36% (11/31) 0.31 [0.09-1.10]
Degree 26% (11/43) 0.30 [0.09-0.951*
Desire to quit smoking
Not strong (1-3) 48% (46/96) 1.0
Strong (4-5) 31% (27/86) 0.64 [0.32-1.271
Understanding o f genetic testing
No (1-3) 55% (46/83) 1.0
Yes (4-5) 26% (26/101) 0.50 [0.24-1.051
*P< 05, **p< 01
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7.1. Relationship between educational attainment and agreement 
that a negative genetic test result would mean that it was safe to 
carry on smoking
100%
no formal 
qualifications
GCSEs A-levels Degree upwards
□  agree 
■  not sure
□  disagree
3.3.5. Correlates of anticipated depressed reaction to a positive result
Smokers who anticipated having a depressed reaction to a positive genetic test result had 
a lower understanding of genetic testing (%2[ 1 ]=7.41, p=.006) and higher levels of 
dispositional pessimism (%2[1]=8.69, p=.013). They were also more likely to believe that 
a positive (higher risk) result would mean they were definitely going to get the disease 
(%2[2]= 14.20, p=001) and that the disease ran in their family (%2[ 1]=6.15, p=.046). 
There was an effect of disease type, with more smokers in the cancer sample anticipating 
a depressed reaction than smokers in the heart disease sample (%2[1]=5.17, p=.023). 
There was no effect of desire to quit smoking, level of nicotine addiction, gender, age, 
education, or leaflet. When the variables that were significantly associated with 
anticipated depressed reaction were entered into a binary logistic regression analysis, the 
effects of understanding, believing that a positive result would mean definitely getting the 
disease, and disease type remained significantly associated with depressed reaction, 
whereas dispositional pessimism and perceived family history-based risk did not. See 
Tables 7.10 and 7.11 for a summary of these results.
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Table 7.10. Factors associated with smokers anticipating a depressed reaction to a
positive genetic test result: unadjusted chi-squares___________________________
n=186 Depressed* Sig.
Dem ographics
Gender Male
Female
26% (24/91) 
39% (34/87)
X2[l]=3.27, p=.071
Age 18-35
36-55
56-75
38% (25/66) 
30% (22/74) 
29% (10/34)
X2[2]=l -27, p=.531
Educational qualifications
No formal
qualifications
GCSEs
A-levels
Degree
37% (11/30) 
30% (21/70) 
32% (10/31) 
31% (13/42)
X2[3]=0.45, p=. 930
Perceived family history
Yes
No-not sure
38% (43/147) 
31% (15/40)
X2[2]—0.53, p=.469
Psychological state
Dispositional pessimism Low (1-2) 
Medium (3) 
High (4-5)
28% (32/115) 
31% (11/36) 
58% (15/26)
X2 [2] =8.69, p=.013
Smoking variables
Desire to quit smoking
Weak desire (1-3) 
Strong desire (4-5)
31% (29/93) 
35% (29/83)
X2[l]=0.28, p=597
Level of nicotine addiction
High addiction (3-4) 
Low addiction (1-2)
32% (25/78) 
33% (33/99)
X2[lH>.03,p=857
Understanding o f genetic testing
Understanding of genetic testing
Agree (4-5) 
Disagree-not sure (1-3)
24% (24/99) 
44% (34/78)
X2[l]=7.41, p=.006
Fatalistic belief about genetic testing
Disagree (1-2)
Not sure-agree (3-5)
14% (8/56) 
41% (50/122)
X2[2]=12.45, p<.001
Leaflet
Leaflet 
No leaflet
33% (25/76) 
32% (33/102)
X2[l]=0.01,p=939
Disease
Cancer 
Heart disease
40% (39/98) 
24% (19/80)
X2[l]=5.17, p=.023
*Depressed = ‘agree’ or ‘strongly agree’ with the item “I f  I  received a positive genetic test result, I  would 
feel depressed”
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Table 7.11. Factors associated with smokers anticipating a depressed reaction to a
positive genetic test result: multiple logistic regression
Depressed M ultivariate odds 
ratio (95% C l)
Dispositional pessimism
Low (1-2) 
Medium (3) 
High (4-5)
28% (32/115) 
31% (11/36) 
58% (15/26)
1
0.82 [0.32-2.08] 
2.13 [0.82-5.56]
Understanding of genetic testing
Yes (4-5) 
No (1-3)
24% (24/99) 
44% (34/78)
1
2.07 f 1.03-4.161*
Fatalistic belief about genetic testing
Disagree (1 -2) 
Not sure (3) 
Agree (4-5)
14% (8/56) 
38% (33/88) 
50% (17/34)
1
3.24 [1.30-8.04]* 
5.66 [1.91-16.761**
Disease
Heart disease 
Cancer
24% (19/80) 
40% (39/98)
1
2.30 [1.13-4.71]*
*p<.05, **p<.01, ***p<.001
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4. Discussion
This study builds on the studies describe in the previous three chapters, and on the 
growing body of research on genetic test evaluation, by shedding some light on the 
characteristics of smokers in the general population who may be motivated to quit by 
feedback on genetic testing for complex diseases, or vulnerable to the harmful effects of 
genetic risk feedback. Roughly a third of the smokers in this study reported that they 
would feel depressed in response to receiving a positive genetic test result for 
susceptibility to cancer or heart disease, and anticipated depression was higher amongst 
smokers with higher levels of dispositional pessimism and lower understanding of 
genetic testing. This was to be expected, given that a) these were the variables associated 
with anticipated depression in the whole survey sample (see Chapter 6) and b) there were 
no differences between smokers and non-smokers (again, see Chapter 6). As before, this 
highlights that public understanding of genetics is essential not only to ensure informed 
participation in public debate about human genetics, and informed consent, but also that a 
lack of understanding could have direct consequences for the psychological wellbeing of 
individuals taking genetic tests in the general population.
Education and understanding were inversely associated with anticipating that a negative 
genetic test result would mean that it was safe to carry on smoking. These findings 
highlight that a lack of understanding could have direct consequences for individuals. 
The findings contribute to the literature by suggesting that desire to quit smoking is an 
important predictor of being motivated, or at least anticipating being motivated, to quit 
smoking by genetic testing for complex disease susceptibility -  regardless of whether the 
test result is positive or negative. This is important because it may shed some light on 
why previous research has found an effect of genetic testing per se on smoking cessation 
but failed to find an effect of the content of the genetic test result itself (McBride et al, 
2002). It is conceivable that smokers who wish to quit may use their genetic test result as 
a motivational tool, whatever the actual result is. For example, a positive result may have 
the expected effect of increasing motivation to quit, as long as self-efficacy is also 
reasonably high. On the other hand, a negative result could have the effect of increasing 
response efficacy -  a smoker who believes that their genetic susceptibility to a smoking-
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related disease is slightly reduced may have a stronger belief that for them it is 
particularly worth quitting. Qualitative data from participants in genetic test feedback 
trials could help to illuminate this issue.
The results from this study suggested that smokers who have a higher desire to quit 
smoking are more likely to opt to take genetic tests for complex, smoking-related 
diseases, possibly because they are more willing to try interventions that they believe 
might help them quit: 52% of smokers with a high desire to quit said that they would 
definitely take a genetic test for cancer or heart disease susceptibility, whereas 31 % of 
smokers with lower desire to quit said this (OR=2.17 [95% Cl: 1.09-4.31]). This raises 
the possibility that motivated smokers may self-select themselves into genetic testing, 
whereas smokers who are vulnerable to the harmful effects may opt out of testing. The 
self-selection hypothesis is further tentatively supported by the observation in the present 
study that smokers in their middle-age were less likely to anticipate being complacent 
about a negative result than those in the older or younger age groups. The relationship 
between middle age and anticipated motivation may be linked to the fact that people in 
this age group are more concerned about being healthy than younger people (Turk- 
Charles et al, 1997) due to their increasing contact and experience of disease. In contrast, 
adolescents are often reported to be optimistically biased about their risk of disease, 
especially when the disease is linked to their health behaviours (Arnett, 2000), and older 
people may feel that if they were going to develop the disease, it would have manifested 
itself already. The findings in the ONS survey (Study 1) that people in their middle-age 
are also the most interested in genetic testing for cancer and heart disease, could suggest 
that the same characteristics that determine interest in genetic testing, also determine 
adaptive behavioural reactions to genetic test results.
There were a number of limitations to this study, that are also of relevance to Studies 2a 
and 2b. One methodological limitation was the use of the term ‘positive genetic test 
result’ to denote ‘positive for an increased susceptibility’ and, conversely, ‘negative 
genetic test result’ to denote ‘negative for an increased susceptibility’. It is possible that 
some respondents thought ‘positive’ meant ‘good’, and an unknown number of 
respondents may have reversed the meanings of negative and positive. However, as
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discussed in Chapter 5, explanation was given about what a ‘positive’ and ‘negative’ 
genetic test result meant every time this was referred to in a question, as this had been an 
issue that came up during pilot interviews and development of the questionnaire. 
Another limitation of this study was that it was not possible to compare smokers’ 
reactions to positive or negative genetic test results with not having taken a genetic test. 
As before, the low response rate and the inability to compare respondents with non­
respondents was a further limitation, as was the fact that this was a cross-sectional 
survey, and the findings concerned anticipated, not actual, reactions to genetic testing.
However, in line with the MRC framework (Campbell et al, 2000), the present findings 
were helpful in developing the design and protocol for Study 3 in which smokers were 
given actual genetic risk feedback for the GSTM1 gene. The findings in this study lent 
further support to the idea that smokers might find genetic testing motivational, and that 
even when there was evidence for complacency in reaction to negative results, this might 
be minimized by ensuring that participants in Study 3 were fully informed and 
understood the meaning the genetic risk information they were to receive.
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CHAPTER 8
Study 3: How do smokers respond to genetic testing for susceptibility to 
lung cancer? An exploratory study in which smokers are randomly 
allocated to receive GSTM1 genetic test results
1. Introduction
1.1. Background
In this thesis three areas of research on psychosocial issues around genetic testing have 
been identified: 1) interest and uptake, 2) psychological impact, and 3) behavioural
impact. As previously discussed, the first two areas have received considerable attention 
in the literature, whilst there remains a need for the behavioural impact of genetic testing 
to be investigated. In addition, Studies 1 and 2 of this thesis examined interest and 
reactions to genetic test results, but used hypothetical scenarios, rather than actual genetic 
test results. Whilst this was helpful and in line with the MRC Framework (Campbell et 
al, 2000), ultimately studies are needed which explore the actual impact of giving people 
in the general population genetic test results for common genetic variants.
When this thesis work began in 2000, there was particular interest in the potential for 
genetic markers of susceptibility to smoking-related diseases to motivate smoking 
cessation. This was part of a growing interest in the use of biomarkers of all kinds to be 
utilized to personalize and individualize disease risk information, and was theoretically 
driven (McClure, 2002). Health psychology and health behaviour researchers were 
interested increasingly in tailoring risk messages to the individual, and at the same time 
there were parallel developments in human genetics; the Human Genome Project was 
starting to lead to the identification of polymorphic genes which apparently could 
contribute to an individual’s risk of developing a behaviour-related disease. This 
inevitably led researchers in the field to ask, what is the potential for information on 
smoking-related disease genes to motivate smoking cessation?
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As highlighted by Campbell et al (2000), one particularly useful way to address this and 
other questions in health psychological research is by use of the randomized controlled 
trial approach. In 2000, one study had used such an approach to look at the impact of 
testing for a common genetic variant on smoking cessation (Lerman et al, 1997). Given 
that, at that time, this trial served as the only model for this kind of study, it is worth 
looking at the design, protocol and methodology employed, as a way of identifying 
potentially useful or potentially problematic aspects of the study which could be included 
or avoided in a new study. Only one further study with a similar design has since been 
published (McBride et al, 2002), which will be discussed in Section 1.2.2.
1.2. Design of the two previous smoking-cessation intervention studies incorporating 
genetic risk feedback
1.2.1. The first study: Lerman etal  (1997)
Lerman et al (1997) used a genetic test for a polymorphism in the CYP2D6 gene as a 
marker of smoking-related disease susceptibility, using a polymerase chain reaction assay 
(A and B alleles; Lerman et al, 1997). The first question is, was this was the most 
appropriate gene to use? The CYP2D6 enzyme (debrisoquine hydroxylase) is most 
widely known for the fact that it is solely responsible for metabolizing the 
antihypertensive drug debrisoquine. The CYP2D6 genotype is expressed in two distinct 
phenotypes: a) extensive metabolizers (about 90% of the population), in whom the major 
portion of the drug is metabolized and b) poor metabolizers (about 10% of the 
population), who are unable to metabolize debrisoquine (Lerman et al, 1997). Lerman et 
al (1997) used the CYP2D6 genotype as a marker of smoking-related disease 
susceptibility because it is also one of the cytochrome family of genes responsible for 
Phase 1 of the metabolism of carcinogens (see Chapter 1). The use of CYP2D6 in this 
trial was justified on the available evidence at that time, which was that case control 
studies provided support for an average two- to three-fold excess risk of lung cancer in 
extensive metabolizers compared with poor metabolizers (Amos et al, 1992; Lerman et 
al, 1997).
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However, there are two key problems with using CYP2D6 for this purpose. The first 
relates to the validity of the test: the gene is involved in the metabolism process and early 
studies did find associations between CYP2D6 and lung cancer susceptibility, but more 
recent reviews have failed to find a consistently robust association with smoking-related 
cancers. For example, in one review of common gene variants (Hirschom et al, 2002), 
polymorphisms in CYP2E1 and CYP1A1 were associated with susceptibility to head, 
neck and lung cancer, but CYP2D6 was not.
The second problem relates to the frequency of the CYP2D6 variant in the population. 
The use of a CYP2D6 polymorphism meant that 92% of the sample was categorized as 
‘high risk’. This meant that the impact of “non-susceptible” status on cessation, 
motivation and mood, could not be evaluated. A further problem raised by the frequency 
of the genotype is that it raises questions about how the risk information is, or should, be 
communicated and presented. For example, in 2000 it was considered that it might be 
appropriate to ‘deliberately mislead’ smokers into believing that their personal genotype 
meant that they were at higher risk than other smokers. This arose partly from a well- 
meaning concern about not causing complacency in those whose genotypes indicated 
lower risk, but was problematic because it required that participants be presented with 
misinformation and misleading risk estimates.
Actually, Lerman and colleagues couched the information in appropriately uncertain 
terms. The genetic testing feedback information used included a discussion of the role of 
genes in metabolism (activation) of carcinogens in tobacco, a description of studies that 
suggest that extensive metabolizers are more susceptible than poor metabolizers who 
make up about 10% of the population, and personal feedback of the results of CYP2D6 
genotype. For example, extensive metabolizers were told that:
Because o f your genetic makeup, you have the ability to activate chemicals 
in tobacco smoke into very dangerous cancer-causing substances. This 
means that your risk for getting lung cancer is not only higher than 
nonsmokers, but may also be higher than other smokers who do not have 
the same genetic makeup.
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To avoid conveying that smoking was somehow safe or low risk for poor metabolizers 
(n=l 1), they were told that:
You do not have the ability to activate specific chemicals in tobacco 
smoke. However, you may still be at risk for lung cancer because your 
body may be able to use other ways to activate cancer-causing chemicals.
Additionally, all participants were informed about the possible risks associated with other 
(untested) susceptibility genes and the risk of heart disease, stroke and emphysema 
because of smoking. The 11 poor metabolizers in the genetic testing group were 
excluded from all analyses because of their low risk status.
The way Lerman and colleagues discussed the risk information with their participants 
draws attention to the importance of considering the details of the genetic risk 
communication process. A major strength of the Lerman protocol was the way in which 
detailed information about the uncertainties inherent in the genetic test was conveyed to 
participants. Its weakness was the use of the CYP2D6 gene. The next area which needs 
attention is the procedure itself. For example, what should the control condition consist 
of? On what criteria should potential participants be included or excluded? Further 
examination of Lerman’s protocol helps illuminate this.
Lerman recruited smokers who smoked at least four cigarettes a day via advertisements 
for “a free smoking-cessation trial involving a minimal-contact intervention”. Smokers 
who were pregnant or had a personal history of cancer (except basal cell carcinoma of the 
skin) were excluded. A total of 1,043 individuals responded to the newspaper 
advertisements and complete the telephone eligibility screening. Of these, 928 met the 
eligibility criteria and were invited to participate. After receiving the description of the 
study requirements, 622 individuals (67%) agreed to participate. Of those who agreed, 
485 completed both visits. Of participants who completed the counseling visits, 427 
completed the 2-month follow-up interview. Thus the final sample comprised 427 
smokers (165 male and 262 female) who smoked at least four cigarettes a day.
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In Lerman et a /’s (1997) study, during an initial visit to the smoking clinic, all 
participants completed a set of self-report questionnaires assessing demographics, 
smoking history, smoking-related cognitions, quitting readiness, and depressive 
symptoms. Participants had the benefits, risk and limitations of participation explained to 
them verbally and in the written consent form, and particular emphasis was given to the 
‘limitations and risks’ of the genotyping procedure, such as the uncertainties in cancer 
susceptibility testing, and the ‘possible risks of loss of privacy or health insurance’. 
Participants who consented provided a blood sample. Two to three weeks after the initial 
visit to the smoking clinic, participants met with a “trained health educator” who 
delivered one of three smoking-cessation interventions, which was determined by random 
assignment. Counselling was based on a guide called, “Free and Clear: A guide to 
quitting smoking on your own. " Counselling began with a motivational review of 
smoking and quitting history based on the baseline smoking history questionnaire. This 
was followed by development of an individual quitting plan. The potential for reductions 
in risks of lung cancer and other smoking-related diseases following cessation was also 
emphasized. All smokers were encouraged to follow a pre-tested self-help nicotine 
fading protocol over a 2-4 week period, which involved switching to lower nicotine 
brands before quitting. They additionally received brief advice on gaining support for 
their efforts to quit smoking and two copies of the Free and Clear support brochure for 
friends and family.
There were a number of strong elements in this design. First, the use of motivational 
interviewing and brief advice allowed a smoking cessation intervention to be delivered in 
a quick way, but at the same time being one which has been shown to be efficacious. 
Second, the use of a self-help booklet was appealing for the same reason. Third, it was 
clearly good that the smoking cessation interventions were delivered by a ‘trained health 
educator’, rather than a non-trained researcher.
A weakness of the study was that smokers were advised that they should follow a 
nicotine-fading approach to quitting. The current evidence suggests that this is not an 
effective way to quit, and that it is better to advise people to set a quit date and to stop
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completely on that date. Also, it would have been better if people had been advised to 
use nicotine replacement therapy, as this doubles the chances of successfully quitting. 
Another pharmacological smoking cessation aid that has recently become available is 
buproprion (Zyban), and advice for participants to discuss this possibility with their GP 
could also be incorporated. A study of this kind conducted in the UK could also draw on 
the NHS Smoking Cessation Service, by directing participants to some of the more 
intensive services provided there, such as the Level 3 group therapy sessions or Level 2 
pharmacy-based counsellors.
The randomizing procedure and alternative conditions included in the study design also 
need consideration. Lerman et al (1997) randomized participants to one of three 
conditions. Smokers in the first condition, the control group, received only the 
intervention outlined above. Participants randomized to the second condition received 
the same complete quit-smoking consultation, plus a 10-minute carbon monoxide 
feedback motivational intervention delivered before the counseling session. The carbon 
monoxide feedback protocol was designed to highlight the deleterious effects of smokers’ 
tobacco exposure relative to the exposures of exsmokers and nonsmokers. Participants 
randomized to the third condition, the genetic testing condition, received the 10-minute 
carbon monoxide motivational intervention, plus the 60-minute counseling (control) 
session, plus an additional 10-minute motivational intervention delivered before the 
counseling, involving feedback of the results of the CYP2D6 genetic test (the core 
components of which are outlined above).
The strength of this three-armed design was that it allowed comparison of genetic 
biomarker feedback with other (carbon monoxide) biomarker feedback. However, the 
design would be less suitable for a smaller trial as the extra group would considerably 
reduce the number of people in each group and thus reduce the already limited power of 
the study to detect differences between groups. A further component that needs 
identifying is therefore the appropriate control group(s) and randomizing procedure.
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To summarise, consideration of the study conducted by Lerman et al (1997) therefore 
indicates that four key areas need to be considered when designing a randomized and 
controlled genetic testing study:
1) What gene should be used?
2) How should the genetic risk information be communicated?
3) What should the ‘standard care’ protocol be for all participants?
4) What is the appropriate control group and randomization procedure?
These issues highlight the complexity involved in designing studies in which genetic test 
results are given to individuals in an exploratory setting, and support the need for the 
phased MRC framework for the design of such an intervention study (Campbell et al, 
2000)3
1.2.2. The second study: McBride et al (2002)
In 2002, a second randomized controlled trial in which genetic risk feedback was 
incorporated into a smoking cessation study was published (McBride et al, 2002). This 
time, the GSTM1 genotype was used. The GSTM1 gene used in McBride et al (2002) 
was more appropriate than CYP2D6 for three main reasons. First, the association 
between GSTM1 and lung cancer susceptibility is relatively robust (Benhamou et al, 
2002; see Chapter 1). Second, 50% of the population has the null genotype and so this 
makes it more suited for use in randomized controlled trials. Third, it is relatively simple 
to explain to people; you either have the gene or not, rather than trying to explain about 
base changes leading to subtle changes in gene products.
Another difference from Lerman et al (1997) was the way in which participants were
recruited. The GSTM1 study was conducted in an inner city community clinic that
provided health care to low-income residents of an urban county in North Carolina.
African-Americans comprised 83% of the patients, and approximately 70% of the
patients had household incomes that fell below the poverty line. Smoking status was
assessed for all patients as part of standard intake. Healthcare providers (physicians,
physician assistants, and nurse practitioners) referred smokers identified by chart notation
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or during their clinic visit to a “smoking specialist” hired by the study team. This was a 
more proactive recruitment procedure than that in Lerman’s study, and uptake of the 
genetic test was higher, at 83%, in this study.
There were also several differences in the procedures used in the two studies. In 
McBride et al (2002), baseline data was collected in two surveys, a screening survey and 
a preintervention assessment telephone survey. The screening survey was administered 
by the smoking specialist immediately after the smokers clinic visit. Smokers were 
eligible if they self-identified as African-American and smoked at least one cigarette per 
day in the prior seven days. The preintervention assessment telephone survey was 
administered by a project assistant within seven days of the clinic visit. Consent for 
blood testing was obtained in a two-step process in this study. This differed from the 
one-stage consent process in Lerman et al (1997). In McBride’s study, all smokers were 
informed that as part of their participation in the trial, they might be asked to give a blood 
sample. Those who agreed were randomized to control group or to the genetic testing 
group. A second level of consent was obtained from those randomized to the genetic 
testing group for provision of the blood sample to be tested for GSTM1. Note that this is 
different to the previous study. In Lerman et al (1997), all participants gave a blood 
sample and received the same information prior to consent, regardless of whether they 
were subsequently randomized into the control group or genetic risk feedback group. In 
McBride et al (2002), the genetic test group received considerably different information 
prior to consenting and prior to receiving their genetic risk feedback.
Smokers in the control group received standard brief advice from their healthcare 
provider in the clinic, and were then referred to the smoking specialist who ‘assessed 
stage of readiness to quit and the appropriateness of nicotine replacement therapy’. 
Within two weeks, all smokers were sent a self-help smoking cessation guide especially 
designed for African-American smokers, “Pathways to Freedom” and, if eligible 
(smoked at least five cigarettes per day and were in the preparation stage of readiness to 
quit), a 14-day supply of 15-mg nicotine patches. Refill kits that included a 7-day supply 
of patches were provided as needed. Participants were allowed to request up to 8 refills 
over the study period (for a total of 10 weeks of therapy). Smokers in the genetic testing
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group, as part of the consent procedure, had the smoking specialist explain the role of 
GSTM1 in “cleaning up cancer-causing chemicals in cigarette smoke” using a flipchart of 
graphically displayed information. Within two weeks of the clinic visit, all participants 
in the genetic testing group were mailed an 8-page test result booklet written at a fifth 
grade reading level. The booklet included the test result, information about the chemical 
constituents of tobacco smoke and the harms of exposure, regardless of genetic makeup. 
Using graphical displays identical to those in the consent process, the booklet described 
whether the result indicated greater susceptibility to lung cancer (GSTM1 missing) or the 
same risk as other smokers (GSTM1 present). Also included was text that described the 
risks of smoking and benefits to quitting for heart and other diseases tailored to the 
participant’s gender, age, and number of years smoked. Those who declined the test 
were sent an identical booklet that included the same graphical displays along with a 
generic description of the test and a question mark in the result box.
Within one week after the test result booklet was sent, the smoker was called to discuss 
the GSTM1 test and their booklet. The counselors attempted a total of four calls with 
each participant over a 12-week period. Between the first and second calls, the 
participant was sent the “Pathways” self-help guide and nicotine patches, if appropriate. 
Four calls were selected to “maintain the salience of the GSTM1 test and encourage the 
smoker to take steps toward quitting”. Counsellors received 15 hours of training related 
to the GSTM1 enzyme, tobacco dependence, motivational interviewing, and social 
cognitive theory. Counsellors used a standardized protocol for the counseling calls. Each 
call was based on motivational interviewing techniques and tailored to be stage 
appropriate. The objective of the first call was to discuss the smokers’ blood test result 
and the importance of smoking cessation. During the call, smokers were asked to have 
their test result booklet open and to follow along as the counselor reviewed the contents, 
page by page. Counselors reviewed the smoker’s test result, asked the smoker to indicate 
their interpretation of the result, and addressed any misunderstanding of the feedback. 
They asked the participant how the test result had influenced his/her thinking about 
smoking. For example, smokers who had the enzyme missing were “reminded of the 
concern they felt after learning of their result and their awareness that they could benefit 
greatly from smoking cessation”.
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There were several specific strengths in this design. First of all, smokers were advised to 
use nicotine replacement therapy. Secondly, a self-help booklet was included in the 
design. One major difference to Lerman’s study was that the genetic test feedback was 
given in the post rather than in person. This was a controversial move as, to our 
knowledge, no other researchers have given people genetic test results in this because of 
the concerns about the availability of genetic counselling (although this regularly happens 
in un-regulated commercial settings). However, McBride et al (2000) had compared 
postal feedback with in-person feedback in a pilot study and concluded that this was 
feasible on the basis that there were no major differences between protocols on affective 
outcomes such as depression. Their use of four counselling telephone calls was thus 
designed to replace the more usual forms of genetic counselling but, given that only 38% 
of participants completed all four calls, this element of the study design was less 
successful than other elements.
McBride’s study also differed from Lerman’s in that cotinine assays were used in an 
attempt to validate self-report outcomes regarding quitting. However, this was also not 
successful because only 39% (24 of 61) of those who reported abstinence and agreed to 
provide a saliva sample returned one. This meant that, as in Lerman et al (1997), self- 
report measures had to be relied upon instead of cotinine. Also, the participants were 
using NRT anyway, which would have affected cotinine levels.
A major strength of McBride’s (2002) study was the use of graphically displayed 
information and the use of the same graphic information in both the consent procedure 
and explanation, and the test result booklet. However, there were problems with how 
they communicated the risk information, describing the GSTM1-present result as the 
same as other smokers, which was misleading and possibly confusing for participants 
(see Chapter 3).
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1.3. Aims of the present study
The present study drew on the designs of the two smoking cessation studies described 
above (Lerman et al, 1997; McBride et al, 2002). In addition, the study design was 
informed by the results of Studies 1 and 2 (described in Chapters 4 and 5 of this thesis), 
which suggested that a) people in the general population were interested in taking genetic 
tests and that b) it may be feasible to give smokers in the general population genetic risk 
feedback as long as considerable care was taken to ensure understanding of the results. 
The aim of the present study was therefore to take elements from the work of Lerman and 
McBride, and use the findings from the hypothetical studies conducted earlier in the 
thesis, to conduct a Phase II study within the MRC framework. The aim of the study was 
not to conduct the ultimate main randomized controlled trial with power to look at actual 
cessation outcomes (Phase III), but remained within the ‘exploratory phase’, aiming to: a) 
test acceptability for patients; b) define outcome measures and other variables; and c) 
using an appropriately controlled and randomized small, exploratory trial design. In the 
present study, smokers were randomly allocated to be offered GSTM1 genetic testing or 
to a control group. One aim was to consider whether this design was acceptable for 
participants.
The study also aimed to build on previous research by addressing the primary 
assumptions that are made in this field, albeit tentatively, bearing in mind the small 
sample size. These are:
1) Giving smokers genetic risk feedback conveying an increased susceptibility to lung 
cancer should increase their motivation to quit smoking;
2) Giving smokers genetic risk feedback conveying an increased susceptibility to lung 
cancer could cause adverse psychological reactions such as depression;
3) Giving smokers genetic risk feedback conveying a decreased susceptibility to lung 
cancer could cause complacency and decrease their motivation to quit smoking.
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2. Method
2.1. Design
Smokers were randomly allocated to a) a genetic testing group or b) a control group. The 
design drew on different elements of the two previous studies which had incorporated 
genetic risk feedback into smoking cessation intervention studies (Lerman et al, 1997; 
McBride et al, 2002). The genetic test used was for the presence or absence of the 
GSTM1 gene, as in McBride et al (2002). Recruitment was more proactive than Lerman 
et al (1997), but less proactive than McBride et al (2002): letters were sent to all smokers 
who had contacted the Camden & Islington NHS Smoking Cessation Service between 
1999 and 2003, offering treatment and/or participation in a study; smokers who returned 
tear-off slips expressing interest were telephoned and invited to participate in the study; 
those who accepted attended a session at University College London. As in Lerman et al 
(1997) and McBride et al (2002), the researcher-advisers conducting the sessions were 
trained in smoking cessation counseling and in genetics. See Appendix F for materials 
used in the recruitment stage of this study.
The researcher-advisers who conducted the sessions were myself (SS) and the London 
IDEAS Knowledge Officer (EH)9. Both of us were trained as Level 2 Smoking 
Cessation Counsellors, for this study. This involved attending two days training provided 
by the NHS Camden & Islington Smoking Cessation Service. In addition, I attended and 
assisted in the running of a number of NHS smoking cessation groups. This proved 
valuable experience in the design and implementation of the study. A third person, BM, 
was also involved in the early stages of data collection, who was a trained nurse and 
smoking cessation counselor. Advice was also received from Professor Martin Jarvis, Dr 
Simon Gal ton, and Professor Robert West, all of whom have expertise in smoking 
cessation. We also received training in genetics and GSTM1 function from a clinical 
geneticist (Dr James Mackay) and a molecular geneticist (Professor Steve Humphries).
9 London IDEAS is one of the six Department of Health and Department of Trade and Industry funded 
Genetics Knowledge Parks (GKPs). IDEAS kindly supported this study by doing the genotyping and 
providing practical support from Eluned Hughes, the Knowledge Officer, who assisted with data collection 
and data management.
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As in both previous studies (Lerman et al, 1997; McBride et al, 2002), the session 
employed motivational interviewing techniques, brief advice, and a self-help booklet. As 
in McBride et al (2002), the use of nicotine replacement therapy (NRT) was 
recommended, but our study differed in that we did not provide the patches ourselves. 
Also, our advice raised the possibility of using Zyban, in line with the NHS 
recommendations. The consent procedure was based on the two-step consent used by 
McBride et al (2002): all participants consented to participate in the study (Stage 1 
consent), but only those randomized to the genetic testing group were taken through the 
Stage 2 consent procedure. The use of graphical illustrations in the consent stage, and the 
use of identical graphics in the result feedback booklet, was also based on McBride et al 
(2002), although different graphics were developed specifically for the present study.
The DNA collection procedure used was the cheek cell swab method, rather than a blood 
test. As in both previous studies, genetic test results were provided within two weeks of 
testing. We elected to give the test results in-person, as done by Lerman et al (1997), 
rather than through the post, as done by Lerman et al (2002). However, we drew on the 
design of McBride et al (2002) by electing to have two telephone follow-up calls. The 
first call, one week after results were given, was designed to be a data collection call but 
also a counseling call to ensure they understood the result and to check they were not 
unduly distressed. The second call, at two month follow-up, was primarily a data 
collection call but again was used as a counseling call if necessary. It was not possible to 
conduct a six-month (McBride et al, 2002) or a one-year follow-up (Lerman et a l , 1997), 
due to time restrictions. Depression, motivation to quit smoking, and perceived risk of 
lung cancer were the primary outcome variables, which were measured at all three main 
time points (baseline, one week follow-up, two month follow-up).
2.2. Ethical approval
Ethical approval for the design of this study was granted in July 2003, by the joint 
University College London / University College Hospitals Ethics Committee (see 
Appendix C).
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2.3. Development of materials
As described in Section 2.1., the development of the session protocols was informed by 
those used by Lerman et al (1997) and McBride et al (2002). However, many changes 
were made as in the early stages of the development of the study, such as the Results 
Session (Phase 2) being dropped with the control group (see Section 2.6.2). See 
Appendix G for protocols.
The flipchart-style A4 laminated booklet used to explain about genetics and GSTM1 to 
smokers in the genetic testing group as part of the consent procedure was developed 
specifically for this study. The 17-page illustrated guide was called “Genetics, Smoking 
and Genetic Testing fo r  GSTM1: An Illustrated Guide”. The guide included background 
information about genetics, genes, enzymes, the role of GSTM1 in metabolism of 
carcinogens, graphical representations of risk, and what would be involved in the genetic 
testing procedure. The illustrated guide can be seen in full in Appendix H.
As part of the development of the Illustrated Guide, ten semi-structured interviews were 
conducted with smokers who were recruited on an opportunistic basis from around the 
University College London area. The smokers were recruited for this pilot by handing 
out copies of an information sheet in and around UCL and by word of mouth. The 
information sheet informed potential interviewees that the interviews were part of a pilot 
investigation into public attitudes towards genetic testing for susceptibility to lung cancer, 
and that one of the aims of the interviews was to help design future research into genetic 
testing. There was no indication in Lerman et al (1997) or McBride et al (2002) that 
either of them had presented the absolute or relative risks conferred by smoking and the 
GSTM1 genotypes, and so one aim of the interviews was to explore smokers’ reactions to 
genetic risk figures and numbers to inform how these might best be presented in the 
actual study. Two graphic presentations of risk were presented, and the figures showed 
that, on average, smokers have a 10% chance of developing lung cancer and that, given 
the relative risk of 30% conferred by the GSTMl-null genotype, this therefore leads to an 
absolute difference of 3% between the two genotypes.
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When asked how they would feel about receiving a ‘high risk’ genetic test result for lung 
cancer susceptibility, prior to seeing either of the graphical illustrations, there was some 
evidence for people reacting with distress. For example, one woman said, "If you’re 
actually doing this test and telling me, yes, I ’ve got a high susceptibility to it, it would 
completely freak me out. ” Also, when asked how they would feel about receiving a ‘low 
risk’ genetic test result for lung cancer susceptibility, again prior to seeing the graphical 
illustrations, a lot of them did seem to anticipate being de-motivated or complacent, e.g. 
“I ’d get very complacent about i t”, and "I t ’s almost a kind o f a carte blanche to smoke 
as much as you like isn’t it However, on seeing the bar chart graphical presentations of 
risk, the interviewees said things like: “Saying it like that doesn’t sound as scary as I  
said”', “It would still have an effect because it’s slightly h i g h e r and “I  said I  would 
view that i t ’s ok fo r  me to smoke, but when you ’re presented with a graph and you ’re 
shown the statistics i t ’s completely different”. These pilot interviews were therefore 
helpful in the development of the Illustrated Guide, in part because the responses strongly 
supported the use of graphical illustrations, and indicated that people appeared to find the 
bar chart the easiest to interpret.
In addition, the self-help booklet provided by the NHS was identified as being suitable 
for use in this study. This 40-page A5 booklet is called “Giving Up For Life”. It 
contains extensive, clear and well-written information on giving up smoking, including 
the health benefits of giving up smoking, management of nicotine withdrawal symptoms, 
and information on pharmacological products.
2.4. Development of genetic testing procedure
The genetic testing process was piloted with five smokers after ethical approval had been
granted, but before the main study commenced. The aim of these five ‘case studies’ was
to look at smokers’ reactions to receiving real genetic risk feedback and to examine the
process of giving genetic feedback with a few informal test cases, before embarking on
the more formally recruited clinic population of smokers. The smokers for the pilot case
studies were recruited opportunistically by word of mouth; two were university educated
and three had minimal educational qualifications; four were male and one was female.
Each smoker was interviewed (by SS) and offered a genetic test for GSTM1. If they
213
Chapter 8: S tudy 3: CS1 M l genetic testing
opted to take the test (which they all did), they received their test result within two weeks, 
in accordance with the approved protocol. Although I was a Level 2 trained smoking 
cessation counselor, as an additional precaution, each smoker in the pilot spent up to 20 
minutes with a Level 3 smoking cessation counselor prior to receiving their test result.
Three of the pilot cases had the GSTM1-present result and two had the GSTM1-missing 
result. One of the main outcomes of the pilot was that the additional smoking cessation 
‘counseling’ appeared to be an unnecessary precaution -  the additional time spent with 
the smoking cessation counselor within the session seemed time-consuming and 
redundant. It was concluded that the level of advice provided by the Level 2 trained 
smoking cessation adviser-researchers (SS and EH) would be adequate. The important 
finding was that the smokers in the pilot all seemed comfortable with the process and 
with receiving genetic risk information, regardless of the test result. Two of the GSTM1- 
present participants reported that they had not been overly anxious about their test result, 
and that they would use a GSTM1-missing result to motivate themselves to quit smoking. 
They both stated that having received a positive test result was a relief but did not affect 
their motivation to quit in either direction. Neither had told their partners that they had 
taken the test, but said they might do now that they knew the result. The third GSTM1- 
present participant was extremely happy about his result, which appeared to be linked to 
the fact that he had a history of lung cancer in his family, and therefore found the 
information particularly reassuring. The main reaction of the first GSTM1-missing 
participant was surprise, due to the fact that he ‘never got ill’, and had therefore assumed 
that he had genes that protected him. Nonetheless, he was unconcerned about his result, 
and gave the impression that it would not affect his motivation to quit smoking. The 
second GSTM1-missing participant was mildly disappointed with the result, and reported 
that she would attempt to use it to help her quit smoking.
Advice was sought from a clinical geneticist (Dr James Mackay) on the issues that had 
been raised in these pilots. His main advice was to make absolutely sure that everything 
possible had been done to explain things clearly to the patient/participant before they 
consented, and to ensure that the researcher-advisers for the main study knew that they 
should make certain that the information had been understood, and that the participants
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were psychologically going to be able to interpret and deal with the information. His 
advice confirmed what had emerged in the earlier studies in the PhD work, Studies 1 and 
2a-c. Dr Mackay continued to be available for consultation on specific cases throughout 
the main study.
2.5. Recruitment
2.5.1. Initial postal contact (Phase -1)
Smokers for the main study were contacted in collaboration with the Camden and 
Islington NHS Smoking Cessation Service. Letters were sent to all individuals who had 
contacted the Camden and Islington NHS Smoking Cessation Service at some point in 
the four years preceding the study. The names and addresses of these individuals were 
obtained from a database kept by, and with permission from, the Camden Smoking 
Cessation Coordinator (Simon Galton) and the Islington Smoking Cessation Coordinator 
(Seher Kayikci). The letter outlined that the Camden and Islington services had recently 
been re-structured, that everyone who had been in touch with the service over the past 
four years was being contacted to see if they would still like help with quitting smoking, 
and that the NHS Smoking Cessation Service was ‘collaborating with researchers at 
University College London on a study investigating whether having a genetic test affects 
the way people think about quitting’. The letter informed the recipient that if they would 
like to receive more details about the smoking cessation services provided by the NHS, or 
about the genetic testing study, they should either call the telephone number on the letter, 
or email the email address provided, or tear off the slip and return it in the freepost 
envelope enclosed. The tear-off form required that they ticked one of two boxes; ‘yes I 
would like further information’ or ‘no I do not want to receive any further information’ 
and, if they did want further information, to indicate their name, daytime telephone 
number, evening telephone number, and times available for calling. The letter informed 
them that one of the signatories (Saskia Sanderson, Simon Galton, or Seher Kayikci) 
would then contact them by telephone with further information. Letters were sent to all 
2,226 individuals on the database.
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Of the 2,226 letters sent out, 427 (19%) forms were returned. Of these, 40 (9%) were not 
interested in receiving any further information either on the genetic testing study, or 
about the Camden and Islington NHS smoking cessation service in general, 32 (7%) 
indicated that they had quit already, and 6 (1%) were no longer at that address.
2.5.2. Telephone contact (Phase 0)
At least two attempts were made to telephone the 359 individuals who had returned the 
form indicating that they were interested in receiving further information. The 
phonecalls were made by SS or EH. As described above, both researchers had received 
training in smoking cessation counseling and were trained Level 2 smoking cessation 
advisers, and both also received several hours training in genetics, metabolism, and the 
GSTM1 gene. Unfortunately, due to difficulties with database management and 
incomplete records, data are available on only 184 (52%) of the calls that were made, but 
these will be reported in order to give an indication of the kinds of proportions of people 
going through at each stage of the study: upon contacting the individuals by telephone, 24 
of the 184 had already quit smoking. Of the 160 who were still smoking, 128 said that 
they were interested in taking part in the study, an additional 3 were deemed at this stage 
to be ineligible due to psychiatric illness or difficulties with the English language, and 29 
were not interested in taking part in the study. Appointments were made with those 
smokers who were interested in taking part, and appointment confirmation letters were 
subsequently sent out (see Appendix F). 61 smokers turned up for the first session and at 
least one follow-up session; these smokers comprised the final study sample. See 
Appendix F for the telephone recruitment protocol which was used for Phase 0, and for 
the appointment confirmation letters which were subsequently posted.
2.6. Procedure
2.6.1. Baseline session (Phase 1)
The researcher-adviser (SS or EH) conducting the baseline session (“Phase 1”) first of all 
checked that the participant was eligible for participation in the study (using the brief 
advice protocol, see Appendix G).
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Volunteers were excluded if:
1. They were under 18 years of age
2. They had smoked fewer than seven cigarettes in the past week
3. They had problems with understanding the English language
4. They had had a diagnosis of lung cancer
5. They were currently on medication for any psychiatric conditions
6. They had ever had any psychiatric condition other than depression (e.g. 
schizophrenia or bipolar disorder)
Points 5 and 6 were deliberately conservative exclusion criteria, to try to exclude any one 
who might be particularly vulnerable to negative psychological reactions. Eligible 
smokers were given an information sheet about the study (see Appendix G) to read and to 
keep. They were given the opportunity to ask questions, and if they were willing to take 
part then they completed the Stage 1 Consent Form (see Appendix G).
The first half of the session was dedicated to collecting information about the 
participant’s smoking habits and giving advice about quitting. All participants were 
given further details about the NHS service and advised to re-contact the service for 
further support. They were also given the NHS smoking cessation self-help information 
booklet called “Giving Up For Life As mentioned above, this 40-page booklet contains 
extensive, clear and well-written information on giving up smoking, including the health 
benefits of giving up smoking, management of nicotine withdrawal symptoms, and 
information on pharmacological products. Baseline variables were measured in the 
second half of the session in an 8-page questionnaire form (see Appendix G).
Participants were then randomized in a 1:2 ratio to either the control group or the genetic 
test group. People who were randomized to the control group finished the session at this 
point. People who were randomized to the genetic test group were given five minutes of 
explanation about the genetic test using the 17-page illustrated guide called “Genetics, 
Smoking, and Genetic Testing fo r  GSTM1: An Illustrated Guide” (see Appendix H). The 
guide was developed specifically for this study, and included background information 
about genes, enzymes, the GSTM1 gene’s role in metabolism, graphical representations
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of risk, and what genetic testing involves. An A4 laminated colour version of the 
illustrated guide was used for the explanation in the session. An A5 black-and-white 
version of the illustrated guide was given to the participants to take and read at home. 
They were given time to ask questions and to consider whether they wanted to take the 
test. If they did not want to, the session finished there (only two people declined to take 
the test). If they did want to, they completed and signed the Stage 2 Consent Form (see 
Appendix G) and then self-administered a cheek-cell swab to collect the cells for the 
DNA analysis.
2.6.2. Results session (Phase 2)
Participants in the genetic testing group were invited to come back to UCL to get their 
test result within two weeks of the baseline session. This result session is also referred to 
as “Phase 2”. “Phase 2” appointments were made with the participants in the genetic test 
group, and at first for controls, to come in for a second session at UCL. However, it 
became apparent that the second session was difficult to justify with the controls, where it 
was unclear why they should attend if they were not getting any results, and many of 
them didn’t turn up. We therefore stopped making Phase 2 appointments with control 
subjects and instead informed them in Phase 1 that the next contact we would make with 
them would be the first telephone follow-up call in three weeks time. A small number of 
controls were therefore seen at this time point in the study.
For those in the genetic testing group, the results session took about 15 minutes. A short 
time was spent on whether they were still smoking including a brief discussion on 
methods of quitting and advice for future successful quit attempts (see Appendix I for 
results session protocol). This was followed with discussion of the test to ascertain 
whether they had understood the meaning of the genetic test. If they did not appear to 
understand or have remembered what the result would mean, it was briefly explained 
again and efforts were made to ensure that they had a clear understanding of what the 
results would mean. All participants were shown two of the risk figures from the 
illustrated guide again.
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The result was only given to the participant when the researcher-adviser judged that the 
participant understood what their test result would mean, and they had confirmed that 
they did want their test result. They were then given their result, by being told verbally 
either “Your test result indicates that you do have the GSTMI gene”, or “Your test result 
indicates that you do not have the GSTMI gene”. They were given the A5 version of the 
illustrated guide again with ‘GSTMI-missing result’ or ‘GSTMI-present result’ written 
on it, and the appropriate risk figures marked inside.
Measures at this time point were obtained by administering a brief two-page 
questionnaire (see Appendix I) which contained: five questions on amount smoked per 
day and motivation to quit smoking; one question on confidence in ability to quit; one 
question on worry about lung cancer over the past week; and a 19-item measure of 
current positive and negative affect (the PANAS). Open-ended questions were also 
asked about their immediate response to their test result and how they felt about it.
2.6.3. One week telephone follow-up (Phase 3)
The one week follow-up (“Phase 3”) was administered to controls and the genetic groups 
three weeks after baseline, and consisted of brief telephone counseling to ensure that the 
participant was not unduly distressed by their test result, and a seven-page questionnaire 
administered over the telephone (see Appendix J for protocol and questionnaire).
2.6.4. Two month telephone follow-up (Phase 4)
The two month follow-up (“Phase 4”) was administered ten weeks after baseline and was 
identical to one week follow-up. The procedure for the whole study is summarized in the 
flow-chart (Figure 8.1) on the following page.
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Figure 8.1. Study flow-chart
P h a s e  3: first 
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Did n o t a tte n d  (n= 67)
G S T M 1 -p re se n t (n= 23 )G S T M 1 -m issin g  (n = 2 0 )
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4 2 7  (19% ) fo rm s re tu rn ed
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2.7. Measures
2.7.1. Phase 1 measures
2.7.1.1. Socio-demographics
2.7.1.1.a. Demographics
The questionnaire included items to assess gender; age; marital status (single, married, 
cohabiting/living with partner, divorced/separated, widowed); number of children (none, 
1, 2, 3, more than 3); ethnic group (white, black, asian, other, do not wish to answer); 
housing tenure (rent from local authority, rent from private landlord, own home, other); 
employment status (employed full-time, employed part-time, unemployed, full-time 
homemaker, retired, student, disabled or too ill to work); educational attainment 
(GCSE/O-level/CSE, vocational qualifications (e.g. NVQ1+2), A-level or equivalent (e.g. 
NVQ3), Bachelor degree or equivalent (e.g. NVQ4), Masters/PhD or equivalent, other, 
no formal qualifications, still studying); car ownership (no, yes one, more than one); and 
religious influence (not at all, a little, quite a lot, completely, not applicable). An open- 
ended question was also included which asked for the participant’s current occupation.
2.7.1.Lb. Health status
General health status was measured using two items, a self-rated health item and number 
of GP visits in the past 3 months. Subjective health was measured using a modified item 
taken from the Health Survey for England (1996): “In general, would you that your 
health is... excellent, good, fair, poor.” GP visits were measured by asking respondents 
how many times they had visited the GP in the past 3 months, with the response options, 
“haven’t been”, “once”, “twice”, “three or more times”.
2.7.1.11. Primary dependent variables
2.7.1.11.a. Depression and anxiety
Depression and anxiety were measured using the Hospital Anxiety and Depression Scale 
(HADS). The HADS is a 14-item scale developed by Zigmond and Snaith (1983) to 
provide a brief state measure of both anxiety (7 items) and depression (7 items). It was 
designed for use in medical out-patient clinics to detect clinical cases of anxiety and 
depression and to assess the severity of anxiety and depression. Each item is scored from
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0 to 3 and so the total scores range from 0 to 21 for the anxiety subscale and also for the 
depression subscale. Higher scores indicate greater anxiety or depression. Based on 
Sigmond and Snaith’s study of 100 medical out-patients, scores from 8 to 10 have been 
taken to indicate possible clinical disorder and from 11 to 21 to indicate probable clinical 
disorder. The HADS is an established measure of severity of the states. The four score 
ranges can be classified as ‘normal’ (0-7), ‘mild’ (8-10), ‘moderate’ (11-14) and ‘severe’ 
(15-21). Unfortunately, in this study, a printing error meant that one of HADS anxiety 
items (“I can sit at ease and feel relaxed”) was missed off of the Phase 3 and Phase 4 
questionnaires. One option to deal with this would have been to miss this item from the 
anxiety scale score calculations for all three time points, and have a scale of 6 items 
instead of 7, but it was felt that replacing the missing item at Phases 3 and 4 with the 
mean of the other 6 ‘anxiety’ items, would enable a better comparison with standardized 
scores.
2.7.1.11.b. Worry about lung cancer
Worry about lung cancer was measured using five items which were adapted (simply by 
replacing the words ‘my illness’ with the words Tung cancer’) from the generic Revised 
Illness Perceptions Questionnaire (IPQ-R: Weinman et al, 1996; Moss-Morris et al, 
2002). The five items were: “When I think about lung cancer I get upset”, “I get 
depressed when I think about lung cancer”, “Lung cancer makes me feel angry”, “Lung 
cancer makes me feel anxious”, and “Lung cancer makes me feel afraid”. The five items 
loaded on to one factor with eigenvalues all above 0.60, which accounted for 69.5% of 
the variance. Reliability test showed the alpha to be .889. This 5-item composite scale 
was used to measure worry about lung cancer. A sixth item, “How often do you worry 
about lung cancer?”, was not included because when it was repeated in Phases 3 and 4 
the wording was slightly different, having been changed to “How often have you worried 
about lung cancer over the past week?”.
2.7.1.11.c. Intention to quit smoking
Intention to quit smoking was measured with the item: “Are you intending to give up 
smoking within the next 6 months?” (no definitely not, no probably not, possibly, yes 
probably, yes definitely) (Martin Jarvis, personal communication).
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2.7.1.11.d. Motivation to quit smoking
Motivation to quit smoking was measured with a single item: “How much do you want to 
give up smoking all together?” (not at all, slightly, moderately, quite strongly, very 
strongly). This measure of motivation, or desire to quit smoking, is used in the annual 
Office for National Statistics assessment of smoking-related behaviours and attitudes in 
the UK (Lader & Goddard, 2002).
2.7.1.11.e. Number o f cigarettes per day
Participants were asked, “How many cigarettes do you usually smoke per day?”. This 
item was taken from one of the most frequently used instruments to measure nicotine 
dependence, the 6-item Fagerstrom Test for Nicotine Dependence (FTND, Heatherton et 
al, 1991). Another item was also included from the FTND, “How soon after waking do 
you smoke your first cigarette of the day?”. This item was included as a baseline 
descriptive measure but was not included as an outcome measure because there were no 
hypotheses regarding the impact of genetic testing specifically on nicotine dependence. 
The ‘cigarettes per day’ item was included as a primary outcome because Lerman et al 
(1997) hypothesized that distress in response to unfavourable genetic test results could 
“promote smoking to achieve the mood-enhancing effects of nicotine” (Lerman, Audrain 
et al, 1996; Lerman et al, 1997).
2.7.1.11.f. Perceived risk o f lung cancer
Perceived risk of lung cancer was measured with seven items. Two items were adapted 
from Sutton et al (1994): “Compared with other smokers of your age and sex, do you 
think your chances of getting lung cancer at some point in your life are: much lower, 
lower, about the same, higher, much higher” and “Compared with nonsmokers of your 
age and sex, do you think your chances of getting lung cancer at some point in your life 
are: much lower, lower, about the same, higher, much higher”. Three items were adapted 
from the Risk Behavior Diagnosis Scale (RBDS: Witte et al, 1995), which is a 12-item 
scale developed to determine which kind of health protective messages work best for 
specific persons or audiences, and is based on the Extended Parallel Process Model 
(EPPM: Witte, 1992). The three perceived susceptibility items in the RBDS that were
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used here were: “It is likely that I will get lung cancer”, “I am at risk for getting lung 
cancer” and “It is possible that I will get lung cancer”. Two conditional items were also 
used: “It is likely that I will get lung cancer if I continue to smoke” and “It is likely that 
I will get lung cancer if I quit smoking”. The response options were strongly disagree, 
disagree, neither, agree, strongly agree. In order to get a reliable scale to measure 
perceived risk, the seven risk items were entered into a factor analysis with varimax 
rotation. This resulted in two factors being extracted -  the only item that did not load on 
the first factor with an eigenvalue above 0.4 was “It’s likely I’ll get lung cancer if I quit 
smoking”. The factor analysis was therefore re-run with this item excluded. This second 
factor analysis resulted in a more satisfactory outcome: all items loaded on a single factor 
with eigenvalues above 0.4 (see Table 8.1. below for factor loadings), the factor 
accounting for 44% of the variance. The alpha coefficient was .704, which indicated that 
the items formed a reliable scale. The items were therefore combined to produce a 6-item 
composite scale, which was used for the main analyses.
Table 8.1. Factor analysis of items measuring perceived 
risk of lung cancer_____________________________
Component Matrix Factorloading
I’m at risk for getting lung cancer .728
It's likely I'll get lung cancer if I continue 
to
smoke
.567
It's likely I'll get lung cancer .836
It's possible I will get lung cancer .626
Compared with nonsmokers, do you think 
your chances of lung cancer are:
.607
Compared with other smokers, do you 
think your chances of lung cancer are:
.596
Extraction Method: Principal Component Analysis. 1 component extracted.
2.7.1.111. Secondary variables
2.7.1.111.a. Self-efficacy/confidence in ability to quit
Three items were included on self-efficacy, taken from Witte et al (1995). These items 
were framed in the following way in the baseline questionnaire: “I am able to quit
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smoking to prevent getting lung cancer”, “I have the time and money to quit smoking to 
prevent lung cancer”, and “I can easily quit smoking to prevent lung cancer” (five 
response options from strongly disagree to strongly agree). Two changes were made to 
these items as the study progressed. First of all, the words ‘to prevent lung cancer’ were 
dropped in the Phase 3 and 4 versions of the questionnaire, because of repeated 
comments from participants that these were unnecessary and made the sentences hard to 
understand. Second, the item pertaining to ‘time and money’ was excluded from 
analyses, due to the fact that people repeatedly reported that this item did not make sense, 
and often missed it out altogether. An additional item was also used to measure 
confidence in ability to quit smoking. This was: “How confident are you that you can not 
smoke, even under difficult circumstances (e.g. when drinking alcohol or coffee, when 
stressed or bored, or when with smokers)?”. Response options were not at all confident, 
not very confident, neither, quite confident, and very confident.
In addition, self-standards (Fishbein et al, 2001: p3-17) were measured using two items: 
“I think of myself as a smoker” and “I think of myself as the kind of person who is able 
to quit smoking” (response options strongly disagree, disagree, neither, agree, strongly 
agree).
2.7.1.111.b. Avoidance
The following three items taken from Witte et al (1994) were used to measure avoidance: 
“When I smoke, I tend to avoid thoughts of lung cancer”, “When I get a cough, I tend to 
avoid thinking about lung cancer”, and “When I smoke, I try to not think about lung 
cancer”.
2.7.1.111.c. Perceived severity
Three items from the Risk Behavior Diagnosis Scale (Witte et al, 1995) were used to 
measure perceived severity in the Phase 1 baseline questionnaire: “I believe that lung 
cancer is severe”, “I believe that lung cancer has serious negative consequences”, and “I 
believe that lung cancer is extremely harmful”. This measure was not included in Phases 
3 and 4.
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2.7.1.111.d. Causal beliefs about lung cancer
Seven items pertaining to causal beliefs were adapted from previous research on bowel 
cancer (McCaffery, unpublished thesis manuscript), the first six of which were modified 
from the Illness Perception Questionnaire (Weinman et al, 1996). These items were 
(with five response options from strongly disagree to strongly agree): “Lung cancer can 
be caused by a germ or a virus”, “Diet can play a major role in causing lung cancer”, 
“Pollution in the environment can cause lung cancer”, “Lung cancer is hereditary -  it 
runs in the family”, “It is just by chance that some smokers get lung cancer”, “Stress is a 
major factor that can cause lung cancer”. The seventh item was “Lung cancer is caused 
by a genetic abnormality”.
2.7.1.111.e. Understanding o f lung cancer
A further item was taken from the IPQ (Weinman et al, 1996) which measured disease 
salience, or understanding of the disease. This was: “I have a clear picture of what lung 
cancer is”. There were originally more understanding items included from the IPQ which 
were discarded after piloting (note: a number of the items used in this study were taken 
from the questionnaire developed for the survey study presented earlier in this thesis, and 
therefore underwent extensive piloting).
2 .7.1.111.f Test result expectation
A measure of test result expectation was advised (Colleen McBride, personal 
communication), and so the following item was included: “If you are offered the genetic 
test for lung cancer risk today and you choose to take it, do you expect your test result to 
tell you that your genetic risk of lung cancer is: lower than average, average, higher than 
average, don’t know”.
2.7.1.111.g. Family and friends history o f smoking-related disease
The following item was included: “Finally, do you know of anyone who has lung cancer 
or any other smoking-related diseases (such as emphysema)? (Please tick any that apply 
and write the details in the space provided): Myself; Family; Friend; Acquaintance; 
Neighbour”.
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2.7.2. Phase 2 measures
2.7.2.L Emotional wellbeing
Emotional wellbeing was measured using the Positive And Negative Affect Schedule 
(PANAS: Watson et al, 1988). In recent research, two broad, general factors -  typically 
labeled Positive Affect (PA) and Negative Affect (NA) -  have emerged reliably as the 
dominant dimensions of emotional experience. To measure these factors, Watson et al 
(1988) developed the PANAS, which consists of two 10-item scales for PA and NA, 
respectively. However, unfortunately yet another error led to one of the items being 
missed in the present study, resulting in a 19-item, and therefore less reliable, measure. 
The PANAS reads: “This scale consists of a number of words that describe different 
feelings and emotions. Please read each item and then mark the appropriate answer in the 
space next to that word. Indicate to what extent you feel this way right now, that is, at the 
present moment.” The response options are: very slightly, a little, moderately, quite a bit, 
extremely. The words included were: interested, distressed, excited, upset, strong, guilty, 
hostile, enthusiastic, proud, irritable, alert, ashamed, inspired, nervous, determined, 
attentive, jittery, active, afraid.
2.7.2.U. Worry about lung cancer
This was measured with a single item taken from the Phase 1 questionnaire: “How often 
have you worried about lung cancer over the past week?”.
2.7.2.iii. Intention to quit smoking
As before, this was measured using the Jarvis item, and was only completed by those 
who had not already quit smoking. Again, scores were from 1 to 5 and participants who 
had already quit smoking were allocated a score of 6.
2.7.2.iv. Motivation to quit smoking
Participants initially answered the question: “Have you quit smoking? (yes/no)”. Only 
those smokers who answered ‘no’ went on to complete the measure of motivation to quit 
and other smoking measures. Motivation to quit smoking was measured using the Jarvis 
(personal communication) measures outlined in Phase 1. The five response options (not
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at all, slightly, moderately, quite strongly, very strongly) were scored from 1 to 5. 
Participants who answered ‘yes’ to having quit smoking, were allocated a score of 6.
2 .7.2.V. Number o f cigarettes per day 
As measured in Phase 1.
2.7.2.vi. Self-efficacy/confidence in ability to quit
This was also measured using a single item taken from the Phase 1 questionnaire: “How 
confident are you that you can not smoke, even under difficult circumstances (e.g. when 
drinking alcohol or coffee, when stressed or bored, or when with smokers)?”.
2.7.2.vii. Attitudes towards genetic test prior to receiving result
Participants were asked the following three closed questions: “Do you remember 
receiving the genetic booklet? (yes/no)”, “Have you read the genetic booklet since then? 
(yes/no)”, and “Have you thought about the genetic test? (yes/no)”. They were then 
asked the following two open-ended questions: “From what you remember of what was 
explained to you last time, what did having the gene mean?”, and “From what you 
remember of what was explained to you last time, what did not having the gene mean?”. 
They were then asked the following three questions: “Have you thought about how you’d 
feel if you got a ‘gene missing’ result? (no/yes, details)”, “Have you thought about how 
you’d feel if you got a ‘gene present’ result? (no/yes, details)”, and “Have you worried 
about your genetic test result? (no/yes, details)”.
2.7.2.viii. Immediate reaction to genetic test result
The protocol instructed the researcher-adviser to “assess and check immediate reaction” 
and to “record details (e.g. frightened, relieved, happy, worried, motivated, etc.)”. Space 
was provided for the researcher-adviser to record the participant reactions.
2.7.3. Phase 3 and 4 measures
The Phase 3/4 follow-up questionnaire included the following measures which were 
taken from the Phase 1 or Phase 2 questionnaires: motivation to quit smoking (Lader & 
Goddard, 2002), intention to quit smoking (Jarvis, personal communication), level of
228
(  b a p u - r  N: S t u d y  3: ( iS 'l  V I 1 g e n e t i c  tcstin*.
nicotine addiction (Heatherton et al, 1991; Jarvis, personal communication), emotional 
wellbeing (PANAS: Watson et al, 1988), causal beliefs about lung cancer (Weinman et 
al, 1996; McKaffery et al), understanding of lung cancer (Weinman et al, 1996), worry 
about lung cancer (Weinman et al, 1996; Moss-Morris et al, 2002), perceived severity 
(Witte et al, 1996), perceived risk of lung cancer (Sutton et al, 1994; Witte et al, 1996), 
self-efficacy/confidence in ability to quit (Witte et al, 1996), self-standards (Fishbein et 
al, 2001), avoidance (Witte et al, 1994), and depression and anxiety (HADS: Zigmond & 
Snaith, 1983).
In addition, questions specific to the genetic test result were also included. Participants 
were asked the following questions: “Do you remember receiving your genetic test 
result? (no/yes)”, “What was your genetic test result? (gene present/gene missing/don’t 
know)” , “Have you thought much about your test result? (no/yes)”, “Have you read the 
genetic booklet since then? (no/yes)”, “Have you worried about your genetic test result? 
(no/yes)”, “From what you remember of what was explained to you last time, what did 
having the gene mean?”, “From what you remember of what was explained to you last 
time, what did not having the gene mean?”, “In your own words, how do you feel about 
your genetic test result?”, and “How, if at all, has your test result affected your 
motivation to quit smoking?”.
Finally, additional items measuring the psychological impact of the genetic test were also 
included. These items were taken from the Multidimensional Impact of Cancer Risk 
Assessment (MICRA) questionnaire (Celia et al, 2002). The MICRA is a 25-item tool 
recently developed to measure the specific impact of result disclosure after genetic 
testing. Seven items were selected, which were (with response options never, rarely, 
sometimes, often): “Feeling anxious or nervous about my test result”, “Having problems 
enjoying life because of my test result”, “Worrying about my risk of getting lung cancer”, 
“Being uncertain about what my test result means about my personal lung cancer risk”, 
“Thinking about my test result has affected my work, social or family life”, “Having 
difficulty talking about my test results with family members”, and “Feeling regret about 
taking the genetic test”. Table 8.2 summarises the variables that were measured at each 
Phase.
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2.8. DNA analysis
DNA analysis was done by Professor Steve Humphries’ group at the UCL Cardiovascular 
Genetics department with funding from the London IDEAS Genetics Knowledge Park. 
Samples were assigned consecutive numbers and sent de-identified except for this 
number to the UCL laboratory. DNA was isolated from cheek swab sample using the 
Schleicher and Schuell protocol based on published methods (Malamud and Tabak 1993). 
The GSTM1 genotype was identified using an allele-specific multiplex PCR assay. 
Genotyping of GSTM1 was carried out using a modification of the published multiplex 
PCR method, which includes b-globin as a positive control for amplification (Li et al, 
2000). Primer sequences were as published (Li et al 2000). A homozygous deletion of 
this gene results in an absence of an amplification product and presence of this gene on 
one or both alleles results in a detectable PCR product of 273 bp. Two genotypes result 
from this analysis: presence or absence of GSTM1. To ensure that absence of the 
GSTM1 PCR product (indicative of increased susceptibility) was not the result of a 
technical error, specimens were amplified for the PCR positive control of the b-globin 
gene as described, with gene-specific primer pairs. Only those with a positive 
amplification product for b-globin and an absent product for GSTM1 were considered 
valid results. Genotyping was carried out by laboratory staff blind as to subject 
identification, and genotype data was sent to the study co-ordinator (SS) for forwarding 
to the subjects. DNA extraction and genotyping was achieved within one week of 
receipt.
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Table 8.2. Measures included at each phase
M EASURE Phase 1 Phase 2 Phase 3 Phase 4
Depression V A1 V
Anxiety V A/ V
Worry about lung cancer V V A1 A/
Intention to quit smoking V V V V
Motivation to quit smoking V a/ V V
Number o f cigarettes per day V a/ A/ A/
Perceived risk o f lung cancer V V a/
Socio-demographics V
Test result expectation V
Family/friends history o f smoking-related disease “ 7
Response efficacy V
Coping/approach-avoidant/information-seeking V
Social norms V
Attitudes towards smoking V
Self-efficacy/confidence in ability to quit smoking V a/ V a/
Avoidance V V V
Severity V V V
Causal beliefs about lung cancer a/ A? v  "
Understanding o f lung cancer V V a/
Self-standards V V
Emotional wellbeing (positive and negative affect) V V w
Attitudes towards genetic test prior to result V
Immediate reaction to genetic test result V
Attitudes towards genetic test at follow-up V V
Impact o f genetic test result 7 ' V
Measures marked in blue are the primary dependent variables.
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2.9. Statistical analyses
2.9.1. Power calculations
The original aim for this study was to achieve a sample size of 180 participants, based on 
the following power calculations. The primary projected analyses were to examine 
whether smokers who received genetic risk feedback were more motivated to quit 
smoking or more worried, than controls. Analyses were also planned to examine 
differences between smokers who received higher risk feedback (GSTM1-missing) 
versus lower risk feedback (GSTM1 -present). Power calculations showed that in order to 
have the statistical power to detect a difference of at least 0.5 standard deviations 
between the two groups 60 subjects would be needed in each of the two genetic risk 
feedback groups. Therefore a total of 120 smokers would be needed to receive genetic 
feedback, and this plus 60 in the control group was to give us our sample size of 180.
However, in the event, complications such as difficulties with recruitment, incomplete 
datasets from individuals over the four data collection time points, and time restrictions, 
meant that a sample size of only 61 was achieved. The numbers within each group were 
20 in the GSTM1-missing group, 23 in the GSTM1-present group, and 18 in the control 
group, but even then not all participants had data at each of the four time points.
This reinforces the fact that this study should not be seen as an attempt to conduct a 
definitive randomized controlled trial but rather a Phase II pilot effort to develop the 
appropriate materials, procedures, and ethically sound methodologies to address 
questions about the impact of genetic tests for complex diseases that have so far been 
neglected in the literature. It is intended that the methods and preliminary results from 
this pilot study will be used to inform a grant proposal for a randomised controlled trial 
based on this study. It is arguably most appropriate to simply look at trends in the data 
that might give some indication of what might be expected in such a larger trial. In the 
interest of thoroughness, statistical analyses have been conducted on the data, but 
interpretation of these analyses should always be done with caution based on the sample 
size.
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2.9.2. Sensitivity analysis: dealing with missing data
There were a lot of missing data in the dataset (see Tables 8.3, 8.4, and 8.5 below) 
because a number of the participants did not have data at all three time points. In 
repeated measures analyses this is problematic because individuals are only included in 
the analyses if they have data at all of the time points, and so the majority of individuals 
would end up being excluded. There are several ways of dealing with missing data, 
including:
a) do not replace the missing values and conduct repeated measures analyses on the 
smaller sample, or conduct univariate analyses only at each time point, possibly using 
bonferroni’s corrections for multiple comparisons;
b) replace each missing value with the series mean (i.e. the mean of the whole sample 
combined for that variable), or;
c) replace each missing value with the group mean (i.e. the mean of each group).
Each of these options has drawbacks. The first option (i.e. do nothing) reduces the power 
of the analyses because they are being conducted on a considerably smaller sample size. 
The second option (replace with series mean) reduces the chances of finding a true 
difference between the groups because it reduces the variance between the groups by 
drawing the mean within each group closer to the overall mean. The third option (replace 
with group mean) increases the chances of finding a false difference between the groups 
because it draws the variance within each group closer to its own mean.
In order to explore these issues, a sensitivity analysis was conducted. This involved 
running three repeated measures analyses on each of six outcome variables (intention to 
quit; amount smoked per day; worry about lung cancer; perceived personal risk; 
perceived comparative risk; confidence in ability to quit). The first repeated measures 
analysis was conducted on the data set without replacing the missing values; the second 
on the data set having replaced the missing values with the series mean; and the third on 
the data set having replaced the missing values with the group mean. All three time points 
(Phase 1/baseline; Phase 3/one week follow-up; Phase 4/two month follow-up) were 
included in the analyses rather than conducting separate repeated measures on ‘Phase 1 -  
Phase 3’ and ‘Phase 1 -  Phase 4’ in order to reduce the number of analyses that were
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being conducted at this stage. The quadratic values combined with examination of the 
graphs were examined to determine whether different patterns appeared to be emerging at 
the two follow-ups. Tables 8.6, 8.7 and 8.8 summarize the results (F-statistics and p- 
values) of the sensitivity analyses. The first column (Time Linear) in each table indicates 
the effects of time on the variable (i.e. in the sample as a whole). The second column 
(Time*Group Linear) indicates whether the effects over time are different between the 
three groups. The third column (Time*Group Quadratic) indicates whether there is an 
effect over time that is not a simple linear relationship.
All three methods of replacement detected a significant increase in intention to quit, a 
significant decrease in amount smoked, and a significant decrease in worry about lung 
cancer across all groups over time (i.e. ‘Time Linear’, see Tables 8.6, 8.7 and 8.8). There 
were differences between the three methods however in terms of the time-by-group 
interactions that were reported as significant (i.e. Time*Group Linear). When none of 
the missing values were replaced, perceived personal risk appeared to be significantly 
higher in the GSTM1-missing group than in the GSTM1-present and control groups 
(F[2]=3.63, p=.040), as did perceived comparative risk (F[2]=4.13, p=.027). This was 
not picked up at a statistically significant level when the means were replaced with either 
method, possibly suggesting that it might reflect some participation bias. As predicted, 
replacing the missing values with the series mean had the most conservative effect, and 
no time*group interactions were detected using this method. When the missing values 
were replaced with the group mean, the reduction in amount smoked (F[2]=3.94, p=.025) 
and the reduction in worry about lung cancer (F[2]=3.62, p=.033) were significantly 
different between the three groups.
The most appropriate approach is probably to replace missing values with the series 
mean, as it is important not to over-interpret or emphasise differences between groups. 
For this reason, in the present study, the series mean approach to missing data was used 
in the repeated measures analyses, and would be advised for a larger Phase III study. 
However, given the small numbers in this study, and the exploratory nature of the study, 
the results were also examined in two more basic ways. First, the values were simply 
eyeballed without replacing missing values and trends were looked at graphically having
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plotted the values on a series of line plot graphs. Secondly, ANOVAs and ANCOVAs 
were conducted comparing the genetic test result groups with the control group 
individually at each time point, and the analyses were repeated comparing the GSMT1- 
missing and GSTM-present groups with one another. The main analyses are described 
more fully in the following section.
2.9.3. Main statistical analyses
The main aim of the analyses was to explore whether the randomly allocated groups 
behaved differently over time on the seven primary outcome variables (depression, 
anxiety, worry about lung cancer, intention to quit smoking, motivation to quit smoking, 
number of cigarettes smoked per day, and perceived risk of lung cancer). Although 
other, secondary, variables were also measured (see Table 8.2), these primary outcomes 
were considered most important because they best reflected the variables examined in 
previous research (Lerman et al, 1997; McBride et al, 2002).
Baseline demographic characteristics of the whole sample were described using 
frequency tables, as were baseline scores on the primary dependent variables. Baseline 
demographic and primary dependent variable comparisons between groups were made by 
comparing proportions using chi-squares if the data was ordinal, or by comparing means 
using analyses of variance (ANOVA) if the data was continuous. Distributions of 
primary dependent variables at baseline were examined using histograms.
Trends over time were first of all examined in the sample as a whole by looking at mean 
scores at each time point. Next, means were reported for all the primary variables by 
group. These values were also plotted on line graphs and examined visually.
The relationships between group and time, i.e. the impact of genetic testing on each of the 
seven primary dependent variables, were explored using one-way ANOVAs, ANCOVAs 
with and without age and gender, and two level (time) repeated measures with covariates 
age and gender. Although repeated measures ANOVAs are the traditional way of 
analysing controlled trials with baseline and follow-up measurements, Vickers and 
Altman (2001) suggest that, when there is a chance imbalance between groups at
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baseline, these analyses could lead to biased results because treatment effects will be 
underestimated by a follow up score analysis and overestimated by looking at change 
scores (because of regression to the mean). By contrast, analysis of covariance 
(ANCOVA) gives the same answer whether or not there is baseline imbalance. 
ANCOVAs including baseline mean as a covariate were therefore also conducted, in 
addition to the repeated measures ANOVAs. Each analysis was conducted on a) the 
control group versus the genetic testing groups combined, and b) the GSTM1-missing 
group versus the GSTM1-present group. Seven repeated measures ANOVAs were also 
conducted including all three groups and three time points to explore the main effects of 
time.
Finally, responses to the open-ended questions in the GSTM1 -missing and GSTM1- 
present groups were presented.
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Table 8.3. Numbers of participants 
with data at each time point in the 
GSTM1 -missing group
Table 8.4. Numbers of participants 
with data at each time point in the 
GSTM1 -present group
Table 8.5. Numbers of participants 
with data at each time point in the 
control group
Subject Phase
1 2 3 4
1. 1 1 1 1
2. 1 1 1 1
3. 1 1 1 1
4. 1 1 1 1
5. 1 1 1 1
6. 1 1 1 1
7. 1 1 1 1
8. 1 1 1 1
9. 1 1 1 1
10. 1 1 1 1
11. 1 1 1 1
12. 1 1 1 1
13. 0 1 1 1
14. 0 1 1 1
15. 1 0 1 1
16. 1 1 0 1
17. 1 1 0 1
18. 1 1 1 0
19. 1 1 1 0
20. 1 1 1 0
Subject Phase
1 2 3 4
1. 1 1 1 1
2. 1 1 1 1
3. 1 1 1 1
4. 1 1 1 1
5. 1 1 1 1
6. 1 1 1 1
7. 1 1 1 1
8. 1 1 1 1
9. 1 1 1 1
10. 1 1 1 1
11. 1 1 1 1
12. 1 1 1 1
13. 1 1 1 1
14. 1 0 0 1
15. 1 1 0 1
16. 1 1 0 1
17. 1 1 0 1
18. 1 1 0 1
19. 1 1 0 1
20. 1 1 0 1
21. 1 1 1 0
22. 1 1 1 0
23. 1 0 1 0
Subject Phase
1 2 3 4
1. 1 1 1 1
2. 1 1 1 1
3. 1 1 1 1
4. 1 1 1 1
5. 0 1 1 1
6. 1 0 1 1
7. 1 0 1 1
8. 1 0 1 1
9. 1 0 1 1
10. 1 0 0 1
11. 1 0 0 1
12. 1 0 0 1
13. 1 0 0 1
14. 1 1 0 1
15. 1 1 0 1
16. 1 0 1 0
17. 1 0 1 0
18. 1 0 1 0
0 indicates missing data 0 indicates missing data 0 indicates missing data
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Table 8.6. Sensitivity analysis: repeated measures analyses without replacing missing 
data
Time Time*Group Time*Group
Linear Linear Quadratic
Intention to quit F[l]=8.68, p=.007 F[2]=0.48, p=.628 F[2]=0.37, p=.696
Confidence in ability to quit F[l]=0.10, p=755 F[2]=1.59, p=.221 F[2]=7.07, p=.003
Amount smoked per day F[1J=27.93, p<.001 F[2]=l .35, p=.277 F[2]=2.13,p= 140
Perceived personal risk F[l]=0.01,p=940 F[2]=3.63, p=.040 F[2]=0.68, p=.515
Perceived comparative risk F[l]=0.70, p=.410 F[2]=4.13, p=.027 F[2]=3.34, p=.050
Worry about lung cancer F[l]=5.36, p=.028 F[2]=2.03, p=.149 F[2]=3.68, p=.038
Table 8.7. Sensitivity analysis: repeated measures analyses replacing missing data 
with series mean
Time Time* Group Time*Group
Linear Linear Quadratic
Intention to quit F[l]=18.31, p<.001 F[2]=0.10, p=.906 F[2]=1.06, p=.353
Confidence in ability to quit F[l]=1.69, p= 199 F[2]=0.13, p=.879 F[2]=7.00, p=.002
Amount smoked per day F[l]=40.05, p<.001 F[2]=0.04, p=.851 F[2]=1.92, p=.156
Perceived personal risk F[1 ]=0.04, p=.851 F[2]=1.92, p= 156 F[2]=0.23, p=.799
Perceived comparative risk F[l]=0.29, p=.593 F[2]=1.91,p=. 157 F[2]=0.63, p=.534
Worry about lung cancer F[ll=9.00, p=.004 F[2]=2.52, p=.089 F[2]=0.72, p=.493
Table 8.8. Sensitivity analysis: repeated measures analyses replacing missing data 
with group mean
Time Time*Group Time*Group
Linear Linear Quadratic
Intention to quit F[l]=17.82, p<.001 F[2]=0.23, p=.792 F[21=2.44, p=.096
Confidence in ability to quit F[l]=1.89, p= 175 F[2]=0.20, p=.820 F[2]=12.12, p<.001
Amount smoked per day F[l]=38.19, p<.001 F[2] =3.94, p=.025 F[2]=9.40, p=<.001
Perceived personal risk F[l]=0.03, p=.872 F[2]=2.97, p=.059 F[21=0.32, p=.730
Perceived comparative risk F[1 ]=0.27, p=.603 F[2]=2.54, p=.088 F[2]=l.l 1, p=.337
Worry about lung cancer F[l]=9.71, p=.003 F[2]=3.62, p=.033 F[21=1.07, p=.350
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3. Results
3.1. Group numbers
There were 61 participants in the sample overall. 18 participants were randomly 
allocated to the control group, and 43 to the genetic testing group.10 Of those in the 
genetic testing group, 20 did not have the GSTM1 gene, and 23 did have the GSTM1 
gene. The table below (Table 8.9) summarises the numbers of participants in each of 
the three resultant groups, and shows that the randomization procedure was successful 
in terms of numbers.
Table 8.9. Numbers of participants in each group
Frequency (n) Percent (%)
GSTM1-missing 20 33%
GSTM1 -present 23 38%
Controls 18 30%
Total 61 100%
3.2. Demographic characteristics of the sample
3.2.1. The whole sample
Of the 61 participants overall, 62% (38) were female and 38% (23) were male. Ages 
ranged from 26 to 79, with a mean age of 49+13. 88% (51) described themselves as 
White, 3% (2) as Black, 3% (2) as Asian, and 10% (6) said ‘other’, ‘do not wish to 
answer’, or did not complete the question. 43% (26) owned their own homes; 26% 
(16) rented from the local authority; and 16% (10) rented from a private landlord. 
Data was missing or classified as ‘other’ for the remaining 15% (9) of the sample. 
There was a similar spread on other measures of socioeconomic status (SES): 33% 
(20) did not own a car; only 13% (19) were in full-time employment; and 61% (36) 
were educated to below degree level. These demographic characteristics are shown in 
full in Table 8.10."
10 Note that participants were randomized on a 1:2 basis; this was done in order to produce three 
roughly equal groups once the genetic testing group had been subdivided into those who received a 
GSTM1-missing result and those who received a GSTM1-present result.
11 Additional characteristics of the sample included: 31 participants had at least one family member 
who had lung cancer or another smoking-related disease, such as emphysema; and six reported that 
they themselves had a smoking-related disease.
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3.2.2. Between-groups comparisons
The three groups (controls, GSTM1-missing, GSTM1-present) were similar in terms 
of ethnicity, housing tenure, car ownership, employment status, and educational 
qualifications (see Table 8.11). However, there were fewer women in the GSTM1- 
present group (44%, 10/43) relative to the GSTM1-missing group (70%, 14/20) and 
the control group (78%, 14/18: x,2[2]=5.81, p=.055). There was also a significant age 
difference between the groups; the mean age of the GSTM1-missing group 
participants was 43+12yrs, whereas in the GSTM1-present group it was 53+14yrs, 
and in the control group it was 50+1 lyrs (F(2,52)=3.57, p=.035). This meant that 
gender and age would need to be included as covariates when analysing group 
differences on the primary dependent variables.
3.3. Dependent variables at baseline
The primary dependent variables were: depression, anxiety, worry about lung cancer, 
intention to quit smoking, motivation to quit smoking, number of cigarettes smoked 
per day, and perceived risk. Baseline frequencies and means are described below.
3.3.1. Descriptives
HADS depression scores ranged from 0 to 13 and had a mean of 4.7+3.3. The range 
for the HADS anxiety scores were 0 to 18, with a mean of 7.9+3.9. These mean 
scores indicated that the sample fell within the ‘normal’ range for depression (which 
is indicated by scores between 0 and 7), and was at the lower end of the ‘mild 
severity’ range for anxiety (which ranges from 8 to 10).
Participants appeared to be quite worried about lung cancer overall at baseline: 52% 
(29/56) agreed or strongly agreed that they got upset when they thought about lung 
cancer; 39% (22/57) strongly/agreed that they got depressed when they thought about 
lung cancer; 39% (11/57) said that lung cancer made them feel angry; 57% (32/57) 
said that lung cancer made them feel anxious; and 58% (33/57) said that lung cancer 
made them feel afraid. On the other hand, only 2% (1/57) said that they worried 
about lung cancer ‘all the time’; 19% (11/57) said ‘quite often’, 21% (12/57) said
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‘some of the time’, 44% (22/57) said ‘not very often’, and 14% (8/57) said ‘never’. 
The mean 5-item worry about lung cancer scale score, which ranged from 1 to 5, at 
baseline was 3.2+0.9.
The majority (89%) of participants reported that they were intending to quit smoking 
in the next six months: 57% (33/58) were ‘definitely’ and 33% (19/58) were 
‘probably’ going to quit. Only 11% (6) said ‘possibly’, ‘no probably not’, or ‘no 
definitely not’. The mean intention to quit smoking score was 4.4+0.7 (range=2-5).
Most participants (88%) also reported high levels of motivation to quit smoking at 
baseline: the majority said that they ‘quite strongly’ (53%, 31/58) or ‘very strongly’ 
(35%, 20/58) wanted to give up smoking all together. O f the remainder, 7% (4/58) 
‘moderately’ wanted to give up, 5% (3/58) ‘slightly’ wanted to give up, and nobody 
responded with ‘not at all’. Scores ranged from 2 to 5 with a mean of 4.2+0.8.
The mean number of cigarettes smoked per day at baseline was 20+8 (range=2-40). 
This indicates quite a high baseline level of nicotine addiction. In addition, 31% 
(18/58) had their first cigarette of the day less than five minutes after waking up, 
while another 33% (19/58) had their first cigarette between 5 and 15 minutes after 
waking. The majority said that they would find it fairly difficult (50%, 29/58) or 
‘very difficult’ (31%, 18/58) to go without smoking for a whole day.
The mean 6-item perceived risk scale score was 3.65+0.55 (with a range from 2.7 to 
5). On individual items, 54% of the sample believed that their risk of developing lung 
cancer at some point in their life was ‘about the same’ as other smokers, and more 
thought that they were at higher risk than other smokers (27%) than thought they were 
at lower risk than other smokers (20%). This provides very slight evidence of 
optimistic bias. The majority recognized they were at higher risk of lung cancer than 
nonsmokers (79%), although it could be argued that it’s surprising that this figure is 
not 100%. On the other measures of perceived risk, 42% strongly/agreed that it was 
likely that they would get lung cancer; 79% strongly/agreed that they were at risk for 
getting lung cancer; 93% strongly/agreed that it was possible that they would get lung 
cancer; 64% strongly/agreed that it was likely they would get lung cancer if they 
continued to smoke; and 18% strongly/agreed that it was likely they would get lung
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cancer if they quit smoking. Also, 15 (26%) participants expected their test result to 
indicate that their risk of developing lung cancer was average; 6 (10%) expected it to 
be lower than average; 12 (21%) expected it to be higher than average. 25 (43%) said 
that they didn’t know.
3.3.2. Distributions
Histograms of the raw data (shown in Figure 8.2) showed that the scores for six of the 
primary dependent variables were normally distributed (depression, anxiety, worry 
about lung cancer, motivation to quit, number of cigarettes smoked, and perceived 
risk of lung cancer). There was a clear skew for one of the variables, intention to quit, 
where the majority of participants reported that they were intending to quit smoking in 
the next six months; this indicates that we should be wary of the results of 
comparisons of means for this dependent variable.
3.4. Dependent variable means at each time point
3.4.1. Whole sample
The overall means at each time point for depression were indicative of a downwards 
trend; in the sample as a whole, raw data values for depression dropped from 4.7+3.3 
at baseline, to 4.6+3.5 at one week follow-up, and 3.5+3.5 at two month follow-up. 
There was a similar downwards trend for anxiety, dropping from 7.9+3.9 at baseline, 
to 7.3+4.1 at one week follow-up and 6.5+4.5 at two month follow-up. Worry about 
lung cancer also appeared to decrease slightly over time (see Table 8.12).
Intention to quit smoking increased in the sample as a whole from baseline (4.5+0.7) 
to one week follow-up (4.8+1.1), and stayed higher at two month follow-up (4.6+1.2). 
Because of the skew in the data, intention to quit was also examined having classified 
participants according to the dichotomous categories, ‘definitely intending to quit / 
already quit’ versus ‘other’. Using this classification, 53% (9/17) controls said ‘yes 
definitely’ at baseline; 67% (8/12) said ‘yes definitely’ or had quit at one week 
follow-up; and 54% (7/13) said ‘yes definitely’ or had quit at two month follow-up. 
67% (12/18) GSTM1-missings said ‘yes definitely’ at baseline; 87% (13/15) said ‘yes 
definitely’ or had quit at one week follow-up; and 75% (12/16) said ‘yes definitely’ or
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had quit at two month follow-up. 52% (12/23) GSTM1-presents said ‘yes definitely’ 
at baseline; 67% (10/15) said ‘yes definitely’ or had quit at one week follow-up; and 
61% (11/18) said ‘yes definitely’ or had quit at two month follow-up. Chi-square 
analyses did not detect differences between the three groups at any of the three time 
points. A similar pattern was found when the smokers were divided into three 
categories: 1) those who were not strongly intending to quit within the next six 
months (i.e. responded ‘no definitely not’, ‘no probably not’, ‘possibly’, or ‘yes 
probably’); 2) those were said that ‘yes, definitely’ they were intending to quit within 
the next six months; or 3) those who had already quit smoking. Using this 
categorization, the difference between groups was not significant at baseline, nor at 
two month follow-up, but was significant at one week follow-up (x [2]=6.48, p=.039). 
This analysis violates the rules of chi-square analyses, in that three of the six cells of 
analysis have less than five cases in them. The remainder of the analyses were 
conducted using mean values in the same way as the other variables (also, when the 
multivariate models were fitted later the standardized residuals did not exceed 3.29: 
see Section 3.5.4.ii).
There was a similar increasing trend for motivation to quit smoking. In addition, 
there appeared to be a dramatic drop in the trend displayed for the number of 
cigarettes that participants self-reported they were smoking per day; the mean number 
of cigarettes smoked per day at baseline was 20+8, this dropped to 13+11 cigarettes 
per day at one week follow-up, and 11+13 at two month follow-up.
There was little change overall on perceived risk of lung cancer, which rose slightly 
from 3.7+0.6 at baseline to 3.8+0.6 at one week follow-up, and then decreased to 
3.6+0.6 at two month follow-up.
3.4.2. Group means
The dependent variable means for each of the three groups at each of the three time 
points, are reported in Table 8.13. In addition, the group means for the two genetic 
testing groups are shown combined in Table 8.14, alongside the control group means 
by way of comparison. To make it easier to look at the trends in the data, the means 
were also plotted on line graphs, which are shown in Figures 8.3 to 8.9.
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Table 8.10. Demographic characteristics of sample
(n=61) N %
Gender Female 38 62%
Male 23 38%
Age range 26 -  79yrs: mean 49yrs (sd 13yrs)
Ethnicity White British 51 88%
Black British 2 3%
Asian British 2 3%
(Other / missing) 6 10%
Housing tenure Own home 26 43%
Rent from local authority 16 26%
Rent from private landlord 10 16%
(Other / missing) 9 15%
Car ownership None 20 33%
One 27 44%
More than one 8 13%
(Missing) 6 10%
Employment status Employed full-time 19 31%
Employed part-time 14 23%
Unemployed 8 14%
Fulltime homemaker 4 7%
Retired 9 15%
Student 1 2%
Too ill to work 3 5%
(Missing) 3 5%
Educational qualifications No formal qualifications 11 19%
GCSEs or equivalent 13 21%
A-levels or equivalent 10 16%
Degree (Bachelors or higher) 24 39%
(Missing) 3 5%
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Table 8.11. Distribution of demographic characteristics by group
(n=61) GSTM1-
missing
GSTM1-
present
Controls Sig.
Total n 20 23 18
Gender Female 70% (14) 44% (10) 78% (14) X2[2]=5.81,
Male 30% (6) 57% (13) 22% (4) p=.055
Age Mean years (sd) 42.7(11.8) 53.4(14.1) 49.6(10.5) F[2,52]=3.57,
p=.035
Ethnicity White British 89% (16) 83% (19) 94% (16) X2[6]—4.12,
Black British 0% (0) 9% (2) 0% (0) p=.661
Asian British 6% (1) 4% (1) 0% (0)
Other 6% (1) 4% (1) 6% (1)
Housing tenure Own home 44% (8) 48% (11) 41% (7) X2[6]-2.48,
Rent from local authority 28% (5) 30% (7) 24% (4) p=.870
Rent from private landlord 22% (4) 9% (2) 24% (4)
Other 6% (1) 13% (3) 12% (2)
Car ownership None 39% (7) 32% (7) 40% (6) X2[4]=2.13,
One 50% (9) 46% (10) 53% (8) p=.712
More than one 11% (2) 23% (5) 7% (1)
Employment status Employed full-time 11% (2) 48% (11) 35% (6) X2[12]=17.97,
Employed part-time 33% (6) 9% (2) 35% (6) p=.l 16
Unemployed 22% (4) 17% (4) 0% (0)
Fulltime homemaker 11% (2) 4% (1) 6% (1)
Retired 11% (2) 22% (5) 12% (2)
Student 6% (1) 0% (0) 0% (0)
Too ill to work 6% (1) 0% (0) 12% (2)
Educational No formal qualifications 11% (2) 17% (4) 29% (5) X2[6]=5.07,
Qualifications GCSEs or equivalent 22% (4) 17% (4) 29% (5) p=.535
A-levels or equivalent 28% (5) 17% (4) 6% (1)
Degree 39% (7) 48% (11) 35% (6)
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Table 8.12. Descriptives of dependent variables: whole sample means at each 
time point________________________________________________________
Outcome variable Timepoint
Baseline
One week 
follow-up
Two month 
follow-up
Depression 4.67 (3.34) 4.58 (3.45) 3.52 (3.47)
Anxiety 7.90 (3.91) 7.34 (4.07) 6.51 (4.45)
Worry 3.19(0.90) 2.84 (0.93) 2.87 (0.93)
Intention to quit 4.45 (0.73) 4.76(1.06) 4.72(1.21)
Motivation to quit 4.17(0.78) 4.48(1.40) 4.46(1.57)
Cigarettes per day 19.55 (8.06) 12.51 (10.59) 10.75 (12.61)
Perceived risk 3.65 (0.55) 3.83 (0.59) 3.63 (0.62)
Means are displayed without replacing missing values. n=61
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Table 8.13. Descriptives of dependent variables: group means at each time point
Timepoint
Outcome Group 
variable
Baseline One week 
follow-up
Two month 
follow-up
Depression
Controls 
GSTM1-present 
GSTM1-missing
3.53 (2.83) 
5.17(3.07) 
5.11 (3.98)
5.83 (3.33) 
4.31 (2.80) 
3.94 (4.01)
3.47 (3.89) 
3.35 (2.50) 
3.76 (4.21)
Anxiety
Controls 
GSTM1 -present 
GSTM1-missing
6.82 (3.84) 
8.57 (4.62) 
8.06 (2.82)
8.85 (4.86)
6.85 (3.74) 
6.73 (3.72)
5.91 (4.10) 
5.89 (4.77) 
7.75 (4.36)
Worry
Controls 
GSTM1 -present 
GSTM1-missing
2.99 (0.94) 
3.30 (0.88) 
3.26 (0.90)
2.51 (0.86) 
2.99 (0.89) 
2.92(1.00)
2.53 (1.02) 
2.77 (0.71) 
3.29 (0.96)
Intention to quit
Controls 
GSTM1-present 
GSTM1-missing
4.35 (0.79)
4.35 (0.83) 
4.67 (0.49)
4.33 (1.07) 
4.60(1.18) 
5.27 (0.70)
4.54(1.45) 
4.56(1.25) 
5.06 (0.93)
Motivation to 
quit
Controls 
GSTM1 -present 
GSTM1-missing
4.18(0.81) 
4.04 (0.88) 
4.33 (0.59)
3.67 (1.37) 
4.40(1.60) 
5.20 (0.78)
4.75 (1.61) 
4.35 (1.41)
4.75 (1.61)
Cigarettes per 
day
Controls 
GSTM 1 -present 
GSTM 1-missing
18.35 (8.82) 
21.30 (7.71) 
18.63 (7.75)
20.08 (9.91) 
11.00 (9.61) 
8.59 (9.62)
14.93 (18.33) 
9.29 (9.08) 
8.76 (9.49)
Perceived risk
Controls 
GSTM 1 -present 
GSTM 1-missing
3.43 (0.42) 
3.61 (0.61) 
3.90 (0.50)
3.72 (0.71) 
3.69 (0.55) 
4.04 (0.52)
3.44 (0.50) 
3.46 (0.66) 
4.00 (0.52)
n=61
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Table 8.14. Descriptives dependent variables: control group versus the genetic 
testing groups (GSTM1) combined
Timepoint
Outcome Group 
variable
Baseline One week 
follow-up
Two month 
follow-up
Depression
Controls
GSTM1
combined
3.53 (2.83) 
5.15(3.45)
5.83 (3.33) 
4.12(5.83)
3.47 (3.89) 
3.54 (3.35)
Anxiety
Controls
GSTM1
combined
6.82 (3.84) 
8.34 (3.90)
8.85 (4.86) 
6.79 (3.67)
5.91 (4.10) 
6.75 (4.62)
Worry
Controls
GSTM1
combined
2.99 (0.94) 
3.28 (0.88)
2.51 (0.86) 
2.95 (0.93)
2.53 (1.02) 
3.01 (0.87)
Intention to quit
Controls
GSTM1
combined
4.35 (0.79) 
4.49 (0.71)
4.33 (1.07) 
4.93 (1.02)
4.54(1.45)
4.79(1.12)
Motivation to 
quit
Controls
GSTM1
combined
4.18(0.81)
4.17(0.77)
3.67(1.37)
4.80(1.30)
4.75(1.61) 
4.55 (1.50)
Cigarettes per 
day
Controls
GSTM1
combined
18.35 (8.82) 
20.11 (7.74)
20.08 (9.91) 
9.76 (9.54)
14.93 (18.33) 
9.03 (9.15)
Perceived risk
Controls
GSTM1
combined
3.43 (0.42) 
3.74 (0.58)
3.72 (0.71) 
3.87(0.55)
3.44 (0.50) 
3.71 (0.65)
The mean values displayed are the raw data without replacing missing values; the analyses o f variance 
were conducted having replaced missing values with the series mean.
n ^ l
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Figure 8.2. Histograms showing distribution of primary dependent variables at baseline
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Figure 8.2. continued
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3.5. Exploration of trends and analyses of variance
3.5.1. Depression
3.5.1.1. Visual examination of trends in means and error bars
The mean values for depression (listed in Tables 8.13 and 8.14, and plotted in Figure 
8.3) suggest that depression decreases over time in both the genetic testing groups 
(GSTM 1-missing and GSTM 1-present), and that there is little difference between the 
two.12 The pattern looks to be somewhat different for the control group, where 
depression appears to increase from baseline to one week follow-up, then decrease 
back down again to baseline level at two month follow-up. The plotted means, 
however, suggest that there could be a difference between groups at baseline, which 
could mean that randomisation was not successful. This possibility was explored 
using ANOVAs (see below).
3.5.1.ii. One-way ANOVAs and ANCOVAs
A one-way ANOVA, with baseline depression as the dependent variable, and 3-level 
group (control, GSTM 1-missing, GSTM 1-present) as the independent variable, found 
no significant difference between groups at baseline, F(2,58)=1.43, p=.248. There 
were also no differences at baseline when gender and age were included as covariates, 
F(4,50)=1.64, p=.205. Combining the two genetic testing groups into one, and re­
running the analysis with the combined 2-level independent variable, also did not 
detect a significant difference, F(3,51)=2.96, p=.091. There was no difference 
between the GSTMl-missing and GSTMl-present groups at baseline, F(3,35)=0.42, 
p=.524. All of these results suggest that randomisation was successful, but it should 
be noted that the small sample size may mean that an actual group difference was not 
detected.13
12 See Appendix K for error bar graphs.
13 None of the standardized residuals for any of the models had an absolute value greater than 3.29; this 
indicates that the models were a reasonably good representation of the data (Field, 2005). Also, unless 
otherwise stated, all statistical results are reported having adjusted for age and gender; see Table 8.15 
for full reporting of results both with and without age and gender as covariates. Finally, all analyses of 
variance were conducted having replaced missing values with the series mean.
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3.5.1.iii. Repeated measures ANOVAs and ANCOVAs including baseline 
depression as a covariate
Depression was included as a primary dependent variable because one of the main 
concerns about genetic testing for common gene variants, such as GSTM1, is that 
people who receive genetic test results which indicate an increased susceptibility, i.e. 
a GSTM 1-missing result, may become depressed in response to their increased risk 
status. In order to explore this possibility, two repeated measures ANOVAs were 
conducted (see Table 8.15 for full reporting of these results). In the first, the acute 
impact of the test result was explored by comparing depression in the GSTM1- 
missing group with the GSTM 1-present group, one week after they received their 
genetic test results (one week follow-up/Phase 3). There was no evidence of any 
difference between the two groups, F(4,34)=0.00, p=.976, indicating that receiving an 
increased risk genetic test result did not increase depression in the short term in 
comparison to receiving a decreased risk genetic test result. The second repeated 
measures analysis also similarly found no short term impact (2 month follow- 
up/Phase 4), F(4,34)=0.01, p=.917.
Although depression did not differ according to test result, there was a significant 
time x group interaction effect between the control group and the GSTM1 testing 
groups combined at one week follow-up, F(l,51)=7.36, p=.009. This indicates that 
participants had different levels of depression at one week follow-up depending not 
on whether they had received a higher or lower risk result, but on whether they had 
taken the genetic test or not. The analyses were re-run, but this time as an ANCOVA 
with Phase 3 depression as the dependent variable, group (control vs. GSTM1 
combined) as the independent variable, and age, gender, and Phase 1 baseline as 
covariates, as advised by Vickers and Altman (2001). The interaction effect was 
reduced but remained significant, F(4,50)=4.09, p=.049. This indicates that we can be 
relatively confident that depression was higher in controls at one week follow-up than 
in the genetic testing groups combined. The effect was not maintained at two month 
follow-up (see Table 8.15).
3.5.1.iv. Depression: conclusion
In conclusion, there was no evidence to support the hypothesis that receiving a genetic 
test result for a common gene variant increases depression. Instead, the findings
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suggest that increased depression in the short term may be a consequence of not 
having taken the genetic test amongst control participants.
3.5.2. Anxiety
3.5.2.i. Visual examination of trends in means and error bars
The trends in anxiety between baseline and one week follow-up appear to reflect a 
similar pattern to depression (see Figure 8.4). However, although the GSTM1-present 
and control groups both drop down at two month follow-up, anxiety in the GSTM1- 
missing group rises back to baseline level. This differs from depression, where all 
groups drop further at two month follow-up.
3.5.2.ii. One-way ANOVAs and ANCOVAs
As with depression, there appears to be a difference at baseline between the control 
group and genetic testing groups, but here again ANCOVA does not indicate a 
significant baseline difference, either between the control group and genetic testing 
group, F(3,51)=1.85, p=.180, or between the GSTMl-missing group and GSTM1- 
present group, F’(3,35)=1.47, p=.233 (see Table 8.16 for full results).
3.5.2.iii. Repeated measures ANOVAs and ANCOVAs including baseline anxiety 
as covariate
Repeated measures ANOVA found no difference between the GSTMl-missing group 
and the GSTMl-present group at one week follow-up, F’(l,35)=0.58, p=454, or at 
two month follow-up, F(l,35)=2.76, p=.105. There was also no difference detected 
when the analyses were re-run as ANCOVAs with baseline anxiety as a covariate.
There was, however, a difference between the control group and the combined 
GSTM1 testing group at one week follow-up using the repeated measures approach, 
F(l,51)=6.57, p=.013, and using the ANCOVA approach recommended by Vickers 
and Altman (2001), F(4,50)=4.48, p=.039. There was no difference at two month 
follow-up (see Table 8.16).
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3.5.2.iv. Anxiety: conclusion
The findings further support the observations made above for depression; receiving an 
increased risk genetic test result appears to have little impact on anxiety relative to 
receiving a decreased risk result, but participants in the trial allocated to the control 
group show higher levels of anxiety at one week follow-up than those randomly 
allocated to the genetic testing group.
3.5.3. Worry about lung cancer
3.5.3.i. Visual examination of trends in means and error bars
Worry about lung cancer appears to drop in all three groups from baseline to one 
week follow-up (see Figure 8.5). The GSTMl-missing group diverges from the other 
two groups at two month follow-up, in that worry appears to increase back up to 
baseline level, whereas it decreases further in the GSTM 1-present group, and stays at 
the same level in the control group.
3.5.3.ii. One-way ANOVAs and ANCOVAs
There were no differences detected between groups at baseline or follow-up using 
ANOVA or ANCOVA adjusting for age and gender (see Table 8.17).
3.5.3.iii. Repeated measures ANOVAs and ANCOVAs including baseline worry 
about lung cancer
None of the analyses conducted detected any differences between groups at any time 
points.
3.5.3.iv. Worry about lung cancer: conclusion
The findings provide no conclusive evidence regarding the effect of genetic testing on 
worry about lung cancer: although no significant differences were found between 
groups, we cannot reject the possibility that there were differences which were simply 
not detected due to the small sample size. This is a reflection of an overall limitation 
of the study.
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3.5.4. Intention to quit smoking
3.5.4.i. Visual examination of trends in means and error bars
The pattern of plotted means suggests that intention to quit increases over time in all 
groups, but does not appear to vary much between groups. The error bar graphs 
possibly suggest that intention to quit could be higher in the GSTM1-missing group, 
particularly at one week follow-up. This data is likely to be affected by a ceiling 
effect, since intention to quit was uniformly high across groups at baseline. See 
Figure 8.6.
3.5.4.ii. One-way ANOVAs and ANCOVAs
In order to test the goodness of fit of the ANOVA models to the data, the standardized 
residuals were saved and examined for all of the seven primary dependent variables, 
but this was particularly important to check for ‘intention to quit’ because of the non­
normal distribution of the raw data for this variable. A residual is the difference 
between the value a model predicts and the value observed in the data on which the 
model is based (Field, 2005). When the residual is calculated for each observation in 
a data set the resulting collection is referred to as the residuals. Standardized residuals 
are the residuals of a model expressed in standard deviation units. Standardized 
residuals with an absolute value greater than 3.29 are cause for concern because in an 
average sample a value this high is unlikely to happen by chance (Field, 2005). All of 
the standardized residuals for intention to quit had values less than 3.29, and were 
reasonably normally distributed, and so it was decided that it would be appropriate to 
conduct analyses of variance on this variable, but with the awareness that the findings 
should be interpreted with caution due to the possible ceiling effects. See Appendix K 
for example histograms of the distribution of standardized residuals for ‘intention to 
quit’ as well as for the other six dependent variables.14
The results did not provide evidence of a difference between the three groups at 
baseline, F(4,50)=0.22, p=.802. The three-level ANCOVA at one week follow-up
14 The histograms displayed are for the standardized residuals of the models fitted to the seven 
dependent variables , with 3-level group as the independent variables, 3 levels of time (Phase 1-Phase 
3-Phase 4) and with covariates age and gender. As mentioned above, standardized residuals were 
checked and indicated acceptable goodness of fit for all models.
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was not statistically significant, although it was possibly indicative of a trend, 
F(4,50)=2.83, p= 068.
3.5.4.iii. Repeated measures ANOVAs and ANCOVAs including baseline 
intention to quit as covariate
None of the repeated measures ANOVAs or ANCOVAs detected significant 
differences between groups at any time point (see Table 8.18).
3.5.4.iv. Intention to quit smoking: conclusion
This variable was included as a primary dependent variable with the intention of 
acting as a proxy for actual smoking cessation in light of the small sample size, and it 
was hypothesised that intention to quit smoking would be higher in participants who 
received GSTM1-missing results. However, no evidence was provided to support this 
hypothesis that receiving a genetic test result indicating an increased risk of a 
smoking-related disease increases intention to quit smoking. Similarly, no evidence 
was provided to suggest that receiving a lower risk result decreased intention to quit 
smoking. Strictly speaking, there was also no evidence to suggest that engaging in the 
genetic testing process led to increased intention to quit compared to being randomly 
allocated to the control group.
3.5.5. Motivation to quit smoking
3.5.5.i. Visual examination of trends in means and error bars
The plotted means for motivation to quit show an interesting pattern; motivation 
appears to be equal between groups at baseline, and at two month follow-up, but there 
seems to be a noticeable difference between groups at one week follow-up. 
Motivation appears to stay low in the controls, increase slightly in the GSTM1-present 
group, and increase more strikingly in the GSTMl-missing group. See Figure 8.7.
3.5.5.ii. One-way ANOVAs and ANCOVAs
The ANCOVAs supported the assertion that there were no differences between the 
three groups at baseline, F(2,50)=0.57, p=.571, but also did not detect any differences 
between groups at follow-up when baseline level motivation was not taken into 
account (see Table 8.18).
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3.5.5.iii. Repeated measures ANOVAs and ANCOVAs with baseline motivation 
as covariate
When baseline motivation was taken into account, the repeated measures ANOVA on 
all three groups did not reach significance, but was indicative of a time x group trend, 
F(2,49)=2.86, p=.067. Further exploration revealed that there was a time x group 
interactive effect for the control group versus the combined GSTM1 testing group, 
F(l,51)=5.65, p=.021, but not for the GSTMl-missing group versus the GSTM1- 
present group, 77(1,34)=0.06, p=.807. These findings were confirmed by the 
ANCOVA with baseline motivation as a covariate, for control versus combined 
groups, F(l,50)=5.11, p=028, and for GSTMl-missing versus GSTMl-present 
groups, 7r(l,35)=0.49, p=.490.
3.5.5.iv. Motivation to quit smoking: conclusion
In conclusion, these findings do not support the hypothesis that receiving a higher-risk 
genetic test result increases motivation to quit smoking, nor do they support the 
hypothesis that receiving a lower-risk result decreases motivation to quit smoking. 
Rather, they support the hypothesis that engaging in the genetic testing process itself 
could have a positive, motivational, effect, in the short term at least. The findings 
were not maintained at two month follow-up.
3.5.6. Number of cigarettes per day
3.5.6.i. Visual examination of trends in means and error bars
The pattern shown for the trends in the number of cigarettes smoked per day in each 
group is probably the most interesting of the dependent variables. The plotted means 
(Figure 8.8) suggest that at baseline, all three groups are smoking similar amounts, 
around 20 cigarettes per day. At one week follow-up, having received their genetic 
test results, both genetic testing groups show a striking drop in the amount smoked, 
down to around 10 per day, and this lower level of smoking appears to be maintained 
at two month follow-up. Whereas the patterns for the genetic testing groups are very 
similar to one another, the control group appears to be doing something slightly 
different; there is little change at one week follow-up -  if  anything, the amount they
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are smoking appears to increase -  and then there is a drop at two month follow-up, 
although not to the same level as the genetic testing groups.
3.5.6.ii. One-way ANOVAs and ANCOVAs
The ANCOVAs conducted at baseline support the assertion that there are no baseline 
differences between the three groups, F(2,50)=0.07, p=930. The ANCOVA 
conducted on all three groups on the follow-up data, without controlling for baseline 
amount, suggests a difference at one week follow-up, i 7(2,50)=3.72, p=.031, but not at 
two month follow-up.
3.5.6.iii. Repeated measures ANOVAs and ANCOVAs with baseline amount 
smoked as covariate
Interestingly, the two methods of looking at the changes over time from baseline to 
one week follow-up produce different results. The repeated measures ANOVA does 
not detect a difference between the three groups, 77(2,50)=0.97, p=.388, whereas the 
ANCOVA with baseline amount as a covariate, does detect a difference, 
F(2,49)=5.28, p=.008.
Comparisons of the GSTMl-missing group with the GSTM 1-present group did not 
provide evidence to suggest that the difference at one week follow-up was due to a 
difference between these two groups, F(l,34)=0.45, p=.509. Instead, as the plotted 
means suggest, comparisons of the control group with the combined GSTM1 testing 
group indicate that this is where the difference lies, F(l,50)=10.15, p=.002. This time 
x group interaction was detected using both the ANCOVA approach (Vickers & 
Altman, 2001), and the traditional repeated measures approach, F(l,51)=8.91, p=.004. 
See Table 8.19 for summary of these results.
3.5.6.iv. Number of cigarettes per day: conclusion
These findings interestingly suggest that participants who receive genetic test results 
reduce the amount they smoke one week following receiving their results, and that the 
result itself, i.e. whether it indicates an increased or decreased susceptibility to lung 
cancer, does not impact on the outcome. The difference was not maintained at two 
month follow-up.
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3.5.7. Perceived risk of lung cancer
3.5.7.i. Visual examination of trends in means and error bars
The plots of the mean perceived risk values for each group don’t suggest any strong 
changes over time, although the trend for the GSTMl-missing group does appear to 
increase slightly, whereas that for the GSTM 1-present group decreases slightly (see 
Figure 8.9). Perceived risk amongst the control group appears to increase slightly 
from baseline to one week follow-up and then drop back down to baseline levels at 
two month follow-up. The error bar chart at Phase 4 (two month follow-up) is 
interesting, because it suggests that perceived risk is markedly higher in the GSTMl- 
missing group than the GSTM 1-present group and the control group.
3.5.7.11. One-way ANOVAs and ANCOVAs
An unadjusted ANOVA at baseline suggested that there was a difference on perceived 
risk between the three groups, F(2,58)=3.24, p=.047, which was just about retained 
when age and gender were controlled for, F(2,50)=3.14, p=.052. This was interesting, 
because none of the other dependent variables varied between groups at baseline, and 
I was taken with the possibility that people may in some way be aware of their genetic 
risk status. However, further exploration using ANCOVA indicated that the group 
difference was between the control group and combined GSTM1 testing group, 
F(l,51)=5.13, p=.028, rather than between the GSTMl-missing and GSTM 1-present 
groups, F(l,35)=1.15, p=.292, which suggests that it was just a chance difference. 
See Table 8.20 for a summary of group comparisons.
3.5.7.iii. Repeated measures ANOVAs and ANCOVA with baseline perceived 
risk as covariate
None of the repeated measures or ANCOVA analyses detected any differences 
between groups at follow-up, although there was some indication of a trend in the 
ANCOVA which examined the difference between the GSTMl-missing group and 
the GSTMl-present group at Phase 4 (two month follow-up), F(l,34)=3.88, p=.057.
3.5.7.iv. Perceived risk: conclusion
In conclusion, there was no strong evidence to suggest that perceived risk differed 
between the groups over time. There was possibly a difference between the two
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genetic testing groups at two month follow-up, with the GSTMl-missing group 
perceiving higher risk of lung cancer than the GSTM 1-present group, but there was no 
evidence to suggest a one week difference between groups.
3.5.8. Main effect of time
A repeated measures analysis of variance including all three groups at all three time 
points found a main linear effect of time on depression, F(l,50)=8.33, p=.005, but the 
effect was reduced and non-significant when age and gender were included as 
covariates, F(l,50)=3.18, p=.081. This, combined with visual examination of the 
plotted means, suggested that depression decreased over time in all groups. A 
similar analysis, but with anxiety as the dependent variable, also found a main linear 
effect of time on anxiety, F(l,58)=9.34, p=.003, but the result was not significant 
when controlling for gender and age, F(l,50)=0.47, p=.497. Similarly, there was a 
main effect of time on worry about lung cancer when gender and age were not 
controlled for, F(l,58)=10.11, p=.002, but not when they were controlled for, 
F(l,50)=0.01,p=.939.
There was a main effect of time on intention to quit smoking when the repeated 
measures ANOVA was run unadjusted, F(l,58)=18.49, p<.001, but not when run 
adjusted for age and gender, F(l,50)=0.99, p=.324. There was no main effect of time 
on motivation, either unadjusted, F(l,58)=2.62, p= 111, or adjusted, F(l,50)=0.15, 
p=.701. There was a main effect of time on cigarettes per day when unadjusted, 
F(l,58)=39.16, p<.001, but not when adjusted, F(l,50)=2.22, p=.142.
There was no main effect of time on perceived risk of lung cancer, either unadjusted, 
F(l,58)=0.05, p=.818, or adjusted, F(2,50)=1.41, p=.241.
3.6. Responses to open-ended questions
3.6.1. Psychological impact on GSTMl-present group
In response to the question, “In your own words, how do you feel about your genetic 
test result?”, the majority of participants in the GSTMl-present group used language 
like “pleased”, “happy”, “it made me feel quite good” (see Table 8.22). A few
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GSTMl-present participants indicated that it had not affected them, saying things like, 
“neither one way or the other, 3% doesn’t make much difference ”.
3.6.2. Psychological impact on GSTMl-missing group
Many participants in the GSTMl-missing group also indicated that they were not 
affected by their result, saying things like, “It hasn’t made much difference to me, not 
important to m e”, “Nothing very deeply, I  suppose a bit surprised”, and “Fine, didn’t 
think about it ”. There were also a number of interesting responses which indicated 
that the GSTMl-missing result had had a significant impact on them, for example:
“Think i t ’s a brilliant idea, made me fee l stronger and more confident, 
another tool fo r  me to use. ”
“Not joyous. I t ’s not good news. I ’m glad I  did it. It adds weight to 
determination. More reflective. ”
“I  feel ok about that. I  feel alright. As I  say, I  don’t think I  would have taken 
the test iflh a d n  ’t thought it was going to help... ”
“A little disappointed that I  wasn’t in the other 50%. But as a smoker, good 
motivational tool. Probably done me good. ”
“Bit o f a nonevent. Difference between 9 and 12, marginal. l% o is what to 
aim for. Novelty factor. ”
3.6.3. Impact on motivation to quit smoking in GSTMl-present group
In response to the question, “How, if at all, has your test result influenced your 
motivation to quit smoking, participants in the GSTMl-present group generally 
reported that the genetic test result had had little impact on their motivation to quit 
smoking, e.g. “I  think my motivation’s stayed the sam e”, “I t ’s probably had no 
impact actually ”, and “It hasn’t really one way or the other, although I  still want to 
give up smoking” (see Table 8.23). A few indicated that, if  anything, their experience 
had increased their motivation to quit:
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“More or less made my mind up to give up but pushed forward. Phoned as 
soon as got back last time and made appointment with clinic. ”
“It certainly has, it's encouraged me to give up. You have a level o f  
protection so no harm yet. ”
3.6.4. Impact on motivation to quit smoking in GSTMl-missing group
Some participants in the GSTMl-missing group reported that their test result had had 
little impact on their motivation to quit, saying things like, “D on’t think i t ’s affected 
me at a ll”. However, many responded that it had had an impact, e.g. “It has made me 
more determined to stop smoking”, and “The whole thing has made me very, very 
determined to quit”, and:
“I t ’s made me think I  don’t want to smoke, it definitely has. I t ’s made me 
think about my father's cholesterol, which I  have a 50% chance o f  inheriting. 
It's made me think much more about the long term future. ”
“I  think fo r  months I ’ve tormented myself about smoking, the groups are 
helping. I  think the result has helped me a lot to think more about it but it's 
not the sole motivation. ”
A number of participants indicated that the process, rather than the result, had 
increased their motivation to quit smoking:
“Don't think so. Process o f coming in has brought it to the forefront o f  mind, 
but nothing to do with results. ”
3.6.5. Understanding of “not having the gene”
Participants generally appeared to have a reasonable understanding of what the 
genetic test results meant. For example, in response to the question, “From what you 
remember of what was explained to you, what did not having the gene mean?”, 
responses included:
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“Body wasn’t producing enzyme that clears toxins from lungs. 9% had, 12% 
didn’t. ”
“I f  you didn’t have the gene you had a 3%o higher chance o f  developing lung 
cancer. ”
See Table 8.24 for all responses to this question.
3.6.6. Understanding of “having the gene”
Similarly, there appeared to be a reasonable level of understanding regarding what 
“not having the gene meant” (see Table 8.25). For example, in response to the 
question, “From what you remember of what was explained to you what did having 
the gene mean?”, participants responses included:
It meant that o f  all the different agents cleaning out my lungs I  have this one. 
I t ’s 9%) versus 13%. ”
“It meant that there was a difference o f  3% in the population. Toxins are 
being cleared out, but doesn ’t mean I  am immune. ”
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Figure 8.3. Depression: line plots of mean values at each time point
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Figure 8.4. Anxiety: line plots of mean values at each time point
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Figure 8.5. Worry about lung cancer: line plots of mean values at each time point
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Figure 8.6. Intention to quit smoking: line plots of mean values at each time point
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Figure 8.7. Motivation to quit smoking: line plots of mean values at each time point
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Figure 8.8. Cigarettes smoked per day: line plots of mean values at each time point
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Figure 8.9. Perceived risk of lung cancer: line plots of mean values at each time point
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Table 8.15. Depression: analyses of variance
Three groups Control group vs. combined GSTM1 group GSTMl-missing group vs. 
GSTMl-present group
Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4
One-way 
ANOVA 
unadjusted 
(or t-test)
F(2,58)=1.43,
p=.238
F(2,58)=l.l 1, 
p=.337
F{2,58)=0.07,
p=.936
F(l,59)=2.89,
p=.094
F(l,59)=2.09,
p=.154
F(l,59)=0.01,
p=.946
F(l,41)=0.01,
p=.919
ANCOVA 
adjusted 
for age and 
gender
F(4,50)=1.64,
p=.205
F(4,50)=0.53,
p=.592
F(4,50)=0.67,
p=.528
F(3,51)=2.96,
p=.091
F(3,51)=0.86,
p=.357
F(3,51)=0.96,
p=.331
F(3,35)=0.42,
p=.524
ANCOVA 
adj. for 
age, gender 
and 
baseline
F(5,49)=2.02,
p=.144
F(5,49)=0.08,
p=.924
F(4,50)=4.09,
p=.049
F(4,50)=0.11, 
p=.745
F(4,34)=0.00,
p=.976
F(4,34)=0.01,
p=.917
Phase 1 
repeated 
measures 
ANOVA 
adj. for age 
and gender
F(2,50)=3.64,
p=.034
F(2,50)=0.75,
p=.480
F(l,51)=7.36,
p=.009
F(l,51)=1.50,
p=.226
F(l,35)=0.12,
p=732
F(l,35)=0.20,
p=.657
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Table 8.16. Anxiety: analyses of variance
Three groups Control group vs. combined GSTM1 group GSTMl-missing group vs. GSTMl-present 
group
Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4
One-way 
ANOVA 
unadjusted 
(or t-test)
F(2,58)=1.01,
p=.372
F(2,58)=1.08,
p=.346
F(2,58)=1.00,
p=.376
F(l,59)=1.83,
p=. 181
F(l,59)=2.17,
p=.146
F(l,59)=0.37,
p=.546
F(l,41)=0.20,
p=.657
ANCOVA 
adjusted for 
age and 
gender
F(4,50)=1.96, 
p=. 151
F(4,50)=1.27,
p=.291
F(4,50)=0.54,
p=.589
F(3,51)=1.85,
p=. 180
F(3,51)=1.48,
p=.230
F(3,51)=T.09,
p=.302
F(3,35)=1.47,
p=.233
ANCOVA 
adj. for age, 
gender and 
baseline
F(5,49)=2.27, 
p=.l 14
F(5,49)=1.10,
p=.342
F(4,50)=4.48,
p=.039
F(4,50)=0.02,
p=.894
F(4,34)=0.01,
p=.929
F(4,34)=1.92,
p=.175
Phase 1 
repeated 
measures 
ANOVA 
adj. for age 
and gender
F(2,50)=3.35,
p=.043
F(2,50)=1.78, 
p=. 178
F(l,51)=6.57,
p=.013
F(l,51)=0.09,
p=.761
F(l,35)=0.58,
p=.453
F(l,35)=2.76,
p=.105
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Table 8.17. Worry about lung cancer: analyses of variance
Three groups Control group vs. combined GSTM1 group GSTMl-missing group vs. GSTMl-present 
group
Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4
One-way 
ANOVA 
unadjusted 
(or t-test)
F(2,58)=0.65,
p=.525
F(2,58)=0.86,
p=.427
F(2,58)=3.06,
p=054
F(l,59)=1.30,
p=.260
F(l,59)=1.73, 
p= 193
F(l,59)=2.89,
p=.094
F(l,41)=0.03,
p=.858
ANCOVA 
adjusted for 
age and 
gender
F(4,50)=0.23,
p=.796
F(4,50)=0.94,
p=.392
F(4,50)=1.24,
p-,298
F(3,51)=0.45,
p=.505
F(3,51)=0.54,
p=.465
F(3,51)=1.84,
p=.181
F(3,35)=0.09,
p=766
ANCOVA 
adj. for age, 
gender and 
baseline
F(5,49)=0.99,
p=.379
F(5,49)=1.29,
p=.283
F(4,50)=0.17,
p=.679
F(4,50)=1.38,
p=.246
F(4,34)=1.83,
p=.185
F(4,34)=1.59,
p=.217
Phase 1 
repeated 
measures 
ANOVA 
adj. for age 
and gender
F(2,50)=0.53,
p=.590
F(2,50)=0.73,
p=.489
F(l,51)=0.00, 
p=. 971
F(l,51)=0.44,
p=.512
F(1,35)=1.74, 
p=.196
F(l,35)=0.75,
p=.392
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Table 8.18. Intention to quit smoking: analyses of variance
Three groups Control group vs. combined GSTM1 group GSTMl-missing group vs. GSTMl-present 
group
Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4
One-way 
ANOVA 
unadjusted 
(or t-test)
F(2,58)=1.14,
p=.326
F(2,58)=3.25,
p=.046
F(2,58)=0.97,
p=.384
F(l,59)=0.41,
p=.527
F(l,59)=2.83,
p=.098
F(l,59)=0.40,
p=.529
F(l,41)=2.00,
p=.164
ANCOVA 
adjusted for 
age and 
gender
F(4,50)=0.22,
p=.802
F(4,50)=2.83,
p=.068
F(4,50)=0.49,
p=.615
F(l,51)=0.01,
p=.909
F(l,51)=2.32,
p=.134
F(l,51)=0.25,
p=.616
F(l,35)=0.29,
p=.596
ANCOVA 
adj. for age, 
gender and 
baseline
F(5,49)=2.85,
p=.0,67
F(5,49)=0.37,
p=.691
F(l,51)=2.79,
p=.101
F(l,51)=0.24,
p=.629
F(l,34)=2.76,
p=.106
F(l,34)=1.22,
p=.278
Phase 1 
repeated 
measures 
ANOVA adj. 
for age and 
gender
F(2,50)=2.12, 
p= 131
F(2,50)=0.15,
p=.863
F(l,51)=2.40,
p=.128
F(l,51)=0.16,
p=.693
F(l,35)=1.89,
p=.178
F(l,35)=1.51,
p=.228
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Table 8.19. Motivation to quit smoking: analyses of variance
Three groups Control group vs. combined GSTM1 group GSTMl-missing group vs. GSTMl-present 
group
Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4
One-way 
ANOVA 
unadjusted 
(or t-test)
F(2,58)=0.70,
p=.503
F(2,58)=4.69,
p=.013
F(2,58)=0.45,
p=.638
F(l,59)=0.00,
p=.980
F(l,59)=6.01,
p=.017
F(l,59)=0.36,
p=.550
F(l,41)=1.43,
p=.239
ANCOVA 
adjusted for 
age and 
gender
F(2,50)=0.57,
p=.571
F(2,50)=2.23, 
p= 115
F(2,50)=0.16,
p=.855
F(l,51)=0.40,
p=.530
F(l,51)=3.31,
p=.075
F(l,51)=0.05,
p=.817
F(l,35)=1.39,
p=.246
ANCOVA 
adj. for age, 
gender and 
baseline
F(2,49)=2.86,
p=.067
F(2,49)=0.13,
p=.877
F(l,50)=5.11,
p=.028
F(l,50)=0.21,
p=.652
F(l,34)=0.49,
p=.490
F(l,34)=0.16,
p=693
Phase 1 
repeated 
measures 
ANOVA 
adj. for age 
and gender
F(2,50)=2.92,
p=.063
F(2,50)=0.19,
p=.829
F(l,51)=5.65,
p=.021
F(l,51)=0.38,
p=.539
F(l,35)=0.06,
p=.807
F(l,35)=0.01,
p=.916
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Table 8.20. Number of cigarettes per day: analyses of variance
Three groups Control group vs. combined GSTM1 group GSTMl-missing group vs. GSTMl-present 
group
Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4
One-way 
ANOVA 
unadjusted 
(or t-test)
F(2,58)=0.77,
p=.469
F(2,58)=4.85,
p=.011
F(2,58)=1.10,
p=.339
F(l,59)=0.56,
p=.456
F(l,59)=8.97,
p=.004
F(l,59)=2.21,
p=.143
F(l,41)=l.ll,
p=.299
ANCOVA 
adjusted for 
age and 
gender
F(2,50)=0.07,
p=.930
F(2,50)=3.72,
p=.031
F(2,50)=0.32,
p=.728
F(l,51)=0.15,
p=.703
F(l,51)=7.14,
p=.010
F(l,51)=0.56,
p=458
F(l,35)^0.00, 
p=.980
ANCOVA 
adj. for age, 
gender and 
baseline
F(2,49)=5.28,
p=.008
F(2,49)=0.69,
p=.509
F(l,50)=10.15,
p=.002
F(l,50)=1.25,
p=268
F(l,34)=0.45,
p=.509
F(l,34)=0.43,
p=.518
Phase 1 
repeated 
measures 
ANOVA 
adj. for age 
and gender
F(2,50)=0.97,
p=.388
F(2,50)=0.77,
p=.468
F(l,51)=8.91,
p=.004
F(l,51)=1.43,
p=237
F(l,35)=0.37,
p=.515
F(l,35)=0.39,
p=.537
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Table 8.21. Perceived risk of lung cancer: analyses of variance
Three groups Control group vs. combined GSTM1 group GSTMl-missing group vs. GSTMl-present 
group
Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4 Phase 1 Phase 3 Phase 4
One-way 
ANOVA 
unadjusted 
(or t-test)
F(2,58)=3.23,
p=.047
F(2,58)=l .85, 
p=.167
F(2,58)=5.13,
p=.009
F(l,59)=3.51,
p=.066
F(l,59)=0.49,
p=.488
F(l,59)=1.92,
p=.171
F(l,41)=2.44,
p=.126
ANCOVA 
adjusted for 
age and 
gender
F(2,50)=3.14,
p=.052
F(2,50)=0.91,
p=.409
F(2,50)=3.98,
p=.025
F(l,51)=5.13,
p=.028
F(l,51)=0.63, 
p=.431
F(l,51)=2.63, 
p=. I l l
F(l,35)=1.15,
p=292
ANCOVA 
adj. for age, 
gender and 
baseline
F(2,49)=0.26,
p=.771
F(2,49)=2.04, 
p=. 141
F(l,50)=0.03,
p=.864
F(l,50)=0.04,
p=.835
F(l,34)=0.84,
p=.367
F(l,34)=3.88,
p=.057
Phase 1 
repeated 
measures 
ANOVA 
adj. for age 
and gender
F(2,50)=0.97,
p=.386
F(2,50)=1.27,
p=.289
F(1,51)=T.98,
p=.166
F(l,51)=0.30,
p=.584
F(1,35)=0.00, 
p=.974
F(l,35)=2.00,
p=.166
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Table 8.22. Psychological impact of GSTM1 genetic testing: response to open-ended question at one week follow-up
GSTMl-present GSTMl-missing
ID Response ID Response
23 Happier that slightly in favour. 139 -
149 Quite happy. Still want to give up. 151 It hasn’t made much difference to me. Not important to me.
274 It made me feel quite good. I know that it’s in my 
favour
211 Indifferent.
309 It was quite a good result for me. Now I need to 
digest it a bit more.
548 Doesn’t worry me at all.
362 It’s an advantage so happy got it. 733 It’s a positive feeling and a scary feeling.
560 Very pleased. I would have been more worried if I 
hadn’t had the result.
816 Not too despondent. Not too gutted.
720 Happy. Pleased. 1030 Nothing very deeply. I suppose a bit surprised.
923 Neutral. 1339 Fine. Didn’t think about it.
946 Pleased. 1653 Disappointed. I think I have an addictive personality and so I could have done 
with the gene.
1006 Happy. I was quite pleased. 1819 Think it’s a brilliant idea, made me feel stronger and more confident, 
another tool for me to use.
1483 Neither one way or the other. 3% doesn’t make much 
difference.
1885 Not joyous. It’s not good news. I’m glad I did it. It adds weight to 
determination. More reflective.
1639 Happy about it. 1959 I feel ok about that. I feel all right. As I say, I don’t think I would have 
taken the test if I hadn’t thought it was going to help. Feel that it might be 
of help to someone somewhere eventually. 3% isn’t a big thing. Not 
worth getting upset about it.
1690 Thought that would be the outcome, thought would 
have the gene.
2220 A little disappointed that I wasn’t in the other 50%. But as a smoker, 
good motivational tool. Probably done me good.
1808 Don’t know. If you’re a worrier, you’ll worry 
anyway, and not if not.
2500 Bit of a nonevent. Difference between 9 and 12, marginal. 1% is what to 
aim for. Novelty factor.
2071 I was pleased. 2501 Not surprised, and in some ways it gives me more reason to stop.
2206 -
Quotes highlighted in green are those referred to in the body of the text.
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Table 8.23. Impact of GSTM1 genetic testing on motivation to quit smoking: response to open-ended question at one week follow-up
GSTMl-present GSTMl-missing
ID Response ID Response
23 No, it hasn’t. No real difference, really want to stop. 139 It won’t be a major factor in me stopping smoking. It hasn’t swayed me either 
way.
149 More or less made mind up to give up but pushed forward. 
Phoned as soon got back last time and made appointment with 
clinic.
151 Don’t think it’s affected me at all.
274 It certainly has, it’s encouraged me to give up. You have a 
level of protection so no harm yet.
211 Don’t think so. Process of coming in has brought it to the forefront of mind, 
but nothing to do with results.
309 It didn’t affect it at all one way or the other. 548 About 10%. Maybe it is a good time to stop. Better not to smoke. Habit rather 
than enjoyment.
362 Nil. 733 It’s made me think I don’t want to smoke, it definitely has. It’s made me think 
about my father’s cholesterol, which I have a 50% chance of inheriting. It’s 
made me think much more about the long term future.
560 Not at all. I’ve lasted this long so... 816 The whole thing has made me very very determined to quit.
720 It hasn’t really one way or the other, although I still want to give 
up smoking.
1030 It has slightly, no question.
923 Not at all. 1339 j Maybe, couldn’t really say. Pregnancy main reason.
946 Enhanced it, ironically. For some weird reason I really am keen to 
give up.
1653 More determined. Initially thought give in, doomed, then makes me more 
determined.
1006 I think my motivation’s stayed the same. 1819 Definitely.
1483 None. 1885 Has had an effect, but not a massive effect.
1639 It’s probably had no impact actually. 1959 I think for months I’ve tormented myself about smoking, the groups are 
helping. I think the result has helped me a lot to think more about it but it’s 
not the sole motivation.
1690 Doesn’t help in stupid illogical. 2220 Definitely. Positive direction.
1808 With help, want to do it. Definitely going to. 2500 Hard to say. HRT and cholesterol results are same. Probably played a part.
2071 It hasn’t. 2501 It has made me more determined to stop smoking.
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Table 8.24. Understanding of “not having the gene response to open-ended question at one week follow-up
GSTMl-present GSTM1-missing
ID Response ID Response
23 - 139 Not having the gene didn’t mean very much because the percentage was so small.
149 Slightly higher risk. 151 It meant that from what is known there’s a 1% increase in risk or less.
274 - 211 Body wasn’t producing enzyme that clears toxins from lungs. 9% had, 12% 
didn’t.
309 There’s a possibility, 12%, that you could develop lung cancer 548 More inclined to get lung cancer.
362 - 733 12-13% rather than 9 or 10%.
560 - 816 3% is minimal.
720 Meant that got 3% more chance, was 12% chance versus 9%. 1030 -
923 - 1339 3% more likely.
946 - 1653 Slightly less ability to do it [clear rubbish from lungsl, 12%.
1006 - 1819 -
1483 Slightly higher risk of getting lung cancer, 3%. 1885 It gives me 3 or 4% more chance of getting lung cancer, but I imagine also related 
to other lung-related disease.
1639 If you didn’t have the gene you had a 3% higher chance of 
developing lung cancer.
1959 Around the average lifespan, 3 more people, 12% for people who haven’t got the 
gene compared to 9% of those who have.
1690 Slightly higher risk. 2220 Increased chance of developing lung cancer... been regurgitating the stats to 
everyone.
1808 Probably get cancer. 2500 12% chance of lung cancer.
2071 - 2501 Highered my percentage rate of getting cancer. 3% or 5% more.
2206 Slightly greater chance of getting lung cancer.
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Table 8.25. Understanding of ‘‘haying the gen e”', response to open-ended question at one week follow-up
GSTM 1-present GSTMl-missing
ID Response ID Response
23 - 139 -
149 Slightly less risk of getting cancer. 151 -
274 The possibility of me catching the Big L is about 2% less. 211 Opposite.
309 I’ve got the gene that fights, that’s filtering the nicotine and 
carbon monoxide, 9%.
548 Less inclined to get lung cancer.
362 Have a 1 or 2% better chance of getting rid of the toxins. 733 -
560 Instead 12% likely to get cancer it’ll be 9%. 816 -
720 Helps breaking up the toxins from the lungs. 1030 -
923 It meant that of all the different agents cleaning out my 
lungs I have this one. I t’s 9% versus 13%.
1339 Smaller chance of lungs filling up as much, 3% difference.
946 To work out if I was in the prone group. 1653 Could have the ability to clear out rubbish from lungs, 9%.
1006 It meant that there was a difference of 3% in the 
population. Toxins are being cleared out, but doesn’t 
mean I am immune.
1819 Are you asking if I understand, then yes I do.
1483 Muck gets cleared up a little better than if I hadn’t had it... 
enzyme or something.
1885 -
1639 - 1959 -
1690 Slightly less chance of getting lung cancer, slightly less at 
risk.
2220 Less chance, reduced risk.
1808 In between, could get cancer, might not. 2500 Non smoker 1%... 9% chance of lung cancer.
2071 My lungs were able to function better or more efficiently. 2501 -
2206 The gene helps you to get rid of toxins in your lungs -  one 
of the genes -  and have a slightly better chance of not 
getting cancer.
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4. Discussion
The three main hypotheses that are generally made regarding the impact of genetic 
testing for lung cancer susceptibility are: 1) giving smokers genetic risk feedback 
conveying an increased susceptibility to lung cancer should increase their motivation to 
quit smoking; 2) giving smokers genetic risk feedback conveying an increased 
susceptibility to lung cancer could cause adverse psychological reactions such as 
depression; and 3) giving smokers genetic risk feedback conveying a decreased 
susceptibility to lung cancer could cause complacency and decrease motivation to quit 
smoking.
These hypotheses are regularly cited, supported by models of health behaviour, and 
partially supported by the study by Lerman et al (1997) described in Section 1.2.1. 
However, interpretation of the work by Caryn Lerman was restricted by the fact that they 
used the CYP2D6 gene, which essentially meant that all smokers in the genetic testing 
group were given genetic risk feedback conveying increased susceptibility to lung cancer. 
They were therefore not able to test hypothesis 3 which states that giving feedback 
conveying decreased genetic susceptibility to lung cancer could have a detrimental effect 
on motivation to quit smoking. Nor were they able to determine whether the differences 
between the control group and CYP2D6 genetic testing group were due to the 
personalised genetic risk feedback or the process of genetic testing more generally.
The recent study by McBride et al (2002; described in Section 1.2.2) did not suffer from 
these drawbacks, because they used the GSTM1 gene which allowed comparison of the 
control group with smokers who received a GSTM 1-missing genetic test result conveying 
increased lung cancer susceptibility, and with smokers who received a GSTM 1-present 
genetic test result conveying decreased lung cancer susceptibility. Their findings did not 
support the hypotheses above. Firstly, they found that, although the genetic testing group 
were more motivated to quit smoking than the control group, the GSTM 1-missing group 
was no more motivated than the GSTM 1-present group. This did not support Hypothesis
1. Secondly, they found that depression decreased over time in all groups, including the 
GSTM 1-missing group. This did not support Hypothesis 2. Thirdly, they found that
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motivation to quit smoking increased in the GSTM 1-present group. This did not support 
Hypothesis 3. A fourth and surprising finding was that the perceived risk of developing 
lung cancer was no higher in the GSTM 1-missing group than in the GSTM 1-present 
group.
A possible conclusion to draw from McBride et aV s (2002) findings was that the process 
of genetic testing increased motivation to change behaviour, but the risk content of the 
information did not. However, the genetic testing group received considerably more 
support than the control group, and it is therefore not possible to conclude that it was the 
genetic testing component of the intervention that led to the behaviour change. It could, 
for example, have been due to the extra telephone counselling that the genetic testing 
group received, but which the control group did not. Especially in light of the lack of 
differences between the GSTM 1-missing and GSTM 1-present groups on perceived risk, 
this imbalance would explain the significant differences between the combined genetic 
testing group and the control group. However, it would not explain the lack of 
differences between the GSTM 1-missing and GSTM 1-present group. The lack of 
differences between the GSTM 1-missing and GSTM 1-present group, particularly in 
terms of perceived risk, could be because the participants failed to correctly interpret the 
genetic risk feedback; this was partially supported by the observation that accurate 
interpretation of the test results was low, according to the study authors.
These possibilities raised the need for a study in which the GSTM1 genetic testing group 
and control group received the same treatment intervention, and which attempted to 
ensure participants’ understood the genetic risk information. This was the aim of the 
present study, the results of which are summarised below.
4.1. Comparison of findings with previous research
4.1.1. Depression
At one week follow-up, participants in this study who received GSTM1 genetic test 
results showed lower levels of depression than participants in the control group; there
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were no differences between the GSTM 1-missing and the GSTM 1-present group. At two 
month follow-up depression had decreased in all groups.
The lack of differences between groups at two month follow-up, and the overall 
decreasing trend in depression over time, replicate the results reported by McBride et al 
(2002); McBride found that, amongst smokers in both the control group and the GSTM1 
genetic testing group, depression decreased steadily over time between baseline and 1 
year follow-up, and that feedback of increased susceptibility to lung cancer was not 
associated with significant increases in depression at two month or one year follow-up 
relative to receiving feedback of decreased susceptibility.
Both sets of findings differ from those reported by Lerman et al (1997), who found that 
depression was higher amongst participants who received CYP2D6 genetic test results 
than controls at two month follow-up, although there were no differences between the 
groups at one year follow-up. The opposing findings could be because smoking cessation 
was higher in the genetic testing group in McBride’s study but not in the genetic testing 
group in Lerman’s study, although this leaves unresolved the question of why they should 
have found different cessation rates.
In conclusion, the present findings do not support the hypothesis that genetic testing 
increases depression amongst smokers, as proposed by Lerman et al (1997), but instead 
strengthens the case proposed by the results of McBride et al (2002), that informing 
smokers that they could be at increased risk of lung cancer on the basis that they do not 
have the GSTM 1 gene, does not lead to increased depression -  at least in people who put 
themselves forward for genetic testing in the research context.
In addition, our findings build on the previous research by picking up an increase in 
depression at one week follow-up amongst participants in the study who were 
randomized to the control group. This was a novel and surprising finding, not reported in 
the two previous studies on common gene variants associated with smoking-related 
disease. However, clinical experience with genetic tests for Huntington’s disease and the 
BRCA1 breast cancer susceptibility gene has shown that individuals who considered
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taking genetic tests, but have not received the test results -  either because the test results 
were inconclusive or because they ultimately chose not to take the test -  show higher 
levels of depression at follow-up than those who do receive genetic test results (Wiggins 
et al, 1992; Lerman, Hughes, Lemon et al, 1998). Because a major reason for individuals 
opting for genetic testing is thought to be to reduce their uncertainty about their risk 
status (Esplen et al, 1999; Braithwaite et al, 2002), it is likely that this increase in 
depression is because the uncertainty about their risk status remains unresolved. Our 
findings suggest that a similar mechanism might have occurred for the participants in our 
study: they opted to participate in the research study because they were interested in 
receiving information about some aspect of their genetic susceptibility to a smoking- 
related disease, and so were disappointed about being randomised into the control group 
and therefore not getting the information they were looking for. This is, obviously, pure 
speculation, and we might not expect such disappointment to be strong enough to be 
reflected in the global measure of depression employed in the study, but does suggest that 
future research may benefit from investigating this issue further.
4.1.2. Anxiety
To some degree, the findings regarding anxiety replicated those regarding depression. 
From baseline to one week follow-up, anxiety increased in the control group, decreased 
in the genetic testing groups, and did not differ between the GSTM 1-missing and 
GSTM 1-present groups. These findings lend further support to the hypothesis that 
participation in genetic testing research could cause short-term adverse psychological 
reactions in participants allocated to the control group. The findings also refute the 
hypothesis that adverse psychological reactions are an inevitable consequence of 
informing smokers they are at increased risk of a smoking-related disease. The studies 
conducted by Lerman et al (1997) and McBride et al (2002) did not assess anxiety, so it 
is not possible to compare our findings here directly with previous studies on genetic 
testing for common gene variants.
4.1.3. Worry about lung cancer
The results regarding worry about lung cancer were inconclusive in the present study:
although no statistically significant time x group interactions were detected, we do not
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know whether this was because there were genuinely no trend differences between 
groups, or whether this was simply due to a lack of power caused by the small sample 
size. However, the pattern of results was similar to that reported by McBride et al 
(2002). They found that, amongst participants in the genetic testing group, worry about 
lung cancer decreased from baseline to six month follow-up and then levelled off, 
whereas it steadily declined in the control group. This was similar to the overall 
decreasing trend that we observed in the present study: worry about lung cancer appeared 
to drop in all three groups from baseline to one week follow-up; then at two month 
follow-up, worry appeared to increase back up to baseline level in the GSMT1-missing 
group, decrease further in the GSTM 1-present group, and stay at the same level in the 
control group. However, McBride et a l’s (2002) timescale was very different to ours, so 
this similarity should be approached with caution. Lerman et al (1997) did not assess 
worry about lung cancer, and so we can’t compare the trends in these studies with theirs.
4.1.4. Intention to quit smoking
It is often hypothesised that giving smokers genetic test results indicating increased 
susceptibility to smoking-related diseases should increase cessation rates, but that 
smokers may be less likely to quit smoking if they receive lower risk results. The sample 
size of 61 participants in the present study was too small to be able to look at actual quit 
rates as an outcome variable, and so intention to quit was used as a proxy measure in the 
hope that this would be better able to detect group differences. However, in the event, no 
time x group interactions were detected, and so the study did not provide any conclusive 
evidence regarding the impact of genetic testing on the proxy, intention to quit smoking.
The studies conducted by Lerman et al (1997) and McBride et al (2002) were much 
larger than the present study, with sample sizes of 427 and 487 respectively, and so they 
were able to look at actual cessation rates. McBride et al (2002) found a significant 
group difference when the GSTM 1-missing and GSTM 1-present groups were combined 
into one: 19% of the combined genetic testing group had quit at six month follow-up 
compared to 10% of the control group. However it was not possible to attribute this 
group difference to the genetic testing process, because participants in the genetic testing 
group received considerably more additional support than those in the control group.
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Lerman et al (1997) found no quitting differences between the control group and the 
CYP2D6 genetic testing group at two month follow-up nor at one year follow-up. 
Therefore, none of the studies to date have conclusively shown that the process of genetic 
testing increases actual smoking cessation, and it is possible that we may have found no 
differences between our control group and combined genetic testing group even if we had 
had a larger sample size.
Although McBride et al (2002) found an impact of the genetic testing process on 
cessation rates, they found no effect of the genetic test result on smoking cessation; 17% 
of the GSTM 1-missing group had quit at six month follow-up compared to 23% of the 
GSTM1 present group, which was a non-significant difference. We also found no 
difference between the GSTM 1-missing and GSTM 1-present group on intention to quit 
smoking at follow-up. Therefore, although we cannot draw any conclusions from our 
results due to insufficient power, it is again possible that we would have found no 
difference even with a larger sample. The findings do not support the hypothesis that 
informing smokers that they are at increased risk of a smoking-related disease increases 
smoking cessation, or intention to quit smoking; nor do they support the hypothesis that 
genetic risk information conveying decreased susceptibility decreases intention to quit 
smoking.
4.1.5. Motivation to quit smoking
At one week follow-up, motivation to quit was higher in the combined genetic testing 
group than in the control group. In the absence of being able to look at actual cessation 
rates, it was useful to be able to address several smoking-related variables in addition to 
intention to quit smoking, and the present findings were interesting because they detected 
a group difference where none had been detected on the intention variable. To some 
degree, the findings mirror those of Lerman et al (1997): despite finding no differences in 
actual cessation, they did find that at one year follow-up the group given the CYP2D6 
genetic risk feedback were more motivated to quit, and had made more quit attempts, 
than the control group. Our findings regarding motivation to quit at one week follow-up 
were nowhere near as robust as those of Lerman and colleagues, because we only 
observed a difference at one week follow-up which was not maintained two months later,
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whereas the data obtained by Lerman et al (1997) reflected a difference at one year 
follow-up. Nonetheless, the findings tentatively support the hypothesis that the process 
of genetic testing increases motivation to quit smoking, in the very short term.
Our findings build on those of Lerman et al (1997) because, by using the CYP2D6 gene, 
they were not able to compare the impact of receiving genetic risk feedback indicating 
increased susceptibility with that indicating decreased susceptibility. In contrast, we 
were able to make this comparison because we used the GSTM1 gene, but we found no 
differences between the GSTMl-missing and the GSTMl-present group. The hypothesis 
that genetic risk feedback indicating increased susceptibility to a smoking-related disease 
increases motivation to quit smoking was therefore not supported, nor that feedback of 
decreased genetic susceptibility decreases motivation to quit smoking. Instead, the 
findings tentatively suggest that the impact of genetic testing on motivation to quit 
smoking may be more to do with the process of genetic testing than the personalised risk 
information contained within the genetic test result itself.
4.1.6. Number of cigarettes per day
Amongst the combined genetic testing group, smoking rates halved from 20 cigs/day at 
baseline, to 10 cigs/day at one week follow-up, and 9 cigs/day at two month follow-up. 
There was no difference between the GSTMl-present group -  amongst whom smoking 
rates went from 21 cigs/day at baseline to 11 cigs/day at one week follow-up -  and the 
GSTMl-present group -  who went from 19 cigs/day at baseline to 9 cigs/day. Smoking 
rates amongst controls went from 18 cigs/day at baseline to 21 cigs/day at one week 
follow-up, and 15 cigs/day at two month follow-up. These findings indicate that 
participants who receive genetic test results reduce the amount they smoke one week 
following receiving their results, and that the result itself, i.e. whether it indicates an 
increased or decreased susceptibility to lung cancer, does not impact on the outcome.
Lerman et al (1997) found no significant effects of genetic testing on smoking rates at 
two month follow-up, but did find a significant interaction effect of genetic testing x 
stage of change. Among smokers in the ‘preparation’ stage, the number of cigarettes 
smoked per day dropped from 22 at baseline to 11 at two month follow-up in the genetic
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testing group, and from 22 to 15 in the control group. Although we were not able to look 
at the interactive effects of group and stage of change, it is interesting to note that these 
figures are strikingly similar to those obtained in our study.
The findings reported here support those reported for motivation to quit smoking: the 
process of genetic testing has a positive effect on smoking-related variables, whereas the 
risk information regarding personal genetic susceptibility itself has little impact.
4.1.7. Perceived risk of lung cancer
McBride et al (2002) found no perceived risk differences between the genetic testing 
group and the control group at any time point, nor did they find any differences between 
the GSTM 1-missing and the GSTMl-present group. Lerman et al (1997) did find a 
difference between the CYP2D6 genetic testing group and control group, but because all 
of the CYP2D6 genetic testing participants were informed that they were at increased risk 
of lung cancer on the basis of their genetic test result, it was not possible to determine 
whether this difference was due to the process of genetic testing, or the content of the risk 
information. In the present study, we found no significant differences in perceived risk 
over time between the control group and combined genetic testing group, but the 
comparison between the GSTM 1-missing group and the GSTMl-present group at two 
month follow-up was of borderline significance, /7(1,34)=3.88, p=.057.
This is important because the mechanism by which it is usually assumed that genetic 
testing should increase motivation to quit smoking is perceived risk: informing a smoker 
that they have an increased genetic susceptibility to lung cancer, should increase their 
perceived risk of developing lung cancer, which should in turn have the effect of 
increasing their motivation to quit smoking. Although the previous findings described 
above partially support the hypothesis that genetic testing increases motivation to quit, 
the fact that the GSTM 1-missing smokers show no higher levels of motivation to quit 
than GSTMl-present smokers, nor do they show strikingly higher levels of perceived 
risk, does not support the hypothesis that the risk information itself leads to the changes 
in motivation.
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4.2. What this study adds
In summary, this study adds to our understanding of the impact of genetic testing for 
common gene variants by supporting McBride et a l’s (2002) findings that depression 
decreases, and motivation to quit smoking increases, amongst smokers who receive 
genetic risk feedback -  regardless of whether the feedback indicates increased or 
decreased lung cancer susceptibility. Our study replicates McBride’s findings even 
though we made efforts to try to reduce the imbalance between the control group and 
genetic testing group in terms of the amount of input the received. The study also adds to 
the literature by suggesting that participants in research trials investigating the impact of 
genetic testing for common gene variants may experience short-term adverse 
psychological reactions if randomly allocated to the control condition, even if offered the 
option of taking the test at the end of the trial, as was done in the present study. Finally, 
the quotes obtained from the participants’ responses to the open-ended questions 
suggested that participants did have a reasonable understanding of their genetic test 
results which, if replicated in future research, would not support the hypothesis that the 
lack of differences in perceived risk between the GSTM 1-missing and GSTMl-present 
groups was due to a lack of understanding of the genetic risk information.
4.3. Limitations and implications of the research
The most obvious limitation of this study was the sample size: in situations where no 
group differences were detected, we were unable to say with any confidence whether we 
believed this truly indicated similar levels in each group, or whether we were simply 
underpowered to detect differences that would have been detected had we had a larger 
sample size. However, the research complied with Phase II of the MRC framework for 
the development of complex interventions (Campbell et al, 2000), which states that 
“appropriately controlled and randomized small, exploratory trial” studies should be 
conducted in advance of Phase III main randomized controlled trials. The aims of the 
‘exploratory phase’, Phase II, are to a) test acceptability and feasibility for providers and 
patients, and b) define outcome measures and other variables. The present study fulfilled 
these kirns by suggesting that genetic testing for common gene variants was acceptable 
for those smokers who chose to participate in the research, and by confirming that
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outcome measures to be included in future research should include a battery of measures 
addressing psychological impact, behavioural impact, and perceived risk. The 
observation that the impact of the genetic test appeared to have little to do with the 
impact on perceived risk of developing lung cancer suggests that future studies may 
benefit from the inclusion and additional analyses of further variables such as self- 
efficacy.
The research was also limited by its generalizability: the final sample size of 61 
participants was whittled down from an initial posting of 2,226 recruitment letters to 
2,226 smokers or ex-smokers. Combined with accounting for people who dropped out of 
the study, this means that the smokers who ended up attending the baseline session, 
turning up for their results, and completing at least one telephone follow-up call, were a 
highly self-selected group. The findings are therefore not generalizable to the general 
population. However, in light of the earlier work presented in this thesis on self­
selection, future research is needed which explores the relationships between self­
selection into research studies and self-selection into genetic testing in the wider social 
context (i.e. commercial and clinical contexts).
An additional limitation was that, although every effort was made to develop a study in 
which the two intervention conditions (control condition and genetic testing condition) 
were matched to one another, it turned out to be difficult to justify the Phase 2 session 
with control group participants, and so this session ultimately was only conducted with 
those in the genetic testing group. Therefore, despite our best intentions, the genetic 
testing group did in fact receive one additional face-to-face session with the researcher- 
adviser, which could have influenced the outcomes. Future studies will need to address 
this difficulty; one potential way to solve this may be to explore whether it will be 
feasible to give participants in the genetic testing group their test results over the 
telephone, and to match this with a follow-up/counseling call to the control group 
participants. Overall, this research suggests that a large Phase III randomized controlled 
trial will be feasible, provided its design takes account of the above limitations and which 
makes the appropriate adjustments.
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CHAPTER 9 
Discussion and conclusions
1. Summary of findings
The aim of this research was to contribute to the debate on determining the clinical 
utility of genetic susceptibility tests for common, complex diseases, by exploring 
psychological issues surrounding genetic testing. The research was conducted within 
Phases 1 and 2 of the MRC framework for the development and evaluation of 
complex interventions designed to improve health (Campbell, 2000), and was 
designed to generate data useful to determining the feasibility of conducting a large 
randomized controlled trial (Phase 3 of the MRC framework), fully powered to look 
at the psychological and behavioural impact of genetic testing for common gene 
variants. The three primary research questions addressed were: i) what is the degree 
of interest in genetic testing for complex diseases in the general population and what 
factors influence individuals decision to have a genetic test, ii) what is the 
psychological impact of genetic testing for complex diseases in the general 
population, and iii) what is the impact of genetic testing for complex diseases on 
health-related behaviour in the general population? In this thesis I have described 
three studies which addressed these research questions; two population-based surveys 
and one small exploratory study in which smokers were randomly allocated to either a 
GSTM1 genetic testing group or to a control group. The main findings of this 
research are summarised and discussed below.
1.1. General public finds genetic testing for common, complex diseases acceptable
This research suggested that people in the general population find the idea of genetic 
testing for common, complex diseases acceptable: 64% and 69% of 1,960 respondents 
to the Office for National Statistics survey indicated that they would personally take a 
genetic test for cancer or heart disease respectively (Study 1, Chapter 4). Previous 
surveys of interest in genetic testing have almost always been for existing genetic 
tests such as those for cancer, and this was the first survey to indicate that interest in 
genetic testing might also be high for other complex diseases, such as heart disease.
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One consideration for future research is that this survey, like most other population- 
based surveys of interest in genetic testing, focused on specific disease types (i.e. 
cancer and heart disease). However, future surveys should be developed which ask 
about interest in genetic testing for common gene variants, or for physiological 
processes such as ‘detoxification’, since these are the genetic tests which are starting 
to emerge, and which are causing so much controversy.
1.2. Most people want to discuss their genetic test result with a health professional
Determining the level of support and counselling which is, or should be, made 
available alongside genetic testing, has emerged as one of the central issues of the 
genetic test debate, and which remains unresolved. The difficulty is this: at present, 
all guidelines stipulate that genetic counselling, i.e. face-to-face support provided by a 
qualified genetic counsellor, should be made available to all people taking genetic 
tests which have significant implications fo r  health (UNESCO, 2003), but no-one has 
yet agreed on which genetic tests have significant implications for health. Whilst 
there is no doubt that genetic tests for rare, single gene disorders should always be 
accompanied by the availability of extensive genetic counselling and support, there is 
considerable disagreement about the extent to which genetic counselling should be 
insisted upon for, say, ‘nutrigenomic’ genetic tests which provide individuals with 
information about their body’s ability to ‘detoxify’ carcinogens or which influence the 
way their body interacts with nutrients.
One way to approach this question is to ask members of the general public directly 
what they think about the appropriate availability of support; this was done in the 
postal questionnaire survey of 1,024 respondents conducted in Oxfordshire in 2002 
(Study 2a, Chapter 5). Although we did not ask specifically about genetic tests for 
‘detoxification’, we did ask about genetic tests for two common complex diseases 
known to be influenced by detoxification (cancer and heart disease) as had been done 
in Study 1 (Chapter 4). We addressed this by presenting respondents with two 
hypothetical scenarios: in the first, they were asked how they would feel if  they 
received a positive genetic test result, which indicated increased disease 
susceptibility; in the second scenario, they were asked how they would feel if they 
received a negative genetic test result, indicating they were not at increased risk. We
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found that over 95% of people said that they would want to discuss their test result 
with a health professional i f  it indicated that their genetic susceptibility to either 
disease was increased. In addition, 93% said that they would feel concerned about 
their genetic test result for heart disease risk, and 43% would feel depressed if the test 
result was for cancer risk. Fewer people, although still a substantial proportion of the 
sample, felt that they would want to talk to a health professional if their result 
indicated that they did not have an increased susceptibility to the disease: 55% if the 
genetic test result was for cancer, and 49% if the result was for heart disease.
Of course, the people responding to this postal questionnaire survey probably had 
limited understanding of genetic testing; indeed the results suggested that over a third 
of respondents did not feel that they had a clear picture of what genetic testing was. 
Therefore, it is likely that their responses would not be the same if they had a better 
understanding of genetics. However, it is vital to note that in the current context, with 
the current limited level of understanding of genetics and genetic testing in the 
general population, people feel that they would want at least the option of talking to a 
health professional about their results. As before, the research was limited by 
focusing on only cancer and heart disease. It will be interesting to see in future 
research whether members of the general public respond in the same way to questions 
about genetic testing which focus more explicitly on common gene variants and 
detoxification processes.
1.3. Written information materials increase understanding o f  genetic testing, but do 
not influence anticipated reactions to genetic test results
Although at present, people state that they would want to be able to discuss their test 
result directly with a health professional, a further consideration is the extent to which 
such genetic counselling might in the future be substituted by other means of advice 
and support, possibly in the form of postal written information materials or web-based 
support programs. This question has become another central policy issue because the 
increasing number of genetic tests has placed a strain on current clinical services and 
already there are not enough genetic counsellors to respond to the increasing demand 
for their service (Parliamentary Office of Science and Technology (POST), 
www.parliament.uk/post/ home.htm, accessed 20 April 2005). Very recently, we
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have seen one or two companies in the commercial sector starting to develop their 
own solutions to this problem, in particular one company based in California called 
DNADirect (www.dnadirect.com). DNA Direct describes how, in the US, it is 
mandated by medical professional societies that genetic tests must be ordered by a 
physician and test results must be interpreted by a genetic counsellor, geneticist or 
specialist, but that the approach is limited by the fact that there are only 1,200 medical 
geneticists and just over 2,000 genetic counsellors in the US, most often based in 
urban areas which restricts access for many portions of the population. To increase 
access to testing, DNA Direct has “created a Web-based genetic testing service that 
redefines traditional face-to-face genetic counselling” and “allows individuals to be 
proactive in managing their care while having toll-free [telephone] access to certified 
genetic experts” (www.dnadirect.com/about). The goals of genetic counselling are: to 
educate and inform individuals of the genetic condition for which they may be at risk; 
to provide support and help them cope; and to facilitate informed decision making 
about both testing and subsequent options (Wang et al, 2004). What we do not know 
is whether written information materials, either postal or web-based, can replace face- 
to-face contact with a counsellor in fulfilling these roles?
This question was briefly explored in a simple experimental study in which the impact 
of a written genetics information leaflet on interest in genetic testing, understanding 
of genetic testing, and anticipated psychological and behavioural reactions to test 
results, was examined. The leaflet was included with a randomly selected half of the 
postal questionnaire surveys sent out in Study 2a (Chapter 5). The results of the study 
showed that, compared to respondents who did not receive the genetics information 
leaflet, respondents who received the leaflet had higher subjective (self-reported) 
understanding of genetic testing, although this effects was less marked in the lower 
SES groups. The leaflet was also associated with higher interest in genetic testing, 
but there were few differences between the groups on anticipated psychological and 
behavioural reactions to genetic test results. The finding that self-reported 
understanding of genetic testing was higher in the leaflet group than the no-leaflet 
group provides some very preliminary support for the suggestion that written 
information leaflets can ‘inform and educate’ individuals considering taking genetic 
tests, albeit not from formal assessment of understanding, but in terms of the 
individual’s feeling that they understood the issues. We found limited evidence in the
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present study to support the idea that written information materials are sufficient to 
reduce adverse psychological reactions, or encourage adaptive behavioural reactions, 
to genetic test results, although in the study we were only addressing anticipated 
rather than actual reactions to results.
Yet again, we are brought back to thinking about the International Declaration on 
Human Genetic Data: “It is ethically imperative that when genetic testing that may 
have significant implications for a person’s health is being considered, genetic 
counselling should be made available in an appropriate manner’' (UNESCO, 2003). 
As before, there is no agreement as to whether web-based counselling or postal 
written information materials are “appropriate ” for genetic tests for diseases or traits 
which are not single-gene disorders. In addition, there is no guidance for researchers 
in this field regarding whether they should also always provide genetic counselling to 
their study participants, even when the genetic test being evaluated is for a single 
common gene variant. Obviously, the results of this study should not be over­
interpreted, since the study addressed a hypothetical genetic testing scenario rather 
than actual genetic testing. However, bearing this caveat in mind, the results 
suggested that postal written information materials might be effective in increasing 
understanding of genetics, but crucially not in the lowest socioeconomic and possibly 
most vulnerable group. In addition, the leaflet had no considerable influence on 
anticipated reactions to genetic test results. All of these findings suggested that, for 
the time being, it might be more advisable for researchers to give genetic test results 
in person than rely on written information materials. On the other hand, the finding 
that the leaflet did have some impact on understanding suggested that there was a 
useful role for clear and easily understandable written and visual information 
materials to complement the verbal information and support provided in research 
studies. The study provided an interesting way in to beginning to think about the 
issues around the clinical aspects of genetic counselling raised by web-based 
companies such as DNA Direct, but it probably did not provide particularly useful 
information in guiding policy decisions about such companies. Future research will 
benefit from exploring the differential effects of different sources of information, 
support and counselling.
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1.4. People self-select themselves into genetic testing on the basis o f  anticipated 
outcomes
Despite the concerns about the potential harms of genetic testing for complex disease 
susceptibility or common gene variants, experience with existing genetic tests for 
diseases such as Huntington’s disease, breast cancer, and cystic fibrosis, suggests that, 
even for these serious and rare conditions, people do not have extreme adverse 
psychological reactions to unfavourable genetic test results. There are two main 
hypotheses that could explain why this has been observed. Firstly, genetic tests for 
these serious diseases has always been accompanied by extensive genetic counselling, 
both before and after testing, and it is likely that this has contributed significantly to 
preventing serious negative consequences of testing. It has not been possible to 
explore this possibility in more detail, because it would have been unethical to 
provide people with a high risk of developing Huntington’s disease with anything less 
than the optimal genetic counselling service. Secondly, there is the possibility of self­
selection. Part of the reason that people do not react adversely to genetic test results, 
even for Huntington’s disease, may be that those who have decided to take the genetic 
test are basing their decision partly on having thought about whether they will be able 
to cope with the result, long before they even reach the genetic counselling 
environment.
It is surprising that this possibility of self-selection is almost never mentioned in the 
current debates about genetic testing for common diseases or gene variants, and yet it 
seems extremely relevant: people who choose to take such tests may only do so if 
they feel capable of coping with the result, whatever the result is, a possibility which 
could minimize the potential for harm. In order to begin to explore this possibility, 
the relationships between interest in genetic testing and anticipated psychological and 
behavioural reactions were examined in the analyses using the postal survey data 
reported in Study 2b (Chapter 6). The findings indicated that there was indeed a 
relationship between interest and anticipated outcomes; for example, 46% of people 
who anticipated regretting having taken the test if  the result was unfavourable 
reported being interested in taking a genetic test for cancer, susceptibility, compared 
to 89% of people who felt that they would not regret having taken the test. These and 
other similar findings could suggest that offering general population people genetic
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risk information may not cause substantial harm, given that those people who would 
have the most adverse reactions would not participate or opt for testing in the first 
place. However, although the findings do support that there is a relationship between 
anticipated outcomes and interest, they also show that, in absolute terms, large 
numbers of people who anticipated adverse outcomes would nonetheless take the 
tests. These findings therefore present a mixed message: on the one hand, vulnerable 
people will probably self-select themselves out of testing to some degree; on the other 
hand, there is still reason to be concerned that some people could have adverse 
psychological reactions to positive genetic test results.
1.5. Lack o f  understanding o f genetic testing could have direct consequences for  
individuaVs psychological wellbeing
The results of study 2b (Chapter 6) also showed that people with lower subjective 
understanding of genetic testing, and higher fatalistic belief about genetic test results, 
were more likely to anticipate feeling depressed in reaction to receiving positive 
genetic test results both for cancer and heart disease risk. Public understanding of 
genetics is essential not only to ensure informed participation in public debate about 
human genetics, and to achieve informed consent, but also because a lack of 
understanding could have direct consequences for the psychological wellbeing of 
individuals taking genetic tests in the general population. These findings highlight 
the importance of making every effort to ensure understanding amongst people taking 
genetic tests, whether in research studies or commercial or clinical settings.
1.6. Smokers may use genetic testing as a motivational tool -  regardless o f whether 
the test result is positive or negative
The research used smoking cessation as a paradigm for exploring the impact of 
genetic testing on a specific lifestyle or health-related behaviour. The findings 
reported in the final analyses conducted on the postal survey data (reported in Study 
2c, Chapter 7), proposed the hypotheses that smokers who have a strong desire to quit 
are more likely to opt for genetic testing for smoking-related disease susceptibility, 
and that they are more likely to anticipate quitting smoking in response to the genetic 
test result -  whether the genetic test result itself is positive or negative. Bearing in
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mind the caveat that this was all hypothetical work, the findings could suggest that the 
same characteristics that determine interest in genetic testing, also determine adaptive 
behavioural reactions to genetic test results. In addition, the findings also suggest that 
smokers who wish to quit may use their genetic test result as a motivational tool, 
whatever the actual result is. For example, a result indicating higher risk may have 
the expected effect of increasing perceived risk, thereby increasing motivation to quit, 
as long as self-efficacy is also reasonably high. On the other hand, a negative result 
could have the effect of increasing response efficacy -  a smoker who believes that 
their genetic susceptibility to a smoking-related disease is slightly reduced may have a 
stronger belief that for them it is particularly worth quitting. Self-efficacy was not 
assessed in this study but future research may be advised to include it as a primary 
dependent or mediating variable.
The findings from the final exploratory study, which used a randomised and 
controlled approach to giving smokers GSTM1 genetic test results (Study 3, Chapter 
8), supported the hypothesis that, amongst smokers who opt for genetic testing, 
motivation to quit smoking increases -  regardless of whether the feedback is 
presented as indicating a slightly increased or decreased susceptibility to lung cancer. 
In addition, the study found no evidence of depression or other adverse psychological 
reactions amongst people given genetic test results for the common gene variant 
indicating increased disease susceptibility (GSTM 1-missing). As referred to in the 
above discussion on self-selection (section 1.4), this may be because smokers only 
opted to participate in the research because they were inclined to use the genetic test 
result as a motivational tool, and because they believed themselves to be able to cope 
psychologically with the results, whatever they might indicate. The findings from this 
study suggested that it is feasible to conduct exploratory studies of this size, as well as 
larger randomized controlled trials, in which people in the general population are 
tested for common gene variants.
2. Limitations of the research
There were many limitations to this research. Study 1, the Office for National 
Statistics (ONS) survey on interest in genetic testing, was limited by being cross- 
sectional so that predictors and outcomes were measured at the same timepoint,
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increasing the chance that there would be positive associations. Future research may 
benefit from including questions on attitudes towards genetic testing annually or bi- 
annually, and tracking changes over time.
Interest in a hypothetical context was assessed rather than actual uptake and, since it 
is known that initial interest consistently over-estimates actual uptake (Lerman, 
Croyle, et al, 2002), it is likely that the present study over-estimated interest. A 
further contributory factor to over-estimation of interest was the information which 
was presented about genetic testing. The information may have suggested that 
genetic testing for common diseases was more imminent than it actually was at the 
time of the study. In relation to this, there was no way of knowing in this study 
whether people were misinterpreting genetic testing to mean testing to detect the 
presence of disease. Previous research has suggested that respondents to surveys 
misinterpret ‘genetic testing’ to mean ‘screening for disease’ (Weinrich et al, 2002), 
which further suggests that interest in genetic susceptibility testing may have been 
over-estimated in the present study. More care should be taken in future studies to 
develop information about genetics which does not mislead respondents. Future 
research will also benefit from exploring respondents’ interpretation of genetic testing 
in more detail.
The finding that family history was associated with interest in genetic testing for heart 
disease but not for cancer was curious, and could have been influenced by the 
inclusion of a question about personal history of diseases. This may have produced a 
slightly more homogeneous sample than would otherwise have been obtained, since 
respondents were not included if they themselves had had a diagnosis of cancer or 
heart disease. Given that personal diagnosis is likely to be correlated with family 
history, this could have influenced the associations observed between family history 
and interest, although it would still not be clear why this should have produced an 
association with testing for one disease but not another. Aside from demographics 
and family history, a number of additional variables were not addressed, such as 
personality traits and perceived susceptibility, which have previously been found to be 
important predictors of interest in genetic testing (e.g. Struewing et al, 1995; Myers et 
al, 1998). These factors are important to investigate since they could mediate some of
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the associations observed in the present study between sociodemographic factors and 
interest.
Advantages of using the ONS omnibus surveys include: the samples are recruited 
from across the country; they represent a broad range of the sociodemographic 
spectrum; and the questions are asked as part of an established survey of a wide range 
of issues -  agreement to participate in the survey cannot therefore be influenced by 
any knowledge about the inclusion of questions addressing the issue of genetic 
testing. Furthermore, the ONS surveys achieve reasonably good response rates, in 
this case 71%, but it is still possible -  indeed likely -  that respondents differ from 
non-respondents, again increasing the likelihood of picking up unrealistically high 
levels of interest in testing.
A major limitation of Study 2, the postal questionnaire survey, was the fact that a low 
response rate of only 51% was achieved. In addition, the study was conducted in 
Oxfordshire, both of which mean that it is not possible to generalize the findings to 
the general population. In particular, although the majority of respondents stated that 
they would want to discuss their test result with a health professional, it is possible 
that the people who responded to the surveys were particularly likely to want to 
discuss health, disease or genetics issues. They may have had more proactive 
approaches to their health for example, or they may have had a particular concern 
about genetic disease in their family. It is possible, therefore, that the findings 
reported here over-estimated the degree to which people in the general population 
would want to discuss their test result with a health professional. The low response 
rate could also have increased the chances of finding that smokers in the sample 
reported that their motivation to quit smoking would be increased by both a positive 
and a negative genetic test result. The fact that only 18% of the sample were 
smokers, supports that these smokers were not representative of the general 
population, in which the general proportion of smokers is around 25%. The smokers 
who responded to this survey may have been particularly inclined to be responsive to 
health-related information.
As with Study 1, the survey was cross-sectional and so causality cannot be inferred 
from the associations between the variables. Also, the study was limited by
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addressing only hypothetical questions relating to interest, and anticipated reactions to 
hypothetical scenarios, rather than actual uptake and impact. These issues are 
particularly problematic in interpreting the associations between anticipated reactions 
to genetic test results and interest in testing, which were discussed in this thesis in the 
context of self-selection. A major limiting factor of this kind of survey work 
generally is that, whilst there is an abundance of evidence showing that intentions 
predict behaviour (albeit with only about 30% accuracy; Marteau & Lerman, 2001), 
interest could nonetheless be construed simply as another facet of global attitudes 
towards either genetics or risk. As discussed in Chapter 6, the pilot work for the study 
suggested that few people had an accurate pre-existing idea of what genetic testing 
was, and it therefore seems possible that respondents to the survey were answering the 
questions having made almost no considered judgements about their responses. In 
which case, both interest and anticipated reactions could simply be reflections of 
attitudes in general towards genetics, medical interventions, or cancer or heart disease. 
This means that the conclusions regarding self-selection on the basis of the 
associations observed between the two variables may have been premature, although 
they are consistent with a considerable body of evidence from the clinical genetics 
literature, such as the evidence for self-selection into genetic testing for Huntington’s 
disease and breast cancer genetic testing.
Study 2 was also limited by the measures which were used. Many of the measures 
were developed in an ad hoc way, and the measures did not fit tightly into a 
theoretical framework. A particular limitation was the measure of ‘understanding of 
genetic testing’, which was a self-report rather than an objective measure. The item 
used in this thesis was “I  have a clear picture o f  what genetic testing is”. It is 
conceivable that this item could be heavily influenced by personality factors such as 
lack of confidence, which would have influenced the relationship observed between 
self-reported understanding and anticipated psychological reactions to test results. 
Another limitation was the study design: using the 2x2 experimental design made it 
difficult to disentangle the different components of the study, and was a reflection of 
the fact that probably too many different research questions were being addressed 
within one study. In future, I would be inclined to use a more simple study design, 
with better pre-defined research questions.
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The fact that people received a questionnaire about cancer or heart disease was also 
problematic, since it meant that respondents in the cancer condition could have had a 
particular interest in cancer, on the basis of family history for example, and similarly 
that respondents in the heart disease condition could have had a particular interest in 
heart disease. This restricted the validity of comparing between the disease 
conditions. Bearing this in mind, a useful research design in the future may be 
present survey respondents with a list of, say, ten different conditions and examine the 
extent to which their responses differ across conditions. In particular, it will be 
interesting to see whether people respond differently when conditions are presented as 
‘diseases’ compared to when they are presented as ‘physiological processes’. One 
example of this would be the detoxification process: are people’s responses to genetic 
testing for lung cancer different to their responses to genetic testing for 
detoxification? Both would conceivably test for the same common gene variants, but 
it would be extremely interesting to start exploring the impact of presenting 
individuals with these different types of information format.
The most obvious limitation of Study 3 was the sample size: in situations where no 
group differences were detected, we were unable to say with any confidence whether 
we believed this truly indicated similar levels in each group, or whether we were 
simply underpowered to detect differences that would have been detected had we used 
a larger sample size. Future research is needed which incorporates genetic testing for 
common gene variants into intervention studies which have carefully defined the 
primary outcome variables of interest, and for which power calculations have 
specified the appropriate numbers of participants needed for each group. A further 
consideration regarding the sample size, was that the final sample of 61 had been 
whittled down from over 2,000 initial letters of recruitment. It is therefore extremely 
likely that part of the reason for the lack of differences on motivation to quit and 
depression between the GSTM 1-missing and the GSTMl-present group was that the 
smokers who comprised the final sample were highly motivated and pre-selected for 
being able to cope with the results. Unfortunately, data was not collected on those 
individuals who were invited to take part in the research, but who declined to do so. 
The collection of this information would have shed light on the extent to which people 
had self-selected themselves into the research study, and on what bases.
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Another limitation of this study was the recruitment process: it was a mistake to ask 
all smokers to whom the letter was sent, to return the tear-off slip if they wanted more 
information about the study or about the NHS service generally. This had been partly 
done as a means of helping the local service get more smokers into their programs, 
but was also done so that we were able to talk to as many smokers as possible. 
However, this part of the recruitment process was time consuming and it would have 
been better had we made the distinction between the study and the service much more 
explicit in the original letter.
Study 3 was also limited by the information which participants received. Everyone 
recruited into the study received some information about the design of the study, and 
informed that they may be randomly allocated to be offered genetic testing, but only 
the smokers in the genetic testing group were given full information about genes, 
detoxification, GSTM1 and so on. It is therefore possible that the differences 
observed between the genetic testing groups and control group were due to the 
additional information which they received as part of the Stage 2 informed consent 
procedure, not due to the genetic testing procedure itself. A future research design 
would benefit from considering this issue of general information about genetics and 
detoxification versus personalised genetic risk information more carefully. Also, 
although we tried to develop a study design in which the two intervention conditions 
(control condition and genetic testing condition) were matched to one another, it 
turned out to be difficult to justify the Phase 2 session with the control group 
participants, and so this session ultimately was only conducted with those in the 
genetic testing group. Therefore, despite our best intentions, the genetic testing group 
did in fact receive one additional face-to-face session with the researcher-adviser, 
which could also have created the differences between the groups. Future research in 
this field will need to ensure that the two conditions are more effectively matched, in 
order to be able to better address which components of the intervention are 
specifically influencing outcomes.
Finally, a further limitation of this study, and indeed of the preceding studies as well, 
was that it was not conducted within a strict theoretical framework, using established 
social cognition models such as the Health Belief Model or the Theory of Planned 
Behaviour. Although these models were taken into consideration in the design,
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implementation and interpretation of this research, it was felt that the key objectives 
of this research were to demonstrate the feasibility of conducting health psychology 
research in the fields of common genetic variation and genetic testing for complex 
disease susceptibility. However, it is recognized that this was a limitation of this 
work, and that future research will benefit greatly from drawing more directly on 
established models of health behaviour.
3. The policy context
In order to put the findings from this research into context, it is useful to re-cap how 
genetics research has developed over the past century, the implications of these 
developments for policy and regulation, and how health psychology and health 
behaviour research may be useful in informing the present debates about the clinical 
utility of the emergent genetic tests for common gene variants.
3.1. Tracing the history of genetics research: from Mendel to the Human 
Genome Project
In order to fully understand the current social complexities surrounding genetics, it is 
necessary to have at least a brief understanding of the history of genetics research 
over the past century. Although the laws of heredity were discovered by Gregor 
Mendel and his peas as far back as 1866, his findings were largely ignored, and were 
not rediscovered until the early twentieth century. In 1944 DNA was recognized as 
the hereditary material (Avery, MacLeod & McCarty, 1944), and the structure of 
DNA was famously determined by Watson and Crick in 1953. The genetic code was 
elucidated shortly afterwards (Nirenberg, 1963), and since then we have seen 
increasingly sophisticated technologies being developed for the purpose of examining 
DNA and genes: in the early 1970s recombinant DNA technologies were developed 
(Jackson et al, 1972; Cohen et al, 1973); the following decade saw increasingly 
automatable methods for DNA sequencing established (Sanger & Coulson, 1975; 
Maxam & Gilbert, 1977).
The development of increasingly sophisticated computational biology and 
technologies is important, because the generation of genetics knowledge is dependent
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on those technologies. For example, the genetic mutation that causes Down’s 
syndrome was determined as far back as 1959, when Lejeune and Jacobs, working 
independently, first determined the cause of Down’s syndrome to be trisomy 
(triplication) of the 21st chromosome (www.ds-health.com/trisomy.htm). This was 
possible with the relatively limited technology available at that time because 
chromosomes can be seen down microscopes, albeit pretty powerful ones. As the 
technologies developed, it was possible to detect not only chromosomal 
abnormalities, but also specific genetic mutations packaged within the chromosomes. 
In 1989, it was discovered that cystic fibrosis was caused by mutations in a single 
gene -  the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. Since that time, 
more than 900 mutations of this single gene have been identified (www.genome.gov). 
Back in 1993, scientists isolated the single abnormal gene that causes Huntington’s 
disease on chromosome 4. The gene codes production of a protein called 
“huntingtin,” whose function is still unknown. But the defective version of the gene 
has excessive repeats of a three-base sequence, “CAG” (www.genome.gov; 
www. st an fo rd. edu).
Crucially, all of these diseases are chromosomal, mitochondrial or single-gene 
disorders. In contrast, the majority of common diseases prevalent in the Western 
world are complex, or multifactorial, caused by multiple genetic and environmental 
factors all interacting with each other. The technologies available in the 1980s were 
unable to examine these interactions effectively, because so much of the human 
genome was unexplored. However, the emergent sequencing technologies were 
showing promise and so, in 1990, the internationally collaborative Human Genome 
Project (HGP) was established. The HGP’s ultimate goal was to generate a high- 
quality reference DNA sequence for the human genome’s 3 billion base pairs and to 
identify all human genes, and powerful analytic technologies were developed for this 
purpose (www.ornl.gov/hgmis/publicat/primer). Although the HGP gave itself 15 
years to complete its task, a working draft of the entire human genome was completed 
in June 2000, and the Project declared finished two years ahead of schedule in April 
2003.
306
C h a p i c r 9 :  D i s c u s s i o n  a n d  c o n c l u s i o n s
3.2. Consequences of the Human Genome Project for genetics research
The sequencing of all of the three billion base pairs in the human genome has led to 
an explosion in gene-disease “association studies”, studies which essentially compare 
the frequency of a specified genetic variation (a gene or a SNP -  a single nucleotide 
polymorphism) in one group (e.g. a group of lung cancer patients) with the frequency 
of the same variation in a second group (i.e. a control group of people without lung 
cancer). A recent study showed that meta-analyses of such genetic association studies 
have increased rapidly over the past decade: between 1994 and 1998 there were 27 
published meta-analyses of genetic association studies, whereas between 1999 and 
2003 there were 90 such meta-analyses (Munafo and Flint, 2004). There are now 
approximately five new gene-disease associations being made per week (Austin, 
2004), and the range of diseases and traits covered by such studies is extremely broad, 
including lung cancer, bladder cancer, obesity, diabetes, anorexia, bipolar disorder, 
depression, emphysema, and cleft lip (Hirschhom et al, 2002). However, it is 
essential to acknowledge the limitations of this research at the present time: the 
survey of 600 positive associations between common gene variants and disease 
showed that most reported associations were not robust; of 166 associations that were 
studied three or more times, only six were replicated consistently (Hirschhom et al, 
2002).
3.3. Clinical applications of genetics research
This explains why the developments in complex disease genetics are yet to be turned 
into clinically useful applications. Almost all of the 300 types of genetic tests 
currently offered on the UK NHS are for rare single gene disorders, such as cystic 
fibrosis and Huntington’s disease (Parliamentary Office of Science and Technology 
(POST), www.parliament.uk/nost/ home.htm, accessed 20 April 2005). However, 
the number of genetic tests being conducted annually by the NHS is steadily rising 
(POST, accessed 20 April 2005), and at least three additional applications of genetic 
testing are anticipated. First, as genetics research progresses, genetic tests should be 
able to identify individuals with an increased genetic susceptibility to common 
diseases, such as heart disease, which will aid clinical management. Second, 
pharmacogenomics (the examination of the relationship between genetic variation and
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an individual’s response to medicine) will mark a departure from the “one size fits 
all” approach to prescribing, to one where the results of a pre-prescription genetic test 
guide subsequent drug selection and dosage levels. Third, genetic testing will aid in 
the area of molecular pathology; the rapid and simultaneous analysis of a number of 
genes offers the potential to obtain a molecular signature for diseases such as cancer 
which have great individual variation, to guide subsequent prognosis and treatment.
3.4. Quality assurance and patient safety
Whatever the application of genetic testing is, quality assurance and patient safety are 
critical issues. ‘Quality’ is a broad concept that applies to all aspects of the genetic 
testing process, right from the laboratory to the test result feedback: clearly it is 
essential that the test itself yields accurate results, and that the lab be competent to 
perform tests to an acceptable standard. But in addition to the analytic phase of 
testing, the clinical interface with the patient is equally critical to ensuring quality 
testing. The approach to quality must therefore be multi-tiered (World Health 
Organisation, www.who.int/uenomics/policv/ quahtvsafetly/en/print/html. accessed 
20 April 2005). Analytic validity, clinical validity, and clinical utility are widely 
accepted as the criteria against which the overall efficacy of a genetic test should be 
assessed. Analytic validity refers to whether the laboratory is competently and 
accurately conducting the test. Clinical validity refers to the extent to which a 
specific genetic variant is associated with the given disease; for example, the 
Huntington’s disease genetic test has high clinical validity because the disease gene 
mutation confers a 100% chance of developing the disease, whereas the BRCA1 
breast cancer genetic test has low clinical validity because the BRCA1 gene mutation 
may confer as low as a 35% lifetime risk of developing the disease. Clinical utility is 
the extent to which the test is useful to the patient. Whether the aim is to diagnose a 
single-gene disease or provide information on a complex disease susceptibility, there 
is wide consensus that all genetic tests should be evaluated on these three criteria. So, 
who ensures that these criteria are adhered to?
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3.5. Ensuring the effective oversight of genetic tests
The human genetics regulatory frameworks of the United States and the UK are 
arguably the most developed at the present time. In the US, the Centres for Disease 
Control and Prevention’s Public Health Practice Program Office, Division of 
Laboratory Systems developed recommendations for quality assurance of genetic tests 
in 1999. US regulation of genetic testing laboratories is currently under the umbrella 
of the Clinical Laboratory Improvement Amendments (CLIA), which extends federal 
regulation over nearly all US clinical laboratories. The quality of genetic testing kits 
is also regulated by the US Food and Drug Administration (FDA). In addition labs 
may conduct voluntary genetic testing proficiency evaluations through professional 
organisations such as the College of American Pathologists (CAP) or the American 
College of Medical Genetics (ACMG). CAP and others have formulated guidelines 
for best practice for labs performing these tests. Similar professional organizations, 
such as the American Society of Human Genetics (ASHG) and the National Society 
of Genetic Counselors (NSGC), along with patient advocacy groups and others, have 
developed standards for geneticists concerning informed consent, counselling 
practices, appropriateness of tests, and other issues. The overseeing body is the 
Secretary’s Advisory Committee on Genetics, Health and Society (SACTGHS).
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), 
established in 2003, ‘safeguards public health by ensuring that medicines and medical 
devices for human use, sold or supplied in the UK, are of an acceptable standard of 
safety, quality, efficacy, and performance’ (Human Genetics Commission, 
www.hac.aov.uk, accessed 20 April 2005). Genetic material for therapeutic use is a 
medicinal produce and is therefore regulated by legislation that applies to medicines. 
The MHRA is an executive agency of the Department of Health with trading fund 
status. The Committee on the Safety of Medicines (CSM), also established in 2003, is 
responsible for providing advice to the UK Licencing Authority (Government Health 
Ministers) on whether new products submitted to the UK MHRA should be granted a 
marketing authorisation. The other statutory body is the Human Fertilisation and 
Embryology Authority, which was established in 1991. In addition, there are three 
main advisory bodies: the Human Genetics Commission (HGC, established 1999); the
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Gene Therapy Advisory Committee (GTAC, established 1993); and the Genetics and 
Insurance Committee (GAIC, established 1999).
Even in the UK and the US, genetics policy is far from fully developed, and genetic 
tests continue to be introduced in an ad hoc manner (POST, accessed 20 April 2005). 
There is international agreement that analytic validity, clinical validity and clinical 
utility should be assessed and confirmed before genetic tests are introduced, but this 
has not yet been fully implemented at a policy level anywhere in the world. What 
legislation does exist, focuses almost exclusively on the quality of the genetic testing 
process within the laboratory -  the clinical utility of the tests goes largely ignored. 
This is fine, if it is agreed that clinical utility is not an important evaluation criteria for 
genetic tests. If, however, it remains to be felt important, then policies and regulatory 
frameworks are going to have to start to find ways to assess utility and implement 
ways of ensuring that genetic tests meet this aspect of the evaluation criteria. The 
policy field, like the genetics research itself, is in its infancy, and many countries in 
the world have no regulation of human genetics tests whatsoever; it was as recent as 
2004 that the European Society of Human Genetics (ESHG) and the European 
Commission’s Expert Group on Genetic Testing expressed the need for harmonizing 
quality standards within genetic testing (WHO, accessed 20 April 2005).
3.6. The relevance of recent developments in the commercial sector
The complexity of regulating genetic tests has been brought into sharp focus by recent 
developments in the commercial sector, particularly companies selling genetic tests 
based on ‘nutrigenomics’ -  the study of the relationship between nutrient intake and 
how our genes function. In 2002, a UK-based company called Sciona 
(www.sciona.com) started marketing a product called ‘Body Benefits Nutrition’ 
which, they claimed, used the ‘latest research’ to “offer their customers a range of 
healthy, informed choices, specially tailored to fit each client’s unique genetic 
makeup”. Although it is not clear from their website exactly what genetic variants 
they test for, their bibliography and examples imply that tests include common gene 
variants such as GSTM1, GSTP1, and MnSOD. In the same year they released a 
press statement saying that ‘Sciona Ltd has received ISO 9001 certification from the 
international certification body Lloyd’s Register Quality Assurance Ltd (LRQA) for
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the provision of genotyping services and products based on generic and lifestyle 
data”. Their claim that this “confirms Sciona’s quality management system meets the 
requirements of the international standard”, highlights the lack of regulatory 
standardization in the UK and Europe -  the Human Genetics Commission makes no 
mention of the LRQA in its statement on relevant bodies regulating genetic tests in 
the UK at the present time (www.hgc.gov.uk).
In addition, the company originally sold its genetic tests direct to the public on the 
internet and on the high street (in The Body Shop, although it quickly pulled out when 
it came under attack for selling the tests). However, in response to criticism from the 
Human Genetics Commission, Sciona now states that “when the implications of the 
information are likely to impact on medical interventions, the service will only be 
provided through a qualified practitioner.” In theory, this is in line with Article 11 of 
the International Declaration on Human Genetic Data (UNESCO, 2003), which states 
that “it is ethically imperative that when genetic testing that may have significant 
implications for a person’s health is being considered, genetic counselling should be 
made available in an appropriate manner” (see Chapter 2). In practice, we are none 
the wiser as to when a genetic test is deemed to have ‘significant implications’ for an 
individual -  again, there has been little discussion or consensus at a local or 
international level as to how this criteria is or should be defined.
A number of other companies also sell genetic tests for common gene variants and 
offer lifestyle advice or more often, ‘customized dietary supplement programs’, on the 
basis of the results. These include: ‘Genovations’ products (‘OsteoGenomic Profile’, 
‘CardioGenomic Profile’, DetoxiGenomic Profile, TmmunoGenomic Profile’, 
‘Genomic Practicum’, and ‘Methylation Test’), which are developed by the Great 
Smokies Diagnostic Laboratories in the US (www. genovations.com): the
‘NutriPhysical Gene SNP DNA Screening Analysis Test Kit’, marketed by Market 
America (www.marketamerica.com); the ‘Nutrigenetic Profile’, ‘Dermagenetics’, 
‘Osteopenia Susceptibility Profile’, and ‘Obesity Susceptibility Profile’ from 
GeneLink, Inc. which is based in New Jersey, US (www.bankdna.com). and the 
ONETest developed and marketed by the Canadian-based One Person Health 
Sciences (www.onepersonhealth.com).
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The quality of information provided on the companies’ websites varies widely, from 
almost no information on any aspect of the genetic tests (e.g. www.bankdna.com), to 
extensive information on the One Person Health Sciences website 
(www.onepersonhealth.com). One Person Health Sciences tests individual’s DNA 
samples for the presence of variations in 19 genes, which “have been chosen because 
they are markers for some of the most essential processes in the body’s metabolism”. 
They cover seven “major areas of metabolic activity”: Antioxidant Activity (GSTM1, 
GSTP1, GSTT1, S0D3, MnSOD); B Vitamin Pathways (CBS, M STR R , MTHFR, 
MTR); Bone Health (C0L1A1, IL-6, TNFalpha, VDR); Detoxification (GSTM1, 
GSTP1, GSTT1); Heart Health (ACE, APOC3, CBS, CETP, eNOS, IL-6, LPL, 
MnSOD, MS MTRR, MTHFR, MTR, S0D3); Inflammation (IL-6, TNFalpha); and 
Insulin Sensitivity (ACE, PPARgamma2). The disclosure of the genetic variants 
which the company is testing for makes it easier to judge the clinical validity of the 
genetic tests which they are marketing; there is therefore possibly a case to be made 
for bringing in regulation which insists companies should disclose this information (as 
implied by Haga et al, 2003).
However, determining the clinical validity of the tests, i.e. the strength of the 
association between the genetic variant and the disease or physiological process, does 
not directly help us determine the clinical utility of the test, i.e. the extent to which the 
information is deemed to be useful by the clinician, patient or consumer. This is 
particularly important given the directive that genetic counselling should be provided 
alongside genetic testing, but only i f  the genetic test result has “significant 
implications for a person’s health” (UNESCO, 2003).
The position of the commercial companies on whether their tests have “significant 
implications” is somewhat contradictory. This can be illustrated by looking at the 
One Person Health Sciences ‘Ethics Statement’
(www.onepersonhealth.com/legal/ethics.isp). It is interesting to observe that they 
attempt to demonstrate that their ONETest for 19 gene variants fulfils the genetic test 
evaluation criteria of clinical validity and clinical utility (they don’t seem to prove 
they have analytic validity) by having four “strict criteria for including any test”: the 
first criterion is that “the test must provide useful information to the individual -  
information on which they can realistically act and which will improve their health
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benefits”. This is a clear attempt to demonstrate that their tests have clinical utility. 
The second criterion is that “links between the variation and specific practical 
beneficial lifestyle choices (e.g. diet) must be established and referenced in multiple 
independent peer reviewed journal articles in scientific literature”. Clearly, they are 
suggesting that their tests have clinical validity.
However, the third and fourth criteria are, “One Person Health will not provide tests 
for single gene diseases directly to the public” and, “One Person Health does not 
provide genetic services for forensic or paternity testing”. Here they seem to be 
distancing their genetic tests for common gene variants, from genetic tests which have 
more significant implications for health and wellbeing, such as those for single-gene 
disorders or paternity. The implication is that, on the one hand, their genetic tests 
have sufficient clinical utility to be of use to consumers, but not so much utility as to 
suggest that their tests should only be supplied by a genetic counsellor (note that their 
test results are given in a “Nutritional and Genetic Report” sent through the post, not 
in-person). Whilst this may be true, we at present have to rely on One Person Health 
to tell us that this is the case regarding their tests -  there are no policy guidelines 
which state whether a genetic test for a common gene variant has clinical utility, nor 
whether it has significant implications for an individual’s health. We are therefore 
faced with a dilemma, how should the clinical utility of genetic tests for common 
gene variants be evaluated?
3.7. Evaluating the clinical utility of genetic tests: a role for health psychology 
and health behaviour research
There is little doubt amongst academics that the marketing of genetic tests for 
common gene variants for clinical purposes is premature, based on the clinical 
validity of the tests: clinical validity is dependent on the gene-disease association 
being validated across studies and should not be considered proven until it has been 
adequately replicated (Ioannidis et al, 2001; Hirschhom et al, 2002) -  this has not 
been demonstrated for the types of tests currently being marketed by companies such 
as Sciona. However, it is safe to say that, although these companies are jumping the 
gun, it is only a matter of time before such tests, especially ‘genomic profiles’ for 
multiple gene variants, demonstrate reasonable clinical validity. At which point, the
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key question will become: do these tests have clinical utility? The ‘utility,’ or ‘use,’ 
of these tests stated not only by the commercial companies (e.g. www.sciona.com), 
but also by the Department of Health (2003) and in the literature (e.g. Bell, 1998; 
Bartsch, 1999; Yang et al, 2000; Peto, 2001; Pharoah et al, 2002; Gray & Ponder 
2003; Austin, 2004), is that individuals identified as high risk will be able to take 
action to reduce their risk -  and often, this action is in the form of making lifestyle 
changes, such as altering dietary choices, increasing exercise levels, or quitting 
smoking. Determining the clinical utility of these types of genetic tests can, therefore, 
be framed as the question: Will genetic testing for common gene variants actually 
lead to beneficial changes in lifestyle choices? This question has to be balanced 
against the alternative question, as some commentators suggest, which is that: Will 
genetic testing lead to adverse psychological reactions in those who receive 
unfavourable results, and reduced motivation to engage in health protective 
behaviours in those who receive favourable results?
The theoretical models developed by researchers in the fields of health psychology 
and health behaviour research are ideally placed to be informative in addressing these 
questions. Perceived disease susceptibility is a central component of many social 
cognition models of health behaviour change such as the Health Belief Model (HBM: 
Rosenstock, 1974), Protection Motivation Theory (PMT: Rogers, 1975; 1983) and the 
Health Action Process Approach (HAPA: Schwarzer, 1992). Using smoking 
cessation as an example, these models suggest that informing smokers that they are 
genetically susceptible to the harmful effects of smoking could increase their 
motivation to quit smoking. However, some fear-appeal models, such as the PMT 
and the Extended Parallel Process Model (EPPM: Witte, 1994; Witte & Allen, 2000), 
suggest that increasing fear amongst individuals who have low self-efficacy could 
actually undermine their motivation to quit smoking, and even make them ‘deny their 
smoking problem’ (Wang et al, 2004). It also follows that informing smokers that 
they are not genetically susceptible could decrease their motivation to quit, and there 
is the danger that people who are found not to be at increased risk could develop a 
false sense of reassurance, feeling invulnerable to the adverse effects of their risk 
behaviouf (Marteau & Lerman, 2001). We might therefore hypothesise on the basis 
of these models that genetic testing for common gene variants may be beneficial to 
those individuals who are identified as having an increased genetic susceptibility to a
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behaviour-related disease and who have high self-efficacy, but harmful to those who 
have low self-efficacy beliefs, or who are identified as having a decreased genetic 
susceptibility.
The methodological approaches employed by health psychology researchers are also 
useful. One method used to address the acceptability of emergent genetic tests has 
been to conduct quantitative surveys of interest in testing amongst the relevant 
groups, either amongst subgroups of people who have been identified as being at high 
risk of the disease in question, or at a population-based level (e.g. Meiser et al, 2000; 
Bratt et al, 2000; Braithwaite et al, 2002). These large-scale survey approaches are 
useful not only because they provide a snapshot of public opinion about genetic tests 
at that moment in time, but also because they help identify characteristics of people 
who may put themselves forward for testing, and conversely those who may avoid it.
Health psychology researchers have also attempted to explore the effects of genetic 
testing using ‘vignette’ studies, or studies in which people are presented hypothetical 
scenarios in which different aspects of the genetic testing process have been 
manipulated (Senior et al, 2000; Wright et al, 2004). These types of studies are useful 
in exploring the effects of a specific genetic test prior to the availability of that test.
Ultimately, as highlighted by Campbell et al (2000), a methodological approach well 
suited to address many questions in health psychological research is the randomized 
controlled trial (RCT). This should prove particularly useful in determining the 
clinical utility, or psychological and behavioural impact, of genetic testing for 
common gene variants, because it directly allows the impact of the actual genetic 
testing on individuals to be examined, whilst controlling for other sources of variance. 
A few studies have been conducted which have employed RCT methodologies 
(Lerman et al, 1997; McBride et al, 2002), the results of which have begun to yield 
useful information on how people -  in these studies they were specifically smokers -  
react to genetic test results for isolated common gene variants (in these studies the 
gene variants were CYP2D6 and GSTM1).
However, there is increasing recognition that the design of studies investigating 
behavioural interventions which are designed to improve health, such as genetic
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testing for common gene variants, should be developed in a phased approach, such as 
that provided by the MRC framework (Campbell et al, 2000). This requires that, prior 
to conducting large-scale, randomized controlled trials, exploratory work should be 
conducted -  such as quantitative surveys and smaller studies utilizing randomizing 
and control groups -  in order to determine the feasibility and acceptability of these 
larger RCTs, and to identify any potential problems or barriers to the intervention 
being successfully implemented.
4. Conclusion
In conclusion, it is hoped that the research presented in this thesis demonstrated that 
the MRC framework for the development and evaluation of complex interventions 
designed to improve health (Campbell et al, 2000) provides a useful framework 
within which to conduct research on genetic testing for common gene variants. It is a 
challenge for health behaviour and health psychology researchers to investigate the 
effects of genetic testing for common gene variants, without coming under attack for 
the same reasons that some commercial companies have been criticized. One 
example of such criticism is that the gene-disease associations for common gene 
variants and common, complex diseases have not yet been reasonably replicated and 
proven, and so it is premature to give individuals genetic risk feedback based on tests 
for these gene variants. However, determining clinical utility, and developing 
appropriate policy for regulating emergent genetic tests, is reliant on the production of 
ethically sound and well-justified empirical research by researchers in the academic 
field. I hope that the research presented in this thesis, and the use of the cautious, 
phased approach recommended by the MRC framework, has generated preliminary 
data that will be useful in designing and interpreting future research, and 
demonstrated that it is possible to provide empirical evidence to inform the debate 
about the utility of genetic testing for complex disease susceptibility.
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The effects of a genetic information leaflet on public 
attitudes towards genetic testing
Saskia C‘. Sanderson, Jane Wardle and Susan Michie
are. tfrGenetics opinion surveys often include information to 
dents have sufficient understanding to give informed re^onses^l  ^
tion is assumed to be neutral, but may skew respodsey. We 'assessed the 
impact of a seemingly “neutral” information leaflet \?n a«iitjdes towards 
genetic testing among 1,024 survey respondent^half^df \vhoafreceived the 
leaflet. The leaflet group reported higher levels 0$ subj^ctiVe understanding of 
genetic testing ( 6 8  percent vs. 53 perceisf)\ \ter£\ino*e interested in genetic 
testing (81 percent vs. 77 percent), apdibdfd mbce_p.osifive attitudes towards 
genetics than people who did iiot receive thV.leaflet. Information leaflets may 
have the intended effect 0/  iji6 rea i^n  ^ und^fcmding, but may also uninten­
tionally influence reported viewy ^ ^genetics^Tn the light of the weight given 
to public consultation in \ today'y governance and legulation of human 
genetics, increased awareness'of hbyr even seemingly neutral information can
influence public, attitudes is recchim&ided.1 /
I  , \
1. Inti*oduc|ion ^ 4   V- /
< y '\, \ .............■\x x \ \  \
The yKTgove^iimfnt’^  advisory body on human genetics, the Human Genetics Commission 
(HQCV'recently stated that it was “not [their] job to offer detailed regulatory advice,” but 
d^thflf tO/'^gauge Opinion and offer suggestions about what the regulation of genetic tests 
might IboX like” (Human Genetics Commission, 2003). This focus on ''gauging public 
opinio^r highlights the weight given to public consultation in the governance of human 
genetic,S411 th£ UK at the present time, and suggests that the results from social surveys of 
public attifrides may have a very real influence on the regulation of human genetics 
technologies.
Surveys of public opinion often suggest that the public feel positive towards human 
genetics, especially in die case of genetic testing, where high levels of public interest in 
genetic testing for disease susceptibility are almost always reported, regardless of disease type 
(e.g. Bosoinpra et al.. 2000; Shaw and Bassi, 2001: Bunn et al., 2002; Sanderson et al., 2004). 
It is clearly important that these surveys represent the public's views regarding human 
genetics as accurately as possible, as well as that they consider possible factors that could— 
deliberately or inadvertently—influence public opinion. One consideration is the way in 
which accompanying information is presented. Because there tends to be an assumption that
© SA GE Publications ISSN  0963-6625 DOL 10.1177/0963662505050993
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the public's, understanding of genetics and genetic testing is limited (Henderson and Maguire. 
1998; Singer et al., 1998). surveys of attitudes towards genetics are often accompanied by at 
least some basic genetics information to ensure that respondents have sufficient understanding 
to answer the questions, e.g. “by genetic test we mean Obviously if is hoped or assumed 
that any information leaflets or other sources of information that accompany surveys should 
increase understanding without directly influencing attitudes.
However, the task of increasing understanding without: influencing attitudes may not be 
straightforward. The considerable body of literature on die relationship between under­
standing and attitudes towards science provides evidence that understanding of science is 
related, albeit sometimes weakly, to holding more positive attitudes rowardy4ctence (Evans 
and Durant, 1995; Wroe and Salkovskis, 1999; Sturgis and Alium, 2004). At the4anie time, 
there is evidence that as people gain more knowledge about some specific h^m^n genetic 
technologies such as cloning, they in fact have more arguments against the tecfiisplogy (e.g. 
Wellcome Trust, 1998), and this is consistent with the observation that.peqple \¥bosaj.e^nore 
knowledgeable about science hold more positive attitudes generator, but have more 
developed arguments against specific technologies (Evans and Durant, \995)i Ip. addition, 
evidence from a different field, that of clinical genetics, suggests thgt .inforijiation that is 
intended to be non-directive could unintentionally influence/attitudes, ^roe and Salkovskis 
(1999) for example, showed that information about geneiics’yand breast cancer given to 
people prior to making a decision about opting for^geneti^xtesfing^influenced both their 
testing decisions and their ratings of the severity of breast cancer, which challenges the 
notion that apparently non-directive mfednatioji ri>ali  ^is\peutral.” There has been little 
investigation of the impact o f the i^dora a^tiorl tfiat accopi^anies surveys, or indeed of 
genetics information leaflets more brc^ly^vdn/didividuals’ attitudes. It is possible that 
efforts to increase understanding of geneti^in order to enable people to make an informed 
response to survey questionsAcould have the Unintentional effect of shifting reported 
attitudes in a more positive directing.
In this paper we exammed whether the inclusion of an information leaflet in a public 
opinion survey influenced ,atfit(tdes\pd Iht^est in genetic testing. The leaflet wTas developed 
with the intention o f mcr^a^ipg'Subjectfre understanding of genetic testing and was intended 
to give the information in ay‘ni?utjrar way. However, given the evidence from clinical 
genetics research, Ave ’anticipated that it might have an unintended effect on attitudes. 
Because the,.htain aim\of the study was to examine the effects of the leaflet on attitudes, we 
elected fo use a self-tepoirt measure of subjective understanding of genetic testing rather than 
a mulpr4tem lheasitr^ d f / ’bbjective” understanding, so that respondents were not deterred 
froa^repl^ing by feeling that they were being “tested.” Measuring actual knowledge would 
ahp hai'eybeen difficult given that this was a postal survey, and so respondents could have 
referred to the leaflet or additional sources of information (e.g. books or relatives) when 
answering the questions. We examined whether the leaflet affected interest in genetic testing 
specificallyfand attitudes towards genetics more generally, and predicted that we would see 
higher interest and more positive attitudes amongst people who received die leaflet than 
those who did not, as a consequence o f the increase in understanding.
2. Methods
Design and procedure
Two thousand adults, aged 18 to 75 years, were selected randomly from a general practice 
register of approximately 8,000 adults in Oxfordshire. England. Materials included an eight-
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page postal survey containing questions on understanding of genetics and attitudes towards 
human genetics and genetic testing, and the information leaflet. People were randomly 
allocated to receive either the survey alone or the survey plus the information leaflet. Half of 
the survey instruments asked questions in relation to genetics and cancer whilst the other 
half asked questions in relation to genetics and heart disease, in a 2 x 2  experimental survey 
design (information leaflet vs. no leaflet: cancer vs. heart disease). For the purposes of this 
paper the two disease groups were combined and any effects of disease condition were 
controlled for in the statistical analyses. Questionnaires and leaflets were sent out in January 
2002. Reminder letters (enclosing another questionnaire) were sent out to non-responders 
after three weeks Ethical approval for this study was granted by the National^^aith Service 
(NHS) Gxfordshne Research Ethics Committee and the University Colleg^Londqn Ethics
Committee. ? \
' V \  \
✓ % >Information leaflet /  /"“N, \  ^
L Q 'The content of the information leaflet used in this study was adapteckfrani a/ two-page 
handout on the website of die American Academy o f Family^lTiysicians cajjbefcl “Genetic 
Testing: What You Should Know.T>1 This information source/wpi chqseh after consideration 
of a number of sources because it was deemed to be thembst ^ uifabjle jfor members of the
general population, much of the information literatjn|e ^VaM^bte t>ejrig targeted more to
individuals and families who have been ij0eatHl^<rqis being at lugh risk of developing 
“genetic diseases.” It was also clear andycfo^cise, ^pd begs \  credible and widely available 
source of mfonnation.. The leaflet wa^ pitted ivitji 71 individuals, a focus group, a lay 
representative of the Patient Invoivemeih^Giodp jr t the general practice at which the study 
was conducted, and a UK genetics specialist, Th  ^aim of this pilot work was to develop the 
content and appearance of th^nfomiation tonrike it as accessible, easy to read, and 
balanced as possible. The final Version of the leaflet was double-sided, A5, color and glossy. 
It was titled “Genetics and K$jilth:\A Brief Introduction," with the subheadings “The 
Genetics and Health S iu ^ ^ ^ n d  yU ^ ^ sity  of London.” The first half of the leaflet 
provided background in|bipfip«M al^ouh-genetics under the subheadings “What are genes?” 
and “Howr are genes^ |i|ea to^di^eaie?" The second half of the information leaflet focused 
on genetic testingMde? the i]^bhe^dings: “What is genetic testing?,” “What does a positive 
test resulHm^to?,\“What dote is negative test result mean?,” and “What are the advantages 
ivah i^ges  ^df generic testing?” In response to pilot work a small amount of 
fionway added wt<ler the subheading “What diseases are genetic tests currently 
a1df|»t£d from the “Understanding Gene Testing” pages of the National 
itute website..- The final version of the information leaflet used in this study is 
flefjom the first author, or can be found on our website/
Understanding o f genetic testing A single item was used to measure self-reported 
understanding of genetic testing. Respondents were asked to indicate how’ much they agreed 
with the statement “I have a clear picture of what genetic testing is” by endorsing one of five 
response options (strongly disagree, disagree, not sure, agree, strongly agree).
Measures
Interest in genetic testing A scale was formed to measure interest in genetic testing by 
calculating die mean of the following four items: 1) “Suppose you had inherited something 
from your parents which made you more likely to develop [cancer] [heart disease] than other
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people, would you want to be told this?”: 2) “Would you be interested in taking a genetic 
test for [cancer] [heart disease] risk?”; 3) “Would you haw a genetic test for [cancer] [heart 
disease] risk if your doctor recommended it?”; and 4) “If it were available now, would you 
have a genetic test for [cancel'] [heart disease] risk in the next 6  months?” The last item was 
adapted from an existing measure (Bosompra et ah, 2000). Four response options were 
given for each question (no definitely not; no probably not; yes probably; yes definitely). 
The scale scores ranged from 1 to 4, with 4 being the most interested The alpha coefficient 
of reliability was 0.90.
Attitudes toward genetics Attitudes toward genetics were measured dsin^a 12-item 
attitude checklist. The checklist was adapted from an existing measure (Michie et jh , 1995), 
and contained four positive words (excited, enthusiastic, optimistic, and^hopeftil); four 
negative words (worried, concerned, pessimistic, and hornfied); andTdur npxed-iieptra 1 
words (cautious, indifferent, mixed feelings, and confused). Participahts y;eie askhd to 
indicate which of the words described their feelings about genetics, by endorsing many or 
as few of the words as they liked. The attitude checklist tyarmed in two ^ays. First, 
analyses were conducted on individual attitude words. Setfondrtwo attitude scales were 
created using data reduction techniques, and analyses wejce conducted; op these two scales. In 
order to create the two scales, we first of all conducted ^  prin’cijpafcoiiiponents analysis with 
varimax rotation to see how the words b^i'Tpa^ed tpgethef falpha coefficients were 
inappropriate because of the checklist sfructpre.of the measure). This produced two factors 
accounting for 30 percent of the variadceKifheyWojrds enthusiastic, optimistic, hopeful and 
excited all loaded on Factor 1 witli Hjalde  ^ pVer .50. Cautious, horrified, concerned, 
pessimistic, and worried all loaded on Factbr 2 with values over .40. Factor 1 was therefore 
labeled “Positive Attitude Scoffer and Factor X.wah>labeled “Negative Attitude Score.” The 
remainder of the mixed-neutrik words had low leadings (between .178 and d.480) on both 
factors, but appeared to have Wgatrbe connotations, loading negativelv on Factor 1 . and
positively on Factor 2. Se^TqSle I for faplor loadings.
(  C
T able!* phctor analysis p i attitude towards genetics items: rotated components
Component
1 2
Positive attitude score Negative attitude score
X
Enthusiastic . m .GOO
■s Indifferent -.178 .coo
/C autious -.238 ,435
Optimistic .622 .000
Horrified .142 .582
Confused -.211 .351
Hopeful .518 .000
Concerned .000 .573
Mixed feelings -.480 .331
Excited .611 .211
Pessimistic .000 .421
Wearied .000 .663
Extraction method: Principal Component Analysis. Rotation method: Varimax 
with Kaiser Normalization. Rotation converged in three iterations.
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Statistical analysis
Statistical analyses were earned out using SPSS for Windows v. 10.0. Demographic 
characteristics (including gender, age, and education) of the sample and the frequencies of 
responses (interest, understanding, and attitudes) overall were examined using frequency 
tables, and responses were compared between educational attainment groups using linear 
regressions. Correlations between interest, understanding, positive attitude and negative 
attitude were examined. The effects of the leaflet on understanding of genetics, interest in 
genetic testing, and attitudes were assessed using linear regressions. In order to test whether 
any effect on attitudes (i.e. interest, positive attitude, and negative attitude) wm attributable 
to the effect on understanding, the size of the regression coefficient was compaii^l^n models 
including or not including the score on understanding- If the attitude effect vkas mediated by 
understanding, then including understanding in the regression equation shobld redp.ee the
apparent effect of the leaflet on attitudes. ^  \  \
"" \  \  /
f  V i\  ; }
S. Results  ^ \  /
/ /" "X ’ij
Demographic characteristics i i \  ]
x \  \  V j  /1,024 (51 percent response rate) survey forms were ^tt^ed^witn sijadilar numbers in the 
two groups (517 in leaflet group, 507 in cpntrol gloup^gnd for each disease focus (512 
where genetic testing questions alluded tp'capeer, afrd 542 fqr heart disease). Demographic 
characteristics of the respondents are pft‘sei(ied ija Tpble 2>Tjrere were low’er proportions of 
non-White British respondents than in tl^generailJK. population, which is probably partly 
due to the geographical location of the stitdy, mit there were no demographic differences 
between the leaflet group and the control group.
* x /
XUnderstanding o f genetic t e s t i t i ^ \  x yv
x x y  x  ‘ /
Overall, 61 percent of t)le Xampte'xelf-Tef>orted that they had an understanding of genetic 
testing (see Table ^:> Sei£repofteej understanding did not vary by gender or age, but 
individuals with htgh^ educ^tiohaTattamnient reported higher levels of understanding than 
those \vitKT<m£r ItevelXof educational attainment: 39 percent with no formal qualifications, 
58 percefct 6 6  percent with A-levels. and 74 percent writh degrees felt they had
a cj^ryinderstandihg ofwhat genetic testing was (p < .0 0 1 ).< 2 > X
Interest i f f  genetic testing
Seventy^ninXpercent of the sample reported that they would “definitely” or “probably” take 
a genetic re# overall (see Table 3). The mean interest scale score was 3.3 ± 0.6 (on a range 
of 1 to 4, where 4 — high interest). Interest in genetic testing was higher' amongst those with 
lower lew is of education (90 percent with no formal qualifications; 81 percent with GCSEs; 
78 percent with A-levels; 75 percent with degrees, p <
Attitudes towards genetics
Attitudes towards genetics tended to be a mixture o f positive and mixed-neutral words: 43 
percent said that they wrere cautious about genetics, 37 percent were hopeful, 33 percent had 
mixed feelings, 32 percent were optimistic and 17 percent were enthusiastic. There was less
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Table 2, Demographic dm aetenstics of the sample
n = 1,024 n Percent
Sex Male
Female
455
568
44
56
Age IS—35 yxs 222 22
36-55 vrs 465 47
56—75 yrs 309 31
Marital status Single 222 22
M arried or cohabiting 798 78
Children 0 246 24 „
1 152 i 5 / ; .
2 396 39 ix V
3 166 16 \
More than 3 58 6
Ethnic group Caucasian 1004 .98-— .,.
Non-Caueasiaa 7 /1 f / r  X
Housing tenure Rent from local authority 76 \ ( s \
Rent from private landlord 73 \ J
Own home ,,-7 9 8 7 ^  \ j  r -  ,
Other / /" > 2\  \
Employment status Employed. | 1: 731 N ’i 72
Education
Not employed \  '406 J
b * « i  ^ ( ' K j r r y
None ‘ V  \  167
i l l
18
17
GCSEs X  -  \  \  \  
/  )  ; \ >
\ /  /  ^N.
367
131
37
13
320 33
\
\  <
of a tendency to report negati\V altitudes touhrf&s genetics: 7 percent were worried, 3 
percent were pessimistic and Igp en ^ t were horrified (see Table 3). The method used to 
calculate the attitude sea lesproduc ed a standardized mean score of zero overall for both the 
positive attitude scale and fiie jQegative attitude scale. People with higher levels of education 
held more positive & p^ tp^ s\i.p^ o^ e6  more highly on the positive attitude scale) than those 
with lower .levels©!1 education {pyA  .026), but there was no association of education with 
negative ahi^idet^caie,.scor^--^?'''= .438). 
y \  v /  \
/  /  \  \  \  \delations understanding interest and attitudes
j^hetic testing was positively correlated with positive attitude towards 
= .196, p  < .0 0 1 ) and negatively ’with negative attitude towards genetics 
(r = = .017). Interest in genetic testing was also positively correlated with positive
attitude towards genetics (r = .253, p  < .001) and negatively correlated with negative 
attitude towards genetics (r = -.167, p  < .001). There was no correlation between 
understanding of genetic testing and interest in genetic testing (r = .057, p = .06), nor 
between positive attitude and negative attitude (r =  .0 0 0 , p — 1 .0 0 ).
genetics
Effect o f the information leaflet on understanding o f genetic testing
The leaflet group reported significantly more understanding of genetic testing (68 percent vs. 
53 percent, p < 001) than the control group in the univariate analysis (see Table 3), and die 
effect was maintained when controlling for gender, age and education (see Table 5). 
Including the information leaflet as a dependent variable in die linear regression did not
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affect the beta weights, i.e. the strength of the associations, between demographic factors 
(gender, age. education) and understanding, which indicates that the effect of the leaflet on 
understanding of genetic testing did not vary between different demographic groups.
Table 3. Interest in  genetic testing, understandine o f genetic testing, positive attitude and negative attitude overall 
and separately for leaflet group and control group
(m =  1,024} Overall Leaflet Control P
Interest m genetic testing* 806 79% 418 81% 388 .71% .043
Interest in genetic te s tin g 3.3 (0 .6) 3.3 (0 .6) 3.2 ii '< o % N .020
Understanding o f  genetic testing* 610 61% 346 68% 264 'VS". < <.001
Attitude towards genetics /  \  V \  \
Individual attitude words*1 \ \
Cautious
Optimistic
43S
325
43%
32%
199
182
3954
35% ?r ...4 7 ^  \  '28*4 >\ v  ^ .016Concerned 17S 17% 72 14% I06 V 2lj*4 / .003
Enthusiastic 172 17% 109 21% ^ - - I k . '~ <.001
Worried 72 7% 28 4%
38%,'
-v. 4 X  V^-- - 9% .041
Hopeful 377 37% 198 >79 ) 
177 j
35% 321
M ixed feelmgs 333 33% 156 ,- X 3 b % \ . 35% .106
Confused 89 9% 3 7 /4 5 2 /
~ ^ 2
10% .078
Excited 73 7%,-~" -  •*! \  c  - 6% .314
Indifferent 44 4% X 52 \ , x4 % 22 4% ..947
Pessimistic 29 '4  10
/  J*
\  2% 19 4% .080
Horrified 19 < 20 2% .784
Positive attitude acade* 0.00 ^ 2 .00/  /  0.11 (1.05) - 0.11 (0.93) .001
Negative attitude scale* 0.00 <1)3Q) \ - 0 . I 0 (0.91) 0.10 <1-11) .001
Proportion o f  respondents who would, /definitely or ^ d fe a b ly  take a genetic test, using a smgle iteanc v y \s * ~measure. \  /4 \  .Mean, (standard deviation) interest flav^ enetk; testing when calculated by taking the mean o f  four separate
‘‘interest’’ items. / -----7  \
e Proportion of respondents w hd ‘‘agreed’’-gi '‘strongly screed’’ w ith the statement “I have a clear picture o f what 
genetic testing is"’ on a five^jx^inf scale. )
d Propoilioa o f  respondents ticked each ,individual word on the attitude checklist. 
c M ean (standard deviation)' /
. V > ^ \  \
/  \  <s x  \  \
/  \  \/  \  \  \
\ /
Table 4.\£on'elations betw een interest in  genetic testing, understandmg o f  genetic testing, positive attitude towards 
genetics, add negative attitude towards genetics
Understanding o f  
genetic testing
Positive attitude 
towards genetics
Negative attitude 
towards genetics
Positive attitude towards genetics Pearson .196**
Sig. .000
Negative attitude towards genetics Pearson -.075* .000
Sig. .017 1.000
Interest m  genetic testing Pearson .057 .253** -.167**
Sig. .069 .000 .000
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed).
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Table 5. Regression analyses of (he associations between demographic 
characteristics, self-reported understanding of genetic testing, with and 
without information leaflet
Dependent variable Beta weight Significance
Under:landing o f  genetic testing
Model 1 Gender (m = 0 , f = l ) .044 .174
A se .045 .179
Education .204 <.001
Model 2 Gender (in= 0 . f=  1) .043 .176
A se .042 .197
Education .215 <.001 I
Leaflet (no leaflet =  0, leaflet = 1) .192 < .001 )c> <,\  /\
\ \
s \Effect o f the information leaflet on interest in genetic testing \ \  j  i
Interest in genetic testing was higher in the leaflet group than the conhol gioup ^Sl percent
X = .0 2 0  on
the interest scale. Table 3). i‘ i \  \i /1 I
\f  \  *'• ( X v’ in ericsEffect of the information leaflet on attitude towards<
Respondents in the leaflet group were more enthusiastic (24 percent vs. 12 percent), more 
optimistic (35 percent vs. 28 percent), fhd l^ss .Cautibus/-(39 percent vs. 47 percent), 
concerned (14 percent vs. 21 percent), ^dW fripdf (5 percent vs. 9 percent) about genetics 
than those in the control group. Figure 1 shows(vthe differences between the two groups for 
all o f the attitude words. \
Overall, the leaflet group r?pdrted more posh&e attitudes towards genetics (0.11 ±  1.05 
vs. -0.11 ±  0.93, p  = .001). <anii less negative attitudes (—0.10 ± 0.91 vs. 0.10 ± 1.11,
- " - v X  X  y V .^ / \  //  X. X
H opeful’ j 
Optin^sffc
■£
\  x©dut)dus 
\  fftixed 
CbQfubQd
lii1
Concerned
Worried
Pessimistic
Horrified
□  No leafiel (n=502)
Leaflet (ri=5t6)
600 10 20 30 40 50
Respondents who endorsed attitude work (%} 
Figure 1. Attitudes towards genetics compared between leaflet conditions.
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p  = .001) than those in the control group (Table 3). The linear regression with positive 
attitude as the dependent variable, and gender, age, and education as control variables (see 
Table 6 ), showed that the effect was independent of demographic effects (beta = -.123, 
p  < .001). To test whether this effect on attitudes was attributable to the increased 
understanding, the understanding score was included in the regression model. The beta 
weight associated with the leaflet was very little reduced (beta = -.090, p  = .005).
Table 6, Regression analyses o f the independence o f the effect o f the ^  
mfonnation leaflet on interest in genetic testing (scale), positive attitude /  p  
towards genetics, and negative attitude towards genetics
S <Dependent variable
Education /  ^
Interest in genetic testing 
Model 1 Gender (m =0, f  =  1)
Age
Education
Model 2 Gender (m = 0. / =  1)
Age
Education
Leaflet (no leaflet = 0, leaflet = 1) 
Model 3 Gender (m -  0, f =  1) a '~~
a*  '
le t= 0, leaflet
, V
Positive attitude 
Model 1 Gen 
Age
Model 2 0 m d ^
Age f
Education 1 j 
A$jepC&et (hb J t e a f l e t l e a f l e t  =  1)
<VX . GtaHr(m-0. f - l )
A y  < \ V
/  j /  L ^ fie t (no leaflet =  0. leaflet = I)
xjflderstanding
/
\
\ \
\
Beta weight Significance
.014 659k •
.155 c oql (
-.130 <.oo^
.014 /
m  (  i^  "004 \
-OSO.y * 's .0 0  j
V K .032 /y
'017 \. .....593
Y o k  \
+ iio  \  ">
.004
M l
/- .055  ^ .096
.079 .018
A 0 6 3 .050
.035 .289
.098 .003
-.064 .046
.049 .140
.103 .001
.126 <.001
-.065 .043
.047 .155
.068 .042
.090 .024
.170 <.001
.029 375
-.145 < .001
-.030 336
> y
Negative attitude
Model 1 Gender (m =0, f = l )
Age
Education
Model 2 Gender (m =  0, f — 1) . 035 .2 79
Age -1 3 1  <.001
Education —.032 .337
Leaflet (no leaflet= 0 , leaflet = 1 ) -.101 .002
Model 3 Gender fm — 0, / =  1) .03 7 .257
Age -.130  < 0 0 1
Education -.017  .012
Leaflet (no leaflet= 0 , leaflet = 1) -.084 .011
Understanding -.059  .076
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indicating that the effect on attitudes was largely independent of the effect on under­
standing.
4. Discussion
In this study we found that including a genetic information leaflet in a human genetics 
survey had the intended effect of increasing respondents’ sense of understanding of genetic 
testing, albeit modestly and on a perceived rather than objective measure. Survey respon­
dents who receive this type of information may therefore be in a better position to answer 
questions about their attitudes to genetics. However, the effect of the leaflet Wipterest in 
genetic testing, and on attitudes towards genetics—increasing positive attitudes and decreas­
ing negative attitudes—suggests that the concerns about non-directivenessarHneutrality 
which have grown up in the field of genetic counseling consultapbnjma^aik^ tte of 
relevance in the context of public opinion surveying or written information ihat^rials^
One possible explanation for this is that the shift in interest anas attitude^ wbs a direct 
consequence of the difference in understanding of genetic testjng'thab^a§also^ofjserved, i.e. 
it was the content of the information that led to the changes matHpide. This fits with the 
historical assumptions that more understanding of spepqe (or gehefics) leads to more 
acceptance (Evans and Durant, 1995). How'ever, th$ results df“the regression analyses 
earned out in this study suggested that the effectpfthe leaflet on attitudes was independent 
of the effect on understanding. An altem^iv^ explanation lS'that it was something about the 
appearance of the leaflet that affected^ttithdes JThte Elafeor^kon Likelihood Model (ELM) 
proposes, for example, that under sohje cricu^istances people form their attitudes in 
response to peripheral cues such as the attractiveness and source of the information provided 
(Petty and Cacioppo, 1986). People in the leaflet gfpup in this study may have become more 
positive in response to the fecMhat the informahbfi leaflet was glossy and colorful, and that 
it came from the University' o^Loikjon. Previous studies have found, for example, that 
universities and scientis^are^tedsmbfe')positively and as more trustworthy sources of 
information about genetics tHarTThe government or commercial companies (Frewer et al., 
1999). Alternatively^ as\^\'roe,al!d ^alkos'skis (2000) suggested, people may become more 
positive and accepting of genetic technologies when they' have been encouraged—or 
‘"prompted’yA-tp fpcu^ on rite positive aspects. It is known that people are more positive 
to\vards vgen^ticKin the context of treating or preventing disease, and so the focus of the 
leaflet/m ‘genetic'‘testiQ1g'x and disease may have positively influenced attitudes. Further
jC  /  / \  V \  v
Judies \yould be heeded to disentangle these possibilities.
\ x AbecOndary finding in this study' was that understanding of genetic testing, and positive 
attitudes ipwards genetics generally, wrere higher amongst respondents with higher educa­
tional d^auiipent. But paradoxically, people with higher educational attainment were less 
likely to express interest in genetic testing than those with less education. In feet this is in 
line with previous studies which have found that people at the lowest educational levels tend 
to be the least informed but the most willing to accept routine medical procedures (Press and 
Browner, 1997). People in the higher education group may pay more attention to, or have 
better access to, sources of information regarding advances in genetic technology, and so 
have a more realistic understanding of the limited predictive capabilities of genetic 
susceptibility testing at the present time. The inclusion of the information leaflet did not 
reduce the educational differences in understanding in our sample, and a future research 
priority may be to develop more effective ways of targeting information at different social 
groups.
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A further finding was that there were at least two dimensions to attitudes when 
measured using a multiple adjective checklist approach. This has additional implications for 
survey methodologies. Measures of attitudes towards genetic s have been criticized by Pardo 
and Calvo (2002) for being weak and subject to misinterpretation, particularly the attitude 
statements wrhich are commonly used. In particular, the single dimension produced by 
attitude statements disallows the possibility of individuals simultaneously holding both 
positive and negative views. Our factor analysis demonstrated that at the very least people 
hold these two sets (positive and negative) of views independently of one another, which 
suggests that attitude scales should be developed which measure at least these twro separate 
constructs. / O '
Unfortunately, it was not possible to determine -which aspects of the in&rckaiQpn leaflet 
had the most significant effects on attitude in this study, and future studies £hould address 
this, for example by varying the content and appearance of the infoimation. lt m^y also be 
interesting to compare people’s responses to different sources of mfoimatiuri.\ucb as 
medical information, self-help group information, and media information. Ah^thV obvious 
limitation of this research w as that a self-report measure of understanljrn^Gf gto^tic testing 
was used. We elected not to have a true knowledge test bbcaiise^nf the .difficulty in 
obtaining objective measures of understanding. Howrever, it is irfipo^an^to find out whether 
these types of simple written information do increase kh^wle^ge/ or only induce an 
illusion of understanding, and also whether they are dr^erbntially effective in more or less 
educated groups. Future studies will need to deyelbp nipre objective measures of under­
standing, and may also consider examining v/hether jhe effects reported here hold over time. 
Despite these caveats, the findings repprtetfhere’ may be of iriterest to health professionals 
and researchers involved in the develojtepedts^f genetic information leaflets, and to those 
involved in assessing public attitudes towa^s genetic testing. As far as we are aware, this 
study is the first to examine thee fleets of a g^etiCyLnformation leaflet on attitudes towards 
genetics in a population sarnpl .^ /  v/
In conclusion, the results 6f,J^i^tudy suggest that including information in genetics 
surveys has the intended effect of Increasing people’s perceived understanding of genetic 
testing, but that there may grlsp be an additional unintended influence on their reported \riews 
on genetics and gene^/estTng,Iil)li|ht of the weight given to public consultation in today’s 
governance^ and regulation of liujiian genetics, an increase in awareness of how even 
seem ingly^^|aixi^fc^^tio1ei ctih influence public attitudes may be recommended amongst 
health^hifesthoitalsj^rps^atchers and pohcy informers.
/ /  . \  \  ' V
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Appendix A
Will genetic testing for complex diseases increase motivation to quit smoking? 
Anticipated reactions in a survey of smokers
Saskia C Sanderson & Jane Wardle
Cancer Research UK Health Behaviour Unit, Department of Epidemiology and Public Health, University 
College London, London WC1E 6BT, UK. Fax: +44-20-7813-2848. Email address: s.sanderson@ucl,ac,uk
Abstract
Genetic testing for smoking-related disease susceptibility might increase motivation to quit smoking, but 
could also have harmful effects by reducing motivation among those who test negative for increased 
susceptibility (i.e. receive a ‘negative genetic test result’), or causing distress in those who test positive for 
increased susceptibility (i.e. receive a ‘positive genetic test result’). The aim of this study was to improve 
understanding of the characteristics of smokers who would be motivated to quit, de-motivated, or distressed 
in response to genetic risk information. A postal quantitative survey was completed by 1,024 respondents, 
of whom 186 were smokers. The questionnaire included questions on anticipated psychological and 
behavioural reactions to genetic test results using a hypothetical scenario, and comparisons were made 
between cancer and heart disease, and between positive and negative genetic test results. 65% of the 
smokers said they would be motivated to quit smoking by a positive genetic test result, and 39% that they 
would be de-motivated by a negative result. More smokers would be depressed by a positive genetic test 
result for cancer than for heart disease (40% vs. 24%). Anticipated motivation in response to a positive 
result was positively associated with desire to quit smoking and inversely with nicotine addiction, whereas 
anticipated depression was associated with fatalism and poorer understanding of genetic testing. 
Anticipated de-motivation in response to a negative result was associated with lower educational level and 
age. These findings suggest that smokers who are motivated to quit may use genetic risk information as a 
motivational tool, and that understanding of genetics may play an important role in determining how 
individuals respond to genetic tests for complex diseases.
Key words: genetic testing, complex diseases, clinical utility, smoking,
Introduction
The question of whether genetic testing will lead to health behavior change becomes ever more 
important as common genetic variants are identified which confer an increased or decreased susceptibility 
to complex, behavior-related diseases. There is growing recognition that health education and health 
behavior researchers will play a central role in evaluating the benefits and risks of new genetic tests for 
common genetic variants associated with complex diseases as they emerge (Marteau, 1999; Collins, Green, 
Guttmacher & Guyer, 2003). The assumption that individuals identified as being at increased risk of 
developing a complex, behavior-related disease, such as lung cancer or heart disease, may be able to 
considerably reduce their risk by making lifestyle changes (Bell, 1998; UK Advisory Committee on Genetic 
Testing, 1998; Day & Wilson, 2001) is supported by the fact that perceived disease susceptibility is a 
central component of many social cognition models of health behaviour change such as the Health Belief 
Model (HBM: Rosenstock, 1974), Protection Motivation Theory (PMT: Rogers, 1975; 1983) and the Health 
Action Process Approach (HAPA: Schwarzer, 1992). In the case of smoking cessation, these models 
suggest that informing smokers that they are genetically susceptible to the harmful effects of smoking could 
increase their motivation to quit smoking. However, some fear-appeal models, such as the PMT and the 
Extended Parallel Process Model (EPPM: Witte, 1994; Witte & Allen, 2000), suggest that increasing fear 
amongst individuals who have low self-efficacy could actually undermine their motivation to quit smoking,
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and even ‘deny their smoking problem’ (Wang et al, 2004). It also follows that informing smokers that they 
are not genetically susceptible could decrease their motivation to quit, and there is the danger that people 
who are found not to be at increased risk could develop a false sense of reassurance, feeling invulnerable to 
the adverse effects of their risky behavior (Marteau & Lerman, 2001).
Empirical data are needed to evaluate the psychological and behavioral impact of genetic testing. It has 
been proposed that behavioral interventions -  which could include giving genetic test feedback - should be 
rigorously evaluated using randomized controlled trials in the same way as pharmacological interventions 
(Friedli & King, 1998; Stephenson & Imrie, 1998). Two randomized controlled trials have evaluated the 
impact of feedback on common genetic variants associated with smoking-related disease susceptibility 
(Lerman et al, 1997; McBride et al, 2002). In both, smokers were randomly assigned either to a smoking 
cessation intervention which included personalized genetic risk information on the basis of genetic testing 
for a common genetic variant, or to a control group. Lerman et al (1997) used the CYP2D6 gene, and 
McBride et al (2002) used the GSTM1 gene, both of which are polymorphic and may contribute to lung 
cancer susceptibility (el Zein, 1997; Rostami-Hodjegan et al, 1998; McWilliams et al, 1995; Houlston et al, 
1999; Vineis et al, 1999; Benhamou et al, 2002). In relation to the impact on smoking cessation, Lerman et 
al (1997) found that the group given genetic risk information were more motivated to quit and had made 
more quit attempts than the control group at one year follow-up, but there were no differences in actual 
cessation rates. They found that the genetic risk information had short-term, but not long-term effects on 
depression and fear relative to controls (for one-year follow-up data see Audrain et al, 1997). In this study, 
the minimal-contact counseling intervention may not have provided enough support for the participants to 
overcome their nicotine addiction, despite their increased motivation. McBride et al (2002) found that 
smokers given the genetic risk information were twice as likely to have actually quit at six month follow-up 
than controls (19% vs. 10%), but there were no differences between those who received a positive (‘higher 
risk’) genetic test result and those who received a negative (‘not higher risk’) genetic test result. They 
found no effect of genetic testing on perceived risk or depression. In this study, those receiving genetic risk 
information received considerably more support than the control group, so disentangling the different 
components of the intervention is difficult. The relative impact of negative genetic test results versus 
positive genetic test results for complex, behavior-related diseases therefore remains to be seen. In 
addition, the smokers who participated in these studies were likely to be more motivated to quit and more 
addicted to nicotine than those in the general population.
The aim of the present study was to advance understanding of the circumstances under which genetic 
testing for smoking-related disease risk might lead either to positive outcomes such as increased motivation 
to quit smoking or to undesirable outcomes such as depression or complacency, by comparing the 
characteristics of smokers in the general population who did and did not anticipate each of those outcomes. 
Comparisons were also made between two different diseases, heart disease and cancer, because one single 
behavior change can effectively reduce an individual’s risk of multiple common diseases. A quantitative 
survey was used for this study because it has been proposed that quantitative surveys and additional pilot 
work be conducted prior to the design and evaluation of randomized controlled trials for complex 
interventions (www.mrc.ac.uk/complex packages.html; Campbell et al, 2000), which would include a 
smoking cessation intervention incorporating genetic risk information. The use of a quantitative survey 
approach will enable us to compare anticipated reactions with actual reactions in future research.
The primary research question addressed in this study was: How do smokers anticipate responding to 
genetic risk information for smoking-related diseases? The three secondary research questions were: What 
are the characteristics o f smokers who would i) be motivated to quit in response to receiving a positive 
( ‘higher risk’) genetic test result for susceptibility to smoking-related disease, ii) believe that a negative 
( ‘not higher risk) genetic test result would mean it was safe for them to carry on smoking (i.e. would be 
de-motivated or complacent), and iii) be at risk o f having a depressed reaction to receiving a positive 
( ‘higher risk) genetic test result. The association between anticipated reactions and subjective 
understanding of genetic testing was also examined because it has been suggested that understanding has an 
impact on smokers’ reactions to genetic test results (Lipkus et al, 2004). In addition, comparisons were 
made between anticipated reactions to two complex diseases, cancer and heart disease, and between 
positive (‘higher risk’) and negative (‘not higher risk’) genetic test results.
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Method
Procedure
The study took place in a General Practice in Oxfordshire in January 2002. The participating practice 
covered a population of 11,000 of whom approximately 8,000 were between 18 and 75 years old. A cross- 
sectional survey design was used, using two versions of the questionnaire, one of which addressed genetic 
testing for susceptibility to cancer and the other, heart disease. The only inclusion criterion was that 
patients should be aged between 18 and 75. Patients were excluded prior to selection if their GP had reason 
to believe that they should not be contacted in relation to the study, such as people with a terminal illness, a 
learning disability or who were unable to give informed consent. After these exclusions, two thousand 
patients were randomly selected from the patient register using a random number generation procedure, and 
a questionnaire was sent in the post to the 2,000 selected adults. Each of the selected patients were sent a 
pack containing: a letter signed by their GP informing them that their practice was involved in a research 
study and inviting them to take part; a Study Information Sheet; a questionnaire (on cancer or heart 
disease); and a pre-paid return envelope. In addition, a genetics information leaflet was included with half 
of the questionnaires in each disease group, which is the focus of another study (Sanderson, Wardle & 
Michie, 2005). Reminder packs were sent after three weeks to patients who had not yet responded. The 
Study Information Sheet -  which all respondents received -  included brief information about genetic testing 
which was defined as: “A genetic test informs a person about their risk o f getting a disease in the future, 
on the basis o f their genetic makeup. A genetic test does not give a simple “yes ” or “no ” answer. It will 
tell a person if  they have a high risk o f getting a disease, but it will not tell them definitely if  or when the 
disease will develop. ” This information was adapted from a two-page handout on the website of the 
American Academy of Family Physicians called “Genetic Testing: What You Should Know” (for more 
information see http://familvdoctor.org/handouts/462.html). This information source was chosen because it 
was deemed to be most suitable for members of the general population, much of the information literature 
available being targeted more to individuals and families who have been identified as being at high risk of 
developing single-gene disorders.
Measures
Demographics The questionnaire included items to assess gender, age, and educational attainment 
(classified as no formal qualifications, GCSEs or equivalent, A-levels or equivalent, or degree or higher).
Perceived family history Perceived (subjective or self-reported) family history was measured with the 
question: “In your opinion, does cancer [heart disease] run in your family? ”, with response options, “yes ”, 
“no ”, and “don’t know”.
Dispositional pessimism Dispositional pessimism was measured using the three items from the short 
version of the revised Life Orientation Test (LOT-R: Sheier & Carver, 1985; Scheier, Carver & Bridges, 
1994): “I f  something can go wrong for me, it will”, “I  hardly ever expect things to go my way”, and “I  
rarely count on good things to happen to me”. Response options were: “strongly disagree”, “disagree”, 
“not sure”, “agree”, and “strongly agree”.
Desire to quit smoking All respondents were asked the dichotomous, yes or no, question, “Do you ever 
smoke cigarettes now? ”. Desire to quit was measured with the item: “How much do you want to give up 
smoking all together? ” (not at all, slightly, moderately, quite strongly, very strongly). This measure of 
desire to quit smoking, or motivation, is used in the annual Office for National Statistics assessment of 
smoking-related behaviors and attitudes in the UK (Lader & Goddard, 2002).
Level of nicotine addiction was measured using the item “How easy or difficult would you find it to go 
without smoking for a whole day? ”. The item is a validated assessment of cigarette dependence (Russell, 
1971), and has the response options very easy, fairy easy, fairly difficult, and very difficult.
Understanding of genetic testing was assessed using the item “I  have a clear picture of what genetic 
testing is”. This item was adapted from the Illness Perception Questionnaire (Weinman et al, 1996). We 
also included an item examining fatalistic belief about genetic testing, “I f  I  received a positive genetic test
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result, I  would feel I  was definitely going to get cancer/heart disease in the future ”, with 5 response options 
from strongly disagree to strongly agree.
Anticipated reactions to positive and negative genetic test results Respondents to the cancer survey 
were asked to imagine that they had had a genetic test for a certain type of cancer. In order to assess 
anticipated reactions to receiving a positive, ‘higher risk’ genetic test result for cancer susceptibility, the 
following question was asked:
How would you feel i f  you received a positive genetic test result for cancer risk? (a positive 
test result means you may be more likely to get that cancer than other people).
Respondents were asked to indicate the extent to which they agreed or disagreed with a series of 
statements which pertained to different emotional and behavioral reactions to the genetic test result. The 
statements were chosen having reviewed the literature on the impact of genetic testing, and were informed 
by pilot interviews. Anticipated motivated reaction to a positive genetic test result was assessed with the 
statement, “I f  I  received a positive genetic test result, I  would definitely give up smoking”; anticipated de­
motivated reaction to a positive genetic test result with, ‘‘I f  I  received a positive genetic test result, I  would 
feel that it was safe for me to carry on s m o k in g and anticipated depressed reaction to a positive genetic 
test result with, “I f  I  received a positive genetic test result, I  would feel depressed”. To assess anticipated 
reactions to receiving a negative (‘not higher risk’) genetic test result for cancer susceptibility, the following 
question was asked:
How would you feel if  you received a negative genetic test result for cancer risk? (a 
negative test result means that you 're not at higher risk o f getting that cancer than other 
people).
Anticipated motivated reaction to a negative genetic test result was assessed with the statement, “I f  I  
received a negative genetic test result, I  would definitely give up smoking”; anticipated de-motivated 
reaction to a positive genetic test result with, “I f  I  received a negative genetic test result, I  would feel that it 
was safe for me to carry on smoking and anticipated depressed reaction to a positive genetic test result 
with, “I f  I  received a negative genetic test result, I  would feel depressed”.
The definitions of positive and negative genetic test results were adapted from the American Academy 
of Family Physicians information sheet described above. Essentially, a positive genetic test result can be 
thought of as indicating ‘higher risk’, and a negative genetic test result as indicating ‘not higher risk’. 
Respondents to the heart disease survey were asked the same questions, but the word ‘cancer’ was replaced 
with ‘heart disease’.
Statistical analyses
Statistical analyses were carried out using SPSS for Windows vlO.l. In order to check that the respondents 
in the cancer sample and the respondents in the heart disease sample were similar demographically, a series 
of cross-tabulations and chi-square analyses were conducted first, with ‘disease type’ as the predictor 
variable and ‘sample characteristics’ as the outcome variables. Anticipated reactions to positive and 
negative genetic test results were described separately for the cancer sample and the heart disease sample 
using frequency tables. Differences between anticipated reactions to genetic test results for cancer versus 
heart disease were examined using Pearson’s chi-square analyses. Differences between anticipated 
reactions to a positive result versus a negative result were compared using paired samples t-tests. Further 
analyses were conducted having collapsed the two disease samples into one, due to the small number of 
subjects in each sample. In order to examine the characteristics of smokers who believed they would be 
motivated to quit smoking by receiving a positive (higher risk) genetic test result, chi-square analyses were 
conducted with the item “I f  I  received a positive genetic test result, I  would definitely quit smoking ", having 
dichotomized responses into ‘motivated’ (agree or strongly agree) versus ‘not motivated’ (not sure, disagree 
or strongly disagree). The predictor variables that were significantly associated with anticipated motivated 
reaction in the univariate analysis, were entered into a binary logistic regression, with the dichotomized 
‘motivated reaction’ item (‘agree’ or ‘strongly agree’ with “I f  I  received a positive genetic test result, I  
would definitely quit smoking”) as the outcome variable. Univariate associations between anticipated de­
motivated reaction (not sure, agree, or strongly agree with the item, “I f  I  received a negative genetic test 
result, I  would feel that it was safe for me to carry on smoking”) and the predictor variables was examined
Appendix A
using a series of Pearson’s chi-square tests. As before, the predictor variables that were significantly 
associated with anticipated de-motivated reaction in the univariate analysis were entered into a binary 
logistic regression. The univariate and multivariate analyses were then repeated a further time with 
anticipated depression (agree or strongly agree with “I f  I  received a positive genetic test result, I  would feel 
depressed”) as the outcome variable.
Results 
Sample characteristics
1.024 (51% response rate) survey forms were returned with equal numbers for each disease (512 where the 
questions alluded to cancer, and 512 for heart disease). Demographic characteristics of the whole sample of
1.024 respondents have been published elsewhere (Sanderson, Wardle & Michie, 2005). In response to the 
question, “do you ever smoke cigarettes now? ”, 102 (20%) of the cancer sample, and 84 (16%) of the heart 
disease sample, responded ‘yes’. This was a total sample size of 186 (18% of the whole sample) when the 
two survey samples were combined. The figure of 18% is somewhat lower than the UK population of 
whom about 26% are smokers. There were no significant differences between the cancer sample and the 
heart disease sample on socio-demographic or smoking variables (see Table 1).
Anticipated reactions: cancer vs. heart disease
Overall, 65% (121) of smokers said that they would definitely quit smoking (i.e. agreed or strongly agreed 
with the statement) following a positive (higher risk) genetic test result. Slightly more agreed when the 
disease in question was cancer (70%) than heart disease (60%), but the difference was not significant 
(X2[l]=1.77, p=.183). The pattern was similar for believing that receiving a positive genetic test result 
would increase their desire to quit smoking. 40% (70) said they might think that it was safe for them to 
smoke if they received a negative (not higher risk) genetic test result (i.e. responded with ‘strongly agree’, 
‘agree’, or ‘not sure’ to the statement), which was taken as a ‘de-motivated’ reaction to receiving a negative 
genetic test result. Responses did not differ by disease (35% in the cancer group had a de-motivated 
reaction vs. 37% in the heart disease group: x2[l]=0.05, p=.634). 24% (45) anticipated that they would 
definitely quit smoking if they received a negative (not higher risk) genetic test result. As before, this did 
not differ by disease (26% in the cancer group vs. 22% in the heart disease group: x2[l]=0.05, p=.502). 
Thus there were no significant differences between cancer and heart disease on any of the anticipated 
behavioral reaction items. However, there was a difference in terms of anticipated depressed reaction: 
smokers were more likely to anticipate having a depressed reaction to a positive (higher risk) genetic test 
result for cancer than for heart disease (40% vs. 24%: x2[l]=5.16, p=.023).
Anticipated reactions: positive result vs. negative result
Because there were no differences between cancer and heart disease responses on the primary outcome 
variable, and because of the small numbers of respondents in each disease group, the two groups were 
combined for the remainder of the analyses.
Paired sample t-tests showed that smokers were more likely to believe that they would find a positive 
(higher risk) result motivating than a negative result; 65% said that they would definitely quit if it was 
positive compared to 24% if it was negative (not higher risk) (p<.001), and 86% said that a positive result 
would increase their desire to quit smoking compared to 36% for a negative result (p<.001, see Table 2). 
They were less likely to believe that a positive result would mean that it was safe to smoke (i.e. be de­
motivated) compared to a negative result (17% vs. 39%, p<.001), and more likely to be depressed by a 
positive result than a negative result (31% vs. 3%, p<.001).
Correlates of anticipated motivated reaction to a positive (higher risk) result
Smokers who had a strong desire to quit were more motivated by a positive result than smokers who had a 
weak desire to quit (78% vs. 55%, p=.001), and smokers who had a lower level of nicotine addiction were 
also more motivated to quit by a positive result than those with a higher level of nicotine addiction (78% vs. 
55%, p=.001). None of the other predictor variables (gender, age, education, perceived family history, 
dispositional pessimism, understanding of genetic testing) emerged as significantly associated with having a 
motivated reaction to a positive test result. The two predictor variables that were significantly associated
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with anticipated motivated reaction in the univariate analysis, were entered into a multiple binary logistic 
regression, with the dichotomized ‘motivated reaction’ item (agree or strongly agree with “I f  I  received a 
positive genetic test result, I  would definitely quit smoking’’) as the outcome variable. Desire to quit was 
maintained as a significant predictor of anticipating a motivated reaction (OR 3.28: 95% Cl 1.66-6.46; 
p=.001), as was nicotine addiction (OR 3.34: 95% Cl 1.67-6.67; p=.001) (see Table 3).
Correlates of anticipated motivated reaction to negative (not higher risk) result
A significant minority of smokers also strongly/agreed that they would definitely quit smoking in response 
to receiving a negative (not higher risk) genetic test result. Again, these smokers were characterized by 
having higher levels of desire to quit smoking (38% vs. 10%: x2[l]=21.15, p<.001) and lower levels of 
nicotine addiction (35% vs. 14%: x2[l]=10.86, p=.001) than smokers who did not anticipate finding a 
negative genetic test result motivational. Anticipating definitely quitting following a negative (not higher 
risk) genetic test result did not differ by any other predictor variables. Both effects were maintained in the 
multivariate analysis.
Correlates of anticipated de-motivated reaction to a negative (not higher risk) result
Smokers who anticipated being de-motivated by a negative genetic test result (i.e. who thought that a 
negative result would mean that it was safe for them to carry on smoking) had fewer educational 
qualifications (x2[3]=10.53, p=.015) (see Figure 1) and a lower understanding of genetic testing (26% vs. 
55%: (x2 [1]=16.85, p<.001) than smokers who did not anticipate being de-motivated. They also had a 
lower desire to quit (48% vs. 31%: (x2[l]=5.15, p=.023), and were less likely to fall into the middle-life age 
category (x2[2]=12.36, p=.002). The predictor variables that were significantly associated with anticipated 
de-motivated reaction in the univariate analysis (desire to quit, understanding of genetic testing, age, and 
education) were entered into a multiple binary logistic regression: the effects of age and education were 
maintained in the multivariate analysis, whereas the effects of desire to quit and understanding of genetic 
testing, were not (see Table 4).
Correlates of anticipated depressed reaction to a positive (higher risk) result
Smokers who anticipated having a depressed reaction to a positive (higher risk) genetic test result had a 
lower understanding of genetic testing (x2[l]=7.41, p=.006) and were more likely to believe that a positive 
(higher risk) result would mean they were definitely going to get the disease (x2[2]=14.20, p=001). They 
also had higher levels of dispositional pessimism (x2[l]=8.69, p=.013). There was an effect of disease type, 
with more smokers in the cancer sample anticipating a depressed reaction than smokers in the heart disease 
sample (x2[l]=5.17, p=.023). There was no effect of desire to quit smoking, level of nicotine addiction, 
gender, age, perceived family history, or education. When the variables that were significantly associated 
with anticipated depressed reaction were entered into a binary logistic regression analysis, the effects of 
understanding, believing that a positive result would mean definitely getting the disease, and disease type 
remained significantly associated with depressed reaction, whereas dispositional pessimism did not. See 
Table 5 for a summary of these results.
Discussion
This paper contributes to the growing body of research on genetic test evaluation by shedding some light on 
the characteristics of smokers in the general population who may be motivated to quit by feedback on 
genetic testing for complex diseases, or vulnerable to harmful effects of genetic test feedback. Roughly a 
third of the smokers in this study reported that they would feel depressed in response to receiving a positive 
(higher risk) genetic test result for susceptibility to cancer or heart disease, and anticipated depression was 
higher not only amongst smokers with higher levels of dispositional pessimism, but also those with lower 
understanding of genetic testing. In addition, education and understanding were inversely associated with 
anticipating that a negative genetic test result would mean that it was safe to carry on smoking. These 
findings highlight that public understanding of genetics is essential to ensure informed participation in 
public debate about human genetics, and also show that a lack of understanding could have direct 
consequences for the psychological wellbeing of individuals taking genetic tests in the general population.
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The findings contribute to the literature by suggesting that desire to quit smoking is an important 
predictor of being motivated, or at least anticipating being motivated, to quit smoking by genetic testing for 
complex disease susceptibility -  regardless of whether the result is positive or negative. This is important 
because it may shed some light on why previous research has found an effect of genetic testing per se on 
smoking cessation but failed to find an effect of the content of the genetic test result itself (McBride et al, 
2002). It is conceivable that smokers who wish to quit may use their genetic test result as a motivational 
tool, whatever the actual result is. For example, a positive (higher risk) result may have the expected effect 
of increasing perceived risk, thereby increasing motivation to quit, as long as self-efficacy is also 
reasonably high. On the other hand, a negative result could have the effect of increasing response efficacy 
-  a smoker who believes that their genetic susceptibility to a smoking-related disease is slightly reduced 
may have a stronger belief that for them it is particularly worth quitting. Qualitative data from participants 
in genetic test feedback trials could help to illuminate this issue.
The results raise the possibility that motivated smokers may self-select themselves into genetic testing, 
whereas smokers who are vulnerable to the harmful effects may opt out of testing. This hypothesis is 
supported by the observation that anticipated reactions are associated with interest in genetic testing 
(Helmes, 2002), as well as the considerable evidence for self-selection in to genetic testing from the 
Huntington’s disease literature (Evers-Kiebooms et al, 2000; Meiser & Dunn, 2000). This hypothesis is 
further tentatively supported by the observation in the present study that smokers in their middle-age were 
less likely to anticipate being complacent about a negative (not higher risk) result than those in the older or 
younger age groups. The relationship between middle age and anticipated motivation may be linked to the 
fact that people in this age group are more concerned about being healthy than younger people (Turk- 
Charles et al, 1997) due to their increasing contact and experience of disease. In contrast, adolescents are 
often reported to be optimistically biased about their risk of disease, especially when the disease is linked to 
their health behaviors (Arnett, 2000), and older people may feel that if they were going to develop the 
disease, it would have manifested itself already. The finding in previous research that people in their 
middle-age are also the most interested in genetic testing for cancer and heart disease (Sanderson et al, 
2004), could suggest that the same characteristics that determine interest in genetic testing, also determine 
adaptive behavioral reactions to genetic test results.
We found few differences between people’s responses to genetic testing for cancer compared to heart 
disease. This is one of the few studies to examine different anticipated responses to complex diseases 
simultaneously and it redresses a limitation of the literature to date that the most information pertains to 
cancer genetics, leaving it unclear whether people’s responses are related to their attitudes towards cancer 
or their attitudes towards genetics and genetic testing more generally. The present findings suggest that 
responses are similar regardless of disease type, although people appear to have slightly more fearful 
reactions to cancer susceptibility results than heart disease.
This research was limited in a number of ways. One methodological limitation was the use of the term 
‘positive genetic test result’ to denote ‘positive for an increased susceptibility’. It is possible that some 
respondents thought that ‘positive’ meant ‘good’, and an unknown number of respondents may have 
reversed the meanings of ‘negative’ and ‘positive’, although that has not been our experience in interviews 
with patients who are being given genetic test feedback. Another limitation of this study was that it was not 
possible to compare smokers’ reactions to positive or negative genetic test results with not having taken a 
genetic test. The low response rate and the inability to compare respondents with non-respondents was a 
further limitation, as was the fact that this was a cross-sectional survey and the findings concerned 
anticipated, not actual, reactions to genetic testing.
However, there is a lack of empirical data informing the current debate about the clinical utility of 
genetic tests for common genetic variants and complex diseases (Gollust et al, 2002). Determining the 
clinical utility of these emergent genetic tests, and developing regulatory policies, will increasingly need to 
take account of the psychological and behavioral consequences for individuals taking the tests (Burke et al, 
2002), in the general population, and away from the clinical context. It is hoped the results presented here 
will contribute to discussions about the potential benefits and pitfalls of genetic testing for complex diseases 
and be used to generate testable hypotheses for future research.
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Table 1. Sample characteristics
C ancer
(n=102)
H eart d isease  
(n=84)
Sig.
D em ographics
Gender Male
Female
51 (50%) 
51 (50%)
41 (49%) 
43 (51%)
X2[l]=0.03,
p=.884
Age 18-35yrs
36-55yrs
56-75yrs
37 (37%) 
39 (39%) 
24 (24%)
29 (36%) 
37 (46%) 
15 (19%)
X2[2]=L12,
p=.572
Educational qualifications No formal qualifications
GCSEs
A-levels
Degree
20 (20%) 
40 (41%) 
16(16% ) 
22 (22%)
15 (18%) 
32 (39%) 
15 (18%) 
20 (24%)
X2[3]=0.31,
p=.958
Perceived fam ily  history
In your opinion, does cancer/heart disease 
run in your family? Yes
No-not sure
22 (22%) 
80 (78%)
21 (26%) 
61 (74%)
X2[l]=0.42,
P -.520
D ispositional pessim ism
Mean o f  3-item composite LOT-R scale Low
Medium
High
67 (67%) 
17(17% ) 
16(16% )
53 (64%) 
20 (24%) 
10(12% )
5C2[2]=L70,
p= 428
Sm oking variab les
Desire to quit smoking: How much do you 
want to give up smoking all together?
Weak desire: Not at all- 
moderately (1-3)
Strong desire: Quite-very strongly 
(4-5)
48 (47%) 
54 (53%)
48 (58%) 
35 (42%)
X2[l]=2-13, 
p - 145
Level o f nicotine addiction: How easy or 
difficult would you find it to go without 
smoking for a whole day?
High addiction: difficult (3-4) 
Low addiction: easy (1 -2)
53 (52%) 
50 (49%)
52 (63%) 
31 (37%)
X2[l]=2.34,
p=. 126
U nderstanding  o f genetic testing
Understanding o f genetic testing: I have a 
clear picture o f what genetic testing is
Disagree-not sure (1-3) 
Agree (4-5)
45 (45%) 
55 (55%)
37 (45%) 
46 (55%)
X2[l]=0.00,
p=.954
Fatalistic belief about genetic testing: If  I 
received a positive [higher risk] genetic test 
result, I would feel I was definitely going to 
get cancer/heart disease in the future
Disagree (1-2)
Not sure-agree (3-5)
30 (30%) 
69 (70%)
27 (33%) 
54 (67%)
X2[ 1 ]—0.19, 
p=.664
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Table 2. Proportions of smokers anticipating having motivated, de-motivated, and
depressed reactions: positive (‘higher risk’) versus negative (‘not higher risk’)
results
R esult % ** n
I w ou ld  defin itely  qu it sm oking
Positive
Negative
Sig.*
65% 121 
24% 45
t [ l 831=11.22, p<.001
It w ou ld  increase m y desire to quit 
sm oking
Positive
Negative
Sig. *
86% 162 
36% 67
t[185]=13 .18 , p<.001
I w ou ld  feel it w as safe for  m e to  
carry on sm oking
Positive
Negative
S ig*
17% 31 
39% 73
t | 1841=6.75, p<.001
I w ou ld  feel depressed
Positive
Negative
Sig.*
31% 58 
3% 5
t[1751=15.44, pc.001
*Results o f paired samples t-tests on continuous variables
**Percent (%) who responded ‘agree’ or ‘strongly agree’ except for the item, “I would feel it was safe 
for me to carry on smoking, where the figures indicate the percent (%) who responded ‘not sure’, 
‘agree’ or ‘strongly agree’
Table 3. Factors associated with smokers anticipating a motivated reaction to a positive (‘higher 
risk’) genetic test result: multiple logistic regression_______________________________________
M otivated M ultivariate odds 
ratio (95%  C l)
Desire to quit smoking
Weak desire (1-3) 
Strong desire (4-5)
54% (51/95) 
78% (66/85)
1.0
3.28 [1.66-6.461**
Level o f nicotine addiction
High addiction (3-4) 
Low addiction (1-2)
55%  (62/80) 
78% (55/101)
1.0
3 .34 [1.67-6.671**
**p=.00l
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Table 4. Factors associated with smokers anticipating a de-motivated reaction to a negative (‘not
higher risk’) genetic test result: multiple logistic regression
D e-m otivated M ultivariate odds 
ratio (95%  C l)
Age
18-35 47% (32/68) 1.0
36-55 24% (18/76) 0.33 |0 .15-0 .75]**
56-75 53% (20/38) 0.59 [0.21-1.63]
Educational qualifications
No formal qualifications 61% (20/33) 1.0
GCSEs 34% (25/73) 0.41 [0.15-1.14]
A-levels 36% (11/31) 0.31 [0.09-1.10]
Degree 26% (11/43) 0.30 [0.09-0.951*
Desire to quit smoking
Not strong (1-3) 48% (46/96) 1.0
Strong (4-5) 31% (27/86) 0.64 [0.32-1.271
Understanding of genetic testing
No (1-3) 55% (46/83) 1.0
Yes (4-5) 26% (26/101) 0.50 [0.24-1.051
*p<.05, **p<.01
Table 5. Factors associated with smokers anticipating a depressed reaction to a positive (‘higher
risk’) genetic test result: multiple logistic regression
D epressed M ultivariate odds 
ratio (95%  C l)
Dispositional pessimism
Low (1 -2) 
Medium (3) 
High (4-5)
28% (32/115) 
31% (11/36) 
58% (15/26)
1
0.82 [0.32-2.081 
2.13 [0.82-5.561
Understanding of genetic testing
Yes (4-5) 
No (1-3)
24% (24/99) 
44% (34/78)
1
2.07 [1.03-4.16]*
Fatalistic belief about genetic testing
Disagree (1-2) 
Not sure (3) 
Agree (4-5)
14% (8/56) 
38% (33/88) 
50% (17/34)
1
3.24 [1.30-8.04J* 
5.66 11.91-16.761**
Disease
Heart disease 
Cancer
24% (19/80) 
40% (39/98)
1
2.30 [1.13-4.71]*
*p<.05, **p<.01, ***p<.001
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Figure 1. Smokers with lower educational attainment were more 
likely to believe that it was safe for them to smoke if they received a 
negative ('not higher risk') genetic test result than smokers with 
higher educational attainment
100%
80%
60%
40%
20%
no formal 
qualifications
GCSEs A-levels Degree upwards
□  agree 
Mnot sure
□  disagree
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APPENDIX B
ETHICAL APPROVAL AND CORRESPONDENCE FOR POSTAL QUESTIONNAIRE
SURVEY (STUDY 2)
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NHS T ru s t
CTC/lmp/CO 1.176
Professor J Wardle & Ms S Sanderson
Royal Free and University College Medical School
Department of Epidemiology & Public Health
University College London
Gower Street Campus
2-16 Torrington Place
LONDON WC1E 6BT
Oxfordshire Clinical Research Ethics Committee 
Research & Development Department 
Room 13, Manor House 
The John Raddiffe Hospital 
Headley Way 
Headington 
Oxford 
0X3 9DZ
Tel: 01865 222547 
Fax: 01865 222699 
Email: Diana.Street@orh.nhs.uk
Dear Professor Wardle & Ms Sanderson 25 October 2001
Re: C01.176 - Genetic testing for lung cancer and nicotine addiction risk: Smokers’ interest and 
anticipated response. Protocol August 2001 -  January 2003
Thank you for your letter of the 15 October 2001 responding to the Committee’s points.
The Committee is quite firmly of the view that researchers should not have access to information within a general 
practice until patients have consented. There is of course no difficulty with the researcher instructing the clerical 
worker in how to undertake the work and reviewing the procedures, but the handling of patient notes should be 
carried out without the researcher being present.
In ail other respects your response does meet the points made by the Committee.
Yours sincerely
Dr C J Chapman 
Chairman
Oxfordshire Clinical Research Ethics Committee
From Oxfordshire Clinical Research Ethics Committee -  C hair D r C J  C hapm an
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Dr C J Chapman
Chairman, Oxfordshire Clinical Research Ethics Committee
Research and Development Department
Room 13, Manor House
The John Radcliffe Hospital, Headley Way
Headington, Oxford 0X 3 9DZ
5 November 2001
Dear Dr Chapman
Re: C01.176 - Genetic testing for cancer risk: Interest and anticipated responses 
amongst smokers and non-smokers. Protocol September 2001 - January 2003
We are writing to let you know of some comparatively minor changes that we would 
like to make to the above study.
1. A consent form was necessary in the original application because people were 
being invited to take part in a genotyping study. However, in the present sample, 
respondents will be involved only in this one survey. It has emerged through pilot 
work that people find it confusing to be asked to return the questionnaire along 
with a consent form for returning the questionnaire (they think that they might be 
consenting to something else). We therefore propose that we include the study 
information sheet as before but without the consent form, simply inviting people to 
return the questionnaire if  they are interested.
2. During our continuing pilot work, it has been suggested that it would be useful to 
provide respondents with a bit more information about genetics and genetic testing. 
In response to this we have developed the enclosed genetic information sheet, 
which we intend to pilot to ensure its suitability and comprehensiveness for a broad 
range o f people. The content has been adapted from the Genetic Science Learning 
Centre website http://gslc.genetics.utah.edu/(‘Basic Genetics'), and the widely 
available book ‘Your Genes, Your Choices' (published by U.S. Science and 
Literacy for Health). So that we can observe whether the information influences 
people’s attitudes, we propose that the extra information be provided only to half 
of the sample at this stage.
We hope the Committee finds these changes acceptable.
Yours sincerely,
Professor J Wardle Ms S Sanderson
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Oxford Radcliffe Hospitals rl7»
NHS Trust
CJC/lmp/CO 1.176
Professor J Wardle
Royal Free & University College Medical School
Department of Epidemiology & Public Health
University College London
Gower Street Campus
2-16 Torrington Place
LONDON WC1E 6BT
Oxfordshire Clinical Research Ethics Committee 
Research & Development Department 
Room 13, Manor House 
The John Radcliffe Hospital 
Headley Way 
Headington 
Oxford 
0X3 9DZ
Tel: 01865 222547 
Fax: 01865 222699 
Email: Diana.Street@orh.nhs.uk
Dear Professor Wardle 26 November 2001
Re: C01.176 -  G en etic  testing  for  lung cancer an d  n ico tin e  add iction  risk: Sm ok ers’ in terest and  
antic ip ated  response. P rotoco l A u gu st 2001 -  Ja n u ary  2003
Thank you for your letter dated the 5 November 2001 requesting approval for the deletion of the Consent Form 
and pilot of Genetic Information Sheet. There seems to be no problem with this, and I can now confirm OxREC 
approval for this addendum.
P lease  note:
■ No significant changes to the research protocol should be made without appropriate research ethics 
committee/chairman’s approval. Any deviations from or changes to the protocol which increase the risk to 
subjects, or affect the conduct of the research, or are made to eliminate hazards to the research subjects, 
should be made known to OxREC.
■ OxREC should be made aware of any serious adverse events.
Best wishes with your continuing study.
Yours sincerely,
Dr C J Chapman 
Chairman
Oxfordshire Clinical Research Ethics Committee
From Oxfordshire Clinical Research Ethics Committee - Chairman: Dr C J Chapman
Appendix B
Oxfordshire Research Ethics Committee (OxREC)____________________   _      j
O xR E C  No: CO 1.176
Title of Project: Genetic testing for lung cancer and nicotine addiction risk: Smokers’ interest and j  
anticipated response. Protocol August 2001 -  January 2003 j
The following documents have been approved by OxREC
Date/Version Approved
Genetic Information Sheet 26 November 2001 ✓
ICH GCP Compliance
The Oxfordshire Research Ethics Committees are compliant with the International Committee on Harmonisation/Good 
Clinical Practice (ICH-GCP) Guidelines for the Conduct of Trials involving participation of human subjects as they relate to 
the responsibilities, composition, function, operations and records of an Independent Ethics Committee/Independent Review 
Board. To this end it undertakes to adhere as far as is consistent with its Constitution, to the relevant clauses of the ICH 
Harmonised Tripartite Guideline for Good Clinical Practice, adopted by the Commission of the European Union on 17 
January 1997.
From Oxfordshire Clinical Research Ethics Committee - Chairman: Dr C J Chapman
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ETHICAL APPROVAL AND CORRESPONDENCE FOR GSTM1 GENETIC TESTING
STUDY (STUDY 3)
Appendix C
A
UCL
UNIVERSITY COLLEGE LONDON
ESTATES AND FACILITIES DIVISION 
RECORDS OFFICE 
FACILITIES SERVICES
Gower Street, London WC1E 6BT
Tel 020 7679 7783 
Fax 020 7419 2810 
Email: r.cum m inqs@ ucl.ac .uk
23 March 2003
Professor J Wardle,
Department o f Epidemiology and Public Health.
University College London 
Gower Street Campus
1-19 Torrington Place 
London WC1E6BT
Dear Professor Wardle,
Data Protection Registration
Thank you for your application for Data Protection Registration for your Project: "Genetic testing for 
lung cancer susceptibility: smokers’ comprehension and the psychological and cognitive impact".
I am pleased to confirm that your Research Project will be covered by the UCL Data Protection 
Registration, reference no. Z6364106, Section 19 Research: Health Research.
Yours sincerely,
Mrs. K.H. Cummings,
Records Manager and Data Protection Officer.
University College London Hospitals
NHS Trust
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NHS
Co- Chairs
Mr M Harrison and Dr R MacAllister
Please address all correspondence to:
Ms Sabrina Baiendra - Ethics Administrator 
Email: sabhna.balendra@uclh.org
2 nd J u n e  2003
The Joint UCUUCLH Ethics Committee: Committee A 
Research & Development 
1st Floor, Vezey Strong Wing 
112 Hampstead Road 
London NW1 2LT 
Tel: 020 7380 9579 
Fax: 020 7380 9937 
Website: w w w .uclh.oru
Our Ref: RM/sm/03A099
P ro fe sso r J a n e  W ard le  
H ealth B ehaviour Unit
D epartm en t of E pidem iology & Public H ealth 
UCL
2-16 T orrington P la c e
APPROVED
D ear P ro fe sso r  W ard le
REC Ref No: (please quote in all correspondence)
REC Name: (please quote in all correspondence
Study Title: Genetic testing for lung cancer susceptibility: smokers comprehension and the
psychological and cognitive impact of testing
T hank you for subm itting  your re s e a rc h  p roposa l for review  by th e  Jo in t UCL/UCLH C om m ittee  for 
Ethics on  H um an  R e se a rc h , w ho review ed your application  on 22nd May 2003. T h e  d o cu m en ts  
review ed w ere  a s  follows:
• R EC application  form
• P a tien t inform ation s h e e t  (version 1, 30th April 2003)
• P a tien t c o n se n t form  (S ta g e  1)
• P a tien t c o n se n t form (S ta g e  2)
• R e se a rc h  P rotocol
• In-Clinic S c re e n e r
• D ata P ro tection  C hecklist
• B aseline  Q u estio n n a ire
• Investigator’s  C .V .'s
Your application w as  ap p ro v ed  in principle, how ever befo re  final approval c an  b e  g ran ted , the 
com m ittee would like you to  re sp o n d  to  th e  following co n ce rn s , w hich a re  d e ta iled  below:
T here  w ere  no ob jec tions on  eth ical g ro u n d s an d  your study  m ay p ro ceed . Y our stu d y  provoked 
som e d e b a te  a m o n g s t th e  C om m ittee  m em b ers, outlined below , an d  I would a p p re c ia te  your views 
on th e s e  com m en ts .
Firstly, Ms S a n d e rso n  a tte n d e d  th e  m eeting  an d  inform ed u s  deletion  of GSTM 1 in c re a se d  th e  
relative risk of ce rta in  c a n c e rs  by 40%, although  th e  ab so lu te  in c re a se  in risk w a s  m uch  lower. W e 
w ere cu rious a s  to  how  th is com plex  inform ation w as  p re s e n te d  to your recruits.
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson 
and Obstetric Hospital, Hospital for Tropical Diseases, The Heart Hospital, The Middlesex Hospital, 
National Hospital for Neurology & Neurosurgery and University College Hospital.
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S econd ly  w e  w e re  intrigued by th e  re su lts  of th e  M cBride study  th a t su g g e s te d  th a t know ledge of 
o n e s  g e n o ty p e  for th is en zy m e m a d e  no d ifferen ce  to  th e  sm oking c e ssa tio n  ra te . T he C om m ittee 
w as  of th e  opinion th a t this resu lt shou ld  b e  co m m un ica ted  to your recru its  in so m e  w ay a s  it m ay 
h av e  so m e  b earin g  on their w illingness to  participate.
Thirdly, w e w ere  a lso  cu rious if you w ould u se  conitine a s  a  b iom arker of sm oking  activity, and  
w h e th e r th is w a s  a ffec ted  by nicotine rep la c e m e n t therapy .
Lastly w e th o u g h t th a t you shou ld  s ta te  w h e th e r th e  blood sam p le  you h av e  co llected  will b e  u sed  for 
any  se c o n d a ry  re se a rc h , o r w h e th e r (and  w hen) they  will be  d estro yed . In addition, how  long will 
vo lu n teer identifiable d a ta  b e  k ep t?
T h e  C om m ittee  h a s  d e le g a te d  authority  to  th e  C hair to  give you approval w hen  it is felt a  satisfactory  
re s p o n se  to  th e  a b o v e  is su e s  h a s  b e e n  received .
W hen  subm itting  th e  re s p o n se  to th e  com m ittee , p le a s e  se n d  rev ised  d o cum en ta tion  w here  
ap p ro p ria te  highlighting the changes th a t you h av e  m ad e  an d  give revised version numbers and 
dates.
Your application has been given a unique reference number please use it on all 
correspondence with the REC______________________________________________
Y ours sincere ly
Dr Raymond MacAllister
Co-Chair
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University College London Hospitals
NHS Trust
The Joint UCL/UCLH Ethics Committees: Committee A 
Research & Development 
1st Floor, Vezey Strong Wing 
112 Hampstead Road 
London NW1 2LT 
Tel: 020 7380 9579 
Fax: 020 7380 9937 
Website: w w w .uc lh .on>
7 th July 2003  0ur Ref; RM/sm/03A173
Co- Chairs: Mr M Harrison and Dr R MacAllister
P l e a s e  a d d r e s s  a l l  c o r r e s p o n d e n c e  t o :
Ms Shelly Moylan - Ethics Administrator (Temp) 
Email: sabrina.balendratriiuclh.ora
NHS
P ro fe sso r  J a n e  W ard le
D ep artm en t of E pidem iology an d  Public Health 
G ow er S tree t C a m p u s
2 - 1 6 Torrington P la c e  A P P R O V E D
London
D ear P ro fe sso r W ard le
REC Ref No: (please quote in all correspondence)
REC Name: Committee A (please quote in all correspondence)
Study Title: Genetic testing for lung cancer susceptibility: smokers comprehension and the 
psychological and cognitive impact of testing
T h e C hair of th e  Jo in t UCL/UCLH C om m ittees on th e  E thics of H um an R e se a rc h  h a s  con sid ered  
your re s p o n se  to  th e  is s u e s  ra ised  by th e  com m ittee  a t th e  ea rlie r review  of your application on 22nd 
May 2003, a s  s e t ou t in o u r le tte r d a te d  2nd Ju n e  2003. T he d o cu m en ts  co n sid e red  w ere  a s  follows:
• R EC application form
• P atien t inform ation s h e e t  (version  1, 30th April 2003)
•  P atien t c o n se n t form  (S ta g e  1)
•  P a tien t c o n se n t form  (S ta g e  2)
• R e se a rc h  P rotocol
• In-Clinic S c re e n e r
• D ata  P rotection  C hecklist
• B aseline Q u estio n n a ire
• Investigator’s  C .V .’s
T he Chair, acting  u n d e r  d e le g a te d  authority, is satisfied  th a t your r e s p o n se  h a s  fulfilled th e  
req u irem en ts  of th e  com m ittee . You a re  th ere fo re  given approval fo r your re s e a rc h  on ethical 
g rounds providing you com ply  with th e  conditions of approval s e t  ou t below:
• You do not recruit an y  re s e a rc h  su b jec ts  u n le ss  you hav e  rece iv ed  a  notification of no  objections 
from th e  R&D office.
•  You do not u n d e rtak e  th is r e s e a rc h  until th e  re levan t T rust m a n a g e m e n t approval h a s  been  
received  (via th e  R&D office).
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson 
and Obstetric Hospital. Hospital for Tropical Diseases, The Heart Hospital, The Middlesex Hospital, 
National Hospital for Neurology & Neurosurgery and University College Hospital.
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• You d o  no t d e v ia te  from , o r m a k e  c h a n g e s  to , th e  protocol w ithout prior w ritten ap p rova l of th e  
R EC, e x c e p t w h e re  th is is n e c e s s a ry  to  e lim inate  im m ed ia te  h a z a rd s  to  re s e a rc h  partic ipan ts or 
w hen  th e  c h a n g e  involves only logistical o r adm in istra tive  a s p e c ts  of th e  re s e a rc h . In su c h  c a s e s  
th e  R E C  sh o u ld  b e  in fo rm ed  within s e v e n  d a y s  of th e  im p lem en ta tion  of th e  c h a n g e .
• You c o m p le te  a n d  re tu rn  th e  s ta n d a rd  p ro g re s s  repo rt form  to  th e  R E C  o n e  y e a r  from  th e  d a te  
on  th is  le tte r  a n d  th e re a f te r  on  an  an n u a l b a s is . T his form  sh o u ld  a lso  b e  u se d  to  notify th e  REC 
w h en  your r e s e a rc h  is co m p le ted  a n d  in th is c a s e  sho u ld  b e  s e n t  to  th is R E C  within th re e  m on ths 
of com pletion .
• If you d e c id e  to  te rm in a te  th is r e s e a rc h  p rem atu re ly  you s e n d  a  rep o rt to  th e  R EC  within 15 days, 
indicating  th e  re a s o n  for th e  early  term ination .
•  Y ou a d v ise  th e  R E C  of an y  u n u su a l o r u n e x p e c te d  re su lts  th a t ra ise  q u e s tio n s  a b o u t th e  sa fe ty  
of th e  re s e a rc h .
• T h e  p ro jec t m u s t b e  s ta r te d  within th re e  y e a rs  o f th e  d a te  of th is  letter.
NHS R EC is com p lian t with th e  In ternational C o n fe re n c e  on  H arm on isa tio n /G o od  Clinical P rac tice
(ICH G C P ) G u id e lin e s  fo r th e  c o n d u c t o f trials involving partic ipation  o f h u m an  su b je c ts .
Your application has been given a unique reference number please use it on all 
correspondence with the R E C ._____________________________________________
Y ours sin cere ly
Dr Raymond MacAllister 
Co-Chair
E nclosure: R E C  R e s p o n s e  Form
R E C  P ro g re s s  R ep o rt
NB: T his is th e  new  s ta n d a rd  fo rm at reply C O R E C  now  req u ire s  u s  to  u se .
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•  You d o  no t d e v ia te  from , o r m ak e  c h a n g e s  to , th e  protocol w ithout prior w ritten ap p rova l of the  
R EC, e x c e p t w h e re  th is is n e c e s s a ry  to  e lim ina te  im m edia te  h a z a rd s  to  re s e a rc h  partic ip an ts or 
w h en  th e  c h a n g e  involves only logistical o r  adm in is tra tive  a s p e c ts  of th e  re s e a rc h . In su ch  c a s e s  
th e  R EC  sh o u ld  b e  inform ed within s e v e n  d a y s  o f th e  im plem entation  o f th e  c h a n g e .
•  You c o m p le te  a n d  re tu rn  th e  s ta n d a rd  p ro g re s s  repo rt form  to  th e  R EC  o n e  y e a r  from  th e  d a te  
on  th is le tte r  a n d  th e re a f te r  on  a n  an n u a l b a s is . T his form  shou ld  a lso  b e  u se d  to  notify th e  REC 
w h en  y o u r r e s e a rc h  is co m p le ted  an d  in th is  c a s e  shou ld  b e  s e n t to  th is R EC  within th re e  m on ths 
of com pletion .
•  If you d e c id e  to  te rm in a te  th is re s e a rc h  p rem atu re ly  you s e n d  a repo rt to  th e  R EC  within 15 days, 
indicating  th e  r e a s o n  for th e  early  term ination .
•  Y ou a d v ise  th e  R E C  o f an y  u n u su a l o r  u n e x p e c te d  re su lts  th a t ra ise  q u e s tio n s  ab o u t th e  sa fe ty  
of th e  re s e a rc h .
•  T h e  p ro jec t m u s t b e  s ta r te d  within th re e  y e a rs  of th e  d a te  of th is letter.
NHS R E C  is co m p lian t with th e  In ternational C o n fe re n c e  on H arm on isa tio n /G ood  Clinical P rac tice
(ICH G C P ) G u id e lin e s  for th e  co n d u c t of trials involving participation  of h u m an  su b je c ts .
Your application has been given a unique reference number please use it on all 
correspondence with the REC. _____________________________________________
Y ours sin cere ly
Dr Raymond MacAllister 
Co-Chair
E nclosure : R E C  R e s p o n s e  Form
R E C  P ro g re s s  R eport
NB: T his is th e  n ew  s ta n d a rd  fo rm at reply C O R E C  now  req u ire s  u s  to  u se
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APPENDIX D
MATERIALS FOR ONS SURVEY (STUDY 1) 
SURVEY INSTRUMENT
Appendix D
NATIONAL STATISTICS OMNIBUS SURVEY - September 2002 Module 319
Attitudes to Human Genetics
A s k  a l w a y s :
M319_Introl
These next questions are about cancer and heart disease and are being asked on behalf of the Department 
of Public Health at the University o f London.
(1) PRESS <1> TO CONTINUE
A s k  ALW AYS:
M319 3M
[*] What do you think are the things that cause a person to develop cancer or increase their chances of 
developing it?
INTERVIEWER: USE PROMPT W HAT ELSE' TO ENSURE FULL CODING.
RECORD ’OTHER SPECIFY’ FOR ALL ITEMS NOT LISTED AND RECORD ANSWER 
VERBATIM.
CODE ALL THAT APPLY. DO NOT PROBE.
SET [27] OF
(1) Nothing
(2) Having a weakened or impaired immune system (Immunosuppression)
(3) A virus/infection/disease
(4) The sun
(5) Pollution
(6) Radiation
(7) Power lines
(8) Smoking
(9) Passive smoking/other substances you breath in e.g. Asbestos
(10
(11
(12
(13
(14
(15
(16
(17
(18
(19
(20
(21
(22
(23
(24
(25
(26
(27
(28
(29
Drinking 
Low fibre diet 
High fat diet
Low fruit and/or vegetable diet
High meat diet
Chemicals in food
Diet in general (unspecified)
Older age
Being male
Being female
Obesity/bcing overweight
Lack of exercise
It's in the genes/Genetics
Family history (a blood relative) who has/had cancer/heart disease
Taking medication
Not going for regular check-ups
Stress
Fate/chance/bad luck 
Other (verbatim specify)
Don’t Know
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NATIONAL STATISTICS OMNIBUS SURVEY - September 2002 Module 319
Attitudes to Human Genetics
ASK IF : o t h e r  IN  M319_3M
SPEC!
INTERVIEWER: RECORD OTHER CAUSE OF CANCER - VERBATIM 
STRING[255]
A s k  a l w a y s :
M319_4M
[*]What do you think are the things that cause a person to develop heart disease or increase their chances 
o f developing it?
INTERVIEWER: USE PROMPT 'WHAT ELSE' TO ENSURE FULL CODING.
RECORD ’OTHER SPECIFY' FOR ALL HEMS NOT LISTED AND RECORD ANSWER 
VERBATIM.
CODE ALL THAT APPLY. DO NOT PROBE.
SET [21] OF
(1) Nothing
(2) Having a weakened or impaired immune system (Immunosuppression)
(3) A virus/infection/disease
(4) Smoking
(5) Passive smoking
(6) Drinking
(7) Low fibre diet
(8) High fat diet
(9) Low fruit and/or vegetable diet
(10) Diet in general (unspecified)
(11) Older age
(12) Being male
(13) Being female
(14) Obesity/being overweight
(15) Lack of exercise
(16) It's in the genes/Genetics
(17) Family history (a blood relative) who has/had heart disease
(18) T aking medication
(19) Not going for regular check-ups
(20) Stress
(21) Fatc/chance/bad luck
(22) Other (verbatim specify)
(23) Don't know
A s k  i f : O t h e r  IN  M 3 1 9 _ 4 M
SPEC2
INTERVIEWER: RECORD OTHER CAUSE OF HEART DISEASE - VERBATIM 
STRING[255]
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NATIONAL STATISTICS OMNIBUS SURVEY - September 2002 Module 319
Attitudes to Human Genetics
A s k  i f :  (M319__5 <> r e s p o n d e n t  h a s  c a n c e r )  OR (M319__7 <> .R espo nd ent h a s  h e a r t
d i s e a s e )
M 319JN TR 02
Nowadays, it is possible to predict whether or not a person is likely to develop certain diseases by 
analysing their genes. This is called genetic testing.
Genetic testing is currently available for a limited number o f diseases, but it may be available for more 
diseases in the future.
(1) PRESS <1> TO CONTINUE
A s k  i f :  (M 319_5 <> r e s p o n d e n t  h a s  c a n c e r )  OR (M 319_7 <> R e s p o n d e n t h a s  h e a r t
d i s e a s e )
A n d :  M 319J5 <> r e s p o n d e n t  h a s  c a n c e r
M319_9
[*] If  it were available would you, in the next 6 months, have a genetic test to see if  you are at risk o f 
developing cancer in the future?
INTERVIEWER: PROBE
(1) No, definitely not
(2) No, probably not
(3) Yes, probably
(4) Yes, definitely
A s x  i f :  (M 319_5 <> r e s p o n d e n t  h a s  c a n c e r )  OR (M 319_7  <> R e s p o n d e n t h a s  h e a r t
d i s e a s e )
A n d :  M 319_5  <>  r e s p o n d e n t  h a s  c a n c e r  
A n d :  M 319_9 IN  [N od . . Y e sd ]
M319_10
Can you say why you gave that answer?
INTERVIEWER: RECORD VERBATIM. ONCE YOU HAVE FINISHED TYPING YOUR 
COMMENTS, PRESS <ALT+S> TO SAVE YOUR COMMENTS AND EXIT BOX
OPEN
Appendix D
NATIONAL STATISTICS OMNIBUS SURVEY - September 2002 Module 319
Attitudes to Human Genetics
Ask i p : (M 319_5 <> r e s p o n d e n t  h a s  c a n c e r )  OR (M319_7 <> R e s p o n d e n t h a s  h e a r t
d i s e a s e )
A m : M 319_7 <> R e s p o n d e n t h a s  h e a r t  d i s e a s e
M319_ll
[*] If  it were available would you, in the next 6 months, have a genetic test to see if  you are at risk of 
developing heart disease in the future?
INTERVIEWER PROBE
(1) No, definitely not
(2) No, probably not
(3) Yes, probably
(4) Yes, definitely
Ask  i r :  (M 319_5 <> R e sp o n d e n t h a s  c a n c e r )  OR (M319_7 <> R e s p o n d e n t h a s  h e a r t
d i s e a s e )
A m : M 319_7  <> R e sp o n d e n t h a s  h e a r t  d i s e a s e  
A m : M 3 1 9 _ ll IN  [Nod . . Y esd ]
M319_12
Can you say why you gave that answer?
INTERVIEWER: RECORD VERBATIM. ONCE YOU HAVE FINISHED TYPING YOUR 
COMMENTS, PRESS <ALT+S> TO SAVE YOUR COMMENTS AND EXIT BOX
OPEN
Asjc i p :  (M 319_5 <> R e s p o n d e n t h a s  c a n c e r )  OR (M 319_7 <> R e s p o n d e n t h a s  h e a r t
d i s e a s e )
A m : (M 319_9 IN  [Nod . .  Y e s d ] )  OR (M 319_9  « DONTKNOW)
M319_13
SHOWCARD C319_ 13
[*]Suppose you learnt today that you had a higher than average genetic risk o f developing cancer in the 
future, would you... RUNNING PROMPT
(1) Try to lead a healthier lifestyle
(2) Feel there was no point in trying to lead a healthier lifestyle
(3) Feel that your lifestyle was as healthy as it could be, or
(4) Would you have no feelings one way or another about your lifestyle?
(5) Can't answer/Don’t know/it would depend (spontaneous)
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Attitudes to Human Genetics
A s k  i f :  (M 319_5 <> R e s p o n d e n t h a s  c a n c e r )  OR (M31'9_7 <> R e s p o n d e n t h a s  h e a r t
d i s e a s e )
A n d :  (M 3 1 9 _ ll IN  [N od  . .  Y e s d ] )  OR (M 3 1 9 _ ll = DONTKNOW)
M31914
SHOWCARD C 3 1 9 J3
[*]Suppose you leamt today that you had a higher than average genetic risk o f developing heart disease in 
the future, would you...
RUNNING PROMPT
(1) Try to lead a healthier lifestyle
(2) Feel there was no point in trying to lead a healthier lifestyle
(3) Feel that your lifestyle was as healthy as it could be, or
(4) Would you have no feelings one way or another about your lifestyle?
(5) Can't answer/Don't know/it would depend (spontaneous)
ASK ALWAYS:
M319_15
Would you be willing for researchers at University College London to contact you in the future to find 
out more on your opinions on human genetics?
INTERVIEWER: PLEASE ENSURE THAT YOU RECORD THE ADDRESS AND TELEPHONE 
NUMBER DETAILS IN THE ADMIN BLOCK FOR RESPONDENTS WHO GIVE PERMISSION.
IF NECESSARY, ASSURE THE RESPONDENT THAT THE INFORMATION GIVEN WILL BE 
USED FOR STATISTICAL RESEARCH PURPOSES ONLY AND WILL NOT BE PRESENTED IN A 
WAY WHICH COULD BE ASSOCIATED WITH NAMES AND ADDRESSES. ALSO THAT THEIR 
NAME AND ADDRESS WOULD NOT BE PASSED ON TO ANY OTHER ORGANISATION 
APART FROM THE ONE THEY HAVE AGREED TO.
(1) Permission given
(2) Permission refused
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Attitudes to Human Genetics
A s k  i f :  M210 .M 2 1 0 _ l  = No (Do n o t  sm o k e  c i g a r e t t e s  a t  a l l  n o w a d a y s )
M319_l
Have you ever smoked cigarettes regularly?
(1) Yes
(2) No
A s k  i f :  M210 ,M 210_1 -  Y e s  (Sm oke c i g a r e t t e s  n o w a d a y s )
M319_2
How much would you like to give up smoking...
RUNNING PROMPT
(1) Not at all
(2) A little
(3) A fair amount
(4) Quite a lot, or
(5) Very much indeed?
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Date: January 2002
From: Dr Mark Drury
Study Reference Number: CO 1.176
G e n e t i c s  a n d  H e a l t h  S u r v e y
Your General Practice has been working with the Imperial Cancer Research Fund (ICRF) over the 
last few years. We are contacting you about a new project that we are involved in with the ICRF. 
The project is looking at people’s views about genetic testing for cancer. There are more details 
on the enclosed information sheet.
You may also find it useful to read the enclosed booklet about genetics called ‘Genetics and 
Health: A Brief Introduction’.
You do not have to take part in this study, but if you do decide to take part then all you have to 
do is fill in the enclosed questionnaire, and send it back in the FREEPOST envelope.
If you would like to find out more about this study, then please call the research team on 
Alternatively, please feel free to call me at the practice on: 
Thank you for your help.
Dr Mark Drury
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SVY12.CPL
THE GENETICS AND 
HEALTH SURVEY
INFORMATION SHEET
You a re  b e in g  invited to  ta k e  p a rt in a  re s e a rc h  study . B efo re  you d e c id e  it is 
im portan t fo r you to  u n d e rs ta n d  w hy th e  re s e a rc h  is b e in g  d o n e  a n d  w h a t it will 
involve. P le a s e  ta k e  tim e  to  d e c id e  w h e th e r  o r no t you w ish to  ta k e  part, a n d  a sk  u s  
if th e re  is an y th ing  th a t is u n c le a r o r if you w ould  like m o re  inform ation . P le a s e  
re m e m b e r  th a t partic ipation  is voluntary , a n d  th a t y o u  d o  n o t  h a v e  to  ta k e  p a r t  in 
th is study .
Why have you been chosen?_________________________________
W e a r e  inviting a  ran d o m  se lec tio n  o f p e o p le  re g is te re d  with y ou r G P  to  fill in o u r 
q u estio n n a ire .
What is the aim of the study?_______________________________
C urrently , g e n e tic  te s ts  a re  only av a ilab le  fo r a  few  d is e a s e s ,  su c h  a s  H un ting ton 's  
d is e a s e  a n d  b re a s t  c a n c e r . H ow ever, m o re  a n d  m o re  g en e tic  te s ts  a re  beco m in g  
av a ilab le  all th e  tim e. T his m e a n s  th a t in th e  fu tu re , g e n e tic  te s t s  m ight b e  av a ilab le  
for o th e r  d is e a s e s ,  su c h  a s  o th e r  ty p e s  of c a n c e r  a n d  h e a rt d is e a s e .
W e b e lieve  it is im portan t to  u n d e rs ta n d  public v iew s a b o u t g e n e tic  te s tin g  for 
d is e a s e  risks, a n d  w e  a r e  particularly  in te re s te d  in c a n c e r  risk. T h e  aim  of th is s tu d y  
is to  find o u t w h a t p e o p le  think a n d  fee l a b o u t g e n e tic  te s tin g  for c a n c e r  risk.
What is a genetic test?_______________________________________
A g en e tic  te s t  inform s a  p e rso n  a b o u t the ir risk o f g e ttin g  a  d is e a s e  in th e  fu tu re , on  
th e  b a s is  o f th e ir g e n e tic  m ak eu p . A g e n e tic  te s t  d o e s  no t g ive  a  sim p le  "yes" o r 
"no" a n sw e r. It will tell a  p e rso n  if th e y  h a v e  a  h igh risk o f ge ttin g  a  d is e a s e ,  b u t it 
will n o t tell th em  definitely  if o r  w h en  th e  d is e a s e  will d ev e lo p .
You will find m o re  inform ation a b o u t g e n e tic s  a n d  g e n e tic  te s tin g  in th e  
acco m p an y in g  book le t *G enetics and Health: A brief Introduction*.
What does this study involve?_____________________________
If you d e c id e  to  ta k e  p a rt th e n  all you h a v e  to  d o  is fill in th e  e n c lo s e d  q u estio n n a ire . 
T o co m p le te  all th e  q u e s tio n s  m ay  ta k e  u p  to  half a n  hour. P le a s e  a n s w e r  a s  m an y  
of th e  q u e s tio n s  a s  you can  a n d  s e n d  it b a c k  to  u s  in th e  F R E E P O S T  (no  s ta m p  
n e e d e d )  e n v e lo p e  prov ided .
(PLEASE TURN OVER PAGE)
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What sort of things will i be asked?
T he q uestionna ire  will a sk  you ab o u t your view s on gene tic  testing  and  cancer. 
What happens to the information?_________________________
T he inform ation th a t you provide is strictly confidential and  only th e  re sea rch  team  
will h av e  a c c e s s  to it. No information ab o u t any  individual will b e  availab le  to any 
o th e r person . Only group  information will b e  given in any  published  o u tco m es from 
th e  study, with no indication of any  participant’s  identity.
Any questions or comments?_______________________________
If you h ave  any  q u estio n s ab o u t th e  study, or need  so m e  help filling in th e  
questionnaire , p le a se  feel free  to  call the  re sea rch  te am  on te lep h o n e  num ber:
Alternatively, you can  sen d  your views or q u es tio n s  to:
Saskia Sanderson 
Genetics and Health Survey 
UCL Health Behaviour Unit 
Epidemiology and Public Health 
2-16 Torrington Place 
London WC1E 6BT
O r email:
s.sanderson@public-health.ucl.ac.uk
W e a re  very in terested  in hearing  p eo p le 's  view s, an d  would be  happy  to  talk to you 
ab o u t any  a sp e c t of gene tic  testing . S o  if you would like an y  further information, or 
if you would like to tell u s your view s on g ene tic  testing , p le a s e  co n tac t th e  ab ove  
te lep h o n e  num ber, a d d re s s  or em ail.
T hank  you very m uch for read ing  this.
This study has ethical approval from the Oxford Clinical R esearch Ethics Committee (OxREC). 
Study Reference Number C 0 1.176
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The Genetics and Health Survey
The aim of this survey is to find out what people think 
about genetic testing.
Accompanying this questionnaire is a booklet called 
‘Genetics and Health: A brief introduction ’. Please read 
the booklet before completing the questionnaire.
Please fill in this questionnaire and return it in the 
enclosed envelope. No stamp is needed.
Your answers will be treated in strict confidence and are 
very important for our research.
We are very grateful for your help with this survey.
If you have any questions please contact:
Saskia Sanderson 
Genetics and Health Survey 
UCL Health Behaviour Unit 
Epidemiology and Public Health 
2-16 Torrington Place 
London WC1E6BT
Tel: 
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F IR S T , SOM E Q U E S T IO N S  ABOUT YOU AND YOUR THO U G H TS ABOUT G EN ETICS
Male F em ale
Are you male or female? □ □
How old are you?
In general, would you say that your health is:
Excellent G ood Fair Poor
□ □ □ □
Roughly how many times have you been to see your GP in the last 3 months?
H aven’t been O nce Twice T hree  or m ore tim es
□ □ □ □
Please indicate how much you agree or disagree with the following statements about genetic 
testing:
Strongly
disagree
Disagree Not
sure
Agree Strongly
agree
I would like to know w hat d is e a s e s  I'm genetically  a t risk of 
getting
□ □ □ □ □
I have  a  d e a r  picture of w hat genetic  testing  is □ □ □ □ □
I would like m ore information ab o u t genetic  testing □ □ □ □ □
Which of the words below best describe how you feel about genetics? (tick as many as you
like)
□  en thusiastic □  indifferent □  cau tious □  optimistic □  in terested
□  hom fied □  confused □  hopeful □  co n cern ed □  mixed feelings
□  excited □  pessim istic □  worried
Please indicate how much you agree or disagree with the following statements about genetic 
research:
Strongly Disagree Not Agree Strongly 
disagree sure agree
All research  into gene tics  is m essing  with natu re  and  is 
therefore wrong
□ □ □ □ □
G enetic re sea rch  will bring cu res  for m any d is e a s e s □ □ □ □ □
R esearch  into cloning is m essing  with natu re  and  is 
therefore wrong
□ □ □ □ □
G enetics a re  a  big part of our lives and  w e should  all take  
an  interest
□ □ □ □ □
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N EX T, A FE W  Q U E S T IO N S  A BO U T YOUR V IE W S  O N  CANCER AND  G E N E TIC  T E S T IN G
H ow  o f te n  d o  y o u  w o rry  a b o u t  c a n c e r ?
N ever N ot very  often  S o m e  of th e  tim e Q uite  often  All th e  tim e□ □ □ □ □
C o m p a re d  w ith  o th e r  p e o p le  o f y o u r  a g e  a n d  s e x , d o  y o u  th in k  y o u r  c h a n c e s  o f  g e tt in g  c a n c e r  
a t  s o m e  p o in t in y o u r  life a re :
M uch low er Low er A bout th e  s a m e  H igher M uch h igher□ □ □ □ □
P le a s e  in d ic a te  h o w  m u c h  y o u  a g re e  o r  d i s a g r e e  w ith  th e  fo l lo w in g  s t a te m e n ts :
Strongly
disagree
Disagree Not
sure
Agree Strongly
agree
1 h av e  a  c le a r p icture  of w hat c a n c e r  is □ □ □ □ □
T h ere  a re  th ings 1 c an  do  to  control w hether 1 g e t c a n c e r  
o r no t
□ □ □ □ □
W hen  found  early , c a n c e r  c an  b e  cu red □ □ □ □ □
If y o u  h a d  a  g e n e t ic  te s t ,  w o u ld  y o u  b e  w illing  to  u s e  th e  fo llo w in g  tw o  m e th o d s ?
No,
definitely
not
No,
probably
not
Yes,
probably
Yes,
definitely
BLOOD CELL T E S T  T his involves having a  b lood 
sam p le  tak en  by a  do c to r o r a  n u rse .
□ □ □ □
MOUTH CELL T E ST  This involves rubbing sev e ra l □ □ □ □
cotton  wool b u d s  on  th e  inside of your m outh
S u p p o s e  y o u  h a d  in h e r ite d  s o m e th in g  fro m  y o u r  p a r e n t s  w h ic h  m a d e  y o u  m o re  likely  to  
d e v e lo p  c a n c e r  th a n  o th e r  p e o p le ;  w o u ld  y o u  w a n t to  b e  to ld  th i s ?
No, definitely not No, p robab ly  no t Y es, p robab ly  Y es, definitely
□ □ □ □
W o u ld  y o u  b e  in te r e s te d  in ta k in g  a  g e n e t ic  t e s t  fo r  c a n c e r  r i s k ?
No, definitely not No, p robab ly  no t Y es, p robab ly  Y es, definitely□ □ □ □
W o u ld  y o u  h a v e  a  g e n e t ic  t e s t  fo r  c a n c e r  r isk  if y o u r  d o c to r  r e c o m m e n d e d  i t?
No, definitely not No, p robab ly  no t Y es, p robab ly  Y es, definitely□ □ □ □
If it w e re  a v a ila b le  n o w , w o u ld  y o u  h a v e  a  g e n e t ic  t e s t  fo r  c a n c e r  r isk  in th e  n e x t 6 m o n th s ?
No, definitely not No, p robab ly  no t Y es, p robab ly  Y es, definitely□ □ □ □
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FOR THE FO LL O W IN G  S E C T IO N , PLEASE IM A G IN E  T H A T  YOU HAVE HAD A G EN ETIC  
T E S T  FOR A C ER T A IN  T /P E  O F CANCER
How w o u ld  y o u  fe e l if y o u  re c e iv e d  a  POSITIVE g e n e tic  t e s t  r e s u l t  fo r c a n c e r  r is k ?  fa positive test 
result means you may be more likely to get that cancer than other people)
If 1 received a positive genetic test result, 1 would... Strongly Disagree 
disagree
Not
sure
Agree Strongly
agree
b e  co n cern ed □ □ □ □ □
regret having had  th e  te s t □ □ □ □ □
feel d e p re s se d □ □ □ □ □
b e  glad tha t 1 knew  of my risk □ □ □ □ □
...w ant to d is c u ss  my te s t resu lt with a  health  p rofessional 
(e g doctor, counsello r o r nu rse )
□ □ □ □ □
feel 1 w as definitely going to g e t that c a n c e r  in th e  
future
□ □ □ □ □
worry tha t it m ay  c a u s e  problem s with life in su rance □ □ □ □ □
worry tha t it m ay c a u s e  p rob lem s with em ployers □ □ □ □ □
...feel that 1 could provide my family with useful 
information ab o u t their nsk  of c an ce r
□ □ □ □ □
How w o u ld  y o u  fee l if y o u  re c e iv e d  a  NEGATIVE g e n e tic  t e s t  re s u l t  fo r c a n c e r  r i s k ?  (a negative 
test result means that you ’re not at higher risk of getting that cancer than other people)
If 1 received a negative genetic test result, 1 would... Strongly
disagree
Disagree Not
sure
Agree Strongly
agree
be concerned □ □ □ □ □
regret having had  th e  te s t □ □ □ □ □
feel d ep re s se d □ □ □ □ □
be glad that 1 knew  of my nsk □ □ □ □ □
w ant to  d iscu ss  my te s t resu lt with a  health  p rofessional 
(e.g . doctor, counsello r or nu rse)
□ □ □ □ □
feel 1 w as definitely NOT going to get th a t c a n c e r  in the 
fu ture
□ □ □ □ □
feel tha t 1 could provide my family with useful inform ation 
abou t their risk of c an ce r
□ □ □ □ □
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SO M E Q U E S T IO N S  A BO U T YOU AND YOUR FAM ILY T O  HELP U S  ANALYSE THE SURVEY
W h at is  y o u r  m a rita l s t a tu s ?
Single M am ed C ohabiting  / living D ivorced / W idow ed
with p a rtn e r s e p a ra te d□□
□ □ □
H ow  m a n y  c h ild re n  d o  y o u  h a v e ?
N one 1 2 3 M ore th an  3
□ □ □ □ □
W hich  o f th e s e  b e s t  d e s c r ib e s  y o u r e th n ic  b a c k g ro u n d ?
W hite Black A sian O ther Do not w ish to  a n sw er□□
□ □ □
To w h a t e x te n t  d o e s  y o u r  re lig io n , o r  re lig io u s  u p b r in g in g , in f lu e n c e  th e  s o r t s  o f d e c is io n s
th a t  y o u  m a k e  a b o u t  life?
Not a t all A little Q uite a  lot C om pletely Not app licab le□□
□ □ □
P le a s e  tick  th e  b o x  w h ic h  b e s t  d e s c r ib e s  y o u r  liv ing  a r r a n g e m e n t:
R en t from local R en t from  private Own h om e O th er
authority landlord □□□
□
No Y es, 1 M ore than  1
D o es  y o u r h o u s e h o ld  h a v e  a  c a r  o r  v a n ?  □ □ □
A re y o u  cu rren tly :
□  em ployed  full-time □  retired
□  em ployed  part-tim e □  s tu d e n t
□  unem ployed □  d isab led  or to o  ill to work
□  full-time ho m em ak er
W h at is  th e  h ig h e s t  level o f e d u c a t io n a l  o r  p ro f e s s io n a l  q u a lif ic a tio n  y o u  h a v e  o b ta in e d ?
□  G C SE /O -level/C SE □  M aste rs /P hD  o r equ ivalen t
□  V ocational qualifications (e .g . NVQ1 +2) □  O ther
□  A-level or equ ivalen t (e .g . NVQ3) □  No form al qualifications
□  B achelor D eg ree  or equ ivalen t (e .g . NVQ4) □  Still studying
Y es No D on't know
Do y o u  e v e r  u s e  th e  In te rn e t?  □ □ □
Y es No
H as a n y o n e  in y o u r  c lo s e  fam ily  h a d  c a n c e r ? □ □
H ave you  e v e r  h a d  c a n c e r ? □ □
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A FEW  MORE Q U E S T IO N S  ABOUT YOU AND YOUR FAMILY
Yes No Not sure
In your opinion, does cancer run in your family? □ □ □
Do any other conditions or illnesses run in your family? □ □ □
Yes No Not sure Do not wish 
to answer
As far as you know, have any of your friends or family 
ever had a genetic test?
□ □ □ □
Have you ever had a genetic test? □ □ □ □
As far as you know, has anyone in your family been 
diagnosed with a genetic illness?
□ □ □ □
Have you been diagnosed with a genetic illness? □ □ □ □
Please indicate how much you agree with each of the following items by ticking the
appropriate box:
Strongly Disagree Not Agree Strongly
In uncertain tim es, I usually expec t the  b e s t
disagree
□ □
sure
□ □
agree
□
If som ething can  go wrong for m e, rt will □ □ □ □ □
I'm alw ays optimistic abou t my future □ □ □ □ □
1 hardly ever expect things to go my way □ □ □ □ □
1 rarely count on good things happen ing  to  m e □ □ □ □ □
Overall, 1 expect m ore good th ings to  h ap p en  to m e than □ □ □ □ □
bad
Yes No
Have you ever smoked a cigarette, even a puff? □ □
Do you ever smoke cigarettes now? □ □
Please tick the box that best describes how you see yourself:
Never-smoker/ Ex-smoker Social smoker Smoker
non-smoker□ □ □ □
• IF  YOU DO SMOKE CIG ARETTES AT ALL PLEASE A N SW ER ALL THE FO LLO W ING  
Q U E S T IO N S  O N  PAGES 7  AND 8
• IF  YOU NEVER SMOKE CIG A RETTES PLEASE GO S T R A I6 H T  TO THE 'FURTHER 
COM MENTS' SE C T IO N  O N  PAGE 8
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SO M E Q U E S T IO N S  A BO U T SM O K IN G  FOR ANYONE W H O  SM O K ES A T ALL
How soon after waking do you smoke your first cigarette of the day?
Less than 5 Between 5 and 15 Between 15 Between 30 Between 1 and Longer than 2
minutes minutes and 30 minutes min. and 1 hour 2 hours hours□□□
□ □ □
How many cigarettes do you usually smoke? per day
OR
per week
How easy or difficult would you find it to go without smoking for a whole day?
Very easy  Fairty easy  Fairly difficult Very difficult□□□
□
How much do you want to give up smoking all together?
Not at all Slightly Moderately Quite strongly Very strongly□□□
□ □
Are you intending to give up smoking within the next 6 months?
No. definitely not No, probably not Possibly Yes, probably Yes, definitely□□□
□ □
For the following section, please imagine again that you have had a genetic te s t  
for a certain type of cancer.
How would you feel about your smoking if you received a POSITIVE genetic test result for 
cancer risk? (a positive test resuit means you may be more iikeiy to get that cancer than other people)
If 1 received a positive genetic test result... Strongly
disagree
Disagree Not
sure
Agree Strongly
agree
I w ould definitely give up sm oking □ □ □ □ □
it w ould in c re a se  my d es ire  to  quit sm oking □ □ □ □ □
1 would feel tha t it w as s a fe  for m e  to  carry  on  sm oking □ □ □ □ □
How would you feel about your smoking if you received a NEGATIVE genetic test result for 
cancer risk? (a negative test result means that you 're not at higher risk of getting that cancer than other people)
If 1 received a negative genetic test result... Strongly
disagree
Disagree Not
sure
Agree Strongly
agree
I would definitely give up  sm oking □ □ □ □ □
it w ould in c re a se  my d es ire  to  quit sm oking □ □ □ □ □
1 would feel th a t it w a s  s a fe  for m e  to  carry  on  sm oking □ □ □ □ □
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FURTHER COMMENTS
Did you find completing this questionnaire...?
Very e a s y  Q uite e a sy Q uite difficult Very difficult□□
□ □
Yes No
Have you read the information leaflet about 
genetic testing?
□ □
I f  you HAVE read the leaflet about genetic testing, please answer the following 
three questions:
Was the information in the leaflet...?
Very e a sy  to read  Q uite e a sy  to  read Q uite difficult to read Very difficult to read□□
□ □
Was the information in the leaflet...?
Very interesting Q uite interesting Not very interesting Not a t all interesting□□
□ □
When you were filling in this questionnaire, did you find the information in the leaflet...?
Very useful Q uite useful Not very useful Not a t all useful□□
□ □
We are very interested in hearing your thoughts on any aspect of this 
questionnaire, so please write any further comments you have in the box below.
Thank you very much for taking the time to fill in th is questionnaire
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What diseases are genetic tests  currently available 
for?
G enetic te s t s  a re  only available a t  th e  moment fo r  a small number of 
diseases. T hese include cystic fib rosis, some types o f b re a s t cOncer 
and bowel cancer. However, more and more genetic t e s t s  a re  being 
developed all th e  time. This means th a t  in th e  fu tu re , genetic te s t s  
might be available fo r  more common d iseases, such as h e a rt disease 
and o th e r form s o f cancer.
How can I  find out more about genetic testing?
This lea fle t provides a general overview of genetic testing . For de ta ils  
on w here you can find out more,
please phone:
or email:
s.sanderson@public-health.ucl.ac.uk
If c -----
A "LARGE PRINT" v ers io n  o f  th is  le a f le t  is a lso  availab le  f o r  
people  w ith  visual d i f f  icu lties.
Genetics and Health
A brief introduction
The Genetics and Health Survey 
University of London
What arc genes?
Genes control th e  development 
and workings of your body.
Genes a re  made o f a  substance called DMA 
...and a re  p resen t in every one o f th e  billions of 
. th a t  make up your body.
Human beings have about 30 ,000 genes. Each gene comes 
d if fe re n t versions called genetic variations. For example, everyone 
has a  s e t  o f genes fo r  eye colour, bu t some people have th e  variation 
th a t  in s truc ts  th e  eyes to  be blue while o th e rs  have th e  variation th a t  
produces green eyes, o r brown eyes.
How are genes related to disease?
Genetic variations can sometimes lead to  disease. Some genetic 
variations occur when a gene, o r a b it o f a  gene, is abnormal or 
damaged. Some genetic variations run in families. Some ju s t  happen by 
chance.
M ost d iseases a re  caused by a  combination of genetic variations and 
environmental fa c to rs . Examples o f environmental fa c to rs  a re  
c ig a re tte s , some types o f food and pollution.
What is genetic testing?
Genetic te s ts  look fo r  genetic variations th a t  may lead to  disease.
They could help show how likely you a re  to  g e t certa in  d iseases in th e  
fu tu re .
Because genes a re  p resen t in every cell in your body, samples can be 
taken from  any convenient place in th e  body. For example, genes from  
th e  mouth cells can be collected by rubbing a co tton  wool bud on th e  
inside of th e  ch eek  The most common m ethod however, is to  tak e  a 
blood sample to  collect genes in th e  blood cells.
in several
What does a positive te st result mean?
A positive t e s t  re su lt means th a t  you have th e  variation you've been 
te s te d  fo r. This means you may be more likely to  g e t a particular 
d isease than  o th e r  people. I t  does not mean th a t  you will definitely 
g e t th e  disease.
What docs a negative te st result mean?
A negative t e s t  re su lt means th a t  you don't have th a t  particular 
variation, so you're not a t  higher risk of ge tting  th e  disease than  o th e r 
people. I t  doesn 't mean th a t  you won't ever g e t th e  disease.
What are the advantages and disadvantages of testing?
T here a re  many advantages and disadvantages of genetic testing .
Below a re  some o f th e  things th a t  you might consider when thinking 
about genetic testing .
What can be gained by being tested?
•  You might not be so w orried about getting  a disease.
•  You might be able to  change your d ie t, s t a r t  exercising, o r  quit 
smoking to  reduce your risk  o f ge tting  a  disease.
•  You might be able to  take  medicine to  prevent th e  disease.
• Some people feel th a t  th e ir  t e s t  re su lts  might provide th e ir  
family mem bers with useful information about th e ir  own risk 
of th e  disease.
J P L JMrAre there any negative effects of genetic testing?
•  You might become more w orried about getting  ill. |
• Some illnesses can 't be prevented  even if you a re  a t  higher 
risk. 5.
•  Some people worry th a t  tes ting  could lead to  problems with 
employers.
•  You might worry about w hether tes tin g  could a f f e c t  your life  
insurance. A
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Isling ton NHS C am den
Primary Care Trust
UCL Primary Care Trust
«Street»
«street2»
«Town»
«Title» «First_Name» «Last_Name»> Health Behaviour Unit 
University College London 
2-16 Torrington Place 
London W C 1E  6BT
« Postcode »
Tel: 
26 March 2005
Dear «Title» «Last_Name»
A while ago you contacted the Camden and Islington smoking cessation services about quitting smoking. The  
service has recently been re-structured and we are contacting everyone who has been in touch with the service 
over the past four years, to see if they would still like help with quitting smoking
If you have recently quit -  well done! Keep up the good work. If you are still smoking, or have recently started 
again, then our new service is here to assist you W e can offer a range of help -  there's something for everyone 
All you have to do is tear off the slip below and return it in the FR EEPO ST (no stamp needed) envelope enclosed 
Alternatively, you can call us on 020 7679 6495 or email us on: s sanderson@public-health.ucl ac uk
W e are also collaborating with researchers at University College London on a study investigating whether having a 
genetic test affects the way people think about quitting Would you like further information about this study?
If you would like to receive more details about the smoking cessation services we provide, or about the genetic 
testing study, please fill in the slip below and return it in the FR EEP O ST (no stamp needed) envelope enclosed. 
One of us will then contact you by telephone with further information W e look forward to hearing from you
Yours sincerely
Saskia Sanderson,
UCL Smoking Researcher
Simon Galton,
Camden Smoking Cessation Coordinator
Seher Kayikci,
Islington Smoking Cessation Coordinator
Please tick one of the following boxes: CD Yes, I would like further information
C3 No, I do not want to receive any further information.
First name: Last name:
Day time telephone number:
Evening telephone number:
Times available for telephone call:
P leas e  return this form  in the F R E E P O S T  (no stam p n e ed e d ) en velo pe prov ided «Study_ID»
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Entered: O Phase 1 letter sent: D
By (name): By (name):
On (date): On (date):
PHASE 0: TELEPHONE RECRUITMENT PROTOCOL
Please follow these guidelines when making the telephone recruitment calls. Please try to keep each 
call down to FIVE MINUTES long.
ID: Date Name of researcher: Call again? □ YES G NO
Start time:   Finish time:
Hello. Is t h a t___________________________________________(insert n a m e )?  Hello, I'm calling about the letter
that you received a  few m onths ago  about quitting smoking. You returned a form saying that you might be 
interested in the NHS stop sm oking service or som e research  th a t’s  currently being conducted. I'm recruiting 
sm okers for a research  study tha t’s  being done at the University of London, that w as referred to in the form 
you sen t back If you have a  few m inutes I could tell you about it and s e e  w hether you might be in terested in 
taking part?
If already quit: Great! Well done! OK then, there 's  no need for m e to take up any m ore of your time. 
Goodbye.
StiH smoking? □  YES C NO
OK The study is researching the psychological im pact of giving people information about their genetic risk 
of lung cancer. It involves coming in to UCL for one  session  with a smoking researcher-adviser, receiving 
som e stop smoking advice, doing a questionnaire and possibly taking the genetic test. The gen e  tha t is 
tested  for has been  found in research  stud ies to be associa ted  with lung cancer risk and other smoking 
related d iseases . [In studies which com pare sm okers who have lung can ce r with sm okers who don ’t, the 
sm okers with lung cancer have been  found to be m ore likely to be missing this gene, which su g g es ts  that it 
plays a part in how likely you a re  to ge t lung cancer and o ther sm oking-related d iseases . W e also know that 
it's involved in how well your body breaks down the  dangerous parts of tobacco  sm oke ] The tes t itself is 
non-invasive, it just involves taking a cheek  cell sw ab using a cotton wool bud, it's not a blood tes t or 
anything like that. Not everyone is offered the test, but if you a re  offered it you do n ’t have to take it if you 
decide not to once you’ve received m ore information in the  sessio n  If you do take it, then you com e back 
one  week later to get your tes t result, and then have a  couple of te lephone follow-up calls a few w eeks later.
D oes this sound like som ething you might be  in terested  in? Study interest: □  YES □  NO □  N/A
If yes:  Great! I’m booking people in for next week. W hat sort of time and day is good for you?
OK. So w e’ll se e  you on (d a te ) at (tim e) I’ll send  you a confirmation letter which h a s  m aps and everything 
on there, and I’ll give you my nam e and direct num ber in c a se  anything com es up in the m eantim e. You can 
contact the research  team  on 020 7679 6642 (Katie Swingewood) or 020 7679 6495 (Saskia) if you have 
any queries in the m eantim e Look forward to seeing  you. G oodbye.
Phase 1 date: □  HI A
Phase 1 time: □  N/A
If no: OK, tha t’s fine. If you would like I could also help put you in touch, or back in touch, with your local 
NHS Stop Smoking Service They can give you further advice and information such  a s  exactly w hat groups 
are  running in your a rea  and which one-to-one se ss io n s  a re  available locally to you. Would you like that 
number, and do you have a  pen?  Good luck with quitting and do give that freephone num ber a ring 
Goodbye.
Islington:
Camden:
0800 093 9030 
0800 107 0401
Barnet: 0800 328 2784
Westminster: 0800 328 8537 Service number given □  YES □  NO □  N/A
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Camden E S S UCL Islington
Primary Car# Trwt Prim ary C are Trust
[NAME]
[ADDRESS]
Health Behaviour Unit 
2-16 Tornngton Place 
University College London 
London W C1E6BT 
Tel: 
26 March 2005
Dear [NAME],
Smoking and genetic testing research study
Thank you very much for agreeing to take part in this research. I am writing to confirm that the date of your 
appointment is
Friday 27 February, 4pm
The appointment takes 45 minutes and consists of:
# a  brief discussion with the smoking researcher-adviser about quitting smoking (including, if you wish, 
information about nicotine replacem ent therapy, zyban, and what the most appropriate behavioural 
support package may be for you);
• completing a short questionnaire, which includes questions on you, your smoking, and your views on
• and, for som e people, the option of taking a genetic test for a gene which is associated  with lung cancer 
risk People who are not offered the test in this session may have the option of taking the test in two 
months time if they wish. You will receive more information about this during your appointment
Our office is based at 2-16 Torrington Place, University College London, WC1E 6BT W hen you arrive, 
please go to the Main Reception and tell them that you are here for the Smoking Study If your 
appointment is after 6pm, please ring on the bell marked ‘HBU UCLi’ and the smoking researcher-adviser 
will come down and meet you
How to reach us by tube: The nearest tube is Goodge S treet tube station Also close by are W arren 
Street and Tottenham Court Road tube stations
How to reach us by bus: Bus num bers 10, 24, 29, 73, 134 and 390 all stop at Gower Street or Tottenham 
Court Road, both of which are about a five minute walk from 2-16 Torrington Place. There are two m aps 
enclosed with this letter which show where we are.
If you have any queries between now and your appointment do p lease call us on 020 7679 6495, we are 
looking forward to meeting you
Yours sincerely
lung cancer,
Saskia Sanderson
UCL researcher and smoking adviser
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APPENDIX G
MATERIALS FOR GSTM1 GENETIC TESTING STUDY 
BASELINE SESSION (PHASE 1): BRIEF ADVICE PROTOCOL, BASELINE AND 
TEST PROTOCOLS, STAGE 1 CONSENT FORM, PHASE 1 QUESTIONNAIRE,
STAGE 2 CONSENT FORM
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PH A S[: ! A brief a d v ic e  p ro to c o l 20  2 04
PHASE 1 A: BRIEF ADVICE PROTOCOL
Entered: □  
By (Name)
O n  ( d a t e ) :
The following guidelines ere for the edvtser/reseercher who has the first contact with the participant 
in Phase 1, and should take no more then TEN MINUTES to complete.
ID :____________ Date:
N am e of adviser/researcher:
Confirm participant’s nam e:
Participant’s borough: EH CAMDEN C  ISLINGTON D  OTHER specify:
Have you used  any of your local CD NO O  YES d e ta i ls : ...........................................
S top Smoking Services in the p ast?
Turned up: □  YES □  NO
Phase 1A start time:
1. GIVE BASIC INFORMATION ABOUT THE 8TUOY (ON WAY TO CLINIC OFFICE) □  CHECK
“Hello, thank you very much for coming in. I’m just going to tell you first about how the study works. There 
are  three p h ase s  in this first session . Everybody who com es in s e e s  m e first for about ten m inutes The 
main aim of this is just to ge t som e basic information down about your smoking, but we also offer a brief 
advice service, b ecau se  som e people com e in partly b ecau se  they w ant to d iscuss som ething specific about 
quitting. You may or may not w ant the brief advice part, but if you do then I have to warn you that it is only 
brief, so  if you feel that you w ant m ore time to talk things through a bit m ore with som ebody, then we can 
strongly recom m end that you arrange to s e e  som eone additional through your local service (which you may 
of course have already done). Som e people are  then referred on to my colleague, depending on certain 
criteria, to com plete a  questionnaire which takes about ten m inutes to com plete D epending on which group 
you go into, som e people are  then also  offered the genetic test today, but you’ll ge t more information about 
that later if you do go into that group. All in all the session  should take no m ore than 45 m inutes m ax.”
2. REVIEW 8MOK1NG BEHAVIOUR AND HISTORY □  CHECK
Number sm oked per day: __________________
W ere you already thinking about quitting or trying to quit or w as the letter a  prom pt?
□  ALREADY THINKING ABOUT QUITTING □  WASN'T THINKING ABOUT QUITTING
How long is it since your last quit a tte m p t? ___________ How long have you stayed quit in the past?
In the past year, how m any tim es have you quit sm oking for at least 24 h o u rs ? ____________
W hat products have you u sed  in the  past?  (e.g. nicotine patches, zyban etc  ) ____________________
W hat counseling have you had in the p ast?  (e g groups, o n e -to -o n e)___________________________
S. CHECK ELIGIBILITY □  CHECK
The aim of the following questions is to check the eligibility of potential participants. P lease  circle YES or NO 
for each  question. Please ONLY invite to participate in the remainder of the study IF ail responses to
all the questions below are NO.
1. Is the client under 18 y ears  of ag e?  YES NO
2. H as the client sm oked less than 7 cigarettes in the last w eek? YES NO
3. D oes the client have any problem s with understanding English? YES NO
4. H as the client ever had a d iagnosis of lung cancer? YES NO
5. Is the patient currently on m edication for any psychiatric conditions? YES NO
6. H as the patient ever had any psychiatric condition o ther than dep ression?  YES NO
(e.g. schizophrenia or bipolar disorder) — —---------------------------
Eligible. DYES □  NO
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4. MOTIVATION TO QUIT SMOKING □  CHECK
Are you seriously thinking about quitting sm oking?
CD YES, within the next 30 days Cl] YES, within the next 6 m onths □  NO, not thinking of quitting
Are you currently registered with a  group or other stop sm oking service? C  NO C  YES
Any further details regarding plans to quit or efforts already m ade tow ards qu ittin g :.........................................
5. BRIEF ADVICE AND MOTIVATION □  CHECK
IMPORTANT: PLEASE CHECK THAT YOU HAVE GIVEN THE PARTICIPANT:
□  THE GREEN SELF-HELP STOP SMOKING BOOKLET
□  THE 0800 HELPLINE DETAILS SHEET
PLEASE TRY TO COMPLETE AS MANY OF THE FOLLOWING POINTS AS ARE APPROPRIATE FOR 
THE INDIVIDUAL. CHECK THE BOXES OF WHICHEVER POINTS YOU COMPLETE.
d ]  MOTIVATE AND ENCOURAGE e  g “you a re  obviously m otivated b ecau se  you returned the letter 
and turned up today", "rem em ber how good you felt w hen you quit before, the  fact that you have 
quit before is a  good sign -  m any people have to try several tim es before they su cceed  for 
good”.
□  SUMMARISE OPTIONS
□  BEHAVIOURAL
1 G roups (phone 0800 num ber to register)
2 O ne-to-one sess io n s  (phone 0800 num ber to ge t details or s e e  G P)
3 S et quit date  (use g reen  booklet)
□  PHARMACOLOGICAL
1 Nicotine rep lacem ent therapy - pa tches, inhalator, gum , tab s  (from G P or chem ist)
2. Zyban/buproprion (from GP)
□  ADDITIONAL ACTIONS include get further information from 0800 helpline, inform or enlist 
support of p eer group or family, d iscu ss further with G P, identify tnggers to sm oking and encourage  
them to develop stra teg ies for countering th ese  (e.g. avoid p laces or activities assoc ia ted  with 
smoking, have cut up vegetab les to hand).
G] ENCOURAGE USE OF COUNSELING e.g . “if you a re  ready to try to give up smoking now, then the 
best thing is to s e e  a  counselor a s  soon  a s  possible, in which c a se  you should phone the  0800 
num ber to register for a group or to ge t the num ber of your n ea re s t one-to-one adviser (pharm acist or 
practice nurse) who you should m ake an  appointm ent with im m ediately ”
□  ENCOURAGE USE O F PHARMACOTHERAPY Advise u se  of nicotine rep lacem ent therapy or 
zyban
□  EMPHASISE COMBINATION OF A PPRO A CH ES BEST e.g . “you need  to com bat both the 
psychological and physical nicotine addiction, and your c h an ces  of succeed ing  a re  m uch greater
if you m ake u se  of both counseling and one  or som e of the range of products which a re  now available 
through your pharm acist or G P”
□  EM PHASISE NEED FOR TOTAL ABSTINENCE
O  CLO SE W hen ten m inutes is up, p lease  em phasize  that although w e encou rage  participants to get
in touch with their local stop smoking service, their involvement at UCL from this point on is purely for 
the  resea rch  study. You m ay also wish to mention that we do not request that people quit smoking in 
order to participate in the research
Phase 1A finish time.
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PHASES 1B AND 1C: BASELINE AND TEST PROTOCOLS
Entered: O Phase 2 letter sent: O
By (name): By (name):
On (date): On (date):
PHASE 1B (BA8ELINE): The following gtiktotinos ore for the advlaar/researchar who has ths SECOND 
contact with ths participant In Phase 1, and should take no more than FIFTEEN MINUTES to complete.
ID: Date:______________________________
Phase 1B start time:
Name of adviser/researcher:
1. GIVE DETAILED INFORMATION ABOUT THE STUDY □  CHECK
Give the participant the Study Information S heet to read and keep for their records, and highlight the 
mam points about the study. Inform them that if they do take part:
o They will com plete a short questionnaire today
o You will then random ize them  to either the genetic test or control group
: If they are in the genetic test group you will give them som e more information about genetics and
the genetic test before asking them to decide w hether they do or do not want to take the test
o If they are offered it and do want to take the test, that will be done today using a  cheek cell sw ab
If they are not offered it today, they can still take it in two m onths time if they w ant to
: They will then com e back for a second session  in two w eeks time, when they will received their
test result if they have taken it, and will then have two telephone follow-up calls after one week 
and two months.
2. OBTAIN 8TAGE1 CONSENT □  CHECK □  N/A (consent not given)
• Ask if they have any questions and answ er them , and then ask if happy to take part
• If they are  happy to participate, give them the S tage  1 C onsent Form and ask them to read it and check 
that they are  happy with all of it and if so, then to initial each  box and print, da te , and sign the top line 
overleaf.
• Meanwhile, com plete your details on a  second S tage 1 C onsent Form and give it to them  to keep for their 
 reCQIJ&______________________________________________________________________________________
3. ADMINISTER BASELINE QUESTIONNAIRE □  CHECK
• Give the participant the B aseline Q uestionnaire to fill in for them selves, and briefly explain what type of 
questions it contains.
• Tell them that it should take about ten m inutes to com plete, and to ask any questions that they want
• You can read it out and fill it in for them  if they would prefer
4. RANDOMIZE TO CONTROL OR GENETIC TEST GROUP □  CHECK
W hen they have com pleted the Baseline Q uestionnaire, pull one of the three pieces of paper out of the 
bag in order to random ize them  to either the control or genetic tes t group
If they are  in the control group then tell them that they have finished for today but can still take the test in 
two m onths time if they want to. Arrange a  date  for their second session  in two w eeks time, and record 
date and time overleaf Thank them for their time and accom pany them  out
If they are  in the genetic tes t group, continue with P h ase  1C overleaf. Group. □  CONTROL □  TEST
Phase 1B finish time
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PHASE 1C (TEST): The following guidelines ere ONLY for participants who have been randomized 
into the genetic test group. They should take no more than TEN MINUTES to com plete.
Phase 1C start lime:
1. EXPLAIN GENETIC TEST U8ING ILLUSTRATED GUIDE □  CHECK
Accept test: □  ACCEPT □  DECLINE O N/A (CONTROL)
2. OBTAIN STAGE 2 CONSENT □  CHECK
3. COLLECT DNA 8 AMPLE □  CHECK
4. CLOSE □  CHECK YOU HAVE GIVEN THEM THE GENETIC BOOKLET
•  Arrange a date for their second session in two weeks time, and record date and time below
•  Thank them for their time and accompany them out
Phase 2 date:
Phase 2 time:
Phase 1C firvsh time:
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Centre Number:
UCLH Project ID number: 03 /0127
Participant Identification Num ber for this study:___________
Form version: 5 (15 .7 .04)
Nam e of Principal investigators: Jane W ardle and Saskia Sanderson
QUIT SMOKING AND GENETIC TESTING STUDY
CONSENT FORM -  STAGE 1 
(CONSENT TO PARTICIPATE IN THE STUDY)
There are two stages of consent in this study. If you agree to this stage (Stage 1), you are agreeing to:
• complete a brief questionnaire today
• complete a brief telephone survey in three weeks time
• complete a brief telephone survey in two months time
• consider taking a genetic test if invited to do so
Please note that no actual genetic testing will be carried out without further consent (Stage 2) being 
obtained. Stage 2 will only be completed after you have received more detailed information about the 
genetic testing process._____________________________________________________________________
Please initial box
1. I confirm that I have read and understood the information sheet dated 15 July 2004, -----
version 7, for the above study and have had the opportunity to ask questions.
2. I confirm that I have had sufficient time to consider whether or not I want to be 
included in the study.
3. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected.
4. I understand that by agreeing to participate in this study I am agreeing to complete a 
questionnaire today and two telephone follow-up surveys.
4. I understand that this is not an agreement to have a genetic test, but that I may be 
invited to take a genetic test at a later stage today, and that invitation to take the 
genetic test will involve receiving further information, having the opportunity to ask 
further questions, and a further consent procedure (Stage 2).
5. I agree to take part in this study.
Continued on next page Page 1 of 2
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UCL
Centre Number:
Participant Identification Number for this study:
UCLH Project ID number: 03 /0127  
Form version: 4 (7.3  04)
QUIT SMOKING AND GENETIC TESTING STUDY
CONSENT FORM -  STAGE 1
Name of Principal investigators: Jane W ardle and Saskia Sanderson
Name of participant Date Signature
Name of Person taking consent Date Signature
Saskia Sanderson 
Researcher (to be contacted 
if there are any problems)
020  7679 6495  
Phone number
Comments or concerns during the study
If you have any  com m ents or concerns you m ay d iscu ss  th ese  w ith the  
investigator. If you w ish  to go fu rth e r an d  com plain ab o u t any  aspect of the  
wTay you have been approached  or trea ted  du rin g  th e  course  of the  study , 
you should  write or get in  touch  w ith the  C om plain ts M anager, UCL 
hospitals. Please quote th e  UCLH project n u m b er a t th e  top th is  consen t 
form.
1 form for participant
I to be kept as part of the study documentation
Page 2 of 2
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PHASE 1 QUESTIONNAIRE
m ___________
FIRST, SOME QUESTIONS ABOUT YOU
Mato Female
Art you male or tom  to? □ □
How old are you?
in general, would you aay tie! your health to:
ExoeBem Good Far Poor
□ □ □ □
Roughly lww fBanytooM torn you Been to ooo your GP in t ie  tost a mouttw?
UNuuueutoflf BtoaoMi FHKHI w^EtER Once TYBoe Three or more tone*
□ □ □ □
SOME QUESTIONS ABOUT YOU AND YOUR FAMILY TO HBUP US ANALYSE THE SURVEY
Whai to your manta! states?
sangto M/touted
□  □
Cohabfltog / iMhg 
««fi partner 
□
Dtooroed/
separated
□
WWowed
□
How many children do you have?
None 1
□  □
2
□
3
□
Morethai 3
□
Which of tfieue beet describee your ethnic b e d g o u n l?
Wttoe Black
□  □
M an
□
Otier
□
Do not Wfeh to answer
□
To wtiaf extent doee your religion, or reUgloue upbringing, Influence the eotte or decsetone that 
you make about llto?
Not at at A m e
□  □
Quito a lot 
□
Comgetety Not amicable
I
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PtMM Sen tie  box wttcti bMt dM critea your M is  airangwrwnt:
Rent m m  local Rent to n  prtwrte Own home Otoer
auffiontY undtocd □□□
□
NO Yes, 1 More man 1
Oo#b your houeaftold lav* a car or van? □ □  □
Arayou currently:
□  employed ftdMlrae □  retired
□  employed part-dme □  student
□  unemployed □  (teamed or too II to wor*
□  MMtrue homemaker
What to your current occupation? pryou a rt nor curmmiy employed, ptosse m d m a wharyour
tost jo6 wasi
What to hie MgflMt level of educitkMial or proteealanal quaimcetlon you have outlined?
□  GCseo-ievePCSE □  Masters/PhD or equivalent
□  Vocafltonari quaincaHons (e.g. NVQ1+2} □  Oder
□  A4evei or equtoatoit {e.g. NVQ3) □  No formal quaffflcations
□  Bachelor Degree or equivalent (e g. WVQ4) □  Stoi studying
SOME QUESTIONS ABOUT SMOKINS
LMdofMuMiMign How aoon after waking do you areoli your flret cigarette of toe (toy?
Lest lhan 5 Betateefi S and 15 Between 1S Between 30 Between 1 and Lonoer than 2
minutes minutes and 30 mftiutes mtn. and 1 Hour 2 hours hours□□□
□ □ □
Hair many togamttu* do you uauedy hm **? per day
OR
uoa wotr
How ea*y or dUTlcult would you nnd It to go without smoking fdr a  whole day?
Very easy Fality easy Fatly difficult Very dfTtaJt
n □ a □
******** Kowreucli do you want to give MpareoMng?
Not a * *  attomtr Moderate* CtoBe straw * Very strong*□ □ □ □ □
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HMtonia** Are you irttaMfttg to  giro up smofclng within foe next 6 m antas?
Mo, deftnfteiy not Mo, probably not Postibty Y n , probably Y es, definitely□ □ □ □ □
How many of your Blende and taH ly &mo*e cigarettes?
M d th em Molt or t e n SOBWC flhMSTM One or Ian ol ajLifM « |)Mine hi w n
them
Frtenbi □ □ □ □ □
FOardy Q □ □ □ □
mm. , How many of your Blende and t a l ly  Biftnfc you sltould quit Btnoklng?
Most of arm Soane or fiera One or tan of NbneofHem
them
Frtends □ □ □ □ □
F t a y  Q □ □ □ □
M*«a« on#*»tni P lease olnria the a is*  bee* wMoh kadlaala bow yo a  Tael atooait uaofctng and cpdtUng.
Sm oftlaB •*—
Good 1 2 3 4 5 € 7 Bad
Desirable 1 2 3 4 5 E 7 Undesirable
FaroaraMe 1 2 3 4 S fi 7 UidfcmontHe
W ise 1 2 3 4 5 E 7 Fooiti*
C o n ed 1 2 3 4 S € 7 Incorrect
Pleasant 1 2 3 4 5 fi 7 Unpleasant
t a y 1 2 3 4 S fi 7 DffTtatit
S a lt 1 2 3 4 s E 7 Dangerous
fYdtainihia 1 2 3 4 s fi 7 UraevdDyabJe
Beneficial 1 2 3 4 5 E 7 Harmful
1 Bee 1 2 3 4 s € 7 IdM Be
Qaftftng vm otln g  Is...
Good 1 2 3 4 s fi 7 Bad
Unites Ira Me 1 2 3 4 5 E 7 Desirable
FavtMaaMe 1 2 3 4 s fi 7 UnfiBKoaiable
W ise 1 2 3 4 5 fi 7 Food til
C o n ed i 2 3 4 5 fi 7 Incorrect
Pleasant 1 2 3 4 5 E 7 Unpleasant
Easy 1 2 3 4 5 fi 7 Dtfflatit
Safe 1 2 3 4 5 E 7 Dangerous
Enjoyable 1 2 3 4 s fi 7 Unergoyable
Beneficial 1 2 3 4 5 E 7 Harmful
1066 1 2 3 4 S € 7 I dtiflue
1
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NEXT, A FEW QUESTIONS A&OUT YOUR VIEWS ON LUN6 CANCER
C*ffdMuaaqmNM i^»« olsnaf 1 MrK*ql Strong?
dbwgree
Disagree Not sure Agree Strongly
agree
I Im e  a clear pidtone of i M  kng cancer It □ □ □ □ □
Lung cancer can be earned by a germ nr a virus □ □ □ □ □
Diet can play ■ nwfrarraie In earning lung canon1 □ □ □ □ □
PohuBon in the environment can cause lung cancer □ □ □ □ G
Lung cancer Is heratMnrjr -  ft iuna an Wm lam ly □ □ □ D □
It It Just by chance that tom e tract ert get lung cancer □ □ □ □ □
atnesa It a  m gor factor that can cause k m  cancer □ □ □ □ □
Lung cancer Is caused by a genetic abnormatty
■moAcral ray —rilWr*of tfcwt 1 fSMrf OGMb
□ □ □ □ □
When I Mnk about; lung cancer I gel upset □ □ □ □ O
I get depressed when 1 Mnk about lung cancer □ □ □ □ □
Lung cancer nuftes me feet angry □ □ □ □ □
Lung cancer rmokes me feel anartout □ □ □ □ □
Lung canceriM ftea me fee! affcaU □ □ □ □ □
■neAoral nfwrtnnraaTfcil: 3
Never Not very 
often
Some Of 
the time
Orte
often
Ail the time
How often do you aw ry abotolung cancer? □ □ □ □ □
How Often Oo you m a y  aboal a g  "a** srouttog □ □ □ □ □
fttqpcr** OfcKy Sbongfy
dbagree
Qukttig smoking it  effective In prerwervtog lunQ cancer Q  f~l
QuUho smoking aorta In preventing hag cancer □  Q
If I quit smoking, t am lets Ifcely to get lung cancer Q  f~j
SrtittfcacyUPPW)
I am abte to g o t smoking □ □ □ □ □
1 have the time and money to quft tracking □ □ □ □ □
I con eaaly quit smoking □ □ □ □ □
£m 4?JUVUi
I believe Mai tung cancer is severe. □ □ □ □ □
I believe tool tong cancer ftas sertaoa negnMe □ □ □ □ □
rartseouencesu
l believe Mat lung cancer Is evtremety harmful □ □ □ □ □
id v icr Agree Btrtrgly
agree
□ □ □
□ □ □
□ □ □
A
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it l« to e*  that I wM get tong cancer.
strongly
ctoagree
□
"Usagnae
□ □
<Airee
□
strongly
aoree
□
I am at rtsfc for petUngi sunn cancer. □ □ □ □ □
It Is pasaMte Burt l vB  get lung canoer. □ □ □ □ □
1 think, of myseff as a smoker. □ □ □ □ □
1 think of my*setf aa the KM of person who b  able to 
outt smokJno.
□ o □ □ □
SumapftMy 2
It Is #kely that 1 artf gel Sung cancer ff i continue to  
smoke.
It Is toety that 1 wtl oettora cancer VI o a t smofcho.
□
□
□
□
□
□
□
□
□
□
Corwoared wth o th e r  smokers of your aoe and s e t  
do you think your chances of gettng king cancer at 
some point In your We are:
Mud*
lower
□
Lower
□
About the 
sane
□
Hfcher
□
Much
ttgher
□
Compared aiKft 0DaaBftfiO.af yoar age ami sea, Bo 
you thMk your chances of geBtog lung cancer al som e 
point In yaurne are:
□ □ □ □ □
SWT MfcfgyJ
How confident are you that you can not smoke, even 
under dffBcult circumstances <e.g. when drinkhg 
akoho or coffee, when stressed or bored, or arisen 
with smokers y*
Not at a# 
confident 
□
Not very 
oonfksent 
□
Heftier
□
Qifie
corrMent
□
very
oonfksent
□
cop*0 ■ w n a -  —a u  lUsruw*# 
Lung cancer to m tranrytng dNaara ao.~
Nat at afilfce 
me Osfbe tkem e Very iBe me
i try to do things which peduce my d u n ce  of geBfcig king cancer □ □ D
I dry to And out Information about lung cancer □ □ □
I kry to keep a to o t aatlbr posafile symptoms □ □ □
v dry to avow ounkksg about It as much as possbie □ □ □
* bry to bm U reading things about iunf cancer □ □ □
t ory not to think about m y risk of lung cancer □ □ □
Strongy Otngree SWUhiMvuemer Agree Strongly
When t smoke, 1 tend to avoid thoaqMs of lung
disagree
□ □ □ □
agree
□
cancer.
When i get a cough, 1 tend to avoid thinking about □ □ □ □ □
King cancer.
When I smoke, 1 try to rvottiHI about lung cancer. □ □ □ □ □
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THE FOLLOWING SECTION ASKS ABOUT YOUR MOOD AND GENERAL OUTLOOK ON LIFE
Please tick a box Tar each statement which best desotoes how often you tea or behaved
fite wav to tw  uaet wee*.
l Teel tense or ‘wound up':
Most of He time A tort of the ttoie Fran time to time, 
occasionally
Not at alt
□ □ □ □
tstBenpy the flings I used toeofoy:
OeflnfteiyasmutH Not quite as much Onlyaltfte Hardy at all
□ □ □ O
t get a sort or frightened feet mg as f  something awful ts about to happen:
Very deflntely and Yes, txit not loo A«»e, dues Not at ali
quite badly bacfy doesn't worry me
□ □ □ □
lean laugh and see He funny sue  of Wngs:
As much as 1 Not quite so much Definitely not so N otatal
always could now much now
□ □ □ D
Worrying noughts go fi rough my mind:
A great deal of the A lot of the Sme From time to time Only occasionally
time tut not too often
□ □ □ □
l teet cheerTUt
Not aft aft Not often Sometimes Most of He time
□ □ □ □
1 can sit at ease and feet relaxed:
Deflrftety Usually Not often Not at an
□ □ □ □
I feel as f  l am Stowed down:
Nearly all the flme Mery often Sometimes Notatafl
□ □ □ □
I get a sort of frightened reel mg tte  'txjtteities'm the stomach
Not at as Occasionally Quite often Very often
□ □ □ G
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I feel restless as ff1 Have In be on the move
DeMefy usually Not Often Mat at an
□ □ □ □
i get a sudden reefing of panic
Not at a* Not very often Quite often Very often
□ □ □ □
l have lost Merest fe) my appearance
DeffnUeiy 1 donttateasm ueh 
care as I should 
□  □
I may not take as 
much cane 
□
I take just as much 
care as ever 
□
i toot forward wttfi enjoyment to things 
Nearly all the ume Very often Sometimes Nat at all
□ □ □ D
I can enjoy a good boot orTV program
Often Someimes Not often Very seldom
□ □ □ □
Tm 4 H a A a p M l iH
f  you are offered the genetic lest tor lung cancer risk today and you choose to tafte It do you expect your
test result to ten you that your genetic risk or lung cancer is
Lower toan Average Higher than Don't know
average average
□  □ □ □
Fwmtgtt+mrf
Fhody. «k) you imam erf anyone who n a i or had lung cancer or any other «moftlri0*reta6ed diseases ^such 
os enHpl1yaema;l,  {P lease Dcfc any that apply and w tte detafl* of the person ondl the d isease In the space 
provided}
D  Myself ............................................. ............................................................................................... .....................
□  Fam iy .....   ...............................................................................................
□  Friend ............................................................ ......................................................................................
Q  AcqhWHance or neighbour .............. ..... ................................ ............... .............................
Thank you very much for taking the time to fill in this questionnaire
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C entre Number;
UCLH Project ID num ber.
Participant Identification N um ber for this study: ______________
Form version: 4 (15.7.04)
N am e of Principal investigators: Ja n e  W ardle and S ask ia  S anderson
QUIT SMOKING AND GENETIC TESTING STUDY
CONSENT FORM -  STAGE 2 
(CONSENT TO TAKE THE GSTM1 GENETIC TEST)
If you are being invited to complete Stage 2 of the consent process for this study, it means that you 
have been allocated to the group who is being invited to take a genetic test for the GSTM1 gene.
Agreeing to Stage 2 of this study involves giving consent to carry out the genetic test for GSTM1 
amongst people who are allocated to the genetic testing group.
Please initial box
1. I confirm that what a genetic test is, the procedure involved in having a genetic test, -----
what GSTM1 is, and how the GSTM1 gene is involved in the cleaning up of cancer
causing agents in cigarette smoke, have been fully explained to me, and that I have had ------
the opportunity to ask questions.
2. I confirm that I have had sufficient time to consider whether or not I wish to have a 
genetic test for GSTM1.
3. I understand that by agreeing to have a genetic test for GSTM11 am agreeing to have a 
cheek cell swab taken which contains DNA and for it to be tested for the presence of 
GSTM1. I also understand that I will receive my test result in a second session within 
one week of my first visit, and that this will be followed up by two telephone follow-up 
calls.
4. I agree to have a genetic test to determine whether I have the GSTM1 gene present or 
not.
Continued on next page Page 1 of 2
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UCL
C entre  Number: UCLH Project ID num ber 03/0127
Participant Identification N um ber for this study:___________ Form version: 4 (15.7.04)
QUIT SMOKING AND GENETIC TESTING STUDY
CONSENT FORM -  STAGE 2
N am e of Principal investigators: Ja n e  W ardle and  S ask ia  S an d erso n
Name of participant Date Signature
Name of Person taking consent Date Signature
Saskia Sanderson 020 7679 6495
Researcher (to be contacted Phone number
if there are any problems)
Comments or concerns during the study
If you have an y  com m ents o r co n cern s you m ay d isc u ss  th e se  w ith the  
investigator. If you w ish  to  go fu r th e r an d  com plain  ab o u t any  asp ec t of 
th e  w ay you have been  ap p ro ach ed  o r trea ted  d u rin g  th e  cou rse  of the 
s tudy , you sh o u ld  w rite o r get in to u ch  w ith the  C om plain ts M anager, UCL 
h o sp ita ls . P lease q uo te  th e  UCLH project n u m b e r a t th e  top  th is  consen t 
form.
form for participant
to be kept a s  part of the  study docum entation
Page 2 of 2
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APPENDIX H
MATERIALS FOR GSTM1 GENETIC TESTING STUDY (STUDY 3): 
ILLUSTRATED GUIDE TO GENETICS
Appendix H
GENETICS, SMOKING, 
AND GENETIC TESTING
FOR GSTM1
AN ILLUSTRATED 
GUIDE
G enetk  Knowledge
LONDON
IDEAS
UCL
Jmgrwin^hleal^
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EVERY CELL IN THE HUMAN BODY CONTAINS DNA
Your body is made up of billions of cells. Inside the centre 
(nucleus) of each of these cells is vour unique set of DNA. 
DNA is a long double-helix shaped string of 3 billion 
chemical building blocks. There are four different types of 
chemical building blocks (called ‘bases’): Adenine (A), 
Cytosine (C), Guanine (G), and Thymine (T).
DNA
X 3 billion.
BODY
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GENES ARE MADE OUT OF DNA
Genes are made up of lengths of these bases, and can be 
anything between 1,000 and 100,000 bases long.
This means that genes are made out of DNA. When 
people talk about DNA and DNA tests, this is exactly the 
same as talking about genes and genetic tests.
BODY
X 1,000 
1 GENE
<
! I
DNA
G EN E S = DNA
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EVERYONE’S SET OF DNA, AND THEREFORE 
GENES, IS UNIQUE
Human beings have about 30,000 genes.
99.9% of DNA is identical amongst all human beings; the 
remaining 0.1% (up to 100,000 bases) differs between 
individuals. This means that everyone’s set of DNA is 
unique. These differences account for some of the 
differences that we see between individuals, for example the 
colour of their hair or eyes.
BLUE EYES BROWN EYES
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GENES TELL’ CELLS TO MAKE PROTEINS
Genes do one very important thing; they contain the 
information needed by the cell to make proteins.
PROTEINS
BODY
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SOM E PROTEINS ARE CALLED ENZYMES’
Proteins are important because they do all the jobs needed 
to keep the cell (and the body) alive and well.
Some proteins in the body form building blocks for 
structures within the cells, such as the protein called 
keratin, from which hair is made.
Others form communication networks within and between 
cells, such as in nerves in the brain and blood in blood 
vessels.
Others are called enzym es which help carry out chemical 
reactions, such as digesting food.
HAIR
NERVES
BLOOD
ENZYMES
These are all made out 
of PROTEINS
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SOME ENZYMES ‘CLEAN UP’ THE TOXINS THAT 
ENTER YOUR BODY
It is the job of some enzymes to protect your body by 
breaking down and flushing out the toxins that are entering 
your body in small amounts from the environment every 
day. We can think of this as the ‘the detoxification 
process’.
These special enzymes work a bit like biological washing 
powder, breaking down the dirt and flushing it away, 
keeping the body clean.
ENZYMES
WASHING
MACHINE
WASTE
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GENES TELL’ CELLS TO PRODUCE THE ‘CLEANING 
UP’ ENZYMES
So, when toxins enter your body, your genes contain the 
information that your cells use to produce the ‘cleaning up’ 
enzymes. These enzymes then break down the toxins into 
detoxified waste. The detoxified waste is then flushed out 
of the body.
THE DETOXIFICATION PROCESS: 
GENES ‘TELL’ CELLS TO PRODUCE 
ENZYMES
TOXINS
LUNGS
1
TOXINS ARE ‘CLEANED UP’ 
AND GOT RID OF AS 
DETOXIFIED WASTE
Appendix H
9
DETOXIFICATION IN NON-SMOKERS AND SMOKERS
Hundreds of genes produce hundreds of different 
enzymes that are all involved in the detoxification 
process. So below on the left you can see how the 
detoxification process works in a non-smoker.
When you smoke cigarettes, you are putting thousands 
of extremely harmful toxins (or chemicals) into your body 
in very high quantities. Some of the ‘cleaning up’ 
enzymes help to clear out some of the toxins in cigarette 
smoke. However, the chemicals in cigarettes are so toxic 
that even with the help of these ‘cleaning up’ genes, your 
lungs may not be able to cope. The diagram below on 
the right shows this. The build up of toxins in your lungs 
can eventually lead to lung cancer.
THE DETOXIFICATION PROCESS THE DETOXIFICATION PROCESS
IN A NON-SMOKER IN A SMOKER
TOXINS TOXINS
LUNGSLUNGS
TOXINS ARE CLEANED UP’ SOME TOXINS ARE CLEANED UP’
AND GOT RID OF AS BUT SOME BUILD UP BECAUSE THE
DETOXIFIED WASTE SYSTEM CAN’T COPE
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THE GSTM1 ENZYME AND THE GSTM1 GENE
One of the ‘cleaning up’ enzymes is called the GSTM1 
enzyme. Cells produce the GSTM1 enzyme using the 
information contained in the GSTM1 gene.
So some of the toxins that enter your body are cleaned 
up by the GSTM1 enzyme which your cells produce 
using the information in the GSTM1 gene.
ONE OF THE GENES INVOLVED IN THE 
DETOXIFICATION PROCESS IS CALLED 
GSTM1
TOXINS
gene
X 100s
LUNGS
TOXINS ARE ‘CLEANED UP’ 
AND GOT RID OF AS 
DETOXIFIED WASTE
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SOME PEOPLE ARE MISSING THE GSTM1 GENE
Everybody has slightly different combinations of the 
detoxification genes. This is because genes are sometimes 
missing or altered in some people. For example, about 50% 
of people in the UK do not have the GSTM1 gene. 
Because their cells are not producing the GSTM1 enzyme, 
smokers who are missing the GSTM1 gene may have even 
more difficulty clearing out the toxins in cigarette smoke 
from their body than other smokers. So, knowing whether a 
person has the GSTM1 gene present or missing may tell us 
a little bit about their body’s ability to ‘clean up’ toxins. This 
information does not tell however tell us anything about the 
presence of absence any of the other detoxification genes.
LUNGSLUNGS
SOME TOXINS ARE REMOVED NO TOXINS ARE REMOVED
BY THE GSTM1 GENE AND ENZYME BY THE GSTM1 GENE AND ENZYME 
BUT SOME BUILD UP SO MORE TOXINS MIGHT BUILD UP
THE DETOXIFICATION PROCESS 
IN A SMOKER WITH 
GSTM1 PRESENT
TOXINS
THE DETOXIFICATION PROCESS 
IN A SMOKER WITH 
GSTM1 MISSING
TOXINS
100s
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GSTM1 AND LUNG CANCER RISK
On average, non-smokers have a 1 in 100 (or 1%) risk 
of developing lung cancer. Smokers on average have a 
1 in 10 (10%) chance of developing lung cancer.
In research studies, smokers with lung cancer have 
been found to be slightly more likely to be missing the 
GSTM1 gene than smokers who do not have lung 
cancer. This suggests that people who are missing the 
GSTM1 gene have a slightly higher risk of developing 
lung cancer than people who have the GSTM1 gene 
present.
The graph below illustrates this. Another way of 
thinking about these figures is shown on the next page 
(p15).
§5. 2 0  -r-------------------------------------------------------------------------------------------
8
§
Non-smoker Smoker with Smoker with
GSTM1 present GSTM1
missing
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If we follow 100 smokers who have the GSTM1 gene up to the age of 
75, we will expect roughly 9 of them to develop lung cancer. If we 
follow 100 smokers who have the GSTM1 gene missing until the age 
of 75, we will expect roughly 12 of them to develop lung cancer.
100 SMOKERS 
WITH GSTM1 
PRESENT
k k k k k k k k k
i f  I I k
k k k k k k k k k k  
k k k k k k 
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k k k k k k k k k k 
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k k k k k k k k k k
k k k k k k k k k k
k k k k k k k k k k  
k k
k k k k k k k k k k
k k k k k k k k k k
k k k k k k k k k k
k k J L k k A  t  I
100 SMOKERS 
WITH GSTM1 
MISSING
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TESTING FOR THE GSTM1 GENE
It is now possible to test whether people have certain 
genes or not. In this study, we are testing to see  
whether people have the GSTM1 gene. Knowing 
whether you have the GSTM1 gene is the same as 
knowing whether you have the GSTM1 enzyme.
It is important to remember that this is not a clinical 
test, it is being used for research purposes only. In 
the future, tests that test for hundreds of these types 
of genes could be available. We are interested in the 
psychological aspects of this, such as whether 
smokers will find this kind of information useful or not.
There are two possible results from the GSTM1 
genetic test: ‘gene missing’ or ‘gene present’.
WHAT DOES A ‘GENE MISSING’ TEST RESULT 
M EAN?
A ‘gene missing’ test result means that you do not 
have the GSTM1 gene. You may therefore have a 
slightly higher risk of getting lung cancer than a 
smoker who does have the GSTM1 gene, because 
your body is producing the GSTM1 enzyme.
WHAT DOES A ‘GENE PR E SE N T ’ TEST RESULT 
M EAN?
A ‘gene present’ test result means that you do have 
the GSTM1 gene. You mav therefore have a slightly 
lower risk of getting lung cancer than a smoker who is 
missing the GSTM1 gene, because your body is not 
producing the GSTM1 enzyme.
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CAN THE GSTM1 GENETIC T E S T  TELL ME 
DEFINITELY W H ETH ER  I’M GOING TO  G ET LUNG 
C A N C E R  O R  N O T ?
No.
The GSTM1 genetic test tells people definitely 
whether or not they have the GSTM1 gene (and 
therefore the GSTM1 enzyme) or not, with almost 
100% accuracy.
What it can’t tell you with any certainty is your exact 
risk of getting lung cancer.
This is because GSTM1 is only one of many, possibly 
hundreds, of different gen es that are all involved in 
producing the enzym es which clean up the cancer- 
causing chemicals in cigarette smoke, and we do not 
know how many of these other gen es you do or do 
not have.
It is also important to remember that other factors 
such a s  alcohol, exercise, and so  on can affect your 
cancer risk.
Of course, the most important thing you can do for 
your health is to quit smoking.
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WHAT DOES HAVING THE GSTM1 TEST 
INVOLVE?
The test is completely painless and can be done 
using a cheek cell swab, which is similar to a cotton 
wool bud. All you have to do is rub the swab on the 
inside of your cheek for a couple of minutes. This 
collects enough DNA to send to the labs and they can 
then test it to see  whether you have the GSTM1 gene 
present or missing. You will then receive your test 
results within two weeks.
ANY QUESTIONS?
Please discuss any questions or concerns you may 
have with the researcher present.
Your result will not be told to anyone else. You can 
talk to your partner, friends, or doctor about it if you 
want.
ARE YOU INTERESTED IN TAKING THE GENETIC 
TEST FOR GSTM1?
If you are interested in taking the test, that’s great. 
The researcher will go through the Stage 2 consent 
form with you and then take you through the process 
of taking your DNA sample.
If you are not interested in taking the test, that’s 
absolutely fine too. It won’t affect your care in any 
way and you’re still eligible to continue being in the 
study if you would like to be.
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THANK YOU VERY MUCH FOR TAKING THE TIME 
TO CONSIDER THE INFORMATION IN THIS 
BOOKLET, AND FOR YOUR PARTICIPATION IN 
THIS RESEARCH STUDY
If you have any questions or comments, please 
contact the research team on:
020 7679 6495
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APPENDIX I
RESULTS SESSION (PHASE 2): MATERIALS 
PROTOCOL, QUESTIONNAIRE
Appendix I
Entered EH
By (names:
On (date)
PHASE 2: FEEDBACK/CONTROL PROTOCOL
This form is for use by the researcher/adviser that is conducting the second session, it should take 
about 20 minutes to complete.
Name of r e s e a r c h e r .________ __________
Participant ID: ________ __________ _
Date: __________ _ _______
1. EXPLAIN AIM OF SESSION Z  CHECK
Group: □  C Z ID  □  Tt □  TO
Turned up Z  YES u  NO
2. REVIEW SMOKING □  CHECK
How has your smoking been since we iast saw you'?
□  S M O K I N G  AS M U C H  AS EVER
□  ' UT DOWN SLIGHTLY
□  ' i i i c o g i  »r 
Z • jU IT  S M O K I N G
If smoking: how many cigarettes per day would you say you have been smoking over the past week? 
  PER DAY □  n .'A
If quit: How long ago did you quit smoking'?
  weeks a n d  __  days ago. O n ________________  (date) □  N/A
Have you set a quit date'?
□  Yes, alone c  No, but planning to with adviser/group
□  Yes, with smoking adviser/group _  No, but planning to on own
Z  N/A
Further details of smoking/plans:
Appendix i
3. G E N E T I C  T E S T  GROUPS: ASSESS MEMORY OP GENETIC T E S T  □  C H E C K  □  N/A (CONTROL)
Do you rem em ber receiving the genetic booklet"? t _  NO □  YES details: .............................
Have you read the genetic booklet since then'? G  NO □  YES details: .............................
Have you thought about the genetic tes t?  1—: NO G  YES details ................................
From what you remember of what was explained to you last time, what did having the gene  m e a n ? .............
•"•-‘i- what you rem em ber of what was explained to you last time, what did not having the gene  m e a n ? ......
Have you thought about how you’d feel 
If you got a ‘gene m issing’ result?
Have you thought about how you’d feel 
If you got a gene presen t  result?
Have you worried about your genetic test result?
G NO □ YES details'
C NO □ YES details
G NO □ YES details
4. EXPLAIN GENETIC TEST FACTS AGAIN USING BOOKLET CHECK □  N/A (CONTROL)
5. GIVE GENETIC TEST RESULT USING BOOKLET_________ i_ CHECK □  N/A (CONTROL)
GSTM1 TEST RESULT: PRESENT / MISSING
I 6 ASSESS AND CHECK IMMEDIATE REACTION G  CHECK L_ N/A (CONTROL)
Details: (e.g., frightened, relieved, happy, worried, motivated etc.)
7. ALL GROUPS: ADMINISTER PHASE 2 QUESTIONNAIRE — CHECK
8. CLOSE
W e will be calling you in one week for your follow-up What time of day is best for you? 
Thank you very much for coining in again.
Approximate date of Phase 3 telephone call 11 week from rx»j
Best time of day for Phase 3 telephone call
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APPENDIX J
FOLLOW-UP MATERIALS:
PHASE 3 PROTOCOL, PHASE 4 PROTOCOL, PHASE 3/4 QUESTIONNAIRE
Appendix J
Entered, 1 
By (name)'
On (date;
PHASE 3: FIRST TELEP H O N E  FOLLOW-UP PROTOCOL
1 This  fo rm  is f o r  u s e  b y  t h e  r e s e a r c h e r  t h a t  is  m a k i n g  t h e  P h a s e  3 p h o n e  call .  It s h o u l d  t a k e  a b o u t  20 
1 m i n u t e s  to  c o m p le te .
Name of researcher:
Participant ID ______________
j ( m n't■ z  t - -  i f
1 EXPLAIN AIM AND STRUCTURE OF PHONE CALL Z  C HECK
: 2 REVIEW SMOKING _  CHECK
How has your smoking been since we last saw you'?
Z  SMOKING AS MUCH AS EVER □  CUT DOWN SLIGHT1 > Z ■ .»■ [n . \ N „  , . .; Z «dJIT SMOKING
If smoking: how many cigarettes per day would you say you have been smoking over the past week?
______ PER DAY □  N/A
If quit: How long ago did you quit smoking? weeks and   jiiays ago. On  ___   (date) Z  N/A
Have you set a quit dated?
,— < es, alone O  No, but planning to with adviser/group
z  Yes, with smoking adviser/group □  No, but planning to on own Z  N A
How soon after waking have you been smoking your first cigarette of the day?
i i i• 1 is Z 5G5 mins Z  15030 nuns z  30-60 mine   H R  -  2 hrs Z  longer than 2 firs
How easy  or difficult would you say that it would be for you to go without smoking for a whole clay?
Z  ERY EASY Z FAIRl : i Z FAIRLY DIFFICULT Z  VERY DIFFICULT
How much would you say that you want to give up smoking at the moment?
G VERY STRON* : r Z G h i .  d -O N C  Z MODR-m ' q  •« Z 'LIGHTLY Z NOT AT ALL
Are you intending to give up smoking within the next 6 months?
Z  YES DEFINITE I 3 Z '  F s  OV3BAB. 3 Z I • *SSIBLY Z  NO PROBABLY Nm I Z NO DEF NOT
Further details of smoking,'plans (cont. overleaf)'
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3, ALL GROUPS: ADMINISTER PHASE 3 QUESTIONNAIRE □  CHECK
5. ALL GROUPS: ASK FOR INTERVIEW CONSENT □  CHECK
W e shall be interviewing a subse t  of people in this study about their views on the test and their rea sons  for or 
against taking the genetic test Would you be  happy to be interviewed, either over the phone or in person, 
about your views about a range of things, including the genetic test?
[I YES
Z  \ o
[ 6. CLOSE □  CHECK
OK, that s great. Thank you very much for your time today. I'll call you again in two months time to s e e  how 
you've got on, and then we can m ake an appointment for you to com e in and do the genetic test with us. if you 
want) Is that all ok? Do you have any questions or further com m ents?
OK then, speak  to you in (month), thanks again and good luck with the quitting, goodbye.
Approximate date of Phase 4 telephone call (2 months from oowt:
Appendix J
Entered L — 
By (name)'
On (date)
PHASE 4: SECOND TELEPHONE FOLLOW-UP PROTOCOL
This form is for use by the researcher that is making the Phase 4 phone cal l ,  it should take about 20 
minutes to complete.
Name of researcher:
Participant ID:
Date
Ttme:
Call again? ~  YES □  NO
1. EXPLAIN AIM AND STRUCTURE OF PHONE CALL _  CHECK
2. REVIEW SMOKING _  CHECK
How has your smoking been since we last saw you'?
Z  SMOKING AS MUCH AS Eh EIk Z uUI f -  >WN SLIGHTLY C CUT DOWN A LOT Z  QUIT SMOKING
If smoking, how many cigarettes per day would you say you have been smoking over the past week?
________ P E R  DAY □  ft  A
If quit: How long ago did you quit s m o k i n g ?  weeks a n d _______ days ago. O n ________ (date) Z  N.'A
Have you set a quit date?
z  Yes. alone___________________________________ __, No, but planning to with adviser-'group
Z  Yes, with smoking adviser/group □  No, but planning to on own □  N/A
How soon after waking have you been smoking your first cigarette of the day?
z  less than 5 mins Z 5G 5 mms □  15-30 mins □  30-60 nuns EU l HR -  2 hrs c  longer than 2 firs
How easy  or difficult would you say that it would be for you to go without smoking for a whole day'?
Z  VERY EASY Z FAIRLY E'*‘w  Z FAIRLY DIFFICULT □  VERY DIFFICUL r
f low much would you say that you want to give up smoking at the moment?
C  V E R Y S T R O N *  Z  m H I E  STRONC Lr Z  M O D E R A T E L Y  C  S L I G H i L Y  Z NO T AT ALL
Are you intending to give up smoking within the next 6 months?
Z  YES DEFINITE id . Z I -  -COBALT , Z  I ‘?SSIE'< * Z NO PROBABLY NOT Z NO DEF NOT
Further details of smoking,'plans (cont. overleaf):
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3. ALL GROUPS: ADMINISTER PHASE 4 QUESTIONNAIRE — CHECK
4. ALL GROUPS: ASK FOR INTERVIEW CONSENT □  CHECK
OK., that's great.. Thank you very much for your time today, and thank you for all your help anti tune with the 
research  study
Goodbye.
2 /2
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Date
J k \
-  - - - - -
IJCL
QUIT SMOKING AND GENETIC T E S T IN G  STUDY
PHASE 3/4 QUESTIONNAIRE
Tel number: R esearcher '
GENETIC TEST GROUPS COMPLETE ALL QUESTIONS BELOW □  CHECK □  N/A (C O N T R O L )
CONTROL GROUP: GO STRAIGHT TO PAGE 3 _  CHECK. □  NIA (T E S T  G R O U P )
Do you rem em ber  receiving your genetic test result - _  NO G YES details
W h a t  w a s  y o u r  g e n e t i c  t e s t  r e s u l t ?
a) G en e  presen t G ene  missing 
C  03
Don't know 
□
Have you thought much about your test result? □  NO □ Y ES details
Have you read the genetic booklet since then? □  NO G YES details
f.lave you worried about your genetic test result? □  NO G YES details
From what you rem em ber  of what w as  explained to you last time, what did having the gene  m ean? .
From what you rem em ber  of what w as explained to you last time, what did not having the gene  m ean?
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I A S S E S S  AND C H E C K  F E E L IN G S  A B O U T  T E S T  R E S U L T  □  C H E C K  □  N/A
in y o u r  o w n  w o r d s ,  h o w  d o  y o u  fee l  a b o u t  y o u r  g e n e t ic  t e s t  r e s u l t ?
Details: (e.g. frightened, relieved, happy, worried, motivated e t c . )  .
How, if a t  all, h a s  y o u r  t e s t  r e s u l t  a f f e c t e d  y o u r  m o t iv a t i o n  t o  q u i t  s m o k in g ?
Psychological impact (MICRA) T h e  fo l lo w in g  q u e s t i o n s  a r e  a b o u t  s o m e  s p e c i f i c  f e e l i n g s  y o u  
m ay h a v e  h a d  a b o u t  y o u r  g e n e t i c  t e s t .  P lea se  answ er  all the questions. P le a se  indicate whether 
you have experienced each  s ta tem ent ‘n eve r’, ‘rarely’, so m e t im e s ' ,  or 'o ften1 in the p a s t w e e k .
Never Rarely Sometimes Often
Feeling anxious or nervous about my test result I] □ □ □
Having problems enjoying life because of my test result ~ ; □ □ □
Worrying about my risk of getting lung cancer _i □ □ □
Being uncertain about what my test result means about my 
personal lung cancer risk
□ □ □ □
Thinking about my test result has affected my work, social 
or family life
_i □ □ □
Having difficulty talking about my test results with family 
members
I] _1 □ □
Feeling regret about taking the genetic test , J □ □
P l e a s e  r e c o r d  a n y  f u r th e r  r e l e v a n t  i n f o r m a t io n  in t h e  s p a c e  p r o v i d e d :
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Fall groups
D ISEASE P E R C E P T IO N S  I COGNITIVE R E P R E S E N T A T IO N S  O F  T H R E A T
For each  of the following s tatements ,  p lease  say whether you ag re e  or d isag ree  with each  one. and whether you 
strongly agree-disagree , or just a g re e d isa g re e .  or neither (circle appropriate response).
1 have a clear picture of what lung cancer  is. S T RO N G L Y  A G R E E -N E IT H E R -S T R O N G L Y -D IS A G R E E
Lung cancer  can be caused  by a g erm  or a virus. S T R O N G L Y 'A G R E E -N E IT H E R -S T R O N G L Y 'D IS A G R E E  
Diet can play a major role in causing lung cancer. S T R O N G L Y /A G R E E -N E IT H E R -S T R O N G L Y  D ISAG REE
Pollution in the environment can ca u se  lung cancer. ST RO N G L Y /A G R EE -N E IT I  lE R -S T R O N G L Y -D IS A G R E E
Lung cancer is hereditary -  it runs in th e  family. ST R O N G L Y /A G R E E -N E IT H E R -S T R O N G L Y /D IS A G R E E  
Its just by c h a n c e  that s o m e  sm o k e rs  g e t  lung c a n c e r  ST R O N G L Y  A G R E E -N E IT H E R -S T R O N G L Y /D IS A G R E E
S tress  is a major factor that can c a u se  lung cancer. S T R O N G L Y /A G R EE -N  v < II l b  '-1 W NGLY D ISAG R EE 
Lung cancer  is caused  by a genetic a b n o rm a l1, s i  itO N G L Y ,A G R E E -N E IT H E R -ST R O N G L Y .D IS A G R E E  
D IS E A S E  C O N C E R N  I EMOTIONAL R E P R E S E N T A T IO N S  O F  THR EAT
W h e n  I think about lung cancer  I g e t  upset. STRO N G L Y /A G R EE -N E IT H E R -ST R O N G L Y .'D ISA G R E E  
I get d ep re ssed  when 1 think a b o u t  lung cancer. S T R O N G L Y -A G R E E -N E IT H E R -S T R O N G L Y 'D IS A G R E E
Lung cancer m akes  me feel angry. STRON« . » A G R E E -N E I  f H ER -S TRONGLY/D ISAGREE
Lung cancer  m akes  rue feel anxious. STRO N GLY-AG REE-N EITHI k  PRGNGLY/DISAGREE
Lung cancer m akes  m e feel afraid. STRO to - -\GREE NEITHER -S T R O N G  t  Y/ DI SAG REE
How often have you worried about lung cancer  over  th e  pas t  w e e k ?
G NEVER
G  \<  H FRY O F T E N  
C  S O M E  O F  T H E  TIM E  
G QUITE OFTEN 
C  ALL THE TIME
Have you worried about any other smoking related d ise ase s  over the pas t w eek?
G YES G  m l
IF YES. W hich o r i e t s R _________ _____________________________________________________
How often have you worried a b o u t____________________  over  the  past w e e k ?
G  ALL THE TIME C  QUITE OFTEN G  'W«ME OF THE TIME G  NOT VERY OFTEN
3-7
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PERCEIVED SEVERITY
I believe that smoking is extremely harmful.
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
I believe that smoking has serious negative consequences. 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
I believe that lung cancer is severe.
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
PERCEIVED RISK / SUSCEPTIBILITY
It is possible that I will get lung cancer.
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
I am at risk for getting lung cancer 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
It is likely that I will get lung cancer 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
It is likely that I will get lung cancer if I continue to smoke. 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
It is likely that I will get lung cancer if I quit smoking 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
Compared with other smokers of your age and sex, do you think your chances of getting lung cancer are
□  MUCH LOWER
□  LOWER
□  ABOUT THE SAME
□  HIGHER
□  MUCH HIGHER?
Compared with nonsmokers of your age and sex, do you think your chances of getting lung cancer are:
□  MUCH LOWER
□  LOWER
D  ABOUT THE SAME
□  HIGHER
□  MUCH HIGHER?
4/7
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SELF EFFICACY
How confident are you that you can not smoke, even under difficult circumstances (e.g. when dnnking alcohol or 
coffee, when stressed or bored, or when with smokers)?
□  NOT AT ALL CONFIDENT
□  NOT VERY CONFIDENT
□  NEITHER
□  QUITE CONFIDENT
□  VERY CONFIDENT
How much do you agree or disagree with these statem ents?
I am able to quit smoking.
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
I have the time and money to quit smoking 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
I can easily quit smoking.
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
SELF STANDARDS
I think of myself a s  a smoker
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
I think of myself a s  the kind of person who is able to quit smoking. 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
AVOIDANCE
I try to avoid thinking about lung cancer or other smoking-related diseases a s  much as  possible 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
When I smoke I try not to think about lung cancer or other-related d iseases 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
When I get a cough, I try not to think about lung cancer or other smoking related diseases. 
STRONGLY/AGREE-NEITHER-STRONGLY/DISAGREE
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7. ALL GROUPS: ASSESS MOOD OVER PAST WEEK
I'm now going to ask you some questions about how you’ve been feeling since we saw you last week Over the 
past week, how often have you felt tense or wound up?
□  MOST OF THE TIME
□  A LOT OF THE TIME
□  FROM TIME TO TIME, OCCASIONALLY
□  NOT AT ALL
Would you say that you still enjoy the things you used to enjoy ..
□  . . .DEFINITELY AS MUCH?
□  . . .NOT QUITE AS MUCH?
□  . . .ONLY A LITTLE?
□  .HARDLY AT ALL?
Please complete this statement. I get a sort of frightened feeling as  if something awful is about to happen .
□  VERY DEFINITELY AND QUITE BADLY
□  YES BUT NOT TOO BADLY
□  A LITTLE BUT IT DOESN’T WORRY ME
□  . . .NOT AT ALL
I can laugh and see the funny side of things .
□  .AS MUCH AS I ALWAYS COULD
□  NOT QUITE SO MUCH NOW
□  DEFINITELY NOT SO MUCH NOW
□  . . .NOT AT ALL
Worrying thoughts go through my mind ..
□  A GREAT DEAL OF THE TIME
□  . .A LOT OF THE TIME
□  .. FROM TIME TO TIME BUT NOT TOO OFTEN
□  ...ONLY OCCASIONALLY
I feel cheerful...
□  ...NOT AT ALL
□  ...NOT OFTEN
□  ...SOMETIMES
□  . MOST OF THE TIME
i feel as  if I am slowed down...
□  . . .NEARLY ALL OF THE TIME □  ...VERY OFTEN □  ...SOMETIMES □  . NOT AT ALL
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I get a sort of frightened feeling like butterflies in the stomal
□  . . .NOT AT ALL
□  ...OCCASIONALLY
□  . . .QUITE OFTEN
□  . ..VERY OFTEN
I feel restless as  if I have to be on the m ove...
□  DEFINITELY
□  . USUALLY
□  . . NOT OFTEN
□  . .NOT AT ALL
I get a sudden feeling of panic...
□  NOT AT ALL
□  . . .NOT VERY OFTEN
□  . . .QUITE OFTEN
□  VERY OFTEN
I have lost interest in my appearance ..
□  ..DEFINITELY
□  .. I DON’T TAKE AS MUCH CARE AS I SHOULD
□  ... I MAY NOT TAKE AS MUCH CARE
□  . I TAKE JUST AS MUCH CARE AS EVER
I look forward with enjoyment to things
□  NEARLY ALL THE TIME
□  VERY OFTEN
□  ...SOMETIMES
□  . ..NOT AT ALL
I can enjoy a good book o r TV program
□  ...OFTEN
□  ..SOMETIMES
□  ..NOT OFTEN
□  ..VERY SELDOM
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APPENDIX K
ERROR BAR GRAPHS AND EXAMPLE HISTOGRAMS OF 
STANDARDIZED RESIDUALS (STUDY 3 )1
1 In addition, the final pages of this Appendix contain a table giving some further details on the
companies discussed in Chapter 9.
Appendix K
Depression: line plots o f means and error bar charts2
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2 Note: The top right hand graph shows the error bars for the values at baseline; the bottom  left hand graph shows the error bars for the values at one w eek follow-up; and the
bottom  right hand graph shows the error bars for the values at two month follow-up. In each o f  the three error bar graphs, the G STM 1-m issing group is on the left, the
GSTM 1-present group is in the middle, and the control group is on the right.
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Anxiety: line plots of means and error bar charts3
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3 Note: The top right hand graph shows the error bars for the values at baseline; the bottom left hand graph shows the error bars for the values at one week follow-up; and the
bottom right hand graph shows the error bars for the values at two month follow-up. In each o f the three error bar graphs, the GSTM1-missing group is on the left, the
GSTM1-present group is in the middle, and the control group is on the right.
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Worry about lung cancer: line plots of means and error bar charts4
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4 Note: The top right hand graph shows the error bars for the values at baseline; the bottom left hand graph shows the error bars for the values at one week follow-up; and the
bottom right hand graph shows the error bars for the values at two month follow-up. In each of the three error bar graphs, the GSTMI-missing group is on the left, the
GSTM1-present group is in the middle, and the control group is on the right.
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Intention to quit smoking: line plots of means and error bar charts5
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5 Note: The top right hand graph shows the error bars for the values at baseline; the bottom left hand graph shows the error bars for the values at one week follow-up; and the
bottom right hand graph shows the error bars for the values at two month follow-up. In each o f the three error bar graphs, the GSTMI-missing group is on the left, the
GSTM1-present group is in the middle, and the control group is on the right.
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Motivation to quit smoking: line plots of means and error bar charts6
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6 Note: The top right hand graph shows the error bars for the values at baseline; the bottom left hand graph shows the error bars for the values at one week follow-up; and the
bottom right hand graph shows the error bars for the values at two month follow-up. In each of the three error bar graphs, the GSTMI-missing group is on the left, the
GSTM1-present group is in the middle, and the control group is on the right.
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Cigarettes smoked per day: line plots of means and error bar charts 7
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7 Note: The top right hand graph shows the error bars for the values at baseline; the bottom left hand graph shows the error bars for the values at one week follow-up; and the
bottom right hand graph shows the error bars for the values at two month follow-up. In each o f the three error bar graphs, the GSTMI-missing group is on the left, the
GSTM1-present group is in the middle, and the control group is on the right.
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Perceived risk of lung cancer: line plots of means and error bar charts
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8 Note: The top right hand graph shows the error bars for the values at baseline; the bottom left hand graph shows the error bars for the values at one week follow-up; and the
bottom right hand graph shows the error bars for the values at two month follow-up. In each of the three error bar graphs, the GSTMI-missing group is on the left, the
GSTM1-present group is in the middle, and the control group is on the right.
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Figure 8.10. Examples of histograms of standardized residuals for repeated measures models
fitted to the seven primary dependent variables
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Motivation to quit smoking
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C o m p an y  and  c o m m e n ts P rod uc ts G e n e tic  v a r ia n ts  te s te d
GeneLink, Inc. e s t. 1994 , New Jersey, US.
wwvV.bankdna.com
GeneLink's mission is "to utilize the latest genetic research 
information and applied technologies to provide products 
and services that can assist in improving the quality of 
life."
The website states that it conducts genetic tests for SNPs 
associated with 1) oxidative stress, 2) bone density, and 3) 
obesity. It  does not state which SNPs specifically are 
tested, and does not provide a bibliography of relevant 
papers. There is no indication what SNPs are tested for, 
and therefore no way of assessing the validity of their 
tests.
Has various US Professors on its scientific and advisory 
board.
Feedback process unclear. Costs and genes not stated.
The GeneLink N utragenetic Profile™ -
genetic profile for oxidative stress -  examines 
"im portant genes related to increased risks 
for oxidative stress, circulatory and heart 
health, bone health, immune function and the  
ability to com bat environmental toxins".
The profile examines "genes of the oxidative stress (O S) fam ily for 
the existence of single nucleotide polymorphisms (SNPs)". Specific 
gene variants not identified.
The Derm agenetics™  profile exam ines  
" im p o rtan t genes re la ted  to  increased risks 
fo r certain  skin conditions, skin irritations, 
p re m a tu re  w rink ling , oxidative  d am age, 
env iron m en ta l stresses and photo -ag ing".
The test is designed to "m easure single-nucleotide polymorphisms, 
which are small variations in DNA. The test looks for SNPs in several 
key OS genes that are associated with oxidative stress. Test results 
can be used to guide consumers to skin therapies or skin products 
containing unique active ingredients and formulations designed to 
help alleviate specific oxidative stress deficiencies in the skin". 
Specific qene variants not identified.
O steopenia Susceptibility  Profile (Patent 
Pending)
"Designed to measure single-nucleotide polymorphisms, or SNPs 
(pronounced "snips"), which are small variations in DNA. The test 
looks for SNPs in several key genes that are associated with bone 
density". Specific gene variants not identified.
O besity Susceptibility  Profile (Patent 
Pending)
"Designed to measure single-nucleotide polymorphisms, or SNPs, 
which are small variations in DNA. The test looks for SNPs in several 
key genes that are associated with obesity. The test provides a score 
tha t can be used as a guide to determ ine w hat level of intervention  
or therapy would be helpful to combat or prevent the problems 
associated with obesity."
DNA Direct, Inc., e s t. 2 003 , San Francisco, US.
www.dnadirect.com
DNA Direct's philosophy: "Real medical information is often 
complex. But we believe consumers can handle these 
complexities. We feel strongly that consumers have the  
right to access and choose the latest, cutting-edge medical 
technology in a way that will benefit them . While we 
recognize that genetic testing can raise uncertainties, we 
believe that consumers should be allowed to m ake their 
own informed choices about testing." Lab analyses are 
CLIA-certified. Cheek cell swab samples are sent to the  
consumer through the post. The consumer obtains their 
test result in a 10-chapter, on-line report. Good quality 
information is provided on all aspects of the testing 
process. Gives references for papers reporting genetic 
association studies results. Differs from GeneLink and 
other nutrigenomics companies because, strictly speaking, 
DNA Direct is not testing for common gene variants (i.e . 
those involved in the metabolism of carcinogens). This is 
appropriate for the current level of genetics knowledge.
Hereditary b reast/ovarian  cancer. Single 
site testing $585; multisite testing $626; Full 
sequence testinq $5 ,311 .
Lab analysis: Analysis of the BRCA1-2 g e n e s  by a CLIA-certified  
laboratory.
Thrombophilia panel (tests for inherited 
blood clotting disorders Factor V Leiden and 
prothrombin). $380.
Lab analysis: analysis of factor V and prothrombin G 202 10A 
g e n e s  by a CLIA-certified laboratory.
H em ochrom atosis (tests for causes of iron 
overload). $199.
Lab analysis: analysis of HFE g en e (C282Y and H36D) by a CLIA- 
certified laboratory.
Cystic fibrosis (tests for the 32 most 
common genetic changes associated with 
cystic fibrosis). $260.
Lab analysis: Analysis of CFTR g en e  (3 2  s ite s )  by a CLIA-certified  
laboratory.
Alpha 1-antitrypsin deficiency (tests for a 
genetic cause of chronic lung and liver 
disease. $330.
Lab analysis: Analysis of the Alpha-1 g en e  by a CLIA-certified  
laboratory.
Company and com m ents Products G enetic variants tested
Genovations™  ©  2002 (G reat Smokies Diagnostic 
Laboratories, est. 1986'). www.aenovations.com
Genovation's claims: "Genovations is the advent of truly 
personalized healthcare. By harnessing the ingenuity of 
new breakthroughs in genomic science with the power of 
preventive biomedicine, Genovations™ offers an innovative, 
advanced health care model for more effectively preventing  
and treating chronic disease. Our predictive genomic 
profiles assess genetic variations in each person that, when 
combined with modifiable factors in the environm ent, may 
increase disease risk. This empowers physicians and 
patients to realize: Earlier, more effective preventive  
interventions-years before disease develops; Precise, 
customized therapies that truly address each individual's 
needs; Improved clinical insight into patients with 
treatm ent-resistant "chronic" conditions."
Website gives misleading information about the current 
state of genetics knowledge, for example: "Through 
carefully targeted dietary, nutritional, and lifestyle changes, 
as well as pharmacological therapies, it is often possible to 
modify the expression of genes and to overcome genetic 
limitations of biochemical pathways. Predictive genomic 
testing allows us to be sm arter clinicians, ones who can 
offer our patients more effective, customized therapeutics 
with few er unwanted side effects." These claims are 
unjustified and exaggerated based on the available  
evidence.
Not possible to determ ine quality of genetic tests due to 
lack of information about specific SNPs tested.
O steoG enom ic Profile "This information is available to established customers and their 
patients only."
From Presentation Slide: "Evaluates SNPs in genes that modulate 
bone formation (collagen synthesis), bone breakdown (resorption), 
and inflam m ation, including key regulatory mechanisms affecting 
calcium and Vitamin D3 metabolism. Identifies individuals who may 
need more than standard bone therapy to prevent osteoporosis."
CardioGenomic Profile "This information is available to established customers and their 
patients only."
From Presentation Slide: "Evaluates SNPs in genes that modulate 
blood pressure, clotting factors, cholesterol balance, nutrient 
m etabolism, inflam m ation, and oxidative stress. Provides basis for 
early nutrient-based prevention of cardiovascular disease."
DetoxiG enom ic Profile "This information is available to established customers and their 
patients only."
No further information available.
Im m unogenom ic Profile "This information is available to established customers and their 
patients only."
From Presentation Slide: "Evaluates SNPs in genes that modulate 
im m une and inflam m atory activity, affecting im m une system  
defense and resistance to infection, as well as chronic inflamm atory  
mechanisms in asthma, allergy, arthritis, and auto-im m une  
disorders."
Genomic Practicum "This information is available to established customers and their 
patients only."
No further information available.
M ethylation T est "This information is available to established customers and their 
patients only."
No further information available.
Gene SNP® DNA Screening A nalysis Test Kit, from  
Market America w ww.m arketam erica.com
Market America says: "Our Gene SNP DNA Analysis 
provides you with customized nutritional program and 
lifestyle recommendations based on genetic profiling 
through DNA analysis... The Gene SNP program provides an 
examination of specific genes and their subtle variations 
called SNPs. Once you discover your genetic code, you can 
then initiate a more pro-active, individualized approach to 
maintaining your health."
Poor quality and am ount of information.
NutriPhysical Gene SNP DNA Screening  
A nalysis T est Kit. $249 .
"The Gene SNPs tested in the Gene SNP DNA Analysis correspond to 
seven m ajor areas of metabolic activity:
heart health;
detoxification;
antioxidants;
bone health;
inflamm ation;
and insulin sensitivity."
Specific SNPs not identified.
Company and com m ents Products G enetic variants tested
One Person Health S cien ces, Inc., e s t. 2 002 , Van 
Couver, Canada. www.oneDersonhealth.com
One Person Health Sciences says it is: "Pioneering the  
developm ent of high throughput mass customized 
nutritional supplement m anufacturing, and is the First 
company to offer truly custom -m ade nutritional 
supplements based on health assessments and the new 
science of Nutrigenomics -  the study of the relationship 
between nutrient intake and how our genes function."
Good information, informs of genes tested for. Some 
unsupported claims, e.g. "Contained in your DNA is an 
accurate d ietary and supplem ent prescription which we can 
translate for your knowledge".
ONETest™. $ 3 2 9 . (or 'free': 
"When you take the genetic test 
your annual vitamin  
subscription will cost just 
$ 6 1 .50 /m o , regular price $89  
per month. Over 12 months 
you will have saved the entire  
am ount of the original cost of 
your genetic test!")
"ONETest™ screens your DNA sample for the presence of variations in 19 
genes. These genes have been chosen because they are markers for some of 
the most essential processes in your body's metabolism and cover seven m ajor 
areas of metabolic activity:
Antioxidant Activity: GSTM1, GSTP1, GSTT1, S 0D 3 , MnSOD  
B Vitamin Pathways: CBS, MS_TRR, MTHFR, MTR 
Bone Health: C0L1A1, IL -6 , TNFalpha, VDR 
Detoxification: GSTM1, GSTP1, GSTT1
Heart Health: ACE, AP0C3, CBS, CETP, eNOS, IL -6 , LPL, MnSOD, MS_MTRR,
MTHFR, MTR, S 0D 3
Inflam m ation: IL -6 , TNFalpha
Insulin Sensitivity: ACE, PPARgamma2
Sciona, Inc., e s t. 2 002 , Boulder, Colorado US 
(previously UK-based, until Jan 2 0 0 5 ).
www.sciona.com
Sciona says: "Sciona is leading provider of personalized, 
science-based healthcare solutions. Using the latest 
research, Sciona has created a powerful set of tools that 
enable manufacturers to customize personal care and 
nutrition products. Sciona's proprietary technology makes it 
both possible and cost-effective for m anufacturers to offer 
their customers a range of healthy, informed choices, 
specially tailored to fit each client's unique genetic 
m akeup."
Specific genes are not listed. However, extensive  
bibliography is included, and examples given include 
GSTM1. Currently not selling nutritional supplements 
alongside genetic test products. Likely to change now US- 
based.
Does not specify genes tested.
N o te  m a n y  p a ra lle ls  w ith  O n e Person H ea lth , In c .
Body B enefits -  Nutrition. The Body Benefits results contain information on:
Heart Health  
B Vitam in Use 
Detoxification  
Antioxidants 
Bone Health 
Inflam m ation  
Insulin Sensitivity
Skincare. No specific information on genes, product not yet available. Sciona says: 
"H ea lthy  skin depends on m ore than  th e  qua lity  cosm etics -  the  
effectiveness o f certa in  ingred ients found in skin care  products depends on 
a person's genetic  profile . Genes are  also a fac to r in p re m a tu re  ag ing, and  
in th e  proper m etabo lism  o f nutrien ts  vital fo r m ain ta in ing  a glowing  
com plexion . Recognizing th a t an ins ide /outs ide  approach is th e  best path  
to  skin care , Sciona is w orking w ith  p artners  to  provide holistic tre a tm e n t  
program s based on an in -d ep th  understanding  o f how individuals respond  
to  p articu lar skin care products.
Sport and Fitness. No specific inform ation on genes, product not yet available. Sciona says: 
"Both e lite  and a m a te u r a th le tes  can b en efit fro m  know ing how genes can  
affec t sport perfo rm ance. The growing body o f research in th is  a rea  can be 
used to  provide personalized advice on tra in ing  m ethods and nutritional 
req u irem ents  -  fo r exam p le , fo r designing an optim al exercise program  to  
achieve  specific goals, such as im proved  endurance or m uscle s tren g th ."
